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Renal Tumors
Lejla Aganovic and Richard H. Cohan
1.1  Introduction
In recent years, there have been dramatic developments in 
imaging assessment of renal tumors and their treatment, 
some of which will be provided in the paragraphs that 
follow.
1.2  Modalities for Imaging Renal Masses
1.2.1  Ultrasound
Although noncontrast ultrasound evaluates the internal mor-
phology of cystic lesions with more detail than CT, it is not 
as sensitive in detecting or accurate in characterizing renal 
masses as CT or MRI. Most consider ultrasound to be diag-
nostically definitive only when it identifies a renal mass as a 
simple cyst.
1.2.2  CT and MRI
Renal tumors may be detected incidentally on CT or MRI 
examinations. On CT, it is quite common for only contrast- 
enhanced images to have been obtained, in which case 
assessment of mass enhancement is limited. When only 
contrast- enhanced CT images are available, it may be diffi-
cult to distinguish hyperdense cysts from solid hypoenhanc-
ing renal lesions. Renal cancers are unlikely to measure 
>70 HU on unenhanced CT and <40 HU on contrast- 
enhanced CT [1].
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Learning Objectives
• To be familiar with the Bosniak cystic renal mass 
classification system
• To learn when very small renal masses can be 
ignored and when they should be followed
• To be aware of ultrasound, CT, and MRI appear-
ance of angiomyolipomas
• To learn about imaging features of non-macroscopic 
fat containing renal masses
• To be familiar with renal cancer staging and use of 
RENAL nephrometry
• To be knowledgeable of the normal imaging appear-
ance of patients after treatment of renal cancer and 
the appearance of treated and untreated metastatic 
disease
• To be aware of unique features related to treatment 
of metastatic renal cancer with targeted chemother-
apeutic agents, including immunotherapy
Key Point
• Patients referred to CT or MRI with known or sus-
pected renal masses should be evaluated with unen-
hanced and at least one contrast-enhanced series 
(with the unenhanced MRI sequences including 
T1-weighted, fat-suppressed, T2-weighted, in- and 
out-of-phase gradient-echo, diffusion-weighted 
images).
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1.3  Very Small Renal Masses (<1–1.5 cm)
Very small renal masses (<1.0–1.5 cm in maximal diameter) 
are detected on nearly half of all adult patients undergoing CT 
scans [3]. Many such renal masses detected with CT and MRI 
cannot be characterized due to their size. Accurate attenua-
tion measurements in these lesions are problematic, due to 
volume averaging and pseudoenhancement. Fortunately, the 
likelihood of any one of these lesions being malignant is 
exceedingly low [3]. The overwhelming majority of these 
lesions will be benign renal cysts.
Because very small renal masses are so common, further 
assessment of all of these lesions is not feasible, even though 
a few will be cancers.
Some homogeneous low attenuation lesions can be con-
sidered suspicious if they appear in high-risk patients, such as 
those with known or suspected hereditary cancer syndromes 
(such as von Hippel-Lindau, hereditary papillary renal cell 
cancer, Birt-Hogg-Dubé, or hereditary leiomyomatosis- renal 
cancer syndrome) [4]. When a very small renal mass is 
deemed suspicious, further evaluation should be performed 
within 6–12 months. Suspicious masses should be followed 
for at least 5 years. While follow-up can be obtained with CT 
or MRI, MRI is more accurate. Even tiny cysts have charac-
teristic high T2 signal intensity. MRI is also much more sen-
sitive to contrast enhancement than is CT, and it is not 
compromised by pseudoenhancement [5].
1.4  Cystic Renal Masses
Many radiologists and urologists classify cystic renal lesions 
using the Bosniak classification system, which was first pro-
posed in 1986 [7] and revised several times, including in 
2005 [8]. This system classifies renal cystic masses into five 
categories, based upon their likelihood of being malignant. It 
is important to emphasize that the Bosniak system was 
designed for use with dedicated renal mass CT and not for 
ultrasound or MRI.
Category I lesions, which constitute the overwhelming 
majority of cystic renal masses, are simple renal cysts. They 
are homogeneous masses. They are anechoic on ultrasound 
and of water attenuation on CT or water signal intensity on 
MRI. They have imperceptible walls and do not contain nod-
ules or calcifications. They do not enhance when contrast 
material is administered. Category I lesions are always 
benign and no follow-up is needed. Category II lesions are 
minimally complex. They may contain one to three septa-
tions or thin peripheral calcifications. Hyperdense renal cysts 
<3 cm in diameter are also Category II lesions. Category II 
lesions are essentially always benign and no follow-up is 
needed. Category IIF lesions contain multiple or thickened 
septa, thickened walls, or coarse calcifications. Hyperdense 
cysts measuring >3 cm in diameter are also Category IIF 
lesions.
Key Point
• Renal mass detection and characterization are max-
imized when delayed rather than early contrast- 
enhanced images are obtained (either in the 
nephrographic phase [NP], which begins 90–100 s 
after initiation of a contrast injection, or the excre-
tory phase [EP], which begins when excreted con-
trast material is first detected in the renal collecting 
system, usually 120 s or more after initiation of 
contrast injection) [2].
Key Point
• Follow-up imaging of tiny renal masses should be 
performed only when they subjectively appear to be 
complex with evidence of heterogeneity, internal 
septations, mural nodules, wall thickening, or 
heterogeneity.
Key Point
• Category IIF cysts have been found to represent 
cancers or progress to become cancers about 11% 
of the time [9] and, for this reason, must be fol-
lowed, with repeat imaging studies performed at 
6 months and then annually for at least 5 years. 
Cancer should be suspected, not when these lesions 
grow over time, but instead if they become increas-
ingly complex.
Key Point
• Most benign and malignant very small renal masses 
grow at comparable slow rates, with many of these 
masses enlarging at a rate of no more than 3–5 mm 
in maximal diameter per year [6]. As a result, inter-
val enlargement of a renal mass cannot be used to 
predict that the mass being followed is malignant. 
Instead, masses should be assessed for changes in 
morphology. These changes include increasing het-
erogeneity or the progression of the other afore-
mentioned complicating features [5].
L. Aganovic and R. H. Cohan
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Studies have indicated that such follow-up can be per-
formed safely. In the series reported by Hindman et al. [9], 
none of 17 Category IIF renal cystic masses that were ulti-
mately diagnosed as cancers developed locally recurrent or 
metastatic disease during the follow-up period. Category III 
lesions contain thickened irregular enhancing septa or walls. 
They are malignant about 50–60% of the time. When malig-
nant, they tend to be less aggressive than other renal cancers. 
Treatment of these lesions is usually recommended due to 
the high risk of malignancy. Category IV lesions are cystic 
lesions that have irregular enhancing walls or enhancing 
nodules. These lesions are nearly always malignant, so treat-
ment is warranted.
The Bosniak system has been adopted for use with ultra-
sound and MRI; however, the percentages of lesions of dif-
ferent categories that are malignant with these modalities are 
not well known. For example, on MRI, about 20% of cystic 
renal masses appear more complex and are assigned to 
higher categories than they would have been if imaged with 
CT [10]. This is largely due to MRI’s ability to detect inter-
nal cyst features not visible with CT.
1.5  Angiomyolipomas (AMLs)
AMLs are the most common benign solid renal neo-
plasms. They are composed of angiomatous, myomatous, 
and fatty elements, in varying relative distribution. Eighty 
percent occur sporadically. The remainder are associated 
with syndromes (tuberous sclerosis or lymphangioleio-
myomatosis) [11].
While nearly all AMLs are echogenic on ultrasound, so 
are some small renal cancers. It has been found, however, 
that the likelihood of a small echogenic renal case being a 
cancer is exceedingly low. In one recent study, only 1 of 
161 small renal masses (measuring 1 cm or smaller) were 
subsequently found to be renal cancers [12]. Acoustic 
shadowing has been identified posterior to some echo-
genic AMLs, but not posterior to any echogenic renal 
cancers [13]. An echoic rim or intratumoral cysts have 
been observed around or in some renal cancers, but not 
any AMLs.
Echogenic masses detected on US are often further evalu-
ated with CT or MRI to determine if macroscopic fat is pres-
ent in the mass. If macroscopic fat is identified on CT or 
MRI, then the mass can be diagnosed definitely as an AML 
(with only case reportable exceptions).
Key Point
• On CT, visualization of at least some small areas 
within a renal mass measuring–(negative) 10 HU or 
less is considered diagnostic of macroscopic fat and 
of an AML [14].
Key Point
• On MRI, fat typically has high T1 and T2 signal 
and loses signal with fat suppression. On opposed-
phase chemical shift imaging, there is a characteris-
tic “India ink” artifact at fat-water interfaces in the 
AML and between the AML and adjacent renal tis-
sue (Fig. 1.1) [15].
a b
Fig. 1.1 MRI of an AML. (a) Axial T1-weighted MR image shows a 
tiny hyperintense mass in the lower pole of the right kidney (arrow). (b) 
Axial T2-weighted MR image with fat suppression shows that the 
lesion has lost signal (arrow), confirming the diagnosis. (c) Opposed- 
phase MR image demonstrates India ink artifact at the interface of the 
renal mass with the kidney (arrow)
1 Renal Tumors
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Occasionally, exophytic AMLs can be difficult to differ-
entiate from perinephric liposarcomas. Some imaging fea-
tures can be used to facilitate differentiation. AMLs are more 
likely to invaginate into the kidneys and produce a focal 
parenchymal defect. Liposarcomas, in comparison, merely 
compress the kidney, without having an associated defect. 
AMLs are more likely to contain large vessels that extend to 
the renal cortex than are liposarcomas [16].
Some AMLs do not contain easily identifiable macro-
scopic fat. These AMLs are referred to as fat-poor AMLs 
(fpAMLs) and include fpAMLs that have the same or higher 
attenuation than normal renal parenchyma on unenhanced 
CT and AMLs with epithelial cysts (AMLEC), which can 
appear as solid masses with small cystic areas or multilocu-
lar cystic lesions [11].
Many studies have attempted to identify small foci of fat or 
other imaging features that might permit fpAMLs to be cor-
rectly distinguished from other solid renal neoplasms. These 
features have included assessing unenhanced CT mass attenu-
ation, CT histograms, quantitatively assessed fat on MRI, and 
the degree and homogeneity of mass of enhancement [11, 17–
19]. Results have been mixed. For example, some fpAMLs 
have higher unenhanced attenuation than normal renal paren-
chyma, but papillary renal cancers can also demonstrate this 
feature [20]. Some fpAMLs have low signal intensity on 
T2-weighted MR images, but papillary renal cancers may also 
demonstrate this behavior. Fortunately, fpAMLs usually dem-
onstrate more MR contrast enhancement than do papillary 
renal neoplasms, so a hypervascular lesion that demonstrates a 
combination of high attenuation on unenhanced CT and/or 
low-T2 signal intensity on MRI is most likely to be an AML.
A rare type of AML is the epithelioid AML (eAML). Some 
epithelioid AMLs behave aggressively. They can spread 
locally to invade the renal vein or IVC, involve regional lymph 
nodes, or even metastasize distantly [11]. Epithelioid AMLs 
do not demonstrate imaging features that allow them to be dif-
ferentiated from other AMLs. While many epithelioid AMLs 
do not contain identifiable macroscopic fat on imaging  studies, 
some do [21]. Because this subtype of AML is so rare, AMLs 
that have a classic appearance on imaging studies should all be 
treated as benign lesions anyway. Exceptions should be con-
sidered to be case reportable.
1.6  Other Solid Renal Masses
Many solid renal masses do not contain identifiable fat. 
This includes oncocytomas and renal cancers. A large num-
ber of studies attempting to distinguish among the various 
nonfat- or minimal-fat-containing solid renal masses on CT 
and MRI have met with limited success; however, a few 
occasionally suggestive imaging features have been 
described.
1.6.1  Oncocytomas
Oncocytomas are benign renal tumors. They may contain 
central scars that can be detected on imaging studies; how-
ever, this feature is not diagnostic. Necrosis in renal cancers 
is indistinguishable from scars in oncocytomas. Further, 
most oncocytomas evaluated on CT do not contain visible 
central scars [22]. One feature that has been used by some to 
differentiate oncocytomas from renal cancers is segmental 
enhancement inversion, in which two differently enhancing 
components identified on CMP images reverse their attenu-
ation on EP images, with the initially higher attenuation and 
briskly enhancing component becoming lower in attenua-
tion than the initially lower attenuation and less intensely 
enhancing component [23]. This feature is not consistently 
detected in oncocytomas and is, therefore, frequently not 
helpful [24].
1.6.2  Renal Cancers
In the past, it was believed that there were only a few types 
of cancer; however, chromosomal analysis has demonstrated 
that there are at least 13 distinct types of renal cancer, with 
most being very rare. This includes clear cell (about 
70–80%), papillary (10–15%), chromophobe (less than 
10%), acquired renal cystic disease-associated, clear cell and 
papillary combined, collecting duct, renal medullary, muci-
nous tubular and spindle cell, succinate dehydrogenase- 
deficient, tubulocystic, and unclassified cancers, multilocular 
cystic neoplasms of low malignant potential, and MiT trans-
location cancers including Xp11.2 [25]. Sarcomatoid renal 
cancer is no longer believed to be a distinct cell type. Instead, 
any type of primary renal neoplasm can dedifferentiate and 
develop sarcomatoid features. While again imaging differen-
tiation among most renal cancers is not possible, some cell 
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1.6.2.1  Clear Cell Renal Cancer
Clear cell renal cancers have the highest metastatic poten-
tial and poorest survival of the major histologic RCC sub-
types. They are usually heterogeneous renal cortical 
masses. On unenhanced MRI, most clear cell cancers dem-
onstrate hyperintensity on T2-weighted images. Due to 
abundant intracellular fat, clear cell cancers can lose signal 
on opposed-phase gradient-echo T1-weighted images. 
Clear cell carcinomas usually demonstrate heterogeneous 
enhancement, with peak enhancement occurring early, on 
CMP images [26] (Fig. 1.2).
1.6.2.2  Papillary Renal Cancer
Most papillary cancers behave less aggressively than do 
clear cell cancers. On contrast-enhanced CT or MRI, papil-
lary cancers tend to be homogeneous. On unenhanced CT, 
they may have higher attenuation than adjacent renal paren-
chyma. On unenhanced MRI, they often are hypointense on 
T2-weighted images and can lose signal on in-phase 
T1-weighted images due to presence of hemosiderin [27]. 
They usually enhance homogeneously, more slowly, and to a 
lesser extent than do other renal cancers, with peak enhance-
ment not occurring until the NP or even the EP [28] (Fig. 1.3).
a b
Fig. 1.2 Clear cell renal cell carcinoma. Contrast-enhanced axial (a) and coronal (b) images obtained during the CMP demonstrate a heteroge-
neously and briskly enhancing left renal mass, subsequently confirmed to be a clear cell RCC
a b
Fig. 1.3 Papillary renal cell carcinoma. Unenhanced (a) and excretory phase (EP) contrast-enhanced (b) axial CT images demonstrate a mildly 
heterogeneous hypoenhancing papillary cancer in the posterior aspect of the mid right kidney
1 Renal Tumors
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1.6.2.3  Chromophobe Renal Cancer
Chromophobe renal cancers are generally well-differentiated 
cancers and, provided that they do not have sarcomatoid 
degeneration, are slow growing and have an excellent prog-
nosis. They do not have a unique appearance on imaging 
studies and cannot be reliably distinguished from other solid 
renal masses that do not contain macroscopic fat.
1.6.2.4  Uncommon Renal Cancer Cell Types
Many of the uncommon renal cancers do not have suggestive 
imaging appearances. A few specific comments about some 
of these cancers can be made, however. Renal medullary, col-
lecting duct, and XP11.2 translocation cancers generally arise 
in the renal medulla. Collecting duct cancers frequently occur 
in older adults; renal medullary and XP11.2 cancers are usu-
ally encountered in young patients [25]. Renal medullary 
cancers typically develop in patients with sickle cell trait [29].
1.6.3  Urothelial Neoplasms, Lymphoma, 
and Renal Artery Aneurysms
It can occasionally be difficult to distinguish centrally located 
RCC from urothelial cancers; however, the correct etiology 
may be predicted in many instances. Unlike RCC, urothelial 
cancers have an epicenter in the renal collecting system, can 
produce renal pelvic filling defects, and tend to preserve the 
normal renal contour. They also rarely contain cystic/necrotic 
areas seen in many, but not all, RCCs [30]. Other centrally 
located renal masses that can be encountered and that can 
occasionally mimic urothelial cancers of RCC include renal 
lymphoma and renal artery aneurysms.
1.7  Solid Renal Mass Growth Rates
Both benign and malignant solid renal masses can remain 
stable in size or enlarge over time, with growth rates of both 
types of lesions usually being similarly slow [31]. It has 
been suggested that a small solid mass that has an average 
growth rate of <3 mm/year over at least a 5-year period and 
that has not changed in morphology should be considered 
stable. Such a lesion, even if malignant, is exceedingly 
unlikely to metastasize. Conversely, rapid growth of a mass 
(by more than 5 mm in 12 months) may indicate aggressive-
ness/malignancy [32].
1.8  Radiomics
In recent years, there has been increasing interest in the utility 
of computer-assisted diagnosis (CAD) in detecting and char-
acterizing genitourinary abnormalities. With respect to renal 
masses, this has centered on the ability of computer- assisted 
techniques to differentiate among different types of renal 
masses. For example, studies using computer-assisted diagno-
sis have demonstrated clear cell renal cancers to have greater 
objective heterogeneity (pixel standard deviation, entropy, and 
uniformity) than papillary renal cancers or AMLs [33]. CAD 
detection of differences in peak lesion attenuation has also 
been used to differentiate clear cell renal cancers from other 
renal neoplasms with some success [34]. Renal mass perfu-
sion parameters have been employed to  distinguish some renal 
cancers of higher Fuhrman grade from those of lower grade 
[35]. These results are promising but preliminary.
1.9  Use of Imaging for Solid Renal Mass 
Differentiation
1.10  Percutaneous Biopsy of Renal Masses
Given the substantial overlap in the imaging features of 
many renal lesions, percutaneous biopsy is necessary for 
determining the nature of many renal masses prior to treat-
ment. Biopsy can be performed accurately and safely [36]. 
The risk of needle tract seeding of tumor is minimal. There 
are only isolated case reports of renal cancer seeding [37]. 
One potential pitfall of biopsy relates to the fact that only a 
few portions of a renal mass are sampled. Areas containing 
higher-grade cancer may not be sampled, leading to underes-
timation of tumor aggressiveness.
1.11  Pretreatment Assessment of Renal 
Cancer
1.11.1  Staging
CT and MRI (obtained during the portal venous phase of 
enhancement) are at least 90% accurate in renal cancer stag-
ing, with the TNM staging system as follows:
Stage Feature
T1a ≤4 cm in greatest diameter and limited to the kidney
T1b >4–7 cm and limited to the kidney
T2a 7–10 cm and limited to the kidney
T2b >10 cm and limited to the kidney
Key Point
• Due to overlap of many imaging findings detected sub-
jectively and using CAD, at the present time, imaging 
differentiation of many malignant from benign nonfat-
containing solid renal masses (or among the various 
types of malignant solid renal masses) is not possible.
L. Aganovic and R. H. Cohan
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Stage Feature
T3a Extension into the renal vein or its branches or invading 
perirenal or renal sinus fat
T3b Extension into the IVC below the diaphragm
T3c Extension into the IVC above the diaphragm or invading the 
IVC wall
T4 Invasion beyond perinephric fascia or into ipsilateral adrenal 
gland
N0 No lymph node involvement
N1 Regional lymph node involvement
M0 No distant metastases
M1 Distant metastases
Mx Distant metastatic status not determined
The most substantial limitation of imaging in stage renal 
cancers results from the fact that both CT and MRI have dif-
ficulty in determining whether a renal cancer has invaded the 
renal capsule and spread into the perirenal or renal sinus fat 
(differentiating T2 from T3 cancer). Perinephric soft tissue 
stranding can be produced by tumor, edema, or blood vessels 
[38]. It is recommended that T3 disease be diagnosed on CT 
or MRI only when nodular tissue is identified in the peri-
nephric space.
1.11.2  RENAL Nephrometry
Many urologists prefer that RENAL nephrometry scoring of 
suspected or known renal cancers also be obtained prior to 
surgery. Nephrometry scoring allows the urologist to predict 
the likelihood that partial nephrectomy can be performed 
effectively and safely [39]. With this system, a renal mass 
receives a score of 1–3 points for each of five features (Renal 
mass size, Exophyticity, Nearness to the renal collecting sys-
tem, Anterior or posterior location, and Location with 
respect to the upper and lower polar lines (see table immedi-
ately below). Tumors that have composite nephrometry 
scores of 4–6 are considered to be very amenable to partial 
nephrectomy, while those that have scores of 10–12 are poor 
candidates for partial nephrectomy. Complete nephrectomy 
should be considered in the latter group.
Feature 1 point 2 points 3 points
R = diameter ≤4 cm >4 to 
<7 cm
≥7 cm
E = exophyticity ≥50% <50% Entirely endophytic
N = nearness to 
collecting system or 
renal sinus
≥7 mm >4 to 
<7 mm
≤4 mm
A = anterior or 
posterior
No points given. Mass is listed as a, p, or 
neither (x)
L = location relative 
to polar lines
Add “h” if touches 







>50% of mass 
crosses polar line or 
crosses midline or 
entirely interlobar
From Ref. [39]
1.12  Renal Cancer Management
Management of renal cancers that have not metastasized 
regionally or distantly now ranges from active surveillance 
(for small [<4 cm] indolent (low Fuhrman grade) tumors in 
elderly patients with significant comorbidities) to thermal 
ablation, partial nephrectomy, or complete nephrectomy [32, 
37]. Patients on active surveillance should undergo subse-
quent imaging every 6 months for a year, followed by annual 
imaging for at least 5 years. Intervention in these patients is 
only considered when masses exceed 4 cm in size or grow by 
>5 mm per year [32].
1.13  Imaging After Renal Cancer 
Treatment
1.13.1  After Renal Mass Ablation or Resection
After successful renal mass radiofrequency or cryoablation, 
there is initial expansion of the ablation site. Initially, some 
enhancement may be detected normally in the ablation bed, 
particularly on MRI exams. This normal enhancement 
resolves over time [40]. In the months following ablation, the 
ablation bed typically decreases but rarely disappears com-
pletely. Other normal post-ablation findings include fat 
invagination between the ablation bed and normal renal 
parenchyma and a peri-lesional halo, changes that create an 
appearance that can be confused with an AML (Fig. 1.4). 
Ablation bed expansion is not typically seen after microwave 
ablation.
Fig. 1.4 Normal post-thermal ablation appearance. An EP contrast- 
enhanced CT image on a patient, who had a left renal radiofrequency 
ablation 7 months earlier, demonstrates a normal post-ablation appear-
ance. Soft tissue attenuation material is surrounded by invaginated peri-
nephric fat, an appearance that can be confused with an AML
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Persistent or recurrent tumor should be suspected after 
ablation if the ablation bed progressively increases (rather 
than decreases) in size, when there is increased perinephric 
nodularity, or when persistent or new areas of nodular or 
crescentic enhancement are detected, with these areas usu-
ally located at the interface of the ablation bed with adjacent 
renal parenchyma [41].
1.13.2  Imaging After Partial or Total 
Nephrectomy
After partial or total nephrectomy, it is common to see 
postoperative inflammatory or fibrotic changes in the sur-
gical bed, along with deformity of the renal contour at the 
site of partial nephrectomy [42]. Gore-Tex mesh along the 
nephrectomy site appears as a linear area of high attenua-
tion along the renal margin.
Complication rates after partial nephrectomy are typi-
cally higher than after total nephrectomy, with complica-
tions including pseudoaneurysm, urinoma, or abscess. If 
urinoma is a concern, delayed imaging >1–2 h after con-
trast administration might prove useful to document the 
urinary leak.
After partial or total nephrectomy, recurrent tumor may 
develop in the surgical bed and/or regionally or distantly. 
Surgical bed recurrences may initially be difficult to differ-
entiate from postoperative scarring/fibrosis, although tumor 
often demonstrates detectable enhancement and enlarges 
over time. Renal cancer usually metastasizes to regional 
lymph nodes, the liver, the adrenal glands, the lungs, and the 
bones. Adrenal cancer metastases from clear cell renal can-
cer can be problematic, since they may contain large amounts 
of intracellular fat. As a result, similar to adenomas, adrenal 
metastases can demonstrate low signal intensity on opposed- 
phase MR images and can also demonstrate pronounced 
(>60%) washout on delayed enhanced CT. Renal cancer 
metastasizes to the pancreas more commonly than do other 
neoplasms [43].
1.13.3  Imaging After Treatment of Metastatic 
Disease
1.13.3.1  RECIST
Patients who present with or develop metastatic renal cancer 
must receive systemic treatment. Imaging is then performed 
regularly to determine whether or not patients are responding 
to their chemotherapy. Metastatic foci are then measured and 
compared, from one imaging study to the next. The most com-
monly used measurement system for assessing tumor response 
to chemotherapy has been the response evaluation criteria in 
solid tumors (RECIST) system [44]. The RECIST 1.1 system 
involves measurements of up to five metastatic lesions (no 
more than two per organ, with each measured lesion being at 
least 10 mm in length). Most metastases are measured in max-
imal dimensions; however, lymph nodes are measured in short 
axis diameter. Complete response is diagnosed when all 
metastases resolve on follow-up imaging. A partial response is 
diagnosed when the sum of all target lesions decreases by 
≥30% from one study to the next. Progressive disease is diag-
nosed when the sum of all target lesions increases by ≥20% or 
more. Any change in between a 30% decrease and a 20% 
increase is considered stable disease.
1.13.3.2  Multikinase Inhibitors
A number of alternative measuring systems have been 
devised, which take into account changes in lesion attenua-
Key Point
• Frequent imaging should be performed after abla-
tion (e.g., at 1, 3, 6, and 12 months). This is because 
residual or recurrent tumor is usually detectable 
within the first few months of ablation [41].
Key Point
• Frequently used hemostatic material can be mis-
taken for infection or tumor, since an occasional gas 
within the material and its low attenuation compo-
nents can persist for months after surgery.
Key Point
• While RECIST 1.1 has worked well for following 
metastatic disease treated by prior standard chemo-
therapy, there are problems with its use in patients 
treated with anti-angiogenesis drugs, including multi-
kinase inhibitors. This is because multikinase inhibi-
tors may produce necrosis (and resulting diminished 
attenuation on contrast-enhanced CT) in responding 
metastatic lesions without these lesions decreasing 
significantly in size. As a result, a patient who is a 
partial responder can be misidentified as not having 
responded to treatment, if only RECIST is used.
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tion, as well as changes in size. This includes the Choi, mod-
ified Choi, and the morphology, attenuation, size, and 
structure (MASS) systems [45, 46]. With the Choi criteria, 
for example, a decrease in target lesion size of only 10% or 
more or a decrease in target attenuation of 15% or more indi-
cates a partial response. With the modified Choi criteria, both 
of these features must be present at the same time.
1.13.3.3  Immunotherapy
In the last few years, patients with metastatic renal cancer 
have been treated with immunotherapy. These agents are 
antibodies targeted to attack receptors on lymphocytes or 
surface ligands on tumor cells. They work by interfering 
with a tumor’s ability to inhibit an immune response. At the 
present time, the immune checkpoints which are being inhib-
ited include those related to cytotoxic T-lymphocyte- 
associated antigen 4 (CTLA4) and the program cell death 
protein 1 receptor on T-cells (PD-1) or its related ligands on 
tumor cells (PDL1 and PDL2) [47].
Initial studies on the efficacy of immunotherapy in treat-
ing patients with metastatic renal cancer have been promis-
ing. Many patients have had sustained responses, which have 
even persisted after therapy was discontinued.
1.13.3.4  Complications of Multikinase Inhibitor 
Treatment and Immunotherapy
Complications encountered in patients undergoing new 
 systemic treatments include hepatic steatosis, cholecystitis, 
pancreatitis, bowel perforation, and arterial thrombosis 
Key Point
• A unique feature of metastases treated by immuno-
therapy is that some responding lesions may ini-
tially appear stable or even enlarge to such an extent 
that progressive disease would be diagnosed if 
a cb
Fig. 1.5 Adrenal metastasis treated with immunotherapy. (a) Initial 
contrast-enhanced CT image demonstrates a large left adrenal mass. (b) 
The mass remains heterogeneous and is larger on a follow-up CT 
obtained 6 weeks later. (c) A follow-up study obtained after another 
4 weeks now shows the mass to be necrotic and smaller
RECIST 1.1 were to be used. An apparent initial 
increase in size should be considered to be uncon-
firmed progressive disease (UPD). UPD must be 
confirmed by another follow-up imaging study in 
no less than 4 weeks [48]. If metastases continue to 
enlarge, then progressive disease can be diagnosed. 
In some instances, however, a subsequent study will 
indicate tumor response (consisting of decreased 
size and/or attenuation), confirming that the initial 
change in size was merely “pseudoprogression” 
(Fig. 1.5). The system for assessing metastatic 
tumor in immunotherapy patients has been modi-




(after multikinase therapy) and colitis (segmental or diffuse), 
pneumonitis, and  dermatitis and, less commonly, thyroiditis, 
hypophysitis, pancreatitis, and adrenal dysfunction (after 
immunotherapy) [49].
1.14  Concluding Remarks
There have been many exciting recent developments with 
respect to the imaging, diagnosis, and treatment of solid 
renal masses in the past few years. This has included the 
identification of imaging features that can differentiate 
among some of the many cystic and solid renal masses. 
Unfortunately, in many patients, overlapping features still 
prevent distinction of renal cancers from benign renal 
lesions. For this reason, biopsy, which can be performed 
safely and without concern for tumor tract seeding, is often 
used for diagnosis. Imaging remains crucial for staging of 
renal cancer, as it is very accurate. In patients with 
 organ- confined disease, imaging can be used to determine 
which patients are candidates for partial versus total nephrec-
tomy. It has become increasingly clear that some patients 
with small malignant renal masses may never need to have 
the masses treated. Novel chemotherapeutic agents have 
greatly prolonged survival of patients with regional or distant 
metastatic disease. Tumor response after treatment with the 
new targeted agents can be sustained but can sometimes be 
delayed. Tumor necrosis without size reduction can be seen 
occasionally and should not be confused with a lack of 
response.
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MRI of the Pelvic Floor and MR 
Defecography
Francesca Maccioni and Celine D. Alt
2.1  Introduction
The female pelvic floor is a complex functional and ana-
tomic system. It is composed of an active muscular compo-
nent and a passive support system. Furthermore, it is 
topographically divided in three main functional and ana-
tomic compartments: the anterior, supporting the bladder 
and urethra; the middle, supporting the vagina and uterus; 
and the posterior or anorectal compartment [1]. When the 
pelvic floor is damaged in its fascial, muscular, or neural 
components at the level of any of its three compartments, 
several pelvic floor dysfunctions or disorders (PFD) may 
arise [2]. As pelvic floor muscles and fasciae act like a unique 
functional entity, dysfunction of one compartment is com-
monly associated with various dysfunctions of the other 
compartments as well. Hence, a multidisciplinary team, 
often called a pelvic floor unit, is strongly recommended that 
includes urogynecologists, urologists, gastroenterologists, 
proctologists, physicians, radiologists, physiotherapists, and 
specialized nurses. Additionally, the correct diagnosis of the 
specific PFD and the identification of all associated disorders 
are mandatory for an effective conservative or surgical treat-
ment. Dynamic MRI provides excellent morphological and 
functional display of the pelvic floor and is therefore addi-
tionally applied for a comprehensive overview of the pelvic 
floor and the entire pelvic structures. Evaluation is best done 
by performing a standardized MRI procedure and using a 
systemic approach to report the MRI findings [3]. To improve 
effective communication between the radiologist and the cli-
nician, it is also relevant to understand the specific lesions 
underlying PFD and to explain the frequent association of 
disorders in different pelvic compartments.
2.2  Functional Anatomy of the Pelvic 
Floor
2.2.1  Pathogenesis
The pelvic floor is an integrated system composed of an 
active component, the striated muscles, and a passive sup-
port system, the suspensory ligaments and fascial cover-
ings, and is associated with an intricate neural network. It 
not only provides support for the pelvic viscera (bladder, 
bowel, uterus) but maintains their functioning, thanks to 
the combined action of the two major pelvic floor struc-
tures: the levator ani muscle (LAM), and the endopelvic 
fascia [1, 2, 4].
2.2.2  Levator Ani Muscle (LAM)
The LAM has two main components: the iliococcygeus and 
pubococcygeus muscles. Various muscle subdivisions of the 
LAM are assigned to the medial portions of the pubococ-
cygeus in order to reflect the attachments of the muscle to the 
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Learning Objectives
• To gain a basic knowledge on anatomy and patho-
physiology of the pelvic floor unit
• To get familiar with the recently published general 
recommendations for standardized imaging and 
reporting of pelvic floor disorder using MRI
• To discuss how to apply these recommendations in 
case-based evaluations
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urethra, vagina, anus, and rectum. These subdivisions of the 
LAM are referred to as the Mm. pubourethralis, pubovagina-
lis, puboanalis, and puborectalis or, collectively, as the M. 
pubovisceralis. More posteriorly, the pelvic diaphragm 
becomes continuous with the ischiococcygeus muscle. The 
LAM contracts continuously, providing tone to the pelvic 
floor against stress coming from gravity and intra-abdominal 
pressure. LAM contraction closes the urogenital hiatus and 
compresses the urethra, vagina, and anorectal junction (ARJ) 
in the direction of the pubic bone. Furthermore, the 
 puborectalis component of the LAM, called the puborectal 
muscle, is an intrinsic and relevant part of the anal sphincter 
complex. It plays a primary role in the defecation process, 
acting as a sling that opens and closes access to the anal 
canal. Relaxation of the puborectal muscle, in fact, opens the 
anorectal angle (ARA); its contraction closes this angle, thus 
impeding defecation.
2.2.3  Endopelvic Fascia
The endopelvic fascia is a layer of connective tissue that con-
nects and attaches the uterus and vagina to the pelvic bones 
[1]. Pelvic organs are supported by a series of fascial (liga-
mental) and elastic condensations of the endopelvic fascia, 
which support the uterus and vagina, preventing genital 
organ prolapse.
2.2.3.1  Pubocervical Fascia
The anterior portion of the endopelvic fascia, the pubocervi-
cal fascia, extends from the anterior vaginal wall to the pubis 
and supports the bladder. Damage to this ligament may cause 
urethral hypermobility and urinary incontinence.
2.2.3.2  Rectovaginal Fascia
The posterior portion of the endopelvic fascia forms the rec-
tovaginal fascia, called Denonvilliers aponeurosis, composed 
of thin, connective tissue in the rectovaginal septum. It fur-
ther extends, along with the cardinal and uterosacral liga-
ments (parametrium), from the posterior cervix and vaginal 
wall toward the sacrum [1]. Damage to or weakness of this 
fascia represents a major cause of rectocele.
2.2.4  Etiology of Pelvic Floor Failure
Obstetric lesions are considered primary causes of pelvic 
floor damage. Lesions of the iliococcygeus muscles are more 
frequent in the first phase of delivery, whereas the pubococ-
cygeus muscles may be damaged in the second phase; mid-
line episiotomy or forceps delivery are associated with anal 
sphincter rupture [2, 5]. During delivery, damage to the ante-
rior portion of the endopelvic fascia (pubocervical fascia) 
may determine urethral hypermobility and/or cystocele, 
whereas a lesion of its posterior portion, the rectovaginal fas-
cia, may result in an anterior rectocele or enterocele [5]. 
Pudendal nerve impairment during vaginal delivery for isch-
emic and mechanical factors diminishes the LAM’s capabil-
ity for providing adequate pelvic support. Other causes of 
pelvic floor weakness include aging, obesity, hysterectomy, 
and the patient’s genetic predisposition.
2.2.5  Indication for Dynamic Pelvic Floor 
Imaging
A pelvic floor disorder (PFD) is characterized by a variable 
association of pelvic organ prolapse (POP) and functional 
disturbances involving the bladder (e.g., urinary inconti-
nence and/or voiding dysfunction), the vagina and/or uterus 
(e.g., sexual dysfunctions), and the rectum (e.g., obstructed 
defecation syndrome (ODS)) [4]. The most common PFD 
are ODS, POP, and urinary incontinence. Nearly 50% of 
multiparous women >50 years of age are affected by these 
disorders, with a negative impact on their quality of life and 
a frequent need of invasive surgical treatments [2, 4].
2.3  Diagnosis of PFD Using Dynamic MRI
Dynamic pelvic floor (DPF)-MRI has emerged a valuable 
alternative technique for assessing PFD and grading POP, 
especially in the posterior compartment [6, 7]. Thanks to its 
multiplanar capability and high soft tissue contrast, MRI 
allows comprehensive morphologic and functional evalua-
tion of all three compartments at the same time, without the 
use of ionizing radiation. It enables real-time assessment of 
functional diseases with dynamic acquisitions, similar to 
conventional defecography [6]. The main limit of MRI is the 
obliged supine position for patient imaging, which is neces-
sary if a closed 1.5-Tesla magnet is used. The supine position 
of MR defecography has been criticized because defecation 
evaluation is not under physiological conditions [8, 9]. 
Key Point
• The pelvic floor should be considered as one unit 
since the three compartments work as one entity. 
Therefore, combined defects of the pelvic floor are 
common and the entire pelvis should be evaluated 
for PFD diagnosis.
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Comparative studies performed with open and closed mag-
nets have ultimately established a good concordance between 
results obtained in the sitting and the supine position, thus 
validating the use of closed MRI for assessing defecation [8]. 
For over 25 years, since its early clinical introduction, 
dynamic MRI for the evaluation of pelvic floor dysfunction 
has been performed with extremely heterogeneous tech-
niques due to the variability of patient preparation, MRI 
equipments, and image evaluation systems [10, 11]. Recently 
a standardized technique for DPF-MRI performance evalua-
tion has been proposed by a ESUR-ESGAR working group 
of experts [3].
2.3.1  General Preparation
According to the recommendations on MR defecography, 
the patient should void for about 2 h before the examination 
to have the bladder moderately filled [3]. A rectal cleansing 
enema the evening before the examination might be helpful 
but is not obligatory needed. To decrease patients’ discom-
fort and to increase patients’ compliance during dynamic 
and evacuation phases, a protective pad or a diaper pant 
should be offered to the patient. Prior to the examination, the 
full history of pelvic floor disorder should be taken, and the 
patient should be trained on how to correctly perform the 
dynamic phases of the examination and the evacuation phase. 
The patient should be informed that the full extent of pelvic 
organ prolapse (POP) and certain abnormalities are only vis-
ible during defecation, which makes evacuation of the gel 
mandatory [3].
2.3.2  DPF-MRI Procedure
2.3.2.1  Patients’ Positioning and Preparation
The given technical aspects of MRI of the pelvic floor relate 
to conventional closed configuration magnets for MR imag-
ing allowing patient positioning in lying body position only 
[3]. The MR defecography should preferably be performed 
with at least 1.5 T using a phased array coil centered low on 
the pelvis to ensure complete visualization of prolapsed 
organs [3]. The patient is placed in the supine position with 
the knees elevated (e.g., on a pillow with firm consistency) 
which facilitates straining and evacuation. No oral or intrave-
nous contrast is necessary. Vaginal filling with 20 cm3 ultra-
sound gel is helpful for better demarcation, but its application 
may be limited due to social or religious backgrounds. 
However, the rectum should be distended with ultrasound 
gel, especially in order to clearly diagnose an intussuscep-
tion and to evaluate the efficacy of rectal evacuation [3].
2.3.2.2  MRI Sequences
The recommended MR-defecography protocol consists of 
static MR sequences (high-resolution T2-weighted images 
(T2WI), e.g., TSE, FSE, RARE) in three planes and dynamic 
MR sequences (steady state, e.g., FISP, GRASS, FFE, 
PSIF, SSFP, and T2-FFE, or balanced-state-free precession 
sequence, e.g., TrueFISP, FIESTA, b-FFE) in sagittal plane 
(squeezing, straining, defecation). Adequate pelvic stress 
during the dynamic sequences is important in order to assess 
the full extent of pelvic floor disorder. Therefore, a clear 
movement of the abdominal wall and the small bowel must 
be seen during dynamic phases. The dynamic sequences 
“squeezing” and “straining” require breath holding, where-
fore the duration should not exceed 20 seconds each [3]. The 
“defecation” sequence should be repeated until the rectum 
is emptied (total time duration around 2–3 min) to show full 
extent of POP and to exclude rectal intussusception [3].
2.3.3  MRI Interpretation
The static images should be analyzed for detection and classi-
fication of structural abnormalities, while the dynamic images 
should be analyzed with regard to functional abnormalities 
assessed by metric measurements of the three compartments of 
the pelvic floor. Due to the different views of the clinical spe-
cialists involved in the treatment of pelvic floor disorder, it is 
suggested to consider adapting the MRI reporting scheme 
according to the specialty of the referring physician [3].
2.3.3.1  Measurement and Grading
The pubococcygeal line (PCL) is the recommended refer-
ence line to measure POP as it practically represents the 
level of the pelvic floor [3]. It is drawn on sagittal plane from 
the inferior aspect of the pubic symphysis to the last coccy-
Key Point
• There is no difference in the detection of clinically 
relevant pathologies regarding PFD when perform-
ing dynamic MRI in sitting position (open magnet) 
or in supine position (closed magnet).
Key Point
• Adequate pelvic stress during straining (clear 
movement of the abdominal wall and small bowel is 
seen) and the evacuation of the rectal gel during 
defecation are crucial so that the examination can 
be considered diagnostic.
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geal joint [10]. After defining the PCL, the distance from 
each reference point is measured perpendicularly to the PCL 
at rest and at maximum strain.
The organ-specific reference point in the anterior, middle, 
and posterior compartment is the most inferior aspect of the 
bladder base (B), the anterior cervical lip (most distal edge of 
the cervix) (C), or the vaginal vault in case of previous hyster-
ectomy (V), the pouch of Douglas (P), and the anorectal junc-
tion (ARJ) (Fig. 2.1a) [3]. Measured values above the reference 
line have a minus sign, values below a plus sign [12].
The anorectal angle (ARA) should be drawn along the 
posterior border of the rectum and a line along the central 
axis of the anal canal on sagittal plane at rest, squeezing and 
maximum straining (Fig. 2.2) [3].
a b
Fig. 2.1 (a, b) Presentation of the metric measurements on sagittal 
plane at rest. (a) The reference points are marked according to the 
PCL. This image at rest presents all reference points in a normal loca-
tion without protrusion or descent. (b) The hiatus at rest presents with a 
normal width and is located in a normal position according to the pelvic 
floor level (PCL) without descent (M-line). PCL pubococcygeal line, B 
bladder neck, C anterior cervical lip, P douglas pouch, ARJ anorectal 
junction, H-line hiatal width, M-line hiatal descent
a b c
Fig. 2.2 (a–c) Anorectal angle variations. (a) Sagittal T2-weighted 
image at rest after rectal filling with gel. The anorectal angle (white 
line) is approximately 85°. The anorectal junction corresponds to the 
apex of the angle, and it is placed at the level of the PCL. (b) Sagittal 
T2-weighted image during squeezing of the pelvic floor. The anorectal 
angle (white line) is reduced to 80°. The anorectal junction remains at 
the level of the PCL. (c) Sagittal T2-weighted image during straining. 
The anorectal angle (white line) opens to 130° due to rectal prolapse 
(160°) and is associated with severe prolapse of the anorectal junction 
(6 cm). PCL pubococcygeal line (black line)
F. Maccioni and C. D. Alt
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To grade pelvic organ prolapse in the anterior and 
middle compartment, the recommended grading system 
starts at +1 cm below the PCL based on the fact that the pel-
vic floor may normally descend and widen up to 2 cm during 
abdominal pressure and the pelvic organs consequently fol-
low the movement of the pelvic floor inferiorly [13]. The 
recommended grading system for cystoceles and uterine 
descent is as follows: °0 = up to +1 cm below the PCL, 
°I = +1 to +3 cm below the PCL, °II = +3 to +6 cm below the 
PCL, and °III = more than +6 cm below the PCL [3].
The position of the anorectal junction is stated to be nor-
mal up to +3 cm below the PCL. The recommended grading 
system for rectal descent is therefore as follows [14]: °0 = up 
to +3 cm below the PCL, °I = between +3 and +5 cm below the 
PCL, and °II = more than +5 cm below the PCL [3, 14].
The anterior rectal wall bulge in rectoceles should be 
reported as pathological from grade °II, as a grade °I  rectocele 
can be observed in nearly 78–99% of parous women, while 
rarely in men [7, 15, 16]: °0 = no outpouching, °I = out-
pouching up to 2 cm, °II = outpouching between 2 and 4 cm, 
and °III = outpouching at least 4 cm [3].
2.3.3.2  Further Evaluation
If a cystocele is present, the differentiation of a distention 
(central defect) or a displacement (lateral defect) cystocele 
can be made, which is relevant for therapy planning [17].
If a herniation of the pelvic peritoneal sac into the recto-
genital pouch (pouch of Douglas) is present, the report should 
include the content of the peritoneal sac [3]. It may contain fat 
(called peritoneocele), small-bowel loops (properly defined 
as enterocele), or sigmoid colon (defined as sigmoidocele).
The change of the ARA expresses the functioning of the 
puborectal muscle. In healthy individuals in the supine posi-
tion, the ARA at rest is between 85 and 95° [6]. During 
squeezing pelvic organs elevate in relationship to the PCL, 
sharpening the ARA by 10–15° (due to contraction of the 
puborectal muscle), while during straining and defecation, 
the ARA becomes more obtuse, typically by 15–25°, than 
when measured at rest (Fig. 2.2) [6].
Anismus is characterized by lack or insufficient relaxation 
of the puborectal muscle and external anal sphincter during 
defecation [6]. Anismus determines constipation and incom-
plete defecation due to a paradoxical contraction of the 
puborectal muscle during straining and defecation, without sig-
nificant variation in the ARA in the different functional phases.
If no evacuation of rectal content at all or a delayed 
evacuation time is present although the compliance is good 
(more than 30 seconds to evacuate 2/3 of the rectal content), 
anismus should be considered [3, 18].
Functional abnormalities like loss of urine through the 
urethra during maximum straining, urethral hypermobility, 
urethral funneling, or a contrary movement of the puborectal 
muscle should be reported if present [3].
Reporting of pelvic organ mobility (the movement of 
the organs compared to their location at rest) can give 
more valuable information than a grading system alone, 
taking into consideration that each woman has a unique 
straining of her pelvic floor and the grade of prolapse alone 
may not fully depict individual manifestation of POP or 
PFD [19].
Pelvic floor relaxation often coexists with pelvic 
organ prolapse. For quantification of the weakness of the 
levator ani and to reflect pelvic floor laxity, the length of 
the hiatus (H-line; extending from the inferior aspect of 
the pubic bone to the posterior wall of the rectum), the 
descent of the levator plate (M-line), and the levator plate 
angle can be evaluated on sagittal plane at rest and during 
maximal straining (Fig. 2.1b) [3]. Generalized pelvic 
floor weakness is also defined as descending perineal 
syndrome. One of the main causes is thought to be exces-
sive anismus.
Structural defects and anatomical abnormalities like 
urethral ligament defect and/or distortion; puborectalis mus-
cle detachment, disruption, atrophy, or avulsion; or diffuse or 
focal iliococcygeus muscle abnormality are commonly 
assessed on static T2-weighted images and should be 
reported if present [3].
2.4  Overview on Compartment-Based 
Symptoms
2.4.1  Anterior Compartment
Stress urinary incontinence (SUI) is the most common type 
of urinary incontinence in women, commonly caused by a 
defect in the urethral support system [20]. Other pathological 
causes have been attributed to urethral hypermobility, intrin-
sic sphincter deficiency, or urethral trauma (e.g., resulting 
from childbearing, surgical trauma, prolonged increased 
abdominal pressure) [21–23]. Women suffering from SUI 
often fear urinary leakage and are therefore impaired in their 
social or physical activities [24].
2.4.2  Middle Compartment
Women affected by levator ani trauma (e.g., caused by vagi-
nal childbirth) may suffer from non-specific complaints as 
abnormal emptying of the bladder, frequency and urgency, 
organ protrusion, pelvic pain, or pressure, as well as from 
dyspareunia and urinary or fecal incontinence [13, 25]. POP 
of the middle compartment may arise from damages of the 
connective tissue or vaginal supporting structures due to age 
or collagen defects. However, an avulsion of the pubovis-
ceral muscle at its inferior aspect or the detachment from its 
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insertion on the arcus tendineus fasciae pelvis band during 
vaginal delivery causes laxity and is propagated as the most 
common cause of pelvic floor dysfunction [26].
2.4.3  Posterior Compartment
The obstructed defecation syndrome (ODS) is the most fre-
quent symptom related to the posterior compartment and 
may be sustained either by mechanical causes (e.g., rectal 
prolapse, rectal descent, rectal invagination, rectocele, 
enterocele) or by a functional disorder (puborectalis syn-
drome, dyssynergic defecation) [6, 27].
Common symptoms of rectal prolapse include constipa-
tion, sensation of incomplete evacuation, fecal incontinence, 
and rectal ulceration with bleeding.
An intrarectal intussusception (invagination of the rectal 
wall) may produce a sensation of incomplete emptying, 
whereas an intra-anal invagination rather produces a sensa-
tion of incomplete or obstructed defecation due to outlet 
obstruction. High-grade intussusceptions are frequently 
associated with a rectocele (Figs. 2.3 and 2.4) [28, 29].
Enteroceles may be symptomatic, causing a sense of full-
ness and incomplete evacuation and occasionally lower 
abdominal pain (Fig. 2.5). However, an enterocele does not 
usually impair evacuation [6].
Fig. 2.3 Tricompartment prolapse in a patient with obstructed defeca-
tion syndrome. In the evacuation phase, a large anterior rectocele devel-
ops (>4 cm) associated with rectal invagination, severe descent of the 
ARJ (>6 cm), cystocele (>4 cm), and vaginal vault prolapse after 
hysterectomy
a b c
Fig. 2.4 (a–c) Rectocele with rectal invagination during progressive 
straining. (a) Sagittal balanced image after filling with rectal gel shows 
an anterior rectocele (3 cm) associated with prolapsed anorectal junc-
tion (5 cm). (b) Progressive straining shows rectal invagination above 
the rectocele. (c) Rectal invagination and rectocele are more evident at 
maximum straining during evacuation
F. Maccioni and C. D. Alt
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Symptoms related to a rectocele include vaginal bulging, 
dyspareunia, the sensation of a mass in the vagina, defeca-
tory dysfunction, constipation, or the sensation of incom-
plete evacuation. The fecal trapping in the rectocele leads 
many patients to empty their bowels by digitating and press-
ing on the posterior wall of the vagina or perineum.
2.5  Concluding Remarks
Dynamic pelvic floor MRI provides relevant morphological 
and functional information on pelvic floor structures for the 
diagnosis of pelvic floor disorder. However, knowledge 
about anatomy and pathogenesis of the pelvic floor unit as 
well as information about patients’ history are crucial for the 
interpretation of dynamic pelvic floor MRI. Additionally, a 
systemic approach to perform and report dynamic pelvic 
floor MRI is crucial to enhance effective communication 
between the radiologist and the clinician for the sake of 
patients’ benefit. The recently published recommendations 
on MR defecography by experts of the ESUR/ESGAR 
should be used, and all patients should undergo the same 
preparation and protocol, regardless of the leading symp-
toms of PFD to guarantee a complete documentation of the 
pelvic floor.
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Benign Disease of the Uterus
Karen Kinkel, Susan M. Ascher, and Caroline Reinhold
3.1  Introduction
Endovaginal sonography (EVS) is the procedure of choice 
for the initial evaluation of benign diseases of the female 
genital tract. When EVS findings are indeterminate, fur-
ther evaluation is often performed with magnetic resonance 
imaging (MRI) due to its excellent soft tissue differentiation, 
multiplanar capabilities, and absence of ionizing radiation. 
MRI is used as a problem-solving tool in benign uterine 
diseases, for example, uterine malformations, adenomyosis, 
and deep endometriosis, and to select appropriate candidates 
for therapies such as myomectomy or different types of hys-
terectomy. The role of computed tomography (CT) is limited 
in the evaluation of benign disease of the female pelvis par-
ticularly due to its lack of soft tissue differentiation. CT is 
primarily employed in an emergency situation, such as in an 
acute abdomen caused by ovarian torsion or pelvic inflam-
matory disease.
3.2  Normal Anatomy of the Uterus
In women of reproductive age, the uterus is approximately 
6–9 cm in length and varies in appearance according to the 
menstrual cycle. On EVS, the thickness of the endometrium 
in premenopausal women increases progressively during the 
menstrual cycle: from 3 to 8 mm in the proliferative phase to 
8–12 mm or more in the secretory phase. The echotexture of 
the endometrium also varies. The endometrium is hypo- to 
isoechoic in the mid-proliferative phase and becomes trilam-
inar in the periovulatory phase. In the secretory phase, the 
endometrium becomes echogenic and may have a nodular 
appearance. In the inner myometrium, subjacent to the 
 endometrium, a thin hypoechoic line is visible called the 
subendometrial halo. This line does not correspond anatomi-
cally to the junctional zone on MRI and is typically thinner. 
The remainder of the myometrium is of intermediate 
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• To be able to identify and classify Müllerian anom-
alies and leiomyomas with ultrasound and MRI
• To diagnose adenomyosis, deep endometriosis, and 
complicated leiomyomas
• To differentiate endometrial polyps from submuco-
sal leiomyoma
Key Points
• The diagnosis of Müllerian anomalies takes into 
account the uterine shape, external contour, and 
width of internal indentation compared to the uter-
ine wall thickness. Associated anomalies of the cer-
vix or vagina are classified separately.
• Classification of leiomyomas indicates how far the 
myometrial anomalies traverse the interface 
between the endometrial/myometrial interface and 
the myometrial/serosal interface. Analysis of T2-, 
T1-, and diffusion-weighted signal intensity and 
contrast enhancement helps in determining treat-
ment strategies in symptomatic patients.
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 echogenicity. Sonographic studies of endometrial thickness 
in postmenopausal women have suggested an upper limit of 
5 mm in patients not on hormone replacement and 8 mm for 
patients receiving hormonal therapy. EVS is highly sensitive 
for detecting endometrial pathology when these cutoff val-
ues are used as guidelines, to determine which patients 
would benefit from endometrial sampling [1]. The presence 
of endometrial thickening on EVS is nonspecific and may be 
due to endometrial hyperplasia, polyps, or carcinoma. The 
uterine zonal anatomy on MRI is best depicted using sagittal 
T2-weighted images (Fig. 3.1).
In the premenopausal woman, the high signal intensity 
endometrium varies in thickness, depending on the men-
strual cycle. In postmenopausal patients, the uterine corpus, 
but not the cervix, decreases in size. On dynamic gadolinium- 
enhanced images, the endometrium is hypovascular relative 
to the myometrium and becomes iso- or hyperintense on 
delayed scans.
3.3  MRI Technique
Patient preparation is an important step to obtain optimal 
image quality. To minimize motion artifacts due to bowel 
motion, patients are asked to fast 6 h prior to imaging. 
Unless contraindicated, intravenous or intramuscular injec-
tion of peristaltic inhibitors, i.e., glucagon or butyl-scopol-
amine, is recommended to further decrease peristalsis 
artifacts. According to the clinical question, additional 
preparation might include bowel cleansing and/or vaginal 
opacification for chronic pelvic pain. Sonographic gel is 
used to opacify the vagina and to allow visualization of 
vaginal duplication or communication. An intravenous line 
is often required to inject contrast agent to determine vas-
cularity of myometrial or endocavitary abnormalities. 
Examinations are usually performed in supine position 
using a body-flex phased-array MR surface coil. Imaging 
of the uterus should be performed using the smallest pos-
sible field of view (20–24 cm), thin sections of 3.5–4 mm, 
and the largest possible matrix size appropriate to each 
individual sequence. These imaging parameters provide 
important anatomic detail, which becomes critical when 
imaging uterine anomalies and endometrial pathology. 
When imaging large leiomyomas, the section thickness and 
field of view (FOV) may need to be adjusted accordingly. 
However, when establishing the myometrial origin of a 
subserosal leiomyoma, thin sections at the level of the ped-
icle are frequently helpful.
The most important sequence is a T2-weighted sequence 
nicely demonstrating the zonal anatomy of the uterus. 
Sagittal sections are best suited to image the uterus. Oblique 
coronal and axial slice orientation according to the long and 
short axis of the endometrial cavity should be applied for the 
assessment of uterine and cervical pathologies. It is impor-
tant to train MR technologists on how to acquire these 
oblique sequences if physician supervision is not possible. 
The short-axis coronal oblique sequence (perpendicular to 
the long axis of the endometrial cavity) is particularly valu-
able for assessing localized endometrial pathology and for 
evaluating the thickness of the junctional zone. It is also 
valuable for determining the extent of a uterine septum. A 
T2-weighted sequence performed parallel to the long axis of 
the endometrial cavity is critical to characterize the external 
uterine contour in patients with Müllerian duct anomalies. 
Since this series is so important in the classification of uter-
ine anomalies, it is best performed earlier in the examination, 
prior to bladder filling, which often displaces the uterus as it 
becomes increasingly distended. If the fundal contour is 
inadequately characterized by the T2-weighted images, 
T1-weighted images parallel to the long axis can facilitate 
Fig. 3.1 Normal MRI Uterine Anatomy Sagittal 3D T2-weighted mul-
tiplanar reconstruction of the uterus and cervix demonstrates normal 
zonal anatomy. There are three zones identifiable in the uterus: the 
hyperintense endometrium, the hypointense junctional zone and the 
intermediate signal intensity of the outer myometrium. Four zones are 
distinguished in the cervix: the hyperintense mucous within the endo-
cervical canal, the intermediate signal intensity of the cervical mucosa, 
the hypointense cervical stroma, and the intermediate signal intensity of 
the outer smooth muscle
K. Kinkel et al.
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characterization of the external contour due to increased 
 contrast between the myometrial fundal contour and the 
overlying fat. Recent software advances allow for a 3D 
T2-weighted acquisition—allowing post-processing of the 
uterus in any plane and potentially obviating the need to 
acquire individual orthogonal 2D T2-weighted sequences.
In addition to T2-weighted sequences, T1-weighted 
sequences with and without fat suppression are helpful to 
distinguish bloody components in adenomyosis or potential 
sarcomas from fat or mucinous components. A T1-weighted 
3D Dixon gradient echo sequence allows for T1-weighted 
in-phase, T1-weighted out-of-phase, T1-weighted water 
excitation, and T1-weighted fat excitation images within a 
single breath-hold. Routine use of this sequence helps stan-
dardize imaging protocols without additional exam time. In 
patients with congenital anomalies, a quick breath-hold 
T1-weighted sequence covering both kidneys is helpful to 
exclude renal agenesis or hydronephrosis.
An axial echo-planar diffusion-weighted imaging (DWI) 
sequence is an increasingly helpful functional imaging tech-
nique whose contrast derives from the random motion of water 
molecules within the extracellular tissue. In specific situation, 
such as patients with a leiomyoma of intermediate T2-weighted 
signal intensity, the high signal intensity of the DWI sequence 
combined with low or heterogeneous T1 signal intensity has 
the potential to differentiate leiomyomas from sarcomas or 
indeterminate myometrial masses with the use of an apparent 
diffusion coefficient (ADC) [2]. However measuring ADCs in 
all leiomyoma regardless T2 or DWI signal intensity is of no 
value and wrongly increases the rate of suspicion.
Gadolinium-enhanced imaging is not needed for most 
benign conditions, but can be useful in selected pathologies. 
We routinely perform contrast-enhanced imaging in patients 
referred for evaluation of endometrial pathology. In addition, 
contrast-enhanced imaging is also performed in patients with 
symptomatic leiomyomas scheduled for laparoscopic sur-
gery or uterine artery embolization, in the latter case with 
additional MR angiography of the iliac arteries. Vascularity 
can help to predict response to treatment, and the enhance-
ment may help distinguish a benign fibroid from a malignant 
leiomyosarcoma.
3.4  Congenital Anomalies
Between the 6th and 11th weeks of gestation, the paired 
Müllerian ducts undergo descent, fusion, and septum resorp-
tion to form the uterus, fallopian tubes, cervix, and upper 2/3 
of the vagina [3]. Müllerian duct anomalies (MDAs) result 
when this process either fails or is interrupted. Depending on 
the anomaly, patients may be asymptomatic with normal fer-
tility and obstetric outcomes, while others may have primary 
amenorrhea, menstrual irregularities, infertility, obstetric 
complications, and/or endometriosis. The reported preva-
lence of MDAs varies widely: 1–5% in the general popula-
tion and 13–25% in women with recurrent fetal loss [4]. The 
ovaries and external genitalia/distal 1/3 of the vagina are 
spared because they originate from the primitive yolk sac 
and sinovaginal bud, respectively. Renal anomalies however 
are present in 30–50% of women with MDAs [5].
Appropriate classification is critical to ensure proper 
treatment. Buttram and Gibbons classified MDAs in 1979, 
and a revised classification by the American Society for 
Reproductive Medicine (formerly the American Fertility 
Society) was published in 1988 [6, 7]. While widely accepted, 
the AFS system had limitations “in terms of effective charac-
terization of anomalies, clinical usefulness, simplicity and 
friendliness” [8]. To address these limitations, the European 
Society of Human Reproduction and Embryology (ESHRE) 
and the European Society for Gynaecological Endoscopy 
(ESHE) established a working group to develop a new 
updated classification system that would be more clinically 
oriented and based on anatomy. The group published their 
consensus classification of female genital tract congenital 
anomalies in 2013. The ESHRE/ESGE system sorts anoma-
lies into classes and subclasses based on increasing severity 
of anatomical deviation, from normal (U0) to unclassified 
cases (U6) (Fig. 3.2).
Use of absolute numbers to define an anomaly was dis-
carded; rather, the new system defines uterine deformity in 
relation to anatomical landmarks, for example, uterine 
wall thickness (UWT) which is defined as the distance 
between the interostial line and a parallel line on the top of 
the fundus [9].
When a MDA is suspected, US is the most commonly 
performed exam and may be diagnostic, especially if a 3D 
US is performed (Fig. 3.3). However, MRI remains the pre-
ferred imaging technique in patients where TVS is not pos-
sible due to vaginal agenesis, in patients with complex 
uterine anomalies, or in diagnostic dilemmas [9]. MRI has 
been shown in multiple studies to have excellent agreement 
with MDA subtype classifications [10].
3.4.1  Class 0 (Normal Uterus)
The normal uterus is defined as having either a straight or 
curved interostial line with an internal indentation ≤ 50% of 
the UWT at the fundal midline (Figs. 3.2, 3.3, 3.4, 3.5, 3.6, 
3.7, 3.8, 3.9, 3.10, 3.11 and 3.12).
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3.4.2  Class U1 (Dysmorphic Uterus)
This category encompasses uteri with a normal uterine out-
line that have an abnormal cavity excluding septa. U1 anom-
alies have three subtypes:
 1. U1a (T-Shaped Uterus)—narrow uterine cavity with 
thickened lateral walls with a normal corpus-to-cervix 
ratio
 2. U1b (Uterus Infantilis)—narrow uterine cavity with nor-
mal lateral walls with an abnormal corpus-to-cervix ratio
 3. U1c (Others)—all other minor deformities of the uter-
ine cavity with a midline, fundal, inner indentation 
<50% UWT
3.4.3  Class U2 (Septate Uterus) (Fig. 3.4)
This category reflects abnormal resorption of the midline 
septum following normal Müllerian duct fusion. The uterus 
has a normal outer contour, but the midline, fundal, inner 
indentation is >50% of the UWT. U2 anomalies have two 
subtypes:
 1. U2a (Partial Septate)—midline fundal inner septum 
divides the uterine cavity above the internal os.
 2. U2b (Complete Septate)—midline fundal inner septum 
divides the uterine cavity up to the internal os. There may 
be associated cervical or vaginal anomalies. Fig. 3.4. 
MRI of the pelvis: T2-weighted axial-oblique image (cor-
onal plane of the uterine cavity) demonstrates a complete 
hypointense septum through the entire length of the 
hyperintense uterine cavity.
The composition of the septum is variable and is often 
myometrial proximally and more fibrous distally [11, 12]. 
Fetal wastage is common in these women with a spontaneous 
abortion rate of 65%. Treatment reflects the makeup of the 
septum. If the septum is primarily fibrous, a hysteroscopic 
septoplasty can be performed with good results. If, however, 
the septum is primarily myometrial, a combined laparo-








a. T-shaped b. Infantilis c. Others
a. Partial b. Completea. Partial b. Complete c. Bicorporeal septate
a. With rudimentary cavity b. Without rudimentary cavitya. With rudimentary cavity b. Without rudimentary cavity
Fig. 3.2 Schematic drawing of the ESHRE/ESGE classification system of uterine congenital anomalies from Ref. [8], dividing uterine anomalies 
in six classes




Fig. 3.3 Ultrasound images of the uterus in a coronal plane of the uter-
ine cavity (modified from Ref. [9], demonstrate how to measure the 
uterine wall thickness (1) as well as the length of the internal midline 
indentation (2) for a normal uterus (a), a partial septate uterus (b), a 
complete septate uterus (c) and a bicorporal uterus (d)
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Fig. 3.4 MRI of the pelvis: T2-weighted axial-oblique image (coronal 
plane of the uterine cavity) demonstrates a complete hypointense sep-
tum through the entire length of the hyperintense uterine cavity
Fig. 3.5 MRI of the pelvis: T2-weighted coronal image through the 
coronal plane of the uterine cavity of the bicorporeal complete uterus 
with an associated double normal cervix (C2). Opacification of the 
vagina with sonographic gel helps to exclude vaginal septa
Fig. 3.6 MRI of the pelvis: T2-weighted axial image through the coro-
nal plane of a “banana”—shaped left hemi-uterus without evidence of a 
rudimentary remnant uterine horn
Fig. 3.7 MRI of the pelvis: T2-weighted coronal oblique view of the 
uterine cavity shows a type 1 submucosal leiomyoma with more than 
50% of the volume inside the uterine cavity. A second leiomyoma lies 
in close contact to the endometrium (class 3 of an intra-mural 
leiomyoma)
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3.4.4  Class U3 (Bicorporeal Uterus, syn: 
Bicornuate Uterus) (Fig. 3.5)
This category is a result of abnormal fusion of Müllerian 
ducts. The uterus will have an abnormal fundal contour with 
an external indentation at the fundal midline >50% of the 
UWT. U3 anomalies have three subtypes:
 1. U3a (Partial Bicorporeal Uterus)—external fundal inden-
tation divides the uterus above the internal os.
 2. U3b (Complete Bicorporeal Uterus)—external fundal 
indentation divides the uterus to the internal os. 
There may be associated cervical and/or vaginal 
anomalies.
 3. U3c (Bicorporeal Septate Uterus)—the width of the mid-
line inner fundal indentation >150% of the UWT.
Vaginal or hysteroscopic septoplasty is reserved for 
patients with an obstructing vaginal septum (U3b) or septate 
form of the anomaly (U3c), respectively.Fig. 3.8 MRI of the pelvis T2-weighted coronal image (axial oblique 
orientation of the uterus) with type 3, 4, 5 and 6 leiomymoma
a b
Fig. 3.9 (a) MRI of the pelvis T2-weighted sagittal image through the 
mid uterine body: a thickened junctional zone is associated with two 
cystic structures containing blood products of various ages. (b) MRI of 
the pelvis T1-weighted fat saturated sagittal image through the mid 
uterine body (same patient and level than in Fig. 3.9a): The hyperin-
tense bloody component of the myometrial cysts makes their identifica-
tion easier in T1 fat suppressed images than in T2 (Fig. 3.9a)
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3.4.5  Class U4 (Hemi-uterus) (Fig. 3.6)
This anomaly is a formation defect resulting in unilateral 
uterine development. The contralateral part ranges from 
absent to incomplete formation (uterine horn remnant). U4 
anomalies have two subtypes:
 1. U4a (Hemi-uterus with a contralateral rudimentary (func-
tional) cavity)—the contralateral horn has a functioning 
endometrial cavity that may or may not communicate 
with the hemi-uterus.
 2. U4b (Hemi-uterus without a contralateral rudimentary 
(functional) cavity)—the contralateral horn is either non-
functional or aplastic.
There is a high association with renal anomalies in these 
patients, especially renal agenesis, ipsilateral to the contra-
lateral rudimentary horn or remnant (40%). Patients with 
rudimentary horns, Class U4a, require laparoscopic surgical 
excision. This is done to prevent hematometra and/or obstet-
ric complications to include uterine rupture [14].
At imaging, the hemi-uterus is deviated to one side of the 
pelvis, and the endometrial morphology is described as “banana-” 
or “bullet-shaped.” Uterine zonal anatomy is preserved, as is the 
endometrial-to-myometrial width and ratio [11]. When present, 
a rudimentary functional horn will have normal zonal anatomy. 
If it is noncommunicating, the endometrial cavity may be dis-
tended with blood, and/or there may be imaging manifestations 
of endometriosis. In cases without a rudimentary functional 
horn, the contralateral uterine horn remnant, when present, 
images as diffuse low to intermediate signal intensity.
3.4.6  Class U5 (Aplastic Uterus)
This anomaly is a formation defect incorporating all types of 
uterine aplasia. It occurs early in gestation. Affected females 
have no unilaterally developed or fully developed uterine 
cavity. U5 anomalies have two subtypes depending on 
Fig. 3.10 Endovaginal 
ultrasound of the uterus in an 
axial orientation with Color 
Doppler shows the 
hyperechoic polyp with a 
central feeding vessel
Fig. 3.11 MRI of the pelvis Sagittal T2-weighted image of the uterus 
with a polyp located at the internal os of the endocervical channel of a 
the signal intensity that is slightly hypointense compared to the normal 
endometrium
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whether or not there is a functional cavity in a uterine rem-
nant if present:
 1. U5a (Aplastic uterus with a rudimentary (functional) 
cavity)—uni- or bilateral functional uterine horn is 
present.
 2. U5b (Aplastic uterus without rudimentary (functional) 
cavity)—full uterine aplasia or a non-cavitary uterine 
horn remnant may be present.
Cases of aplastic uterus may have coexisting defects. For 
example, the Mayer-Rokitansky-Küster-Hauser (MRKH) 
syndrome is characterized by agenesis of the vagina, cervix, 
and uterus.
Treatment for Class U5 patients with a rudimentary cavi-
tary horn is not well worked out. For patients with MRKH 
syndrome, treatment is focused on enabling sexual function 
via creation of a neovagina.
On MRI, a uni- or bilateral cavitary rudimentary horn 
is characterized by increased T2-weighted signal intensity 
in the cavity, whereas a uni- or bilateral uterine horn rem-
nant without a cavity images as diffuse low to intermedi-
ate signal intensity on T2-weighted images. For females 
with MRKH syndrome, fatty and connective tissue is seen 
in the expected location of the upper 2/3 of the vagina. No 
normal cervix or uterus is present. A truncated vagina 
may be seen between the urethra anteriorly and the rectum 
posteriorly.
3.4.7  Class U6 (Unclassified Cases)
A sixth class was established for cases of “infrequent 
anomalies, subtle changes or combined pathologies that 
could not be allocated correctly to one of the six groups,” 
Classes 0–5 [8].
3.4.8  Classification of Congenital Anomalies 
of the Cervix and the Vagina
Coexisting anomalies of the cervix are classified from C0 to 
C4 according to the presence of a normal cervix (C0), a sep-
tate cervix (C1), a double “normal” cervix (C2), and a unilat-
eral (C3) or complete cervical aplasia (C4) [8] (see Fig. 3.5). 
The classification of coexisting vaginal anomalies ranges 
from V0 (normal vagina) to V4 (vaginal aplasia) and distin-
guishes three types of vaginal septum: V1 is longitudinal 
nonobstructing, V2 longitudinal obstructing, and V3 trans-
verse septum or imperforate hymen [8].
a b
Fig. 3.12 (a) MRI of the pelvis Sagitall T2-weighted image through 
the uterine midline demonstrate a hypointense mass obliterating the 
posterior vaginal cuff and the retro-cervical region. Dark bandlike 
hypointense structures stretch towards the anterior rectal wall. (b) MRI 
of the pelvis: Corresponding axial T2-weighted image through the 
upper vaginal cuff shows lateral extension to both uterosacral ligaments 
and posterior extensions to the anterior rectal wall. Some fluid lies in 
the right para-rectal space delineating the posterior part of the normal 
distal right uterosacral ligament
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3.5  Leiomyoma (Figs. 3.7 and 3.8)
Ordinary leiomyomas, also called fibroid or myoma, repre-
sent benign smooth muscle tumors that can be nondegener-
ated or degenerated with five subcategories according to the 
type of degeneration (cystic, hemorrhagic, fatty, hyaline, or 
myxoid). The presentation at MRI shows various T2 and T1 
signal intensities according to the subcategory. Variants of 
leiomyoma are intermediate types of leiomyoma that can be 
either mitotically active, cellular, atypical, or smooth mus-
cle tumors of uncertain malignant potential (STUMP) [15]. 
There is currently no clinical or imaging characteristic to 
distinguish efficiently between ordinary leiomyoma, a very 
frequent gynecological tumor, and their intermediate vari-
ants. Leiomyosarcoma is an uncommon malignant smooth 
muscle tumor that is difficult to differentiate from ordinary 
leiomyoma.
On EVU leiomyomas classically represent as well- 
circumscribed hypoechoic masses, often associated with 
posterior shadowing due to calcification or at the interface 
with the normal myometrium. Depending on the site of 
development, leiomyomas are further subdivided into sub-
mucosal, intramural, or subserosal according to the FIGO 
classification of causes of abnormal uterine bleeding [16]. 
Submucosal fibroids can be either pedunculated (type 0) or 
of more (type 1) or less (type 2) than 50% within the cavity.
A type 3 leiomyoma contacts the endometrium. The type 
4 leiomyoma is purely intramural without contact with the 
endometrium or the serosa.
Type 5 contacts the serosa, is subserosal, and has more 
than 50% intramural, and type 6 is subserosal with less than 
50% intramural.
Type 7 is subserosal and pedunculated and type 8 other 
(e.g., cervical or broad ligament).
MRI is useful for distinguishing leiomyomas from other 
myometrial pathology and solid pelvic masses, especially in 
patients with nondiagnostic or equivocal ultrasound findings. 
The presence of feeding vessels originating in the myome-
trium further supports the uterine origin of the mass. 
However, if a mass is adjacent to the uterus and is of interme-
diate or high signal intensity relative to the myometrium on 
T2-weighted images, the differential diagnosis includes both 
degenerated leiomyoma and extrauterine tumors (benign and 
malignant). In these patients, the diagnosis of leiomyoma 
should be reserved only for cases where the uterine origin of 
the mass is firmly established. Occasionally, it may be diffi-
cult to distinguish a pedunculated subserosal leiomyoma 
from an ovarian fibroma, since both lesions may be hypoin-
tense on T2-weighted images. This distinction is likely not 
significant as the latter is rarely malignant.
The risk of development of a leiomyosarcoma increases 
with age and in black woman. The previously held view of 
rapid growth being at greater suspicion for sarcomas is no 
longer maintained as benign leiomyomas can grow rapidly 
and sarcomas slowly [17]. Although studies focusing on 
the differential diagnosis between leiomyomas and sarco-
mas introduce new criteria at MRI, surgical procedures 
have been modified because morcellation of an unsuspected 
leiomyosarcoma increases dissemination [18]. According 
to a retrospective study using MRI to differentiate 26 
benign and 25 uncertain or malignant leiomyomas, the per-
formance of MRI reached an accuracy of 92.4% using a 
combination of T2-weighted, B1000, and ADC features 
[2]. The diagnosis of malignancy could be excluded for 
leiomyomas that had either low (ordinary) or high T2 sig-
nal intensities (myxoid), as well as intermediate T2 and low 
B1000 signal intensities (cystic). For leiomyomas with 
intermediate T2 and high B1000, further characterization 
required the use of T1 signal intensities. If T1 signal inten-
sity was high, the leiomyoma had hemorrhagic or fatty 
degeneration and was benign. If T1 signal intensity was 
low or heterogeneous, ADC values obtained at B1000 at 
1.5 T were useful and only in this specific situation. A cut-
off value of 0.8 was predictive of a sarcoma, above 1.2 of a 
benign leiomyoma, and from 0.8 to 1.2 of a leiomyoma of 
uncertain malignancy.
Symptomatic leiomyoma are a burden for the women 
affected, as well as society. In the USA, symptomatic leio-
myoma remains the number one cause of hysterectomies per 
year and costs up to 34.4 billion dollars annually—reflecting 
both the direct costs of providing care to women and the 
indirect costs associated with lost work days and pregnancy- 
related issues [19]. These statistics have led to an increase in 
uterine-conserving therapies for affected women [20]. MRI 
provides a comprehensive evaluation for women who are 
potential uterine artery embolization (UAE) candidates. It 
accurately displays leiomyoma size, number, and location 
[21]. Additionally, in at least 20% of cases, MRI identifies 
autoinfarcted, comorbid, or alternative conditions that pre-
clude UAE as primary therapy [22]. Following UAE, MRI is 
able to assess treatment response and identify complications 
such as leiomyoma delivery and pyomyoma [22–25].
3.6  Adenomyosis (Fig. 3.9)
Adenomyosis is defined as ectopic endometrial cells sur-
rounded by stromal tissue within the myometrium and must 
be differentiated from leiomyoma, although these conditions 
frequently coexist. Differentiating the two entities may be 
critical because uterine-conserving therapy is established for 
leiomyomas, whereas hysterectomy remains the definitive 
treatment for debilitating adenomyosis. MRI is extremely 
accurate in making this distinction, especially in patients with 
diffuse adenomyosis with junctional zone widening >12 mm 
and foci of increased signal on T2-W sequences [26].
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The hyperintense foci correspond to the heterotopic endo-
metrial tissue. The surrounding muscular hyperplasia results 
in the low-signal myometrial lesion or widening of the junc-
tional zone.
Hemorrhagic foci can be seen on T1-weighted sequences 
in approximately 20% of patients due to the presence of pro-
gesterone receptors. However, the imaging features of focal 
adenomyosis can overlap with those of leiomyomas [26–28]. 
Imaging characteristics that favor the diagnosis of focal ade-
nomyosis include a lesion with poorly defined margins, a 
lesion that is elliptical in shape extending along the endome-
trium, a lesion that has little mass effect upon the endome-
trium relative to its size, and a lesion with high signal 
intensity striations [radiating from the endometrium into the 
myometrium]. Cystic adenomyosis needs to be differentiated 
from a leiomyoma with central hemorrhagic degeneration or 
a unicornuate uterus with an obstructed noncommunicating 
rudimentary horn.
3.7  Myometrial Contractions
Myometrial contractions can mimic leiomyoma or adenomy-
osis. They usually change or resolve over the course of the 
exam. Contractions correspond to transient low signal inten-
sity lesions within the myometrium that deform the endome-
trium while sparing the outer uterine contour. Kinematic 
sequences using a single-shot fast spin-echo T2-weighted 
technique (HASTE, SSFSE) can differentiate true widening 
related to adenomyosis from apparent widening of the junc-
tional zone due to myometrial contractions or uterine peristal-
sis, a physiologic rhythmic form of  myometrial contraction 
most marked during the menstrual and periovulatory phase 
that can present as diffuse widening of the junctional zone.
3.8  Endometrial Pathology
Endometrial polyps are among the most common pathologic 
lesions of the uterine corpus. Patients with postmenopausal 
bleeding and endometrial polyps usually undergo endome-
trial sampling and removal of the polyps. Endometrial pol-
yps have a variable appearance at EVS but are typically 
echogenic with an intact overlying endometrium or subendo-
metrial halo. A vascular pedicle is usually identified at color/
power Doppler imaging (Fig. 3.10).
Figure 3.11 MRI of the pelvis Sagittal T2-weighted 
images of the uterus: A polyp is located at the internal os of 
the endocervical canal with signal intensity that is slightly 
hypointense compared to normal endometrium.
Large polyps are frequently heterogeneous in signal 
intensity [29]. On T2-weighted sequences, the fibrous core is 
seen as a hypointense area within a polyp. The addition of 
gadolinium-enhanced sequences significantly improves the 
detection rate of endometrial polyps. Endometrial polyps 
show a variable degree of enhancement after gadolinium 
administration. Small polyps enhance early and are well 
delineated against the hypointense endometrial complex on 
early dynamic scans. In addition, a vascular stalk can fre-
quently be identified during the arterial phase.
Endometrial synechia results from traumatic injury to 
the endometrium and may be demonstrated both with EVS 
and MRI. Sonohysterography improves the detection of 
endometrial synechiae. In severe cases of Asherman’s syn-
drome resulting in an obliterated uterine cavity, synechiae 
may result in infertility, recurrent pregnancy loss, and 
amenorrhea. On EVS, synechiae present as echogenic or 
hypoechoic bands traversing the endometrial cavity. These 
bands can be thick and broad or thin and easily disrupted. 
On MRI, these bands are hypointense on T2-weighted 
sequences and usually show enhancement after gadolinium 
administration.
3.9  Benign Pathology of the Cervix 
and Vagina
Bartholin’s cysts are caused by retained secretions within the 
vulvovaginal glands, mostly as a result of chronic inflamma-
tion or trauma. They are located in the posterolateral parts of 
the lower vagina and vulva, whereas nabothian cysts are 
retention cysts of the cervical glands and clefts.
Gartner duct cysts represent remnants of the caudal end of 
the Wolffian or mesonephric ducts and are typically located 
in the anterolateral wall of the vagina above the inferior mar-
gin of the symphysis pubis.
Müllerian cysts, representing embryologic remnants of 
Müllerian (paramesonephric) ducts, are the most common 
congenital cysts of the female genital tract and can be found 
from the introitus to the level of the cornua. They are typi-
cally lined by mucinous, columnar epithelium. At the level 
of the vagina, they are most commonly located anterolater-
ally and are indistinguishable from Gartner duct cysts. The 
majority of Müllerian cysts are small and asymptomatic. 
Large, symptomatic cysts require excision.
3.10  Deep Endometriosis
Endometriosis is a common gynecological disease, defined 
by functional ectopic endometrial glands and stroma outside 
the uterus. When located elsewhere than in the ovary or on 
the superficial peritoneum, endometriosis is often referred to 
as being deep usually lying 5 mm below the peritoneum 
within the bladder, vaginal, or bowel wall. Other localiza-
tions include the area behind the cervix, the upper vaginal 
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cuff, the ureter, the round ligament, the parameter, the utero-
sacral ligaments, the presacral nerves, the anterior abdomi-
nal wall, and/or the diaphragm. According to the European 
Society of Urogenital Radiology (ESUR), guidelines for 
imaging endometriosis with MRI agreed that the diagnosis 
of deep pelvic endometriosis requires the joint presence of 
morphological and signal intensity anomalies [30]: tissue 
areas corresponding to fibrosis with a signal close to that of 
pelvic muscle on T1-weighted and T2-weighted images; 
hyperintense foci on T1-weighted and/or fat-suppressed 
T1-weighted MR images, corresponding to hemorrhagic 
foci; and small hyperintense cavities on T2-weighted images. 
Morphological anomalies depend on the localization of deep 
endometriosis. Within the frame of this chapter, only retro-
cervical, uterosacral ligaments and vaginal localization are 
specified (Fig. 3.12a, b). Retrocervical endometriosis is also 
called endometriosis of the torus uterinus and corresponds at 
MRI to a T2 hypointense band in the upper midportion of the 
posterior cervix. Endometriosis of the uterosacral ligament 
demonstrates as an irregular nodule or thickening compared 
to the normal ligament. When bilateral it usually includes the 
torus uterinus and presents as an arciform anomaly. Vaginal 
endometriosis obliterates the posterior vaginal cuff with a T2 
hypointense mass behind the posterior wall of the cervix. 
The nodule or mass may contain foci of high T2- and 
T1-weighted signal intensities. Vaginal endometriosis and 
endometriosis of the uterosacral ligaments are often associ-
ated with rectosigmoid endometriosis.
3.11  Concluding Remarks
Ultrasound is the first-line diagnostic tool for most benign 
uterine condition. MRI is an extremely useful complement in 
symptomatic patients with indeterminate or complex uterine 
presentation, particularly before surgery.
References
 1. Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal 
ultrasound to exclude endometrial cancer and other endometrial 
abnormalities. JAMA. 1998;280:1510–7.
 2. Thomassin-Naggara DS, Bonneau C, et al. How to differentiate 
benign from malignant myometrial tumors using MR imaging. Eur 
Radiol. 2013;23:2306–14.
 3. Troiano RN, McCarthy SM. Müllerian duct anomalies: imaging 
and clinical issues. Radiology. 2004;233:19–34.
 4. Behr SC, Coutier JL, Qayyum A. Imaging of Müllerian Duct 
Anomalies. Radiographics. 2012;32:1619–20.
 5. Li S, Qayyum A, Coakley FV, Hricak H. Association of renal 
agenesis and Müllerian duct anomalies. J Comput Assist Tomogr. 
2000;24:829–34.
 6. Buttram VC Jr, Gibbons WE. Müllerian anomalies: a proposed 
classification. (An analysis of 144 cases). Fertil Steril. 1979; 
32:40–6.
 7. The American Fertility Society classifications of adnexal adhe-
sions, distal tubal occlusion, tubal occlusion secondary to tubal 
ligation, tubal pregnancies, Müllerian anomalies and intrauterine 
adhesions. Fertil Steril. 1988;49:944–55.
 8. Grimbizis GF, Gordts S, Di Spiezio Sardo A, et al. The ESHRE/
ESGE consensus on the classification of female genital tract con-
genital anomalies. Hum Reprod. 2013;28:2032–44.
 9. Grimbizis GF, Di Spiezio SA, et al. The Thessaloniki ESHRE/
ESGE consensus on diagnosis of female genital anomalies. Hum 
Reprod. 2016;31(1):2–7.
 10. Mueller GC, Hussain HK, Smith YR, et al. Müllerian duct anoma-
lies: Comparison of MRI diagnosis and clinical diagnosis. AJR Am 
J Roentgenol. 2007;189:1294–302.
 11. Pellerito JS, McCarthy SM, Doyle MB, et al. Diagnosis of uter-
ine anomalies: relative accuracy of MR imaging, endovaginal 
sonography, and hysterosalpingography. Radiology. 1992;183: 
795–800.
 12. Zreik TG, Troiano RN, Ghoussoub RA, et al. Myometrial tis-
sue in uterine septa. J Am Assoc Gynecol Laparosc. 1998;5: 
155–60.
 13. Chandler TM, Machan LS, Cooperberg PL, et al. Müllerian 
duct anomalies: from diagnosis to intervention. Br J Radiol. 
2009;82:1034–42.
 14. Jayasinghe Y, Rane A, Stalewski H, Grover S. The presentation and 
early diagnosis of the rudimentary uterine horn. Obstet Gynecol. 
2005;105:1456–67.
 15. Arleo EK, Schwartz PE, Hui P, et al. Review of leiomyoma vari-
ants. AJR. 2015;205:912–21.
 16. Munro MG, Crithcley HOD, Fraser IS, for the FIGO Working 
Group on Menstrual Disorders. The FIGO classification of causes 
of abnormal uterine bleeding. Int J Gynaecol Obstet. 2011; 
113(1):1–2.
 17. Peddada SD, Laughlin SK, Miner K. Growth of uterine leiomyo-
mata among premenopausal black and white women. Proc Natl 
Acad Sci U S A. 2008;105(19):887–19,892.
 18. FDA. UPDATED Laparoscopic Uterine Power Morcellation in 
Hysterectomy and Myomectomy: FDA Safety Communication 
2014. Available at: http://www.fda.gov/MedicalDevices/Safety/
AlertsandNotices/ucm424443.htm.
 19. Cardozo ER, Clark D, Banks NK, et al. The estimated annual cost 
of uterine leiomyomata in the United States. Am J Obstet Gynecol. 
2012;206:21.e1–9.
Take-Home Message
Ultrasound is the first-line imaging technique to local-
ize an anomaly of the uterus to either the myometrium 
or the endometrium. MRI has ideal capabilities in tis-
sue characterization and requires careful comparison 
between T2- and T1-weighted sequences. Image ori-
entation perpendicular to the axis of the uterine corpus 
helps to assess the impact of an anomaly on the uterine 
cavity.
K. Kinkel et al.
33
 20. Jacobson GF, Shaber RE, Armstrong MA, Hung Y-Y. Changes 
in rates of hysterectomy and uterine conserving procedures for 
treatment of uterine leiomyoma. Am J Obstet Gynecol. 2007;196(6): 
601.e1.
 21. Jha RC, Ascher SM, Imaoka I, Spies JB. Symptomatic fibroleio-
myomata: MR imaging of the uterus before and after uterine artery 
embolization. Radiology. 2000;217:228–35.
 22. Nikolaidis PN, Siddiqi AH, Carr JC, et al. Incidence of nonviable 
leiomyomas on contrast material enhanced pelvic MR imaging 
in patients referred for uterine artery embolization. J Vasc Interv 
Radiol. 2005;16:1465–147.
 23. Kroencke TJ, Scheurig C, Poellinger A, et al. Uterine artery embo-
lization for leiomyomas: percentage of infarction predicts clinical 
outcome. Radiology. 2010;255:834–41.
 24. Kitamura Y, Ascher SM, Cooper C, et al. Imaging manifestations 
of complications associated with uterine artery embolization. 
Radiographics. 2005;25:S119–32.
 25. Radeleff B, Eiers M, Bellemann N, et al. Expulsion of dominant 
submucosal fibroids after uterine artery embolization. Eur J Radiol. 
2010;75:e57–63.
 26. Reinhold C, McCarthy S, Bret PM, et al. Diffuse adenomyosis: 
comparison of endovaginal US and MR imaging with histopatho-
logic correlation. Radiology. 1996;199:151–8.
 27. Togashi K, Ozasa H, Konishi I, et al. Enlarged uterus: differen-
tiation between adenomyosis and leiomyoma with MR imaging. 
Radiology. 1989;171:531–4.
 28. Mark AS, Hricak H, Heinrichs LW, et al. Adenomyosis and leiomyoma: 
differential diagnosis with MR imaging. Radiology. 1987;163:527–9.
 29. Grasel RP, Outwater EK, Siegelman ES, et al. Endometrial polyps: 
MR imaging features and distinction from endometrial carcinoma. 
Radiology. 2000;214:47–52.
 30. Bazot M, Bharwani N, Huchon C, et al. European society of uro-
genital radiology (ESUR) guidelines: MR imaging of pelvic endo-
metriosis. Eur Radiol. 2017;27(7):2765–75.
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.
org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropri-
ate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. 
The images or other third party material in this book are included in the book's Creative Commons license, unless indicated otherwise in a credit 
line to the material. If material is not included in the book's Creative Commons license and your intended use is not permitted by statutory regula-
tion or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
3 Benign Disease of the Uterus
35© The Author(s) 2018
J. Hodler et al. (eds.), Diseases of the Abdomen and Pelvis 2018–2021, IDKD Springer Series,  
https://doi.org/10.1007/978-3-319-75019-4_4
Therapy Monitoring of Oncologic 
Disease in the Abdomen (Including  
PET/CT)
Irene A. Burger and Regina G. H. Beets-Tan
4.1  Introduction
The importance and the volume of scans for therapy moni-
toring are steadily increasing for oncologic diseases. 
Numerous reasons account for that. Most important is the 
occurrence of an increasing number of new and more spe-
cific therapies requiring early outcome measures preceding 
first results on survival benefits. Furthermore, the specific 
therapeutic approaches concomitant with longer therapy 
windows lead to an increase in mixed response results, 
requiring reliable evaluation by imaging approaches.
Therefore, an increasing need emerged, and focus has 
been put on how to best evaluate such early onset of thera-
peutic efficacy. In this chapter we will provide a brief over-
view on the most commonly used imaging modalities, their 
benefits and their pitfalls focusing on the evaluation of 
 therapeutic efficacy with CT, MRI, and molecular imaging 
(PET/CT) of several abdominal tumors such as GIST, neuro-
endocrine tumors, and metastatic prostate cancer.
Furthermore, the increase of neoadjuvant therapy for 
high-risk tumors significantly improved outcome in various 
tumor entities. Here imaging is essential not only for overall 
response assessment but also to determine resectability. 
Therefore we will address the importance of endorectal 
ultrasonography (ERUS) and MRI in locally advanced rectal 
tumors treated with neoadjuvant (chemo)radiotherapy.
4.2  Assessment of Local Response 
to Neoadjuvant Treatment in Rectal 
Cancer
The local recurrence rate after rectal cancer surgery has sig-
nificantly decreased from 40% three decades ago to 3% with 
current multimodality imaging and therapy. Three major 
steps have been taken forward: the introduction of the total 
mesorectal excision (TME) surgery, preoperative radiother-
apy with or without chemotherapy, and imaging. The risk fac-
tors associated with local recurrence are the T stage, N stage, 
distance of the tumor to the mesorectal fascia, extramural vas-
cular invasion, perineural invasion, lymph vessel invasion, 
and histological grade. Rectal cancer patients are now treated 
according to their risk for local recurrence with a differenti-
ated treatment—immediate TME surgery for the low-risk 
tumors and preoperative neoadjuvant chemoradiotherapy for 
the very high risks. The decisions on preoperative treatment 
are based on risk assessment not only by digital rectal exami-
nation and endoscopy but also by imaging. Endorectal ultra-
sonography (ERUS) and MRI are considered as the two best 
locoregional imaging methods to assess the risk factors at 
primary staging and to evaluate local response to neoadjuvant 
treatment, while CT is restricted to distant staging. Here we’ll 
focus on local response evaluation with MR and ERUS.
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• To understand the opportunities and limitations of 
the different modalities for therapy monitoring 
based on anatomical and physiological imaging
• To know the pearls and pitfalls in therapy monitor-
ing of gastrointestinal stromal tumors, neuroendo-
crine tumors, and metastasized prostate cancer
• To learn about the evidence, pearls, and pitfalls of 
imaging for the local assessment of response to neo-
adjuvant (chemo)radiotherapy in locally advanced 
rectal tumors
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4.2.1  Selection of Patients for Neoadjuvant 
Therapy
The importance of the involvement of the mesorectal fascia as 
a prognostic factor and as a parameter of surgical quality has 
been recognized and confirmed in the last 30 years [1]. The 
ideal plane of resection in a total mesorectal excision is just 
outside the mesorectal fascia, and a positive circumferential 
resection margin can be the result of inadequate TME surgery. 
Preoperative assessment of involvement of the mesorectal fas-
cia is crucial. An involved mesorectal fascia can be reliably 
determined on MRI and is defined as a closest distance of 
≤1 mm between the tumor and the mesorectal fascia. These 
tumors should be treated with a preoperative (chemo)radiation 
regimen providing an opportunity for downsizing. Regardless 
of the choice for neoadjuvant treatment strategies, it is however 
important for the surgeon to know the exact anatomical relation 
of the tumor to the mesorectal fascia and the surrounding struc-
tures in order to obtain a complete resection, and MRI can pro-
vide this information. A number of studies in the past decades 
demonstrated that MRI could reliably identify the mesorectal 
fascia and predict its involvement [2, 3]. In a European multi-
center study, the depth of extramural tumor invasion was com-
pared between preoperative MRI and histology in 311 patients 
undergoing primary surgery; accuracy to within 0.5 mm was 
achieved in 95% of cases [4]. It is now widely adopted that 
MRI is the most accurate method for the assessment of an 
involved or threatened mesorectal fascia (Fig. 4.1).
a b
c d
Fig. 4.1 cT2N2 low rectal tumor before neoadjuvant chemoradiother-
apy. Endoscopy shows a sessile semicircular mass anteriorly located 
just above the anal canal (a–d). T2-weighted MRI shows a semicircular 
tumor low anterior which is limited to the bowel wall. There is a suspi-
cious large node in the mesorectum, visualized on the sagittal 
T2-weighted MR image. DWI (b1000) image confirms a rectal cancer 
with a restricted diffusion
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4.2.2  Assessment of Local Tumor Response 
and Resectability
Assessment of local tumor response is generally per-
formed by digital rectal examination, endoscopy, and 
MRI 6–8 weeks after completion of neoadjuvant chemo-
radiotherapy [5]. MRI can indicate tumor volume shrink-
age. Reported negative predictive values (NPVs) as high 
as 90% for the detection of an involved mesorectal fascia 
suggest that MRI can accurately identify clearance of an 
initially suspicious invaded mesorectal resection margin. 
The high NPV is at the expense of a PPV as low as 50%. 
As a result of the irradiation, the initial tumor mass often 
becomes fibrotic, and it may be very difficult to distinguish 
on T2-weighted MRI between fibrosis with and without 
minimal residual tumor. This holds true also for fibrotic 
masses adjacent to the mesorectal fascia, the reason why in 
such a setting one should be cautious to overcall persistent 
involvement of a mesorectal fascia after chemoradiother-
apy (Fig. 4.2) [6, 7].
Restaging MRI can therefore be valuable as a road map 
for surgeons and to decide whether tumor regression visual-
ized on MRI justifies alteration of the initial resection plan. 
The obvious prerequisite for the value of a restaging MRI is 
that both the surgeon and the patient must be willing to 
change the initial plan.
4.2.3  Assessment of Complete Response 
After Chemoradiotherapy
Rectal cancer patients with clinical complete or near 
complete response after chemoradiotherapy have shown 
to have a good oncological outcome with a nonopera-
tive management with survival figures as good as when 
these patients would have undergone a resection. This 
treatment shows an improved functional outcome without 
compromising oncological outcome. Habr-Gama et al. 
and the group of Beets et al. were pioneers of these so-
called watch and wait policy [8, 9]. Today more and more 
patients with clinical complete response are considered a 
watch and wait policy.
A watch and wait treatment for the clinical complete or 
near complete responders requires accurate assessment of 
response to chemoradiotherapy and accurate monitoring of 
response. Although this is generally done by digital rectal 
examination, imaging has shown its benefit. The two impor-
tant questions are whether there is still a significant volume 
of residual tumor within the fibrotic tumor bed and whether 
there are still involved nodes after CRT. When it comes to 
primary T staging, MRI is the preferred staging method for 
large advanced tumors, while ERUS remains the best 
method to image the superficial tumors limited to the sub-
mucosa (T1) [10].
a b
Fig. 4.2 T2-weighted MRI of a locally advanced rectal tumor before 
(a) and after (b) neoadjuvant chemoradiotherapy. The tumor located in 
the mid-high rectum anteriorly invades the peritoneal reflection and 
shows a mass effect. It can often be difficult to know whether the tumor 
is invading in or only pushing the bladder wall and dome. After chemo-
radiotherapy the tumor has significantly shrunk and for a large propor-
tion becomes fibrotic. Anteriorly it has retracted from the bladder dome 
but not from the peritoneal reflection, and there is a fibrotically thick-
ened peritoneal reflection. The surgeon should be notified of this find-
ing so that he can perform a wider excision including the peritoneal 
reflection
4 Therapy Monitoring of Oncologic Disease in the Abdomen (Including PET/CT)
38
Nevertheless, for assessment of the ypT stage of rectal 
tumors after neoadjuvant treatment, MRI does not outperform 
ERUS. A meta-analysis of over 1500 patients reported a disap-
pointingly low overall performance with a pooled overall sen-
sitivity of 50% and specificity of 91% [11]. Subgroup analyses 
showed a pooled sensitivity of only 19% and specificity of 94% 
for the MRI assessment of pathological complete response 
(ypT0). Although the performance of MRI for assessment of 
small tumor remnants limited to the bowel wall (ypT0–2) is 
higher, the sensitivity of 55% remains insufficient for clinical 
decision-making. The findings above suggest that both ERUS 
and MRI are limited in the detection of small tumor remnants 
within fibrotic tissue after neoadjuvant chemoradiotherapy of 
rectal cancer. Some authors have shown that the combination 
of visual assessment of morphological features on post-chemo-
radiotherapy MRI with objective assessment of tumor shrink-
age by magnetic resonance volumetric measurements can yield 
accuracies as high as 87% [12, 13]. Curvo-Semedo et al. and 
Ha et al. found AUCs (areas under the ROC curve) of 0.70–0.84 
for the assessment of pathological complete response with 
magnetic resonance volumetric measurements by manual 
delineation of tumors [14]. This is very time-consuming and 
thus not a standard practice. Many studies have reported the 
benefit of diffusion- weighted MRI (DW-MRI) for the detection 
of residual disease within the fibrotic scar. A meta-analysis has 
shown that DW-MRI can improve the diagnostic performance 
of restaging MRI for the assessment of a pathological complete 
response with an increase in sensitivity from 19% to 84% [11]. 
A multicenter retrospective study in 120 patients with rectal 
cancer reported a high NPV of 90% for DW-MRI for the 
assessment of a pathological complete response, indicating that 
the visual analysis of DW-MRI is especially valuable for the 
detection of residual tumor and for ruling out a complete 
response [15]. Visual analysis of DW-MRI (at b800 or b1000) 
is now recommended in international clinical guidelines as a 
valuable adjunct to digital rectal exam and endoscopy. Patients 
assessed as (near) complete response with these tools can be 
safely considered for a watch and wait treatment [5]. Figure 4.3 
shows the typical DW-MR and endoscopic image of a clinical 
complete response.
Overall, there is little evidence concerning restaging with 
ERUS after neoadjuvant treatment. In a study by Mezzi et al. 
and Napoleon et al., ERUS after neoadjuvant treatment was 
only accurate in 47% and 46% of patients, respectively. 
Fibrotic, necrotic, and inflammatory changes after preopera-
tive radiotherapy can lead to misinterpretation of ERUS 
images [16, 17]. Radovanovic et al. found a good accuracy 
rate for restaging rectal cancer after neoadjuvant 
 chemoradiation (75%) [18]. However, ERUS was insufficient 
in discriminating a complete pathological response, in fact the 
only key factor of importance in clinical decision-making, as 
described by the groups of Habr-Gama and Beets [8, 9]. The 
largest study, by Pastor et al., reported an accuracy of only 
47% for the ERUS assessment of complete response. 53% of 
tumors identified as yT0 by ERUS were understaged [19].
4.2.4  Assessment of Response for Nodal 
Disease
Node-positive disease is one of the most important risk fac-
tors for both local and distant recurrence and is generally 
considered an indication for neoadjuvant therapy. Identifying 
mesorectal nodal disease with any imaging technique 
remains difficult because size criteria used on its own result 
in only a moderate accuracy. The majority of mesorectal- 
involved nodes are smaller than 5 mm resulting in inaccura-
cies when size is used as a cutoff for nodal disease. 
Meta-analyses showed no significant differences between 
the three modalities, EUS, CT, or MRI, which were all asso-
ciated with sensitivities for primary staging around 60–70% 
[20]. Because the majority of mesorectal nodes disappear or 
shrink after chemoradiotherapy, restaging nodes after CRT 
can be more accurate with known improved sensitivities 
around 70–75%. Nevertheless, assessment of nodal involve-
ment in rectal cancer in general remains a challenging task 
for any imaging method, and at the moment of writing, this 
problem has not been solved.
4.3  Assessment of Response for Systemic 
Disease
The World Health Organization (WHO) recognized the need 
for standardized criteria across clinical trials very early, pub-
lishing the initial WHO handbook for reporting results of 
cancer treatment in 1979 [21]. Since then a number of guide-
lines and updates have been published.
4.3.1  Response Based on Morphology 
for Chemotherapy
The most commonly applied response criteria for systemic 
disease are Response Evaluation Criteria in Solid Tumors 
(RECIST) that have been updated to RECIST 1.1 [22]. Based 
on the changes of target and nontarget lesions, patients are 
categorized into four groups: complete response (CR), par-
tial response (PR), stable disease (SD), and progressive dis-
ease (PD). To simplify readouts only five target lesions (TL), 
maximum of two in the same organ, shall be assessed by the 
maximum diameter. Lymph nodes are measured by the short 
axis and need to be larger than 1.5 cm to be considered as 
target lesions. Sclerotic bone lesions are considered nontar-
get lesions (NTL), as well as cystic lesions, if they do not 
have large solid components. The sum of all diameters from 
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TLs needs to decrease more than 30% to be considered as a 
partial response or increase by 20% (more than 5 mm) to 
indicate progressive disease.
Response RECIST 1.1
PD Increase of TL diameters by ≥20% (with at least an 
increase of 5 mm), progressive NTL, new lesions
SD No PR or PD
PR Decrease of TL diameters by ≥30%, no new lesions
CR Disappearance of all extranodal TLs, all LN < 1 cm, no 
progressive NTL, normalization of tumor marker
4.3.2  Response Based on Morphology 
for Immunotherapy
Classical chemotherapies directly kill tumor cells lead-
ing to shrinkage of tumor volume based on the efficacy 
of the therapy. Immunotherapies activate the immune sys-
tem of the patient with different response patterns depend-
ing on the mechanism of drug action [23]. Summarized 
morphologic response based on immunotherapy will often 
need more time compared to conventional therapies, and 




Fig. 4.3 DW-MRI and endoscopy of a clinical complete response after 
neoadjuvant chemoradiotherapy. Endoscopy shows complete regres-
sion of the in Fig. 4.1 visualized tumor with only a white scar tissue 
with telangiectasia at the irradiated tumor bed (a–d). T2-weighted MRI 
shows a minimal fibrotic wall anteriorly without any distortion of the 
wall anatomy. DWI (b1000) image shows no restricted diffusion in the 
tumor bed. On the sagittal T2-weighted MR image, the initially suspi-
cious node has decreased in size and shows no suspicious features of 
malignancy. The patient was successfully treated and closely monitored 
within a watch and wait regimen. Ten years in follow-up still alive with-
out recurrent disease
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(1) immediate response, (2) durable stable disease, (3) 
response after initial increase (flare), and (4) response with 
new lesions.
For accurate interpretation of the response pattern, under-
standing of the drug mechanism is crucial. Therapeutics 
leading to an increasing migration of T cells into the tumor 
(CTLA-4 blocking, e.g., ipilimumab) will be more likely to 
have an initial increase in tumor size [24]. iRECIST is based 
on RECIST 1.1 to select TL and NTL; if however PD is seen 
on first follow-up, this is interpreted as iUPD (unconfirmed 
progressive disease); only if tumor increase of more than 
30% is confirmed on the second follow-up (4–8 weeks later), 
a confirmed progression iCPD will be noted. If the tumor 
remains stable, iUPD will remain the interpretation, and only 
if criteria for partial or complete response are met, iPR or 
iCR will be given [23].
Besides accurate interpretation of early pseudoprogres-
sion, the recognition of immune-related response (irR) is 
crucial as well. Inflammatory changes can result in acti-
vation of sarcoidosis with enlarged lymph nodes or adre-
nalitis with enlarged suprarenal glands. This is not only 
challenging for morphologic imaging but also for PET/
CT since irR can show intensive 18F–fluorodeoxyglucose 
(FDG) uptake [25]. Immunotherapies are already a clini-
cally established option for patients with melanoma or 
lung cancer. However, more indications also for abdomi-
nal diseases will follow soon, such as prostate cancer (sip-
uleucel-T), kidney cancer (nivolumab), or bladder cancer 
(pembrolizumab).
4.3.3  Response Based on FDG PET
Numerous publications showed a good correlation between 
the decrease in FDG accumulation in tumor lesions and 
therapy response [26]. Therefore, PET response evalua-
tion was postulated, including EORTC PET response rec-
ommendations (1999) and the PET response criteria in 
solid tumors (PERCIST) pioneered by Wahl et al. in 2009 
[27]. Both methods follow the model of RECIST with four 
adapted response categories: complete metabolic response 
(CMR), partial metabolic response (PMR), stable metabolic 
disease (SMD), and progressive metabolic disease (PMD). 
Numerous studies compared the original EORTC PET cri-
teria with PERCIST in the past 8 years showing similar 
results. However, the use of PERCIST seems preferable 
for clinical trials due to a better standardization [28]. Both 
methods recommend the use of standardized uptake values 
(SUV) normalized to the lean body mass (SUL). However, 
if possible PERCIST favors the use of a SULpeak (average 
value in the hottest 1 cm3 sphere within the tumor), instead 
of SULmax (only one maximum voxel) to reduce the intrinsic 
variability.
Response PERCIST—Based on SULpeak (SULmax)
PMD SUL increase by at least 30% and at least 0.8 SUL 
units of the target lesion or increase in target lesion size 
by 30% or development of at least one new lesion or 
unequivocal progression of nontarget lesions
SMD Increase or decrease of SUL by less than 30%
PMR Decrease of SUL by ≥30% and at least 0.8 SUL unit 
difference and no new FDG-avid lesions and no increase 
in size >30% of the target lesion and no increase in SUL 
or size of nontarget lesion
CMR FDG uptake indistinguishable from surrounding 
background and SUL less than the liver
It is important to note that all these recommendations are 
focusing on FDG PET for the evaluation of metabolic 
response of solid tumors. Tumor dedifferentiation does not 
correlate with receptor expression in the same way like 
FDG. Therefore, PERCIST per se is not necessarily appli-
cable for the increasing use of receptor imaging in oncologic 
diseases, e.g., somatostatin receptor II (SSTR II) for neuro-
endocrine tumors or prostate-specific membrane antigen 
(PSMA) for prostate cancer.
4.4  Monitoring GIST Molecular Targeted 
Systemic Therapy
4.4.1  Monitoring GIST with CT/MRI
With the introduction of tyrosine kinase inhibitors imatinib 
mesylate (Glivec®) in 2002 for gastrointestinal stromal 
tumors (GIST), a new area of molecular-targeted systemic 
therapy began, followed by a variety of targeted agents for 
various indications [29, 30]. Those new therapeutic 
approaches result in new patterns regarding response assess-
ment, with the classical reduction in tumor size assessed by 
RECIST criteria often being detected weeks to months later 
[31]. Classical response patterns that can be observed in liver 
metastasis include appearance of new lesions, increase in 
size with decrease in attenuation, increase in attenuation 
(internal hemorrhage), and temporal changes. These patterns 
can be explained by the primary effect on tumor vascularity 
leading to hypoenhancement and therefore pseudoprogres-
sion on contrast-enhanced CT scans in the classical portove-
nous phase, with combination of intratumoral edema and 
internal hemorrhages [32]. To integrate these observations 
into clinical response assessment, Choi et al. suggested that 
either a decrease in size by 10% (largest diameter) or a 
decrease in attenuation by 15% on portovenous contrast- 
enhanced CT should be rated as response [33]. More recent 
approaches for optimal response assessment for GIST 
included the use of dual-energy CT, with calculation of 
iodine-related attenuation as a superior predictor for response 
compared to simple density used for the Choi criteria [34]. 
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MRI can be used in undetermined cases to detect intratu-
moral hemorrhage and to assess vascularity of the lesions. 
Furthermore Tang et al. showed that an increase in ADC val-
ues after 1 week of therapy is associated with good treatment 
response [35]. Both methods dual-energy CT and MRI have 
not been clinically validated to date.
4.4.2  Monitoring GIST with PET
In the first safety and efficacy report on imatinib (2001) 
including 40 patients, the use of FDG PET was documented 
for a subgroup of 17 patients, where the decrease in FDG 
uptake correlated well with the outcome and preceded CT 
findings according to RECIST criteria [29] (Fig. 4.4). This 
led to numerous studies integrating FDG for response assess-
ment with variable cutoff values to indicate response. 
Therefore, the ESMO Clinical Practice Guidelines for GIST 
suggest the use of FDG PET/CT for early detection of tumor 
response under targeted therapy [36]. Choi et al. used modi-
fied EORTC criteria of a decrease in SUVmax of more than 
70% or an absolute value of SUVmax < 2.5 as a cutoff [33]. 
Holdsworth et al. investigated optimal cutoffs for FDG PET 
based on 63 patients using ROC analysis and suggested a 
decrease of SUVmax of more than 40% or an absolute value of 
SUVmax < 3.4 outperformed EORTC criteria in their cohort 
[37]. Nevertheless, the most commonly used cutoff for new 
drug trials is still EORTC criteria with a decrease of >25% of 
SUVmax indicating partial response [38]. Recently published 
data from the Dutch GIST registry on the impact of FDG 
PET displayed a changed patient management in 27% of 
GIST patients, due to a lack of metabolic response. 
Furthermore, the registry data showed that especially patients 
without KIT exon 11 mutations had limited response to tyro-
sine kinase inhibitors, with a change in management based 
on FDG PET in 52% of these patients [39].
4.5  Monitoring Liver Disease After SIRT
Selective internal radiotherapy (SIRT) using yttrium-90 
(90Y) resins or glass microspheres is an increasingly used 
palliative therapy option for patients with non-resectable pri-
mary liver tumors or metastatic hepatic disease. Clinical 
evaluation of patients prior to SIRT includes contrast- 
enhanced CT of the chest and the abdomen to rule out exten-
sive extrahepatic disease, liver MRI to assess tumor burden, 
and selective angiography to evaluate vascular anatomy and 
hepatic shunt with technetium-99m labeled aggregated mac-
roalbumin (99mTc-MAA) [40].
a b c d
Fig. 4.4 MIP FDG PET and fused axial FDG PET/CT images of two 
patients with highly avid GIST tumors. The first patient presented with 
metastatic small bowel GIST (a) and showed subtotal response after 
4 weeks of therapy with imatinib (b), with only minimal decrease in 
size. For the second patient with extensive pleural GIST manifestation 
(c), follow-up PET after 4 weeks showed no response to neoadjuvant 
imatinib (d), followed by immediate surgical resection
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4.5.1  Monitoring SIRT with CT/MRI
Early response assessment after SIRT using anatomical imaging 
can be limited due to delayed reduction in tumor size and initial 
pseudoprogression due to edema and sharper demarcation of 
tumor boundaries on conventional imaging (Fig. 4.5). Early 
investigations with serial contrast enhanced CT (ceCT) images 
showed a maximum decrease in tumor size at 3–21 months 
(median 12 months), concluding that blood tumor markers (e.g., 
CEA for colorectal metastasis) were superior in therapy 
response assessment compared to contrast-enhanced CT [41].
The calculation of arterial perfusion (AP) using dynamic 
contrast-enhanced CT prior to SIRT was the best predictor 
for good treatment response and overall survival in patients 
[42]. Furthermore, follow-up perfusion CT showed a signifi-
cant decrease of AP in hepatic metastasis 4 weeks after SIRT 
in patients with long-term response, compared to nonre-
sponders [43]. Dual-energy CT is a new technology, allow-
ing the creation of iodine maps as promising tools to evaluate 
and quantify tumor viability, utilizing iodine maps measur-
ing the amount of iodine per lesion. Although this approach 
requires validation and standardization, it showed promising 
first results for hepatic radiofrequency ablation [44] and 
could also be a promising tool for SIRT therapy response 
assessment.
Functional MRI was suggested to be used to assess 
response to SIRT, as well. A post-therapeutic increase in 
ADCmin of more than 22%, 4 weeks after SIRT, was signifi-
cantly associated with a superior overall survival (18 vs. 
5 months, p < 0.001), while tumor size did not show any 
significant decrease after 4 weeks [45].
4.5.2  Monitoring SIRT with PET
Early on FDG PET was used to assess the reduction of 
hepatic metastatic load after SIRT [46]. Studies comparing 
response assessment between FDG PET/CT and ceCT gen-
Fig. 4.5 Axial post-contrast MRI before and 2, 6, and 12 months after SIRT therapy, showing the long-standing pseudoprogression over 6 months, 
with improved delineation of metastases on the first scan after SIRT and final partial morphologic response after 12 months
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erally show a higher predictive value for FDG PET com-
pared to ceCT [47], as published, e.g., in a review article in 
2014, where PET/CT revealed superiority over ceCT using 
RECIST for early response assessment [48]. Other groups 
investigated the PET-based volume metrics such as the 
metabolic tumor volume (MTV) or the total lesion glycoly-
sis (TLG) rate and came to the conclusion that those param-
eters correlate better with outcome compared to plain tumor 
size or SUVmax [49] measured in the PET scan. For accurate 
response assessment with FDG PET, potential pitfalls have 
to be considered. The two most prominent limitations are 
false-negative results caused by partial volume effects in 
small lesions (<1 cm) or diabetes and false-positive results 
caused by abscess formation or inflammatory changes [50]. 
A combination of FDG PET/CT with ceCT can reduce 
these limita-tions.
Despite the fact that earlier prediction of response to 
SIRT with FDG PET is possible, there is no established 
clinical role for FDG PET in assessing tumor response after 
SIRT. This might be attributable to a lack of additional treat-
ment options. Therefore, early knowledge of a limited 
response to this palliative therapy will change treatment 
only in very few cases. Nevertheless, it is crucial to know 
the potential limitations and possibilities of the various 
imaging modalities to prevent false interpretation of early 
morphologic changes for accurate judgment of therapeutic 
response.
4.6  Monitoring Neuroendocrine Tumors
Well-differentiated neuroendocrine tumors (NET) are slow- 
growing lesions and therefore usually assessed with contrast- 
enhanced CT scans for staging and detection of progression. 
New therapeutic approaches such as the combination of 
everolimus with octreotide long-acting repeatable are sys-
tematically assessed based on progression-free survival 
according to RECIST and chromogranin A blood values 
[51]. Also the recently published NETTER-1 trial investi-
gated the efficacy of peptide-based systemic radiotherapy 
(SRT) with 177Lu-Dotatate based on conventional imaging. 
Tumor progression was defined as a primary endpoint docu-
mented with either CT or MRI. The secondary endpoint was 
overall survival. An increase of progression-free survival 
from 10.8% in the control group to 65.2% in the 177Lu-Dotatate 
group was observed after 20 months. On interim analysis of 
survival, the estimated risk of death was 60% lower in the 
177Lu-Dotatate group than in the control group [52].
Similar to SIRT and targeted therapies, the morphologic 
response lags behind physiologic changes and pseudopro-
gression due to edema, and improved tumor delineation of 
liver lesions can be observed. This is crucial, since progres-
sion under therapy is a potential reason to stop current treat-
ment according to the European Neuroendocrine Tumor 
Society (ENETS) consensus guidelines. Therefore, a har-
monization and combination of anatomical and molecular 
imaging as well as biomarkers was suggested for monitor-
ing SRT [53]. No standardized procedures have been estab-
lished yet on how to interpret molecular imaging (e.g., 
68Ga-DOTATATE PET/CT) results after SRT. Only one pub-
lication summarizing results of 33 patients undergoing early 
therapy response assessment with 68Ga-DOTATATE after 
1 cycle of SRT was published so far. They came to the con-
clusion that a decrease of the tumor to spleen ratio (SUVT/S) 
correlated well with progression-free survival (p = 0.002), 
while a decrease in SUVmax did not reach significance [54] 
(Fig. 4.6).
4.7  Monitoring Metastasized Prostate 
Cancer (I)
4.7.1  Conventional Monitoring 
of Metastasized Prostate Cancer 
with CT and Bone Scans
Imaging response assessment for prostate cancer is notori-
ously difficult on anatomical imaging and therefore plays 
only a secondary role for treatment evaluation in new 
drug trials that commonly focus on survival and PSA val-
ues instead [55, 56]. For the trials investigating efficacy 
of abiraterone and alpharadin (223Ra), progressive disease 
was defined as an increase in PSA values or a morphologic 
progression according to RECIST (lymph nodes (> 2 cm) 
or visceral metastasis selected as target lesions; progres-
sion defined as an increase of >20% of target lesions or 
two or more new lesions on bone scans not consistent with 
tumor flare). Bone scans were included since around 68% 
of prostate cancer patients will develop bone metastasis, 
and most of these lesions are unmeasurable disease accord-
ing to RECIST [57]. It is well established that bone scans 
have a higher sensitivity for bone metastasis compared to 
CT. However, healing bone metastases will initially react 
with increasing mineralization and therefore also with an 
increase in activity on 99mTc-bone scans or 18F–flouride 
PET/CT the so-called tumor flare. This typically lasts for 
3 months after therapy but can be seen as late as 6 months 
after treatment [57]. Therefore, 99mTc-bone scans and 18F–
flouride PET/CT alone are both limited for response assess-
ment in prostate cancer patients. To still be able to include 
bone lesions for response assessment, bone-specific 
response criteria were suggested by MD Anderson incor-
porating CT and MRI information indicative for response 
(e.g., sclerotic fill- in or rim of lytic lesions) together with a 
decrease of tracer uptake on bone scans to improved evalu-
ation of bone lesions [58] (Fig. 4.7).
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a b
Fig. 4.6 68Ga-DOTATATE MIP images of a patient before (a) and 12 months after (b) SRT with 177Lu-Dotatate. With excellent response of most 
of the bone metastasis to therapy, without significant changes on CT
a b
Fig. 4.7 Sagittal CT and PET/CTs of bone metastasis before (a) and after (b) chemotherapy showing increasing and new sclerotic lesions with a 
complete decrease on FDG PET consistent with good metabolic response
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4.7.2  Monitoring Metastasized Prostate 
Cancer with MRI and PET/CT
The use of FDG PET/CT is very limited in prostate cancer 
patients since only a small subgroup of highly dedifferentiated 
tumors will have increased glucose uptake. With improvements 
in technology, the use of diffusion-weighted imaging (DWI) 
became feasible not only for small areas but for whole-body 
exams. First preliminary results showed that ADC values could 
not differentiate between responders and nonresponders in 
patients undergoing chemotherapy [59]. However, this technol-
ogy is still in its infancy, and other groups showed a good cor-
relation between decrease in PSA and increase in ADC values 
for patients under antiandrogen therapy [60]. Assessment of 
nodal, visceral, and osseous metastasis with one exam is pos-
sible with 18F- or 11C–choline or 68Ga-prostate-specific mem-
brane antigen (PSMA) PET/CT. A good correlation between 
apoptosis and decrease in SUV on 11C–choline PET/CT scans 
was shown after neoadjuvant docetaxel chemotherapy and 
complete androgen blockade in locally advanced prostate can-
cer patients [61]. The prospective use of choline PET/CT for 
response assessment of standardized docetaxel first-line che-
motherapy on the other hand showed no correlation between 
changes in choline uptake and clinical assessments of progres-
sion based on RECIST 1.1 and PSA values [62].
There is a fast-increasing use of 68Ga-PSMA PET/CT for 
early biochemical recurrence detection in prostate cancer 
patients. The clinical utility of 68Ga-PSMA PET for treat-
ment response is not established (Fig. 4.8). First investiga-
tions showed promising results using 68Ga-PSMA PET to 
evaluate 223Ra therapy response [63]. The use of 68Ga-PSMA 
PET for response assessment to androgen deprivation ther-
apy (ADT) will need careful prospective evaluation, since 
preliminary in vitro results showed that ADT is increasing 
the cellular expression of PSMA; therefore, a novel “tumor 
flare” might be observed in these patients [64].
a b
Fig. 4.8 68Ga-PSMA PET before (a) and after (b) two cycles of 177Lu-PSMA therapy with heterogeneous response: significant reduction in PSMA 
expression and size in all lymph node metastasis; however increase in PSMA expression and size of the bone metastasis
Take-Home Messages
• After neoadjuvant therapy, rectal cancer resectabil-
ity is essential for treatment planning. Restaging 
MRI shows tumor regression and clearance of the 
mesorectal fascia. If nonoperative management is 
considered in very good responders, diffusion-
weighted MRI combined with digital rectal exami-
nation and endoscopy accurately assesses clinical 
complete response.
• Systemic therapy response assessment with imag-
ing is generally based on morphology. However, 
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5.1  Biliary Tract
Jeong Min Lee, M.D.
5.1.1  Congenital Biliary Anomalies
5.1.1.1  Choledochal Cyst
Choledochal cyst involves congenital cystic dilatation of any 
portion of the extrahepatic bile ducts, and most choledochal 
cysts are diagnosed in childhood; however, up to 20% of 
cysts manifest in adults. It is classified based on the spectrum 
of morphologic changes in the bile ducts. The most common 
classification scheme is the Todani modification of the 
Alonso-Lej classification.
Todani type I—single cystic dilatation of the extrahepatic 
bile duct (EBD).
Todani Type II—true diverticula of the EBD.
Todani Type III—choledochocele or ectasia of an intramural 
EBD segment.
Todani Type IV—multiple and can have both intrahepatic 
and extrahepatic components.
Todani Type V (Caroli disease)—cystic dilatation of the 
intrahepatic bile ducts (IBDs).
Complications of choledochal cysts in adults include rup-
ture with bile peritonitis, stone formation, cholangitis, liver 
abscess, and cholangiocarcinoma (CC). CC arising in a cho-
ledochal cysts appears as an intracystic soft tissue density 
mass or irregular thickening of the cyst wall [1].
5.1.2  Choledocholithiasis
Regardless of whether bile duct dilatation is present, the visible 
ducts should be scrutinized to identify and characterize filling 
defects, the vast majority of which represent stones [2]. 
Detectability of a bile duct stone on CT depends on the calcium 
content and requires precontrast CT. Depending on the compo-
sition, stones may show soft tissue attenuation, near-water 
attenuation, or fat attenuation with peripheral calcification. 
Stones are manifested as a signal void on T2-weighted imaging 
or MRCP (Fig. 5.1). On T1-weighted imaging, cholesterol 
stones are generally iso- or hypointense, while pigment stones 
are hyperintense due to the presence of metal ions. ERCP is 
highly accurate for the detection of small choledocholithiasis 
and also provides access for therapeutic intervention.
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Learning Objectives
• To discuss typical imaging features of common 
cholangiopathies.
• To discuss the imaging diagnosis of premalignant 
tumors of the gallbladder and bile duct.
• To explain the classical and emerging classification 
systems of cholangiocarcinoma.
• To discuss the strengths and weaknesses of imaging 
modalities and the role of multimodality and multi-
parametric approaches in the diagnostic work-up of 
biliary malignancies.
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5.1.3  Inflammatory Disorders (Cholangitis)
5.1.3.1  Suppurative Cholangitis
Acute bacterial cholangitis is a potentially life-threatening 
infection, usually arising in the setting of bile duct 
 obstruction, with ensuing bacterial contamination, stagnant 
bile, and increased biliary pressures. Choledocholithiasis 
accounts for up to 80% of cases of acute cholangitis 
(Fig. 5.2). CT or MRI shows diffuse, concentric wall thick-
ening of the bile duct with associated periductal edema and 
mural enhancement, with or without pneumobilia [3]. 
Marked inhomogeneous parenchymal enhancement in the 
arterial is frequently present in patients with acute suppura-
tive cholangitis [4].
5.1.3.2  Recurrent Pyogenic Cholangitis
Recurrent pyogenic cholangitis is characterized by steno-
sis or strictures of the peripheral ducts, with decreased 
branching and abrupt tapering (“arrowhead appearance”) 
associated with disproportionate dilatation of the central 
and extrahepatic bile ducts [5]. Sonography, CT, and 
MRCP not only allow the correct diagnosis to be made but 
also serve as a vital road map for subsequent intervention 
by illustrating the location and extent of disease [6]. 
MRCP findings of RPC include IBD or EBD stones, mul-
tiple strictures of IBD, short-segment focal EBD stricture, 
localized dilatation of lobar or segmental bile ducts with a 
predilection for the lateral segment of the left lobe and the 
posterior segment of the right lobe, bile duct wall thicken-
ing, abrupt tapering, and decreased arborization of the 
IBDs [7]. CC associated with RPC most frequently occurs 
in segments with a high stone burden or at atrophied seg-
ments, and suggestive imaging features of CC develop-
ment include progressive atrophy of affected hepatic 
segments or lobes and narrowing or obliteration of the 
portal vein [8, 9].
5.1.3.3  Primary Sclerosing Cholangitis
PSC is a progressive cholestatic disease characterized by 
inflammation and fibrosis of the bile duct which is com-
monly associated with inflammatory bowel disease [10]. 
Diagnosis of primary sclerosing cholangitis can be made by 
typical cholangiographic findings and the exclusion of sec-
ondary causes. The typical cholangiographic features 
include diffuse, multifocal short-segmental strictures and 
mild dilatation in the intrahepatic and extrahepatic bile 
ducts alternating with normal ducts, which sometimes 
 produce “beaded” appearance [5] (Fig. 5.3). Patients with 
PSC have a 10–15% lifetime risk of developing CC [11], 
and CC in PSC usually presents as a periductal infiltrating 
type CC associated with dominant stenosis [11]. Suggestive 
imaging findings of CC in PSC include irregular dominant 
stricture with a shouldered margin, prominent mural 
 thickening, and rapidly progressed dilatation of the bile duct 
proximal to the stricture.
5.1.3.4  IgG4-Related Cholangitis
IgG4-related sclerosing cholangitis is the biliary manifesta-
tion of IgG4 sclerosing disease, a recently recognized  disease 
entity that manifests histologically as infiltration by abun-
dant IgG4-positive plasma cells [7]. Differentiation of 
IgG4-SC from other types of sclerosing cholangitis, espe-
Fig. 5.1 70-year-old male patient with choledocholithiasis (arrows) in 
the retropancreatic portion of the hepatocholedochal duct as seen on 
coronal T2-weighted breathheld MR sequences. Note the distention of 
the DHC and further concrements in the chronically inflamed 
gallbladder
Fig. 5.2 25-year-old male patient post liver transplant with chronic 
cholangitis showing multiple concrements and sludge in the intrahe-
patic biliary system with widening of the biliary ducts and surrounding 
inflammatory changes as seen on axial T2-weighted fat-saturated MR 
images
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cially from PSC or bile duct cancers, is clinically important 
as IgG4-SC shows a dramatic response to steroid therapy 
[12]. Unlike in PSC, multifocal strictures in IgG4-related 
sclerosing cholangitis are long and continuous and are asso-
ciated with prestenotic dilatation. An elevated serum IgG4 
level and the presence of extrabiliary IgG4 sclerosing disease 
(e.g., involvement of the pancreas, kidneys, thyroid gland, 
and salivary glands) are strongly suggestive of IgG4-related 
sclerosing cholangitis [7]. In cases of IgG4-SC, CT or MR 
imaging demonstrates long-segmental, symmetrical, circum-
ferential wall thickening and delayed contrast enhancement 
of the involved bile ducts [5].
5.1.4  Neoplasms
5.1.4.1  Benign Tumors of the Bile Ducts
Common benign tumors of the bile ducts include bile duct 
hamartoma, adenoma, biliary papillomatosis, and biliary 
cystadenoma.
Biliary Hamartoma
Biliary hamartoma, also known as von Meyenburg com-
plex, manifests as multiple or innumerable cysts, typically 
less than 1.5 cm, distributed in both lobes of the liver 
[13, 14].
Biliary Cystadenoma (Biliary Mucinous Cystic 
Neoplasms)
Biliary cystadenomas and cystadenocarcinomas are rare, 
multilocular cystic tumors of biliary origin, and more than 
85% of these tumors occur in middle-aged women [15]. 
Biliary cystadenomas typically appear as cystic masses with 
a well-marginated capsule, internal septa, and mural nod-
ules, with rare capsular calcification [14]. Although imaging 
features of cystadenomas and cystadenocarcinomas overlap, 
malignant cystadenocarcinomas tend to have a thicker wall 
and thicker internal septa and more often contain intratu-
moral papillary and polypoid projections [13].
Intraductal Papillary Neoplasm of the Bile Duct 
(IPNB)
Two major premalignant bile duct tumors include biliary 
intraepithelial neoplasia (BilIN) and intraductal papillary 
neoplasms of the bile duct (IPNB), both of which can 
progress to CC. IPNB shows a diverse spectrum of prema-
lignant lesions toward invasive CC according to the loca-
tion of the origin and presence of mucin hypersecretion. 
Typical imaging features of IPNB are the presence of 
intraductal tumors and bile duct dilatation [16]. IPNB with 
mucin secretion often causes dilatation of the downstream 
duct and patulous ampulla of Vater due to mucin hyperse-
cretion [17]. On imaging, this can be seen as aneurysmal 
dilatation of the bile duct with or without visible intra-
ductal mucin-secreting tumors, and the upstream duct can 
also be dilated [18, 19].
5.1.4.2  Malignant Tumors of the Bile Ducts
Cholangiocarcinoma is an adenocarcinoma arising from the 
bile ducts (Fig. 5.4). On the basis of macroscopic growth pat-
terns, CC can be categorized into mass-forming (MF), 
periductal- infiltrating (PI), and intraductal-growing (IDG) 
types according to the classification proposed by the Liver 
Cancer Study Group of Japan (LCSGJ) [20]. Not only diag-
nosis of cholangiocarcinoma but also appropriate categoriza-
tion of bile duct tumors based on their morphologic features 
and location on cross-sectional imaging studies, including 
computed tomography and magnetic resonance imaging, is 
Fig. 5.3 52-year-old female patient with primary sclerosing cholangi-
tis and typical beading of the intrahepatic biliary system (arrows) as 
seen on coronal MRCP images. Note the normally configured extrahe-
patic biliary duct
Fig. 5.4 73-year-old female patient with recurrence of cholangiocarci-
noma (arrows) following right-sided hemihepatectomy with hepaticoje-
junal anastomosis, on equilibrium phase contrast-enhanced MR 
imaging
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important to predict their biologic behaviors and choose rel-
evant treatment strategies [16]. MF-type ICC typically mani-
fests as a large non-encapsulated mass of lobulated or 
irregular contour, which typically shows early peripheral rim 
enhancement with progressive centripetal enhancement on a 
CT and MR imaging, and is frequently accompanied by 
hepatic capsular retraction and dilated peripheral bile ducts 
[16]. IDG-type CC appears as a polypoid or papillary tumor 
within the dilated bile duct lumen and has a growth pattern of 
superficial mucosal spreading [16].
Perihilar CC usually presents as a narrowed perihilar 
duct with irregular wall thickening which typically shows 
progressively delayed enhancement and upstream bile duct 
dilatation on CT or MRI [21]. Long-segmental involve-
ment (>12 mm), a thickened (>1.5 mm) wall, luminal 
irregularity or asymmetry, and incremental enhancement 
may favor a malignant stricture, while benign strictures 
often involve short segments and a smooth transition [7, 
22]. For perihilar cholangiocarcinomas, the local extent of 
the tumor is most commonly described using the Bismuth-
Corlette (BC) system. Tumors are classified into type I 
(tumor involving only the common hepatic duct below the 
first confluence), type II (tumor involving the first conflu-
ence without involvement of second confluences), type III 
(tumor involving either right (IIIA) or left (IIIB) second 
confluence), and type IV (tumor involving both right and 
left second confluence). In general, BC type IV, BC type 
III with contralateral liver atrophy or contralateral vascu-
lar invasion, invasion of the main portal vein or common 
hepatic artery, and the presence of distant metastases are 
regarded to be unresectable [23]. As surgical complete 
resection is the only potentially curative treatment, it is 
critical to determine the type and extent of surgery for 
selection of the most appropriate surgical candidates with 
imaging. However, accurate staging of many CCs still 
remains challenging due to the small size of the tumors 
involved and the complex anatomy of the bile duct and 
adjacent structures as well as the high frequency of ana-
tomical variations [24]. A multimodality approach using 
CT, MRI with MRCP, direct cholangiography, endoscopic 
ultrasound, and positron emission tomography has most 
frequently been applied to surgical candidates [24].
5.2  Gallbladder 
Daniel T. Boll, M.D.
5.2.1  Normal Anatomy
Located along the undersurface of the liver in the plane of the 
interlobar fissure between the right and left hepatic lobes, the 
gallbladder is a round tubular structure with a cross-sectional 
diameter of up to 5 cm and a normal wall thickness of 
1–3.5 mm [25, 26].
The bile-filled lumen of the gallbladder measures water 
isodensity (0–20 Hounsfield units) on CT and water- 
isointense signal characteristics on T2-weighted MR imag-
ing; formation and retention of sludge may create gradients 
of signal intensity/density, resulting in a parfait-like appear-
ance. The vicarious excretion of CT contrast material from 
prior contrast-enhanced CT imaging as well as utilization of 
hepatocyte-specific contrast materials in hepatic MR imag-
ing may alter the imaging appearance of bile on CT as well 
as MR imaging [27, 28].
5.2.2  Congenital Variants and Anomalies
5.2.2.1  Agenesis of the Gallbladder
Being a rare malformation (0.01–0.2% in autopsy series), 
agenesis of the gallbladder results from a developmental fail-
ure of the caudal division of the primitive hepatic diverticu-
lum or failure of vacuolization. It may result in biliary tract 
symptoms and formation of extrahepatic and intrahepatic 
gallstones in up to 50% of patients [25, 29].
5.2.2.2  Duplication of the Gallbladder
The duplication of the gallbladder is an equally rare malfor-
mation (0.02% in autopsy series), resulting in a longitudinal 
septum, divides the gallbladder cavity, and each cavity drains 
through its own cystic duct. Embryologically, duplication of 
the gallbladder is the result of an incomplete revacuolization 
of the primitive gallbladder. Differentiation from gallbladder 
folds, a bilobed gallbladder, a choledochal cyst, or a gallblad-
der diverticulum may be challenging on imaging studies [30].
5.2.2.3  Phrygian Cap of the Gallbladder
This most common anomaly of the gallbladder through a 
septation between the body and the distal fundus may be 
seen in up to 6% of all patients. Two types have been 
described: the retroserosal more concealed type and the 
serosal type with the peritoneum outlining the fundus 
reflecting on itself and overlying the body of the gallbladder 
[25, 31].
5.2.2.4  Multiseptate Gallbladder
Septations throughout the gallbladder, creating communicat-
ing chambers, may lead to stasis of bile and formation of 
gallstones [32].
5.2.2.5  Diverticula of the Gallbladder
True gallbladder diverticula are congenital in nature and con-
tain all three muscle layers. Pseudodiverticula are develop-
mental in nature and are usually associated with 
adenomyomatosis and contain little or no smooth muscle 
layers in their walls. (Pseudo)Diverticula can occur at any 
location throughout the gallbladder wall [25, 33].
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5.2.2.6  Ectopic Gallbladder
Various locations of the gallbladder have been described; of 
particular interest is the intrahepatic location of the gallbladder, 
which is entirely surrounded by hepatic parenchyma. 
Intrahepatic subcapsular locations may particularly complicate 
the diagnosis of an acute cholecystitis as secondary signs of 
inflammation may be subtle or masked entirely. Shrinkage of 
the liver in patients with cirrhosis, as well as patients with 
chronic obstructive pulmonary disease, may show gallbladders 
interposed between the liver surface and diaphragm [25, 34].
5.2.3  Pathologic Conditions
5.2.3.1  Gallstones
The appearance of gallstones in cross-sectional imaging is pri-
marily composition based; most gallstones contain various 
admixtures of bile pigment, cholesterol, and calcium. Larger 
proportions of calcium may render gallstones hyperdense on 
CT imaging, while pure cholesterol stones may be lower in CT 
density than surrounding bile; central inclusions of gas mostly 
consist of nitrogen and may lead to flotation of gallstones.
The high signal intensity of bile on T2-weighted images allows 
better delineation of hypointense gallstones compared to 
T1-weighted sequences. While cholesterol stones are usually 
hypointense in appearance on T1-weighted images, pigment stones 
tend to have higher signal intensities. Central areas of T2 hyperin-
tensity usually corresponds to fluid-filled clefts [25, 35, 36].
5.2.3.2  Acute Cholecystitis
An obstruction of either the gallbladder neck or the cystic duct 
may lead to increased intraluminal pressures and eventually 
result in an inflammation of the gallbladder wall. Gallstones 
lodged in the neck of the gallbladder or the cystic duct leading 
to biliodynamic obstruction as well as pressure- induced muco-
sal ischemia and injury are the preeminent reason for acute 
cholecystitis. Ultrasound, CT, and MRI may show distinct fea-
tures of acute cholecystitis, such as cholecystolithiasis, gall-
bladder wall thickening, pericholecystic fluid and inflammation, 
thickened bile, an indistinct interface between the gallbladder 
wall and liver capsule, and potentially gallbladder perforation 
(Fig. 5.5). Gallbladder perforations can be subdivided into 
acute, subacute, and chronic stages; a subacute perforation 
with a surrounding abscess is the most frequently encountered 
type of gallbladder perforation. The use of hepatobiliary con-
trast agents in MR imaging may provide additional functional 
information about cystic duct patency [25, 37, 38].
In emphysematous cholecystitis, an additional vascular 
compromise of the cystic artery is hypothesized to accelerate 
the development of gas-forming organisms in the resultant 
anaerobic environment with eventual penetration of gas into 
the gallbladder wall. A more frequent occurrence in diabetic 
patients, as well as the male population with an acalculous 
gallbladder, potentially hints at a separate pathogenesis in 
contrast to calculous cholecystitis [39].
Inflammation causing ulceration of the mucosal lining and 
subsequent necrosis may lead to hemorrhagic  cholecystitis. 
The intraluminal hematoma that may be seen on CT and MRI 
may, however, be difficult to differentiate from high- intensity/
high-density bile. An accompanying perforation of the gall-
bladder wall may lead to hemoperitoneum [40].
Coexisting cardiovascular disease predisposes patients 
with acute cholecystitis to develop gangrenous wall segments. 
Intraluminal membranes and irregularity of the gallbladder 
wall intermittently perforated and potentially surrounded by a 
pericholecystic abscess are key imaging features.
5.2.3.3  Acalculous Cholecystitis
In approximately 5% of all patients with acute cholecystitis, 
no intraluminal stones can be found. Long stays in intensive 
care units and abdominal trauma may lead to increased vis-
cosity and subsequent stasis of bile leading to obstruction 
and mucosal ischemia [25, 41].
5.2.3.4  Chronic Cholecystitis
Repetitive mucosal trauma through preexisting gallstones as 
well as recurrent attacks of multiple acute cholecystitic epi-
sodes may contribute to the poorly understood pathogenesis 
of this fairly common disease. A florid inflammatory 
response to irritations may also indicate a genetic predisposi-
tion. While cross-sectional imaging of chronic cholecystitis 
may not substantially differ from acute cholecystitis, the 
greatest difference appears to be a contracted state of the 
gallbladder in chronic cholecystitis compared to the acute 
scenario. A decreased gallbladder ejection fraction is often-
times associated with chronic cholecystitis [25].
Microperforations through mucosal ulcers as well as rup-
tured Rokitansky-Aschoff sinuses may lead to penetration of 
Fig. 5.5 49-year-old male patient with acute calculous cholecystitis as 
seen on portal venous contrast-enhanced CT imaging. Note the gall-
bladder wall thickening and surrounding fluid (arrow) as well as the 
intraluminal gallstone
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bile into the gallbladder wall, resulting in the formation of 
xanthogranulomas representing the hallmark of xanthogranu-
lomatous cholecystitis. Gallstones are almost always present, 
and an irregular configuration of the gallbladder wall is fre-
quently observed. Xanthogranulomatous lesions in the wall 
can also lead to interim mural abscess formations. These may 
appear hypodense on contrast-enhanced CT imaging as well 
as hyperintense nodules on T2-weighted MR imaging 
sequences. Differentiation from gallbladder cancer may be 
challenging; however, a patent mucosal lining/luminal surface 
is more indicative of xanthogranulomatous cholecystitis [25].
Impaction of gallstones inside the cystic duct with subse-
quent compression of the common hepatic duct and resultant 
inflammation are mechanisms leading to the Mirizzi syndrome. 
A fairly low insertion of the cystic duct into the common hepatic 
duct may predispose this patient subpopulation. Differentiating 
the inflammatory origin of the stricture of the common hepatic 
duct from a neoplastic process may be challenging; the lack of 
lymphadenopathy, as well as a distinct focal mass, may be help-
ful secondary signs. Erosion of gallstones through the gallblad-
der wall directly into the adjacent bowel via a cholecystoenteric 
fistula is the most common mechanism to form a gallstone ileus, 
in particular within the distal ileum [25, 42].
Chronic inflammatory changes of the gallbladder wall 
may lead to dystrophic calcifications associated with thick 
fibrous tissue layers of the gallbladder wall, indicating a por-
celain gallbladder. The porcelain gallbladder is frequently 
associated with gallbladder carcinoma [17] (Fig. 5.6).
5.2.3.5  Hyperplastic Cholecystosis
A benign proliferation of normal gallbladder wall tissue 
characterizes this noninflammatory condition.
A deposition of cholesterol-laden macrophages into the 
lamina propria of the gallbladder wall may lead to formation 
of cholesterol polyps and other hallmark cholesterolosis. 
Due to their small size, these polyps are best seen on ultra-
sound imaging [25, 43].
A hypertrophy of the muscular wall with corresponding 
mucosal overgrowth and formation of intramural diverticula 
and sinus tracts, then called Rokitansky-Aschoff sinuses, is 
the hallmark of adenomyomatosis. This disease can be seen 
diffusely infiltrating the gallbladder wall, may have an annu-
lar appearance, or may be very focal. Detection of a thick-
ened gallbladder wall in addition to small cystic spaces on 
CT and MR imaging helps to differentiate adenomyomatosis 
from gallbladder cancer [43].
5.2.3.6  Gallbladder Neoplasms
Benign neoplasms of the gallbladder are rare and usually 
represent adenomas, which are, incidentally, (0.3–0.5%) 
found during cholecystectomies [25].
During the sixth or seventh decades of life with a female 
predilection of 2:1–3:1, gallbladder carcinomas, occur his-
topathologically usually as adenocarcinomas; however, 
adenosquamous, squamous, or neuroendocrine carcinomas 
can also be found, may arise from the gallbladder wall. 
Predisposing factors associated with gallbladder carci-
noma are gallstones (75% of patients with gallbladder car-
cinomas have gallstones), porcelain gallbladder, genetic 
factors, as well as pancreaticobiliary ductal unions (reflux 
of pancreatic juice into the common bile duct leading to 
chronic inflammation) (Fig. 5.7). On cross-sectional imag-
ing, either a mass is seen replacing the gallbladder fossa or 
the mass is noted filling most of the enlarged and deformed 
gallbladder. In invasion of surrounding structures, in par-
ticular the liver, the hepatoduodenal ligament, the right 
hepatic flexure, or the duodenum is frequently observed. 
Lymphatic spread to the regional and distant lymph nodes 
is very common, and gallbladder carcinoma hematogenous 
metastasis to the liver, intraductal tumor spread, as well as 
Fig. 5.6 69-year-old female patient with chronic cholecystitis with 
thickening of the gallbladder wall (arrow) without substantial pericho-
lecystic fluid surrounding this acalculous gallbladder as seen on portal 
venous phase contrast-enhanced CT imaging
Fig. 5.7 65-year-old female patient with gallbladder carcinoma, 
infiltrating the liver (arrow), and multiple intrahepatic metastases 
(arrowheads) with gallstones on T1-weighted contrast-enhanced MR 
imaging using a hepatocyte-specific contrast agent in a 5-min delayed 
phase
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peritoneal seeding is also fairly common. Biliary obstruc-
tion may be observed in up to 50% of patients [25, 44, 45].
Secondary lymphoma to the gallbladder is rare and may 
be seen in disseminated lymphomatous stages; primary lym-
phoma involving the gallbladder is extremely rare [46].
Metastases to the gallbladder is also a rare disease and can 
originate from any source; however, malignant melanoma is 
the most common cause of metastatic tumors, accounting for 
more than 50% of all cases of gallbladder metastases [47].
5.3  Concluding Remarks
Familiarity with the typical clinical and radiologic appear-
ances of various etiologies of gallbladder disease, cholangi-
opathies, and biliary malignancies is important for accurate 
image interpretation, and thus enabling optimal clinical and 
surgical management.
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Take-Home Messages
• An appreciation of the pathologic basis of gallblad-
der and biliary disease, combined with careful 
inspection of the imaging appearances, is vital for 
the correct interpretation of biliary studies.
• Differential diagnosis of various cholangiopathies 
is important because specific management exists 
and prognosis can be different according to the 
type of disease.
• Awareness of the underlying risk factors and mor-
phologic characteristics of gallbladder disease and 
cholangiocarcinoma is important for accurate diag-
nosis and for differentiation from other hepatic 
tumorous and non-tumorous lesions.
• Imaging studies play important roles in the diagno-
sis and treatment planning of patients with biliary 
malignancies, and multimodality and multipara-
metric imaging approaches can provide comple-
mentary information in evaluating the tumor extent 
and resectability.
Key Points
• Imaging of gallbladder and biliary disease often 
requires a multimodality imaging approach.
• Sclerosing cholangitis is a spectrum of chronic pro-
gressive cholestatic liver disease characterized by 
inflammation, fibrosis, and stricture of the bile ducts, 
which can be classified as primary and secondary 
sclerosing cholangitis. A systematic approach com-
bined with the appropriate clinical settings and 
imaging findings can be helpful for differentiating 
the various causes of sclerosing cholangitis.
• Although tissue biopsy or surgery is needed for the 
definitive diagnosis of many of biliary strictures, 
certain imaging characteristics of the narrowed seg-
ment (e.g., thickened wall, long-segment involve-
ment, asymmetry, indistinct outer margin, luminal 
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liver parenchyma) may favor a malignant cause.
• Biliary malignancies typically demonstrate arterial 
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into the portal venous phase, related to the fibrotic 
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gitudinal tumor extent, vascular invasion, anatomi-
cal variation of the bile duct and vessels, future 
remnant volume, and presence or absence of distant 
metastasis should be considered.
• Intraductal papillary mucinous neoplasms of the bile 
duct (IPMN-B) bear a striking similarity to IPMN 
of the pancreas with regard to its histopathologic 
features and frequently show intraductal tumors, 
mucobilia, and diffuse dilatation of upstream and 
downstream bile ducts.
• Knowledge of congenital variants and anomalies of 
the gallbladder anatomy is essential to understand 
and characterize gallbladder disease.
• Pathogenesis of gallstone formation and resultant 
acute and chronic cholecystitis and their complica-
tions influences treatment decisions.
• Differentiating inflammatory gallbladder disease 
from gallbladder neoplasms can be challenging in 
early stages; recognizing imaging features which 
raise the suspicion for potential underlying neoplasms 
is essential in guiding potential treatment options.
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Pathways for the Spread of Disease 
in the Abdomen and Pelvis
James A. Brink and Brent J. Wagner
6.1  Introduction
Disease may spread through the abdomen and pelvis by a 
variety of mechanisms. For example, intra-abdominal malig-
nancies may metastasize through hematologic routes, and 
tumors may spread by directly invading adjacent tissues and 
organs or via the lymphatic system. When tumors break 
through the visceral peritoneum, they may also spread via 
intraperitoneal seeding. While hematologic spread of disease 
is beyond the scope of this chapter, direct invasion, lym-
phatic extension, and intraperitoneal seeding will be dis-
cussed relative to the anatomy that guides these pathways for 
the spread of disease in the abdomen and pelvis [1].
Direct invasion and lymphatic extension occur through the 
peritoneal ligaments and mesenteries that interconnect the 
abdominal viscera with other organs in the abdomen and pel-
vis, the retroperitoneum, and the body wall. Moreover, these 
structures guide the flow of peritoneal fluid through the abdo-
men and pelvis, thereby dictating the routes of spread through 
intraperitoneal seeding. In short, understanding these pathways 
for the spread of disease ties closely to a clear understanding of 
a ligamentous anatomy of the abdomen and pelvis.
6.2  Peritoneal Ligaments as Conduits 
for the Spread of Disease
The upper abdominal viscera is interconnected by three pairs 
of ligaments: the gastrohepatic and hepatoduodenal liga-
ments (that together comprise the lesser omentum), the gas-
trosplenic and splenorenal ligaments, and the gastrocolic 
ligament and transverse mesocolon. Each of these ligamen-
tous pairs contains one ligament that bridges to the retroperi-
toneum: the hepatoduodenal ligament, the splenorenal 
ligament, and the transverse mesocolon. Thus, disease from 
the abdominal viscera may spread to the retroperitoneum 
and vice versa through these ligamentous pairs.
6.2.1  Gastrohepatic and Hepatoduodenal 
Ligaments
The gastrohepatic and hepatoduodenal ligaments form an 
important pathway of disease from the lesser curvature of the 
stomach to the porta hepatis and retroperitoneum. The gas-
trohepatic ligament extends from the lesser curvature of the 
stomach to the porta hepatis, inserting into the fissure for the 
ligamentum venosum. Containing the left gastric artery, the 
left gastric vein or coronary vein, and associated lymphatics, 
the gastrohepatic ligament may be recognized on cross- 
sectional imaging as the fatty plane connecting the lesser 
curvature of the stomach to the left lobe of the liver and con-
taining these vessels (Fig. 6.1). Nodes in the gastrohepatic 
ligament are typically 8 mm or less in diameter, somewhat 
smaller than elsewhere in the abdomen [2]. Care must be 
taken to avoid misidentifying unopacified loops of bowel, 
the pancreatic neck, or the papillary process of the caudate 
lobe as enlarged nodes in the gastrohepatic ligament [3, 4].
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A unique feature of the gastrohepatic ligament is continu-
ity of its subperitoneal areolar tissue with the perivascular 
fibrous capsule of the liver (Glisson capsule). This anatomic 
continuity provides a direct pathway for the spread of disease 
from the gastric lesser curvature into the left hepatic lobe via 
the gastrohepatic ligament and vice versa. Both neoplastic 
and inflammatory conditions can spread in this fashion 
(Fig. 6.2). Gastric and esophageal cancer commonly spread 
via lymphatic extension and direct invasion through the gas-
trohepatic ligament, allowing these tumors to spread to the 
liver, and conversely hepatoma and cholangiocarcinoma may 
spread to the stomach through these pathways as well.
The free edge of the gastrohepatic ligament is the hepato-
duodenal ligament, and together, the gastrohepatic and hepa-
toduodenal ligaments comprise the lesser omentum. The 
hepatoduodenal ligament is the thickest ligament in the upper 
abdomen owing to the portal structures that it contains: the 
portal vein, the hepatic artery, the common bile duct, and 
associated lymphatics. The hepatoduodenal ligament extends 
from the porta hepatis to the flexure between the first and sec-
ond duodenum forming a tent-like structure that extends from 
superior to inferior as it courses from anterior to posterior. 
The foramen of Winslow, or epiploic foramen, lies immedi-
ately posterior to the ligament connecting the right posterior 
perihepatic space with the lesser sac [5]. Here, nodes at the 
base of the hepatoduodenal ligament at the epiploic foramen 
(in the portocaval space) can be quite prominent in size 
and still normal. These nodes can be up to 2.0 cm in trans-
verse dimension and up to 1.5 cm in anteroposterior dimen-
sion and still be normal. Pathology within these nodes may be 
difficult to identify but may be suggested when the nodes 
assume a more spherical shape or have central necrosis [6, 7].
A host of neoplastic and inflammatory conditions spread 
commonly via the hepatoduodenal ligament from the porta 
hepatis to the retroperitoneum, following antegrade flow of 
lymphatic fluid from the liver and biliary tree to nodes sur-
rounding the duodenum and pancreas. However, lymphatic 
extension can also occur in a retrograde fashion through these 
lymphatics, originating from disease in nodes surrounding 
the superior mesenteric artery, as may occur in pancreatic and 
colon cancer, and spreading up the lymphatic channels in the 
hepatoduodenal ligament to the liver (Fig. 6.3).
Structures intimately related to the hepatoduodenal liga-
ment may also spread via direct invasion through the ligament, 
as occurs commonly with gastric cancer arising in the lesser 
curvature and spreading to peripancreatic and periduodenal 
lymph nodes via the gastrohepatic and hepatoduodenal liga-
ments. Many inflammatory conditions also spread commonly 
through the hepatoduodenal ligament including inflammatory 
processes within the gall bladder and biliary tree. Pancreatitis 
may also spread via this pathway as well. Occasionally, vascu-
lar complications may be seen in the hepatoduodenal ligament 
related to both malignant and inflammatory conditions cours-
ing through it. These include portal vein thrombosis as well as 
hepatic arterial pseudoaneurysms [1, 5].
6.2.2  Gastrosplenic and Splenorenal 
Ligaments
An important highway of disease is provided in the left upper 
abdomen by the gastrosplenic and splenorenal ligaments, con-
necting the gastric greater curvature to the splenic hilum and 
the retroperitoneum, respectively (Fig. 6.4). The gastrosplenic 
Fig. 6.1 Transaxial CT image demonstrates the gastrohepatic ligament 
(GHL), seen as a fatty plane interposed between the lesser curvature of the 
stomach and the lobe of the liver. The GHL contains the left gastric artery 
(arrow), the left gastric vein (coronary vein), and associated lymphatics
Fig. 6.2 Transaxial CT image demonstrates a heterogenous mass 
(arrow) centered in the gastrohepatic ligament (GHL), with invasion of 
the left hepatic lobe and the stomach. Prospectively, it was unclear as to 
the organ of origin, but it proved to be a hepatoma extending through 
the GHL to involve the stomach
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ligament is a rather thin delicate structure that  connects the 
superior third of the greater curvature of the stomach to the 
splenic hilum. This ligament contains the left gastroepiploic 
and short gastric vessels and their associated lymphatics. The 
gastrosplenic ligament can direct diseases arising in the stom-
ach to the splenic hilum, and both neoplastic and inflamma-
tory disease may invade the spleen via this pathway.
Posteriorly and medially, the gastrosplenic ligament is 
continuous with the splenorenal ligament. Once disease 
reaches the splenic hilum from the stomach via the gastro-
splenic ligament, it may turn and extend to the retroperito-
neum via the splenorenal ligament. Here, disease may 
surround and invade the pancreatic tail and compromise the 
splenic artery and splenic vein (Fig. 6.5) [8, 9]. Just as gastric 
disease can spread to the retroperitoneum via this ligamen-
tous pair, both inflammatory and neoplastic disease of the 
pancreas may spread in the opposite direction to the splenic 
hilum and greater curvature via the splenorenal and gastro-
splenic ligaments, respectively [1].
6.2.3  Gastrocolic Ligament and Transverse 
Mesocolon
As the gastrohepatic and hepatoduodenal ligaments in the 
right abdomen and the gastrosplenic and splenorenal liga-













Fig. 6.4 The gastrosplenic ligament (GSL) and splenorenal ligament 
(SRL) comprise the left wall of the lesser sac and provide a conduit for 
the spread of metastatic disease from the greater curvature of the stom-
ach to the retroperitoneum and vice versa (Reprinted with permission 
from Myers MA. Dynamic Radiology of the Abdomen: Normal and 
Pathologic Anatomy, New York: Springer, 1994)
a b
Fig. 6.3 Transaxial CT images through the porta hepatis (a) and the 
uncinate process (b) demonstrate bulky lymphadenopathy (arrows) in 
the hepatoduodenal ligament (HDL) in a patient with gallbladder carci-
noma. Tumor has spread bidirectionally within the HDL proximally (a) 
and distally to the insertion of the HDL on the second portion of the 
duodenum
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disease from the upper abdominal viscera to the retroperi-
toneum, the gastrocolic ligament and transverse mesocolon 
form a similar pathway in the mid-abdomen. The gastrocolic 
ligament (greater omentum) connects the inferior two thirds 
of the greater curvature of the stomach to the transverse 
colon (Fig. 6.6). On the left, the gastrocolic ligament is con-
tinuous with the gastrosplenic ligament, and on the right, it 
ends at the gastroduodenal junction near the hepatoduodenal 
ligament. Embryologically, the gastrosplenic ligament gives 
rise to the gastrocolic ligament and the transverse mesocolon 
in the adult, with fusion of the anterior and posterior leaves 
of the embryonic gastrosplenic ligament. In consequence, 
the gastrocolic ligament has a potential space within it that 
can fill with fluid when tense ascites in the lesser sac dis-
sects open this potential space. This can result in a cyst-like 
appearance within the gastrocolic ligament/greater omentum.
The gastrocolic ligament contains the gastroepiploic ves-
sels and associated lymphatics which can help identify the 
ligament as the fatty plane connecting the stomach to the 
transverse colon. Both benign and malignant diseases from 
the inferior two thirds of the greater curvature of the stomach 
may spread to the transverse colon via this pathway, and vice 
versa (Fig. 6.7). The transverse mesocolon completes the 
pathway from the stomach to the retroperitoneum in the mid- 
abdomen; disease involving the stomach and transverse colon 
are connected via the gastrocolic ligament, and disease 
involving the transverse colon and pancreas/retroperitoneum 
are connected by the transverse mesocolon. In addition, the 
greater omentum continues inferior to the transverse colon as 
a fatty veil that forms an important nidus for carcinomatosis, 
as commonly occurs with ovarian, gastric, colon, and pancre-
a b
Fig. 6.5 Transaxial CT images through the gastrosplenic ligament 
(GSL) (a) and the splenorenal ligament (SRL) (b), in a patient with 
lymphoma. Tumor is seen within the GSL, interposed between the gas-
tric greater curvature and the spleen (a), and within the SRL, encasing 







Fig. 6.6 The gastrocolic ligament (GCL) joins the greater curvature of 
the stomach (G) to the transverse colon (TC). In concert with the trans-
verse mesocolon, a pathway of disease is formed between retroperito-
neal structures such as the pancreas (P) and the duodenum (D) to the 
anterior aspect of the intraperitoneal cavity (Modified from Langman J., 
Medical Embriology, New York: Saunders, 1971)
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atic cancers [10, 11]. Sometimes, gastroepiploic collaterals 
may be recognized in the gastrocolic ligament which should 
raise concern about the possibility of splenic venous compro-
mise as what commonly occurs in pancreatic carcinoma.
The transverse mesocolon connects the transverse colon 
to the retroperitoneum but also forms a broad conduit for 
disease across the mid-abdomen; bare areas link the pancreas 
to the transverse colon, spleen, and small bowel (Fig. 6.8). 
The transverse mesocolon is continuous with the phrenico-
colic ligament and the splenorenal ligaments in the left abdo-
men, with the small bowel mesentery in the mid-abdomen, 
and with the duodenocolic ligament in the right abdomen. 
The transverse mesocolon may be recognized as the fatty 
plane that connects the transverse colon to the  retroperitoneum 
at the level of the uncinate process of the pancreas. As this 
structure lies commonly in a paracoronal orientation, recog-
nition of the middle colic vessels and associated lymphatics 
within the mesocolon can aid in its identification. Pancreatic 
disease, both benign and malignant, often spreads ventrally 
into the transverse mesocolon and then on to the transverse 
colon (Fig. 6.9). Pancreatitis often results in adjacent fluid 
collections that can dissect open the potential space within 
the transverse mesocolon formed by fusion of the anterior 
and posterior leaves of the embryonic gastrosplenic liga-
ment. Free fluid in the lesser sac is often confused with con-
tained fluid collections within the transverse mesocolon.
The duodenocolic ligament, the right edge of the trans-
verse mesocolon, forms an important pathway for the spread 
of right colon cancers via lymphatic drainage from the right 
colon passing through this ligament. Tumors of the right 
colon may spread via these lymphatics to deposit in nodes 
around the duodenum and pancreas [1]. Gastric outlet 
obstruction may occur once this adenopathy becomes suffi-
ciently severe to obstruct the second duodenum explaining 
how cancers of the right colon may result in upper gastroin-
testinal obstruction on rare occasion.
6.3  Peritoneal Spaces as Pathways 
for the Spread of Disease
Peritoneal fluid flows naturally through the peritoneal spaces 
that are defined by the peritoneal ligaments and mesenteries 
in the abdomen and pelvis. However, certain neoplastic and 
inflammatory conditions within the peritoneal cavity may 
leverage this natural flow of peritoneal fluid to spread through-
out the peritoneal spaces. Tumors that arise from the perito-
neal lining or break through the visceral peritoneum may 
shed their cells directly into the peritoneal fluid. Similarly, 
Fig. 6.7 Transaxial CT image through the gastrocolic ligament (GCL) 
demonstrates a gastric ulcer extending into the GCL (black arrow) with 





Fig. 6.8 The transverse mesocolon (TM) provides an important con-
duit for the spread of disease across the mid-abdomen. It is continuous 
with the splenorenal ligament (SRL) and phrenicocolic ligament (PCL) 
on the left and with the duodenocolic ligament on the right. In its mid-
portion, it is continuous with the small bowel mesentery (SBM) 
(Reprinted with permission from Myers MA. Dynamic Radiology of 
the Abdomen: Normal and Pathologic Anatomy, New York: Springer, 
1994)
Fig. 6.9 Transaxial CT image through the transverse mesocolon 
(TMC) in a patient with pancreatic adenocarcinoma demonstrates inva-
sion of the TMC with necrotic tumor (arrows). The tumor in the TMC 
has fistulized with the transverse colon resulting in gas accumulating 
within the necrotic debris
6 Pathways for the Spread of Disease in the Abdomen and Pelvis
62
inflammatory processes within the peritoneal cavity may also 
leverage this natural flow of ascitic fluid and spread through-
out the peritoneal spaces of the abdomen and pelvis. A thor-
ough knowledge and understanding of this anatomy can help 
narrow the differential diagnosis for intra- abdominal patholo-
gies and may help radiologists better predict the organ of ori-
gin and likely route of spread for certain conditions (Fig. 6.10).
6.3.1  Left Peritoneal Space
The left peritoneal space is comprised of four compartments: 
the left anterior perihepatic space, the left posterior perihe-
patic space (gastrohepatic recess), the left anterior sub-
phrenic space, and the left posterior subphrenic space 
(perisplenic space).
Anteriorly, the left peritoneal space extends to the right as 
the left anterior perihepatic space, ventral to the left lobe of 
the liver. It is bounded laterally on the right by the falciform 
ligament and on the left by the anterior wall of the stomach. 
Posteriorly, it extends along the diaphragm and is limited by 
the left coronary ligament, the left superior extension of the 
bare area of the liver (Fig. 6.11a).
Along the medial margin of the left hepatic lobe, the left 
anterior perihepatic space turns to form the left posterior 
perihepatic space as it extends along the inferior margin of 




























Fig. 6.11 Left (a) and right (b) perihepatic spaces. The left and right 
perihepatic spaces are bounded posteriorly by the coronary ligaments. 
The reflections of the coronary ligaments mark the site of the nonperi-
tonealized “bare area” of the liver (LL left lobe of the liver, LK left 
kidney, S stomach, TC transverse colon, P pancreas, D duodenum, Lu 
lung, L liver [right lobe], A adrenal, K kidney, C colon) (Reprinted with 
permission from Myers MA. Dynamic Radiology of the Abdomen: 









Fig. 6.10 Posterior peritoneal reflections and recesses. Intraperitoneal 
fluid flows naturally from the pelvis to the upper abdomen. Flow occurs 
preferentially through the right rather than left paracolic gutters owing 
to the broader diameter of the right gutter. In addition, flow in the left 
paracolic gutter is cut off from reaching the left subphrenic space by the 
phrenicocolic ligament. The transverse mesocolon divides the abdomen 
into supra- and inframesocolic spaces. In the right inframesocolic 
space, fluid is impeded from draining into the pelvis via the small bowel 
mesentery. Owing to natural holdup of fluid at the root of the small 
bowel mesentery and sigmoid mesocolon, these structures are naturally 
predisposed to involvement with serosal-based metastases in the setting 
of peritoneal carcinomatosis (Reprinted with permission from Myers 
MA. Dynamic Radiology of the Abdomen: Normal and Pathologic 
Anatomy, New York: Springer, 1994)
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ligamentum venosum. Also known as the gastrohepatic 
recess, the left posterior perihepatic space is bounded on the 
left by the lateral wall of the stomach and is juxtaposed to the 
anterior wall of the duodenal bulb, the anterior wall of the 
gallbladder, and the porta hepatis [8]. Fluid in the gastrohe-
patic recess is separated from fluid in the superior recess of 
the lesser sac by the lesser omentum as it inserts into the fis-
sure for the ligamentum venosum. Fluid collections in the 
gastrohepatic recess are relatively easy to drain owing to the 
lack of intervening structures between this space and the 
body wall, along the medial margin of the left hepatic lobe. 
Conversely, fluid collections in the lesser sac may be more 
difficult to approach percutaneously owing to the presence of 
intervening vasculature in the lesser omentum.
Laterally in the left abdomen, the left anterior subphrenic 
space connects with the left anterior perihepatic space 
across the mid-abdomen. This space is cut off from the left 
paracolic gutter by the phrenicocolic ligament, unlike the 
right subphrenic space which communicates freely with the 
right paracolic gutter. Thus, fluid can accumulate within the 
left anterior subphrenic space by passing ventral to the 
stomach, but once it enters this space, it is relatively static 
owing to the phrenicocolic ligament. Thus, fluid in the left 
anterior subphrenic space is a common site for peritoneal 
carcinomatosis and abscess formation consequent to perito-
nitis [12].
The posterior extension of the left anterior subphrenic 
space is the left posterior subphrenic space also known as the 
perisplenic space (Fig. 6.12). The bare areas of the spleen 
that result from insertion of the gastrosplenic and splenore-
nal ligaments into the splenic hilum may be highlighted by 
fluid that surrounds the spleen within the perisplenic space 
[13–15]. Superiorly, the perisplenic space surrounds com-
pletely the upper margin of the spleen [16].
6.3.2  Right Peritoneal Space
The right peritoneal space is comprised of three compart-
ments: the right subphrenic space/right anterior perihepatic 
space, the right posterior perihepatic space (hepatorenal 
recess/Morison’s pouch), and the lesser sac.
The right subphrenic space surrounds the upper margin of 
the liver, separating it from the right hemidiaphragm 
(Figs. 6.11b and 6.12). Posteriorly and medially, the right 
coronary ligament (bare area of the liver) forms the postero-
medial border of the right subphrenic space [17] (Fig. 6.13).
Inferior to the right coronary ligament, the hepatorenal 
recess (Morison’s pouch) is the medial extension of the right 
subphrenic space, located between the right lobe of the liver 
and the anterior border of the kidney.
The lesser sac is the leftward extension of the right poste-
rior perihepatic space/hepatorenal recess/Morison’s pouch 
as it extends through the foramen of Winslow. The lesser sac 
is comprised of superior and inferior recesses [9, 18]. Fluid 
in the superior recess of the lesser sac surrounds the caudate 
lobe producing a reverse C-shaped configuration as it sur-
rounds this structure (Figs. 6.14 and 6.15). A raised perito-
neal reflection along the posterior aspect of the lesser sac 
serves as an anatomic boundary that separates the superior 
from the inferior recesses. This gastropancreatic plicae con-
tains the proximal left gastric artery and may be recognized, 
particularly when surrounded by ascitic fluid in the superior 
and inferior recesses.
The inferior recess of the lesser sac is bounded laterally 
by the gastrosplenic and splenorenal ligaments, inferoposte-
riorly by the transverse mesocolon, and anteriorly by the 
stomach. Percutaneous drainage of fluid in lesser sac collec-
tions is problematic owing to the presence of abdominal 
organs, ligaments, and mesenteries that surround both supe-
rior and inferior recesses completely [19].
6.4  Concluding Remarks
Upper abdominal disease may spread from the upper 
abdominal organs to the retroperitoneum and vice versa via 
the gastrohepatic and hepatoduodenal ligaments in the right 
abdomen, the gastrosplenic and splenorenal ligaments in the 
left abdomen, and the gastrocolic ligament and transverse 
mesocolon in the mid-abdomen. Disease in any of these 
ligamentous pairs can suggest the organ of origin and, in 
Fig. 6.12 Transaxial CT image from a patient with carcinomatosis sec-
ondary to gastric cancer demonstrates fluid in the left posterior sub-
phrenic space (black arrow) and fluid in the right and left anterior peri-
hepatic spaces, separated by the falciform ligament (white arrows)
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some cases, the location of the disease within the organ. 
Peritoneal ligaments and mesenteries also guide the flow of 
intraperitoneal fluid throughout the peritoneal spaces that 












Fig. 6.14 The boundaries of the superior recess of the lesser sac may 
be recognized when fluid engulfs the caudate lobe. The lesser omentum 
separates this fluid from fluid in fissure for the ligamentum venosum 
which is in continuity with the left posterior perihepatic space (gastro-
hepatic recess) (IVC inferior vena cava, Ao aorta) (Reprinted with per-
mission from Myers MA. Dynamic Radiology of the Abdomen: Normal 
and Pathologic Anatomy, New York: Springer, 1994)
Fig. 6.15 Transaxial CT image through the superior recess of the 
lesser sac in a patient with gallbladder cancer (same patient as is illus-
trated in Fig. 6.3). Malignant ascites has accumulated in the superior 
recess of the lesser sac (arrows), seen with a characteristic reverse 
C-shaped configuration surrounding the caudate lobe
a b
Fig. 6.13 Coronal (a) and sagittal (b) reformatted CT images from a patient with peritoneal mesothelioma demonstrate fluid in the right sub-
phrenic space (white arrows) bounded posteriorly by the right coronary ligament (black arrow)
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de novo or extend into the peritoneal cavity may spread 
through these spaces and deposit in predictable areas within 
the peritoneal cavity.
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Key Points
• Disease may spread through the abdomen and 





• Direct invasion and lymphatic extension occur com-
monly through the peritoneal ligaments and mesen-
teries that interconnect the abdominal viscera
• Intraperitoneal spread occurs by seeding the perito-
neal cavity with cells that spread via the natural 
flow of peritoneal fluid via the peritoneal spaces
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Take-Home Message
A thorough understanding of the peritoneal ligaments 
and mesenteries as well as the peritoneal spaces that 
they define can inform the pathways by which inflam-
matory and neoplastic diseases may spread throughout 
the abdomen and pelvis.
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7.1  Part I
7.1.1  Urinary Tract by Ultrasound: The BUK 
Approach
A systematic approach to the urinary tract by ultrasound: the 
BUK approach.
7.1.1.1  Introduction
In the past, most imaging evaluations of the infant or child 
with signs or symptoms of a urinary tract abnormality began 
with a plain X-ray of the abdomen, a so-called KUB, with 
the letters standing for, from “top to bottom,” kidneys, ure-
ters, and bladder. Today, however, imaging usually begins 
with an ultrasound of the fetus, and the standard approach is 
to survey the urinary tract of the infant and child from the 
“bottom to top” that is, to begin with the bladder and then to 
look at the ureters and finally the kidneys, in other words, a 
BUK instead of a KUB approach.
7.1.1.2  Bladder
The bladder is a urine-filled structure in the fetal pelvis seen 
as early as 8 weeks gestation by transvaginal ultrasound. 
Usually two (occasionally one) umbilical arteries encircle 
the normal bladder and provide a landmark for finding the 
bladder. The bladder fills and empties periodically as the 
fetus voids, so an “absent” bladder may actually be an empty 
bladder which becomes “present” as it refills.
After birth, the normal urinary bladder appears as an 
anechoic urine-filled structure surrounded by a thin wall. 
The layers of the wall include the echogenic outer serosa, the 
central hypoechoic muscularis, and the inner echogenic 
mucosa. Wall thickness depends on the degree of distension. 
During and at the end of voiding, a normal bladder wall can 
appear thick and irregular. The bladder is pliable and thus the 
shape depends on adjacent structures. Whereas a full bladder 
is spherical, a partially full bladder can assume many shapes 
and tends to be trapezoidal in the transverse plane. It is cen-
tered posterior to the rectus abdominis muscles and its mid-
line linea alba. The rectum is posterior to the bladder in boys 
and girls with the vagina/uterus interposed between the rec-
tum and bladder in girls. The bladder is often imaged first in 
infants because that is the most likely time to see a full blad-
der, before excitement or irritation leads to urination 
(Fig. 7.1).
Radiologists often assume that the bladder is normal or 
that the fluid-filled structure in the pelvis is automatically the 
bladder. This leads to mistakes. For example, bladder exstro-
phy, a rare condition in which the bladder forms as a plate on 
the anterior pelvic wall, is diagnosed by noticing the absence 
of a normal bladder on fetal ultrasound. However, 50% of 
children born with bladder exstrophy are diagnosed 
 postnatally because people fail to check if a normal bladder 
is present.
Other fluid-filled structures in the pelvis can be mistaken 
for the bladder. These include large ureteroceles, ovarian 
cysts or masses, and the dilated (obstructed) vagina.
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The ureters start at the renal pelvis, course down on the psoas 
muscles, cross the internal iliac vessels, and then enter the 
bladder posterolaterally. The fetal ureters are typically invis-
ible unless they are dilated. The more dilated the ureter, the 
more tortuous it becomes because dilation increases width 
and also length. Extremely dilated ureters can be mistaken 
for dilated loops of bowel (Fig. 7.2).
In children, dilated ureters are often first noticed as tubu-
lar anechoic structures located posterolaterally while imag-
ing the bladder. Peristalsing boluses of urine or “ureteral 
jets” are seen entering the bladder by color Doppler. There 
are no established values for normal or abnormal ureteral 
widths by ultrasound. However, a normal ureter in a child is 
3–4 mm in diameter. Normal fluid-filled ureters can be seen 
peristalsing. Visualizing the ureter does not mean that it is 
abnormal.
Ureteral dilation is due to vesicoureteral reflux (VUR), 
obstruction, or both reflux and obstruction. Vesicoureteral 
reflux is the reverse flow of urine from the bladder to the 
kidney. Reflux of infected urine leads to pyelonephritis. 
Dilated ureters continue to peristalse and the changing 
diameter is commonly seen by ultrasound. The most 
common test to distinguish obstruction from reflux is a 
voiding cystourethrogram (VCUG), also called a mictur-
ating cystourethrogram (MCUG). If the VCUG shows 
reflux, the dilatation of the ureters and kidneys is due to 
reflux. If the refluxed material does not drain well at the 
end of the test, then either reflux coexists with obstruc-
tion. Drainage films are important to make this distinc-
tion [1]. If there is no reflux, then the dilation is due to 
obstruction.
The most common congenital cause of ureteral obstruc-
tion is primary megaureter. This is due to a functional 
obstruction at the orthotopic ureterovesical junction. Seventy 
a b
Fig. 7.1 (a, b) Two transverse images of the bladder demonstrate (a) a 
full urinary bladder. Note the square or trapezoidal configuration. The 
rectus abdominis muscles (arrowheads) are anterior to the bladder wall. 
During or just after micturition (b), the wall can appear thick and 
irregular
Fig. 7.2 A dilated fetal ureter can be confused with dilated bowel. 
However, the ureter (URT) connects the bladder (BLD) to the kidney 
(LK). Normally, a fetal ureter is not visualized. In infants and children, 
a normal peristalsing ureter can be visualized and not necessarily 
abnormal
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percent of patients with primary megaureter improve with 
time. The width of the diameter of the ureter can help to pre-
dict resolution [2]. Obstructed ureters may also be ectopic, as 
what occurs with the upper pole of a duplex kidney or, more 
rarely, a single ectopic ureter.
When the reflux is severe, the megacystis-megaureter 
association may lead to enlargement of the bladder (mega-
cystis) and dilation of the ureter or ureters (megaureter) [3]. 
The bladder enlarges because there is recycling of urine so 
that the bladder never fully empties and is constantly refilling 
with refluxed urine from the ureters, and it eventually dilates. 
Severe megacystis-megaureter can lead to urinary retention.
7.1.1.4  Kidneys
Kidneys normally migrate from the fetal pelvis to the normal 
renal fossae at 4–6 weeks gestation. The renal fossae are 
paraspinous, centered at the lumbar vertebral level of L1–L2. 
Kidneys are first seen in utero at 10 weeks gestation. Nearby 
landmarks include the echogenic spine, and the suprarenal 
hypoechoic boomerang-shaped adrenal glands, and the liver 
and spleen. The adrenal cortex is hypoechoic and the medulla 
echogenic. The normal suprarenal or adrenal gland can be up 
to one-third the size of the kidney in the second trimester.
When the kidney does not migrate to the normal location, 
it is ectopic. Since kidneys normally ascend from the fetal 
pelvis to the renal fossae, ectopic kidneys are typically some-
where in-between. Occasionally, when the liver or diaphragm 
has not formed normally, ectopic kidneys may be present in 
the chest. Kidneys may also fuse while ascending, forming 
cross-fused ectopic kidneys, horseshoe kidneys, or lump 
kidneys.
When a kidney is absent from the renal fossa in utero, 
50% are ectopic and 50% are absent [4]. When there is a soli-
tary kidney, 23% are associated with other congenital anom-
alies, including those in the VACTERL association. Thirty 
percent of these patients have vesicoureteral reflux (personal 
unpublished data).
The normal echogenicity of a kidney in an infant or 
child is more variable than in an adult. In adults, normal 
kidneys are hypoechoic compared to the liver. In infants 
and children, normal kidneys may be relatively isoechoic 
or hypoechoic. In newborns and premature infants, rela-
tively echogenic kidneys may still be normal. In addition, 
kidneys are separated into lobes, with a central hypoechoic 
medulla and a peripheral relatively hypoechoic cortex. The 
adjacent lobes create an undulating cortex which is 
described as normal fetal lobation. The normal indenta-
tions between renal lobes are distinguished from scarring 
as the indentation is between the pyramids, versus cen-
tered at the tip of the pyramids in scarring. The hypoechoic 
pyramids become isoechoic to adjacent renal parenchyma 
over time and are occasionally confused for masses or 
cysts (Fig. 7.3).
Compared to adults, renal masses are relatively uncom-
mon in children. Renal tumors tend to be very large. The 
most common solid tumor in an infant is a mesoblastic 
nephroma. Despite their large size, they tend to be benign. 
The most common childhood renal tumor is Wilms’ tumor. 
In the past three decades, the survival rate of children with 
these tumors approaches 90% [5]. Simple cysts are relatively 
uncommon compared to adults. If more than one simple cyst 
is identified, cystic renal disease should be considered, 
including autosomal dominant polycystic disease. Cystic 
tumors, including cystic nephroma or focal cystic dysplasia, 
are uncommon. When the whole kidney develops as abnor-
mal, cysts with no normal renal parenchyma, a multicystic 
dysplastic kidney is formed.
The collecting tubules in the medullary pyramids drain 
into the minor calyces which drain into the major calyces 
and into the renal pelvis. When there is urinary tract dilation, 
there is progressive dilation of the pelvis and calyces. This is 
described by many terms, including pyelectasis in utero and 
hydronephrosis in fetuses and children.
There are many ways of describing the dilated urinary 
tract. The only system which unifies prenatal and postnatal 
imaging into one system is the Urinary Tract Dilation System 
(UTD) which was created by radiologists, urologists, and 
nephrologists. The six common descriptions are (1) anterior 
posterior renal pelvic diameter, (2) calyceal dilation, (3) ure-
teral dilation, (4) renal parenchymal thickness, (5) renal 
parenchymal echogenicity, and (6) bladder appearance. In 
fetuses,  oligohydramnios which may be due to urinary tract 
abnormalities is also described [6–8].
Prenatal urinary tract dilation or hydronephrosis is com-
mon, present in 1–4% of pregnancies. Most prenatal hydro-
nephrosis is mild and resolves [9, 10]. The most common 
pathology to cause pelvic and calyceal dilation without ure-
Fig. 7.3 The typical characteristics of a kidney in an infant are 
hypoechoic medullary pyramids and fetal lobulation which gives a 
lobular contour to the kidneys
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teral dilation is ureteropelvic junction obstruction. This is 
due to an intrinsic obstruction at the ureteropelvic junction or 
occasionally is due to a crossing anomalous renal vessel. The 
vessel causes obstruction when there is increased urine pro-
duction and the vessel kinks the ureteropelvic junction. 
These obstructions, unlike intrinsic ureteropelvic junction 
obstructions, are intermittent and cause pain only during 
obstruction.
The greater the degree of prenatal or postnatal hydrone-
phrosis, the greater the likelihood of ureteropelvic junction 
obstruction. The likelihood of vesicoureteral reflux is the 
same regardless of the degree of dilation [11]. MAG-3 and 
MRU examinations are both useful for quantifying the 
degree of obstruction and relative renal function [12].
There are certain entities that tend to affect the entire uri-
nary tract: the bladder, ureters, and kidneys. The three most 
common entities are duplex kidneys with complete ureteral 
duplication, posterior urethral valves, and prune belly 
syndrome.
When there is complete ureteral duplication, the upper 
pole ureteral orifice is ectopic (the Weigert-Meyer rule). 
The ectopic upper pole ureter terminates anywhere from 
the trigone of the bladder, inferiorly and medially to the 
base of the bladder (the so-called ectopic pathway). In 
boys, ectopic ureters terminate above the urethral sphincter 
in the proximal urethra and Wolffian duct remnants includ-
ing the ejaculatory ducts, vasa, and seminal vesicles. In 
females, ectopic ureters can extend below the urethral 
sphincter or into the vagina and can cause daytime and 
nighttime wetting. When the ectopic ureter is obstructed or 
ends in a ureterocele, it dilates. A ureterocele is cystic dila-
tion of the intramural portion of the ureter, which appears 
as a thin-walled cyst in the bladder and is continuous with 
the ureter. The more ectopic the ureter, the more dysplastic 
the associated upper pole parenchyma. The lower pole is 
the analog of the single system ureter. There may be 
 coexisting lower pole reflux or ureteropelvic junction 
obstruction.
Posterior urethral valves are thin leaflets which cause 
obstruction in the posterior urethra, at the base of the veru-
montanum, in boys. The valves cause a variable degree of 
bladder outlet obstruction, bladder wall thickening, and vari-
able hydroureteronephrosis. Often the degree of left and 
right urinary tract dilation is asymmetric. The hydrouretero-
nephrosis may be due to reflux, obstruction, or both. VCUG/
MCUG diagnoses both the posterior urethral valves and 
reflux. Although this diagnosis can be suspected in utero, 
milder cases present in childhood with infection or milder 
hydroureteronephrosis. In severe cases, the kidneys may be 
dysplastic and high pressures may lead to forniceal rupture, 
urinomas, and urine ascites (Fig. 7.4).
Prune belly syndrome can mimic posterior urethral 
valves. The triad of cryptorchism, dysplastic kidneys, and 
severe reflux can appear radiographically similar to posterior 
urethral valves. The bladder is dilated but thinner than in 
boys with valves, the ureters are severely dilated, and the 
kidneys are dysplastic. However, children with prune belly 
syndrome have lax anterior abdominal wall musculature and 
no posterior urethral valves despite a dilated posterior ure-
thra. The anterior urethra may also be dilated, the so-called 
megalourethra.
7.1.1.5  Summary
If one systematically looks at the bladder, ureters, and kid-
neys (BUK), the urinary tract will be evaluated completely. 
The most common mistake is that people assume that the 
bladder is normal. Ureteral dilation should be evaluated 
carefully, as dilation distinguishes hydronephrosis (typi-
cally due to ureteropelvic junction obstruction) from hydro-
ureteronephrosis (typically caused by primary megaureter 
or reflux). An MCUG/VCUG distinguishes reflux from 
obstruction. When evaluating the kidney, carefully assess its 
a b c
Fig. 7.4 (a–c) Posterior urethral valves, depending on severity, can 
affect the appearance of the bladder, ureters, and kidney. In this exam-
ple of severe posterior urethral valves, (a) the bladder wall is thick and 
irregular; (b) there is severe hydronephrosis (H) characterized by pelvic 
and peripheral calyceal dilation, thinning and cystic dysplasia of the 
renal parenchyma, and ureteral dilation (U); and (c) A VCUG demon-
strates posterior urethral valves (arrowhead) with severe dilation of the 
posterior urethra
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presence, echogenicity, and for the presence and degree of 
urinary tract dilation. The common entities which affect the 
bladder, kidney, and ureters are duplex kidneys with com-
plete ureteral duplication, posterior urethral valves, and 
prune belly syndrome.
7.2  Part II
7.2.1  Female Genital Tract
Ultrasound is the most important imaging technique in child-
hood pelvic imaging. MRI is only used in complex cases.
7.2.1.1  Normal Development
The paramesonephric (Müllerian) ducts are paired structures 
that undergo fusion and resorption that form the uterus, prox-
imal fallopian tubes, and upper vagina. The distal segments 
of the Müllerian ducts fuse in the midline forming the utero-
vaginal canal. The development of the uterus is complete by 
12 weeks’ gestation. Interruption of normal fusion and 
resorption of the Müllerian ducts give rise to a broad spec-
trum of Müllerian duct anomalies. Lower part of the vagina 
and ovaries arises from the urogenital sinus and the primitive 
yolk sac, respectively [13].
7.2.1.2  Uterus
In the newborn girl, the female internal genitalia are promi-
nent due to the maternal and placental hormone exposure in 
utero. The endometrium is normally clearly seen as an 
 echogenic stripe at the center of the uterus. After 2–3 months 
until puberty, the uterus is relatively small and tubular in 
configuration (2–4 cm) with the cervix being as large and 
as thick as the fundus (<1 cm). The endometrium lining is 
relatively inconspicuous. During puberty the fundus of the 
uterus enlarges and becomes bulbous in contour. The post-
pubertal uterus is around 5–8 cm in length and has a pear-
shaped appearance. The endometrial lining undergoes 
cyclic changes associated with the menstrual cycle [14] 
(Fig. 7.5).
7.2.1.3  Congenital Abnormalities
Female genital tract anomalies may result from agenesis, 
hypoplasia, or abnormalities related to disorders in lateral 
fusion, vertical fusion, or resorption. Congenital Müllerian 
anomalies occur in around 1.5% of females and are strongly 
associated with renal anomalies (in 30–50%) [15]; however 
congenital Müllerian anomalies are not associated with ovar-
ian anomalies.
Ultrasound examination of the uterus should be per-
formed in all female neonates with MCDK, unilateral renal 
dysplasia, single kidney, or adrenal hyperplasia due to the 
high risk of associated female tract anomalies.
Additional MRI can be valuable as MRI provides great 
anatomical detail of both the endometrium and outer contour 
of the uterus [14].
Imperforate hymen is the most common obstructive 
anomaly of the female pelvis [16]. Usually there are no other 
associated abnormalities. Ultrasound shows fluid distention 
of the vagina with a lesser degree of cervical/uterine disten-
tion. Echogenic debris within the fluid is due to mucous 
secretions in neonates and blood in postmenarcheal girls. 
This fluid-debris level helps to distinguish a dilated vagina 
from the bladder or other cystic pelvic masses.
Partial or complete failure of resorption of the septum 
between the two Müllerian ducts results in a septate uterus. 
The external surface has a normal configuration and there are 
two endometrial cavities. The septum is complete if it 
extends to the cervical os. There is a single cervix.
Bicornuate uterus results from partial non-fusion of the 
Müllerian ducts. The external surface is deeply indented. A 
common challenge is to differentiate between a bicornuate 
uterus and a septate uterus. This distinction is clinically 
important because the septate uterus carries a high risk of 
miscarriage. The absence of the indentation of the external 
contour (<1 cm cleft) with the presence of duplicated 
 endometrial cavity is the key feature to diagnose a septate 
uterus rather than a bicornuate uterus [17].
Complete non-fusion leads to a didelphys uterus. Two 
cervices are inevitably present. Unicornuate uterus occurs 
when there is a complete or near-complete arrested 
a b c
Fig. 7.5 (a–c) Sagittal image of a neonate (a), 4-year-old (b) and 18-year-old (c) girl, illustrates the relative large uterus in the newborn, the more 
tubular appearance in a child and the pear-shape appearance in the adolescent girl
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 development of one of the Müllerian ducts resulting in a 
single- horned uterus with a single round ligament and 
fallopian tube [16]. Presence of endometrium in a 
 rudimentary horn is a clinically important finding because 
there is an increased prevalence of endometriosis, pelvic 
pain and higher risk of problems during pregnancy 
 (miscarriage, ectopic pregnancy, preterm labor, and uter-
ine rupture).
Complete arrested development of both Müllerian ducts 
is also known as the Mayer-Rokitansky-Kuster-Hauser syn-
drome. In this syndrome there is a congenital absence of the 
proximal vagina, cervix, and uterus with normal external 
genitalia [17]. Primary amenorrhea is the most common clin-
ical presentation.
7.2.1.4  Ovaries
Ovaries can be distinguished from other pelvic structures by 
identifying small follicle cysts within the ovaries that can be 
seen from birth. The size of the follicles decreases during a 
hormonally quiescent period. The conspicuity and number of 
follicle cysts increases after adrenarche (around 10–11 years 
of age) and puberty [18].
7.2.1.5  Ovarian Cysts and Other Lesions
In the fetus and in the neonatal period, large ovarian cysts are 
occasionally detected due to maternal and placental hormone 
exposure. Most neonatal cysts are asymptomatic and resolve 
within the first year of life. Complications from larger ovar-
ian cysts include torsion, bleeding, and strangulation in an 
inguinal hernia [14].
7.2.1.6  Ovarian Torsion
Torsion is caused by partial or complete rotation of the ovary 
and/or fallopian tube around the infundibulopelvic ligament. 
In the neonate ovarian torsion occurs due to a cyst. During 
childhood torsion is most often caused by an ovarian mass 
(cystic teratoma). The sonographic features of ovarian tor-
sion include enlarged ovary with peripherally located folli-
cles. Often the ovary is located in the midline of the lower 
abdomen with the uterus deviated toward the affected side. 
Sometimes the whirlpool sign of twisted vascular pedicle 
can be seen. Doppler findings can be widely variable related 
to the dual blood supply of the ovaries (uterine and ovary 
artery) [14].
7.2.1.7  Ovarian Neoplasm
Ovarian neoplasms are extremely rare in the neonate and infant. 
The most common benign ovarian tumor in childhood is a cystic 
teratoma, accounting more than 90% of all benign ovarian 
tumors. Most cystic teratomas have a complex appearance on 
sonographic imaging that depends on the relative amount of fat, 
calcium, serous fluid, and hair within the lesion [19].
7.3  Part III
7.3.1  Male Genital Tract
7.3.1.1  Normal Development
The descent of the testis occurs at two stages. The intra- 
abdominal descent takes place at 10–15 weeks’ and the 
inguinoscrotal descent occurs at 26–40 weeks’ gestation 
[13]. At ultrasound, the testis is a homogenous bean-shaped 
structure, which has an echogenic mediastinum as one of its 
landmarks. Blood flow is normally homogeneous.
7.3.1.2  Congenital Abnormalities
Ultrasound is often used to identify the location of the unde-
scended testis (also called cryptorchidism) with variable suc-
cess. Some people advocate the use of MRI. However, the 
appearance of a smaller, ectopic testis is often similar to 
lymph node with either ultrasound or MRI. The echogenic 
mediastinum and the homogeneous blood flow can be useful 
ultrasound characteristics to distinguish the testis from an 
inguinal node.
7.3.1.3  Testicular Torsion
Testicular torsion can occur in newborns and infants. They 
will present with an enlarged, discolored scrotum. The testis 
is often unsalvageable because the torsion is discovered too 
late. Extravaginal torsions are more common in infancy, com-
pared to intravaginal torsions, which occurs during puberty.
Ultrasound findings of testicular torsion are complete 
absence of blood flow in the testis in comparison to the other 
side. With prolonged torsion the affected testis becomes 
hypoechoic. Most often the testis lies more cranially within 
the scrotal sac and the twisted spermatic cord can be seen. 
The most important part of the examination is to compare the 
findings with the normal side (Fig. 7.6) [20].
Fig. 7.6 Sagittal ultrasound image shows an inguinal hernia in a 
female infant that contains uterus and both ovaries
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7.3.1.4  Inguinal Hernia
Indirect, sliding hernia inguinalis is an uncommon finding in 
male and female neonates, especially in premature infants 
(up to 30%) due to a patent processus vaginalis (Fig. 7.7). 
The bowel, ovaries, and fallopian tubes are the organs that 
are most commonly incarcerated. Ultrasound is an accurate 
method to determine the content of inguinal hernia. Peristalsis 
with the herniated bowel loops suggests viability.
References
 1. Lebowitz RL. The coexistence of obstruction and reflux in children. 
Australas Radiol. 1984;28:124–5.
 2. McLellan DL, Retik AB, Bauer SB, et al. Rate and predictors of 
spontaneous resolution of prenatally diagnosed primary nonreflux-
ing megaureter. J Urol. 2002;168:2177–80; discussion 2180
 3. Mandell J, Lebowitz RL, Peters CA, et al. Prenatal diagnosis of the 
megacystis-megaureter association. J Urol. 1992;148:1487–9.
 4. Chow JS, Benson CB, Lebowitz RL. The clinical significance of 
an empty renal fossa on prenatal sonography. J Ultrasound Med. 
2005;24:1049–54; quiz 1055-1047
 5. Smets AM, de Kraker J. Malignant tumours of the kidney: imaging 
strategy. Pediatr Radiol. 2010;40:1010–8.
 6. Nguyen HT, Benson CB, Bromley B, et al. Multidisciplinary 
consensus on the classification of prenatal and postnatal uri-
nary tract dilation (UTD classification system). J Pediatr Urol. 
2014;10:982–98.
 7. Chow JS, Darge K. Multidisciplinary consensus on the classifica-
tion of antenatal and postnatal urinary tract dilation (UTD classifi-
cation system). Pediatr Radiol. 2015;45:787–9.
 8. Chow JS, Koning JL, Back SJ, et al. Classification of pedi-
atric urinary tract dilation: the new language. Pediatr Radiol. 
2017;47:1109–15.
 9. Tombesi MM, Alconcher LF. Short-term outcome of mild isolated 
antenatal hydronephrosis conservatively managed. J Pediatr Urol. 
2012;8:129–33.
 10. Alconcher LF, Tombesi MM. Natural history of bilateral mild iso-
lated antenatal hydronephrosis conservatively managed. Pediatr 
Nephrol. 2012;27:1119–23.
 11. Lee RS, Cendron M, Kinnamon DD, et al. Antenatal hydronephro-
sis as a predictor of postnatal outcome: a meta-analysis. Pediatrics. 
2006;118:586–93.
 12. Dickerson EC, Dillman JR, Smith EA, et al. Pediatric MR urogra-
phy: indications, techniques, and approach to review. Radiographics. 
2015;35:1208–30.
 13. Servaes S, Epelman M. The current state of imaging pediatric geni-
tourinary anomalies and abnormalities. Curr Probl Diagn Radiol. 
2013;42:1–12.
 14. Muller LS. Ultrasound of the paediatric urogenital tract. Eur J 
Radiol. 2014;83:1538–48.
 15. Chan YY, Jayaprakasan K, Zamora J, et al. The prevalence of con-
genital uterine anomalies in unselected and high-risk populations: a 
systematic review. Hum Reprod Update. 2011;17:761–71.
 16. Paltiel HJ, Phelps A. US of the pediatric female pelvis. Radiology. 
2014;270:644–57.
 17. Behr SC, Courtier JL, Qayyum A. Imaging of mullerian duct anom-
alies. Radiographics. 2012;32:E233–50.
 18. Herter LD, Golendziner E, Flores JA, et al. Ovarian and uterine 
sonography in healthy girls between 1 and 13 years old: correlation 
of findings with age and pubertal status. AJR Am J Roentgenol. 
2002;178:1531–6.
 19. Epelman M, Chikwava KR, Chauvin N, et al. Imaging of pediatric 
ovarian neoplasms. Pediatr Radiol. 2011;41:1085–99.
 20. Munden MM, Trautwein LM. Scrotal pathology in pediatrics with 
sonographic imaging. Curr Probl Diagn Radiol. 2000;29:185–205.
Fig. 7.7 Transverse image of both testes in a 14-year-old boy shows 
absent vascularity of the right testis consistent with torsion. Comparison 
with the normal side is an important part of the ultrasound study
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.
org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropri-
ate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. 
The images or other third party material in this book are included in the book's Creative Commons license, unless indicated otherwise in a credit 
line to the material. If material is not included in the book's Creative Commons license and your intended use is not permitted by statutory regula-
tion or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Key Points
• Ultrasound is an essential tool in the evaluation of 
the urogenital tract in infants and children.
• Look systematically at the bladder, ureters, and kid-
neys to evaluate congenital urinary tract anomalies.
• The finding of dilated ureter distinguishes UPJ 
obstruction from reflux/primary megaureter.
• In the newborn girl, the female internal genitalia are 
prominent due to the maternal and placental hor-
mone exposure in utero.
• Female genital tract anomalies are strongly associ-
ated with renal anomalies.
• Indirect, sliding hernia inguinalis is a common find-
ing in male and female neonates, especially in pre-
mature infants (up to 30%) due to a patent processus 
vaginalis.
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Adnexal Diseases
Andrea Rockall and Rosemarie Forstner
8.1  Introduction
Adnexal masses are common and may present symptomati-
cally with pelvic or abdominal pain or may be identified inci-
dentally during the course of imaging for another indication. 
The majority of adnexal masses are benign, but a small num-
ber will be borderline tumors or invasive cancer. In the case 
of a benign lesion, the aim is to reassure the patient and man-
age according to the clinical need, without subjecting the 
patient to over-extensive or inappropriate surgery [1]. 
Conversely, in cases that demonstrate features with a higher 
likelihood of ovarian malignancy, referral to a specialist cen-
ter will ensure the best possible outcome for the patient.
One major difficulty is that undertaking a biopsy to con-
firm the nature of an adnexal mass is not advised, if there is 
no peritoneal disease beyond the ovary. Biopsy could result 
in spillage of a potentially confined tumor and increase stage 
and risk for patient. Therefore, the clinical decision on how 
aggressively to manage the ovarian mass relies on the avail-
able clinical and image findings, rather than histology.
The clinical context at the time of presentation is relevant. 
The age and menopausal status of the patient and the pres-
ence of acute or chronic pain or fever may inform the inter-
pretation of image findings. In premenopausal women with 
pain, a pregnancy test is indicated in order to rule out possi-
ble ectopic pregnancy as a cause of an adnexal mass.
Ultrasound is the first-line imaging modality, allowing the 
characterization of most adnexal masses. MRI is indicated in 
the characterization of sonographically indeterminate 
masses, whereas CT is indicated for further staging of a sus-
pected ovarian cancer on US.
8.2  Imaging Modalities to Assess 
an Adnexal Mass
8.2.1  Ultrasound (US)
Optimally, transvaginal ultrasound (TVUS) and transabdomi-
nal ultrasound (TAUS) are combined to provide characteriza-
tion of the adnexal mass and its differentiation from the uterus 
or other pelvic abnormalities. TAUS also provides informa-
tion of ancillary findings that may be crucial for the diagno-
sis, e.g., presence of peritoneal implants, ascites, pleural 
effusion, and lymph node enlargement, and assessment of the 
kidneys and the bowels. For characterization of an adnexal 
mass, the following imaging features indicative of malig-
nancy have been widely used: wall irregularity, thick septa-
tions (3 mm), papillary projections, solid components, and 
large size (4 cm) [1–3]. Unfortunately these features overlap 
with those of benign pathologies, e.g., tubo-ovarian abscess, 
corpus luteum cyst, endometriomas, and some rare benign 
tumors. Recently, the IOTA simple rules model has been 
introduced to preoperatively assess adnexal masses with 
US. Five sonographic imaging features each defining the B 
(benign) and M (malignant) categories are used to distinguish 
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Learning Objectives
• To know the most common benign ovarian lesions
• To be aware of the indications for MRI of adnexal 
masses
• To know the sequences for basic and fully opti-
mized MRI of adnexal masses
• To be able to use an algorithmic approach to charac-
terize adnexal masses
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between malignant and benign adnexal masses [4–6]. Thus, 
in expert hands approximately 78–80% of complex adnexal 
masses can be diagnosed with US alone. Limitations include 
mostly benign solid masses, e.g., endometriomas, fibromas, 
thecomas, and rare other ovarian tumors.
8.2.2  Magnetic Resonance Imaging (MRI)
MRI is recommended as a second-line imaging technique to 
evaluate adnexal masses that remain indeterminate on US 
[7]. MRI combines excellent contrast resolution and lack of 
nonionizing radiation, which is of utmost importance in 
 children and in the reproductive age. It is most useful in 
women with a low pretest probability of malignancy of the 
adnexal mass. Studies show high diagnostic sensitivity (67–
100%) and specificity (77–100%) [8–16].
Typical MRI protocols include T2-weighted imaging in 
two planes, usually the sagittal T2-weighted imaging provid-
ing overview of the uterus and the ovaries and a transaxial 
T1- and high-resolution fast spin echo (FSE) T2-weighted 
imaging sequence covering in thin slices the ovaries [7]. If 
the ovaries are not seen, oblique axial T2-weighted imaging 
taken along the long axis of the uterus will visualize the ova-
ries in atypical position along their ovarian axis. In equivocal 
cases, this plane or alternatively a coronal plane also serves 
in solving important differential diagnostic issues, e.g., the 
nonovarian origin of a parauterine mass (i.e., pedunculated 
uterine leiomyoma). Features of subserous uterine leiomyo-
mas present presence of bridging vessels between the mass 
and the myometrium or the claw sign of the uterine myome-
trium. In contrast, demonstrations of follicles within or in the 
periphery of the mass and the ovarian beak sign are typical 
features of ovarian origin of a pelvic mass [7].
The majority of adnexal lesions can be characterized by their 
specific signal characteristics on T1- and T2-weighted imaging. 
Simple fluid has homogeneous low signal on T1-weighted 
imaging and high SI on T2-weighted imaging. Fat and hemor-
rhage have high SI on T1-weighted imaging. Fat suppression 
(FS) on T1-weighted imaging is used to differentiate fat-con-
taining dermoids from hemorrhagic cystic lesions [7]. In solid 
and in cystic adnexal masses, characterization is best performed 
by complementing the basic sequences with DWI and intrave-
nous administration of gadolinium [11, 15, 16]. For character-
ization of adnexal masses, the recommended high b value is 
between 800 and 1200 mm/s2. Optimally, dynamic multiphase 
contrast-enhanced (DCE) MRI is used to characterize adnexal 
masses, as the time- intensity curve of a solid aspect of the mass 
in relation to the myometrium will provide important differen-
tial diagnostic information. Subtraction images are essential to 
evaluate enhancing aspects within hemorrhagic lesions, e.g., of 
nodules within endometriomas. Fasting for 4 h, application of 
antiperistaltic medication, and examination with a medium full 
bladder are used to optimize the image quality [7].
8.2.3  Computed Tomography (CT)
In clinical practice contrast-enhanced CT is widely used to 
assess abdominal pathologies, and usually this is accom-
plished by covering the abdomen and the pelvis. For charac-
terization of a sonographically indeterminate mass, CT is not 
recommended, as it is inferior to both MRI and US to assess 
solid and hemorrhagic masses. CT is, however, the modality 
of choice to stage suspected ovarian cancer [17]. Another 
role of CT is in the emergency setting, where it is widely 
used to assess the acute abdomen, for both gynecological 
and non-gynecological causes [18].
8.2.4  Positron Emission Tomography/
Computed Tomography (PET/CT)
PET/CT using fluoro-2-deoxy-D-glucose (FDG) has currently 
no role in characterizing of adnexal lesions. Physiological 
uptake in premenopausal age in normal ovaries and in corpus 
luteum cysts is a well-known cause of misinterpretation [19]. 
FDG uptake can also be seen in benign ovarian tumors, such as 
dermoids, as well as in inflammatory and infectious processes. 
However, in postmenopausal age FDG avid uptake in the ova-
ries is typically associated with malignant disease. Currently 
the role of PET/CT includes assessment of suspected recur-
rence in two scenarios in patients with ovarian cancer: a) in 
biochemically suspected recurrence and no evidence of disease 
with other imaging techniques or b) to exclude systemic dis-
ease in surgical potential candidates with localized disease.
8.3  Adnexal Masses on MRI
Imaging characteristics of benign and malignant ovarian 
masses are summarized in Table 8.1.
8.3.1  Benign Cystic Ovarian Masses
8.3.1.1  Ovarian Cysts
In reproductive age physiological ovarian cysts constitute the 
vast majority of adnexal masses. Ovarian follicles and follicu-
lar cysts share the same imaging features of thin-walled 
lesions with watery contents, but per definition the term cyst 
should be reserved only to those larger than 3 cm in size [1]. 
Due to their high prevalence in premenopausal age, cysts 
ranging from 3 to 5 cm do not require further follow-up, 
unless they are symptomatic [1]. Ovarian cysts include either 
follicular cysts or corpus luteum cysts. The latter derive from 
failure of regression or hemorrhage into the corpus luteum. 
Corpus luteum and corpus luteum cysts typically have a well-
vascularized thicker wall that may be crenulated and often 
contain blood products. Thus they display a lacelike appear-

















































































































































































































































































































































































































































































































































































































































































































































































































































































ance in US and not watery contents but signal intensity of 
blood products on MRI (high SI on T1-weighted imaging and 
FS T1-weighted imaging or hemosiderin). Typical is unilater-
ality and regression in a 2-3 months interval.
8.3.1.2  Endometriomas
Endometriomas present endometriotic cysts of the ovaries and 
constitute the most common manifestation of endometrio-
sis. Most commonly they present bilateral thick-walled uni- 
or multiloculated cystic lesions containing blood  products. 
Pathognomonic features include high SI on T1-weighted imag-
ing and FS T1-weighted imaging and low SI on T2-weighted 
imaging (shading) (Fig. 8.1) [20]. The T2 dark spot sign pre-
senting focal mural clot is another typical feature [21]. As in 
unilocular hemorrhagic cysts the distinction between endome-
triomas and hemorrhagic cysts may sometimes be difficult, 
follow-up US is recommended. Only functional cysts will 
resolve. Bilaterality and multicystic appearance favor endo-
metrioma. Adhesions with low SI bands and distortion of the 
ovaries, the uterus, or the bowel are other typical findings in 
endometriosis. As deep endometriosis, particularly involving 
the posterior fornix or the rectosigmoid colon, is often associ-
ated with endometriomas, this area should also be scrutinized.
8.3.1.3  Benign Teratomas (Mature Cystic 
Teratomas or Dermoid Cysts)
The typical finding of a mature teratoma is that of a unilocu-
lar cystic lesion containing fatty elements. Often a mural 
nodule, the Rokitansky nodule or dermoid plug, projects into 
the lesion. It is composed of a variety of tissues and typically 
demonstrates fat and calcifications, representing teeth or 
bones. A minority (approx. 15%) of mature cystic teratomas 
will demonstrate no fat or only small foci of fat within the 
wall or the Rokitansky nodule [22].
As US features of dermoids may overlap with those of 
other entities, such as endometriomas or ovarian carcino-
mas, CT (Fig. 8.2) or MRI (Fig. 8.3) is performed in sus-
pected dermoids, as they allow a specific diagnosis. In both 
a b
c
Fig. 8.1 Right ovarian endometrioma. Coronal FSE T2-weighted 
imaging shows a septate right cystic ovarian lesion with thin walls (a) 
(arrow). It demonstrates diffuse moderate hypointensity and adjacent 
very low SI (shading effect) relating to chronic hemorrhage. (b) 
Transaxial T1-weighted imaging and (c) FS T1-weighted imaging 
(arrow) demonstrate high SI characteristic of internal blood products. 
There is no evidence of internal or mural nodularity
A. Rockall and R. Forstner
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of these techniques, identification of fat is the pivotal find-
ing. On MRI, the fatty component will demonstrate high SI 
on both T1- and T2-weighted imaging, with the lipid-laden 
cyst fluid demonstrating a similar high SI on T1-weighted 
imaging and intermediate SI on T2-weighted imaging. 
Chemical shift artifact is often seen at the fat-fluid interface 
in dermoid cysts as bright or dark bands along the fre-
quency-encoding gradient on T2-weighted imaging. Use of 
FS T1-weighted imaging enables dermoid cysts (which 
drop the SI) to be distinguished from hemorrhagic lesions or 
endometriomas (which retain high SI). In lipid poor der-
moids chemical shift imaging techniques may assist in 
defining the correct diagnosis. Due to their very slow 
growth, surveillance is a treatment option in dermoids 
smaller than 5 cm in size.
Rarely, malignant transformation may develop within a 
dermoid cyst; most frequently this is squamous cell cancer in 
a woman of advanced age. Capsular penetration is the most 
reliable sign to establish this extremely rare complication [23].
8.3.1.4  Cystadenomas
Cystadenomas present common epithelial ovarian tumors, 
accounting for up to 50% of tumors in reproductive age and 
for up to 80% of benign ovarian tumors in postmenopausal 
age [24]. Both have now been recognized as precursors of 
ovarian cancer and may slowly transform to borderline 
tumors and to invasive ovarian cancer [25]. Serous cystade-
nomas are more common than mucinous cystadenomas. 
Although an overlap exists, imaging features aid in the dif-
ferentiation of serous from mucinous cystadenomas [24]. In 
general, both entities are thin-walled cystic lesions (Fig. 8.4). 
Serous cystadenomas follow the pattern of a simple cyst or 
of a multiseptate mass, whereas a mucinous cystadenoma is 
typically a large multilocular lesion with locules of various 
fluid contents [26]. On MRI, cysts in mucinous tumors dem-
onstrate various signal intensities on T1- and T2-weighted 
imaging, giving rise to the so-called “stained-glass” appear-
ance. This is because on T1-weighted imaging locules with 
watery mucin generate lower SI than locules with thicker 
mucin. The opposite is generated on T2-weighted imaging. 
Cystadenomas can be differentiated from hydrosalpinx due 
to their complete septations on multiplanar imaging.
8.3.2  Benign Solid Ovarian Tumors
These present a rare subgroup of ovarian tumors mostly com-
prising fibromas, thecomas, and Brenner tumors. They are 
usually unilateral solid ovarian tumors found in perimeno-
pausal age [27]. In clinical practice they have to be differenti-
ated from their mimickers, the more common pedunculated 
uterine leiomyomas. Signs defining the ovarian origin are 
pivotal for the differentiation. Due to their composition of 
fibrous tissue, they usually display typical features of benign 
adnexal masses with solid elements displaying very low SI on 
T2-weighted imaging. In degenerative changes including 
edema, cystic changes, or torsion, their differentiation from 
malignant masses is challenging. However, when such a solid 
lesion demonstrates low SI on DWI using a high b value, 
malignancy can be ruled out [12, 16]. Mild and slow gado-
linium (type 1) enhancement pattern is seen in the majority of 
cases. The triad of an ovarian fibroma, ascites, and pleural 
effusion constitutes the benign Meigs syndrome, which can 
be associated with elevated CA-125. Unlike fibromas, more 
than half of thecomas express estrogenes and may present 
with uterine bleeding, endometrial hyperplasia, or endome-
trial cancer [27]. Dense amorphous calcifications are a typi-
cally feature in Brenner tumors in CT.
Fig. 8.2 Benign teratoma. CT shows a well-defined cystic lesion with 
thin walls (arrow). Its fatty contents allow the specific diagnosis of a 
benign teratoma. Calcification presenting teeth within its superior 






Fig. 8.3 Benign teratoma. MRI shows a right adnexal mass of 2 cm in 
size (arrow). It displays high SI on transaxial FSE T2-weighted imaging 
(a) and internal chemical shift artifact. High SI on T1-weighted imag-
ing (b) and loss of signal on FS T1-weighted imaging (c) are character-
istic of fatty contents. A nodule, the Rokitansky nodule, is seen at its 
posterior aspect in a–c. On DWI using b1000 s/mm2 (d) and on ADC 
(e), the lesion displays diffusion restriction that is due to its sebaceous 




Fig. 8.4 Benign ovarian cystadenoma. Axial T2 (a) and Axial T1 fat 
sat with contrast (b). There is a normal left ovary with follicles (short 
arrow). There is a unilocular thin-walled cyst with no solid tissue fol-
lowing contrast administration (long arrow). The uterus (U) enhances 
brightly. AdnexMR score is 2
A. Rockall and R. Forstner
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8.3.3  Borderline and Malignant Ovarian 
Tumors
Borderline tumors account for approximately 15% of ovar-
ian tumors. The vast majority of ovarian malignant lesions 
include invasive epithelial ovarian cancer and metastases. 
The latter constitute 15% of malignant ovarian masses and 
originate mostly from breast and the GI tract cancer. In con-
trast, sex cord-stromal tumors (granulosa cell and Sertoli- 
Leydig cell tumors) and malignant germ cell tumors are rare 
tumors, mostly found in young age.
Borderline tumors are now considered as precursor 
lesions that gradually progress to different subtypes of epi-
thelial ovarian cancer type II. Serous high-grade ovarian 
cancer, the most common ovarian cancer, shares features 
of tubal and primary peritoneal cancer. It seems to develop 
de novo rapidly and is characterized by rapid dissemina-
tion into the peritoneal cavity and usually presents with 
tumor dissemination outside the pelvis and ascites at diag-
nosis [28].
Likelihood of malignancy increases with the presence of 
septations, mural nodules, and papillary projections (Fig. 8.5). 
MRI features suspicious for malignancy include mass 4 cm, 
cystic lesion with solid component, irregular wall thickness 
of 3 mm or more, septal thickness of 3 mm or more, pres-
ence of papillary projections or nodules, and presence of solid 
mass with necrosis and early, bright contrast enhancement [3, 
16, 29]. In addition, ancillary criteria for suspected malig-
nancy include direct local tissue invasion, peritoneal depos-




Fig. 8.5 Serous borderline ovarian tumor. (a) T2-weighted image dem-
onstrates a papillary formation arising from the anterior wall of a uni-
locular cyst. (b, c) T1 fat-saturated images before and after contrast 
demonstrate enhancement of multiple papillary structures at a different 
position in the cyst. (d) The time-intensity curve in the solid tissue is 
type 2 (short arrow is the enhancement curve of the papillary formation, 
and long arrow is the enhancement curve of the outer myometrium). 
AdnexMR score is 4
8 Adnexal Diseases
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MRI is used for risk stratification in cystic and solid adnexal 
masses. Time-intensity curves types 1, 2, and 3 obtained from 
the solid aspects of such masses are associated with benign, 
borderline, and invasive tumors [16]. Gadolinium also 
improves peritoneal and omental implant detection in case of 
ovarian carcinoma. Due to the overlap of ADC values, DWI 
is less useful to characterize indeterminate adnexal masses, 
but it is pivotal to assess peritoneal carcinomatosis [14–17].
CE-CT remains the technique of choice for staging ovar-
ian carcinoma [17] (Figs. 8.6 and 8.7).
8.4  Risk Stratification of Adnexal Masses 
Using the AdnexMR Score
When interpreting an adnexal mass on MRI, an algorithmic 
approach is strongly advocated. A risk stratification can also 
be applied (Table 8.2) [16].
 1. The first step is to identify if indeed there is a pelvic mass, 
as occasionally a physiological ovarian mass may have 
resolved by the time of MRI. If there is a pelvic mass, 
then it is important to be sure whether it is arising from 
the ovary. Non-ovarian masses, such as leiomyomata, 
peritoneal inclusion cysts, or gastrointestinal stromal 
tumors, or some extraperitoneal lesions, such as 
Schwannoma, may be misinterpreted as adnexal on US. It 
is most important to check for the presence of normal 
ovaries, and this can also be challenging on MRI when a 
large mass fills the pelvis. It may be helpful to follow the 
a b
Fig. 8.6 Disseminated peritoneal disease in tubo-ovarian cancer on 
MRI (a) axial T2 and (b) axial b1000 diffusion image. Left ovarian 
mass (short arrow) and peritoneal disease (long arrow). The solid tissue 
of the ovarian mass is intermediate in signal intensity. The ovarian solid 
tissue and the peritoneal disease are very bright on the diffusion image. 
AdnexMR score is 5 due to the presence of peritoneal disease
Fig. 8.7 Ovarian cancer. CT demonstrates a solid and cystic ovarian 
mass adjacent to the uterus (u). Findings indicative of peritoneal dis-
semination in the pelvis and abdomen include large amounts of ascites 
and peritoneal deposits at the right diaphragm, bowel surface, and pel-
vic peritoneum (arrows)
A. Rockall and R. Forstner
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gonadal vessels down into the pelvis, and the presence of 
follicles or a corpus luteum cyst, if present, is confirma-
tory. If two normal ovaries are identified, then the 
AdnexMR score is 1, and the MRI should focus on char-
acterizing the non-ovarian mass.
 2. If there is an ovarian lesion, then the next question is 
whether the cyst has benign features. This could include 
a unilocular cyst with no enhancing solid tissue, a typical 
endometrioma, or a mature cystic teratoma. Lesions with 
no wall enhancement or lesions with solid tissue that are 
homogeneously low signal intensity on both T2 and high 
b value DWI, with low enhancement, are almost cer-
tainly benign. These lesions all fall into an AdnexMR 
score of 2.
 3. If an ovarian lesion does not comply with the above find-
ings, then the presence and enhancement pattern of solid 
tissue is important. Solid tissue is defined as enhancing 
tissue in an irregular septation, papillary formation, or 
mural nodule or mass. The normal ovarian stroma, smooth 
wall or smooth septation, or non-enhancing internal 
debris is not defined as solid tissue. If solid tissue enhances 
with a low level type 1 time-intensity curve, the lesion is 
scored as AdnexMR score 3.
 4. If solid tissue is present and it enhances with a time- 
intensity curve type 2, the lesion is considered indetermi-
nate on MRI, AdnexMR score 4.
 5. If solid tissue is present and it enhances with a time- intensity 
type 3 or if there is peritoneal disease, then the lesion is 
highly likely malignant and the AdnexMR score is 5.
By following this approach, most masses can be allocated 
a score according to the risk of malignancy, allowing the best 
clinical management for the patient.
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Absence of wall enhancement
Low b = 1000 sec.mm2 and low T2-weighted 
signal intensity within solid tissue
 3.  Probably benign 
mass
Absence of solid tissue
Curve type 1 within solid tissue
 4.  Indeterminate MR 
mass
Curve type 2 within solid tissue
 5.  Probably 
malignant mass
Peritoneal disease
Curve type 3 within solid tissue
Take-Home Messages
• Ultrasound is highly effective in the diagnosis of 
adnexal masses and can direct the treatment 
approach in most cases.
• It is important for radiologists to recognize the fea-
tures of common benign and physiological findings.
• MRI is a second-line imaging modality which can 
be helpful in the characterization of sonographi-
cally indeterminate masses, acting as a problem-
solving tool.
• For MRI, we recommend an algorithmic approach 
which includes DWI and contrast-enhanced sequences 
with DCE as the preferred contrast technique.
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Adrenal Imaging
Isaac R. Francis and William W. Mayo-Smith
9.1  Introduction
The objectives of this chapter are as follows: (1) to describe 
the different workups for adrenal masses, depending on the 
clinical scenario, (2) define adrenal incidentaloma, (3) 
describe the imaging techniques to differentiate benign from 
malignant adrenal masses, and (4) discuss the recommended 
imaging algorithms of workup of an incidental adrenal mass.
The adrenal gland is made up of the catecholamine- 
producing medulla and the steroid-producing cortex. It is a 
common site of primary tumors (functional and nonfunc-
tional) and of metastases. The workup for an adrenal mass 
depends on the patient’s clinical scenario and whether detec-
tion or characterization is the primary goal of imaging. In 
general, it is useful to separate the workup of an adrenal 
mass into one of three algorithms:
 1. Detection of an adrenal tumor in a patient with a known 
biochemical (adrenal hormonal) abnormality
 2. Detection and characterization of an incidental adrenal mass 
in a patient with a known primary malignant neoplasm
 3. Characterization of an incidental adrenal mass in a patient 
with no underlying malignancy
9.1.1  Detection of Biochemically Active 
Adrenal Tumor
Biochemically active adrenal neoplasms originating in the 
adrenal cortex produce an excess of either glucocorticoids, 
aldosterone, or androgens or, if originating in the adrenal 
medulla, an excess of catecholamines. Cushing’s syndrome 
results from an overproduction of cortisol by the adrenal cor-
tex, and approximately 80% of these cases are due to stimula-
tion of the adrenal glands by a pituitary adenoma. A primary 
adrenal cortical tumor is seen in 20% of patients with 
Cushing’s syndrome, and <1% have ectopic production of 
ACTH by a non-pituitary neoplasm, which may be located 
either in the chest, abdomen, or pelvis. The workup of patients 
presenting with Cushing’s syndrome involves a dexametha-
sone suppression test, pituitary magnetic resonance imaging 
(MRI) to look for a pituitary adenoma, and computed tomog-
raphy (CT) depending on the suspected source of ACTH pro-
duction. If pituitary and adrenal neoplasms are excluded and 
an ectopic source of hormone secretion is suspected, then a 
chest and abdominal/pelvis CT should be performed.
Conn’s syndrome results from an adrenal cortical tumor 
producing elevated levels of aldosterone, leading to increased 
sodium retention, hypertension, and potassium wasting. The 
diagnosis is suspected in a hypertensive patient with low 
serum potassium and is confirmed by measuring the ratio of 
serum aldosterone to renin levels. When the diagnosis is sus-
pected based on biochemical assays, CT scans using thin 
collimation (2–3 mm) targeted to the adrenals are useful to 
attempt to differentiate a small adrenal neoplasm from bilat-
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Learning Objectives
• To provide an overview as how to approach the 
evaluation of adrenal mass in various clinical 
scenarios
• To provide an understanding of the various imaging 
techniques available to detect and characterize 
adrenal masses
• To understand the differentiating features between 
benign and malignant adrenal masses
86
eral hyperplasia. If findings are equivocal on CT, as is often 
the case especially in the older populations, then adrenal 
venous sampling to localize and lateralize the site of elevated 
aldosterone production should be performed. At some medi-
cal centers, adrenal venous sampling is the initial study of 
choice especially in patients older than 40 years.
Pheochromocytomas originate from the adrenal medulla and 
produce an excess of catecholamines, causing hypertension. 
These tumors are solitary and occur sporadically in the majority 
of cases. However, these tumors can be seen in subjects with var-
ious syndromes such as MEN type II, von Hippel-Lindau, and 
neurofibromatosis type I. More recent studies show that about 
25% of pheochromocytomas may be familial. Subjects with 
mutations in the succinate dehydrogenase subunits have a high 
risk of developing pheochromocytomas and paragangliomas.
The most appropriate first-line test is the measurement of 
plasma metanephrines. If these are equivocal, urinary meta-
nephrines can be measured. Once the diagnosis has been 
established biochemically, the primary role of the radiologist 
is to determine the location of the pheochromocytoma. Over 
95% of pheochromocytomas originate in the adrenal glands; 
therefore, CT or MRI examination of the abdomen and pel-
vis is sufficient. Extra-adrenal paragangliomas also can 
occur anywhere along the sympathetic chain. MRI of pheo-
chromocytoma typically demonstrates a T2 hyperintense 
mass, although the finding is nonspecific, as pheochromocy-
tomas can also have intermediate signal intensity on 
T2-weighted images, thus simulating adrenal cortical carci-
noma; also, other adrenal lesions can be T2 hyperintense 
(adrenal cysts and hemangiomas/lymphangiomas).
While metaiodobenzyl-guanidine (MIBG) scintigraphy 
has high specificity (>95%) for the diagnosis of pheochro-
mocytoma, its sensitivity is only 77–90%. Recent studies 
have suggested that MIBG scintigraphy should be used 
selectively and only in patients with familial or hereditary 
disorders, in the detection of metastatic disease, and in 
patients with biochemical evidence for pheochromocytoma 
and negative CT or MRI. These studies also concluded that 
MIBG scintigraphy does not offer any added advantage in 
patients with biochemical evidence for a pheochromocy-
toma, no hereditary or familial diseases, and when a unilat-
eral adrenal mass is detected on CT or MRI [1, 2].
The standard treatment of a biochemically active adrenal 
tumor is laparoscopic or open resection.
9.1.2  Staging Patients with Known 
Underlying Extra-Adrenal Malignancy
Evaluation of the adrenal gland in the oncology patient is 
problematic because, although it is a frequent site of metas-
tases, benign adrenal adenomas are much more common in 
general and even in patients with an underlying malignancy 
(adenomas are detected in 2–5% of autopsy series). Thus, the 
presence of an adrenal mass in these patients does not neces-
sarily implicate metastases. The role of imaging in the oncol-
ogy patient is to detect an abnormality of the adrenal gland 
and characterize it as either benign or malignant. PET imag-
ing is being used more frequently in the staging of many neo-
plasms in oncology patients. Adrenal metastases tend to 
demonstrate increased activity, having a greater uptake rela-
tive to the liver or background, while most benign adenomas 
do not. More recent studies have confirmed the high sensitiv-
ity of PET/CT in detecting malignant lesions but the speci-
ficity is lower (87–97%). This loss of specificity is attributable 
to a small number of adenomas and other benign lesions that 
can have increased uptake, thereby mimicking malignant 
lesions [3, 4].
Depending on the primary tumor, CT or PET/CT is a use-
ful first-line exam to stage a known neoplasm. If the patient 
demonstrates an adrenal mass as well as multiple sites of 
metastatic disease, then characterization of the adrenal mass 
is not important. If the adrenal mass is the only abnormality, 
further evaluation is required to characterize the mass and 
differentiate an adenoma from a metastatic focus.
Currently, there are two main criteria used in CT and 
MRI, to differentiate benign adenomas from malignant adre-
nal masses: (1) the differences in intracellular lipid content 
of the adrenal mass, and (2) the vascular enhancement and 
washout patterns. Approximately 80% of adenomas (lipid-
rich adenomas) have abundant intracytoplasmic lipid in the 
adrenal cortex and thus are of low density on unenhanced CT 
or show signal loss on out-of-phase chemical shift MRI 
(CSMRI). Conversely, most metastases have little intracyto-
plasmic lipid and thus do not have a low density on non-
contrast CT. At a threshold of 10 HU, CT has a 71% 
sensitivity and 98% specificity for characterizing lipid-rich 
adrenal adenomas. While a low HU is useful to characterize 
lipid-rich adenomas, it is estimated that up to 20% of adeno-
Key Points
• The role of imaging in patients with suspected bio-
chemically active adrenal tumors is to locate the 
tumor.
• In patients with Conn’s syndrome as imaging find-
ings can be nonspecific especially in older patients, 
adrenal venous sampling may be required to 
 lateralize the side of hyperfunction.
• Adrenal cortical carcinomas are usually large 
 heterogeneously enhancing masses.
• MIBG scintigraphy is not 100% accurate in 
 detecting pheochromocytomas.
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mas do not contain sufficient lipid to be of low density on 
unenhanced CT, i.e., the lipid-poor adenomas [5–7]. 
Histogram analysis (evaluating microscopic levels of lipid 
on a pixel-by-pixel basis) has been used to differentiate ade-
nomas from metastases on non-contrast- and contrast- 
enhanced CT [8]. However, this approach has limited use in 
current clinical practice.
The differences in contrast enhancement and washout, 
between adenomas and metastases, can be used to dif-
ferentiate them. Lipid-rich and lipid-poor adenomas both 
enhance rapidly with intravenous contrast (iodinated CT 
contrast or MR gadolinium chelates) but also have rapid 
washout. Metastases also enhance vigorously with dynamic 
intravenous contrast administration, but the washout is 
more prolonged than in adenomas. This difference in con-
trast washout has been exploited in CT to further differenti-
ate benign from malignant adrenal lesions by calculating 
washout values [9, 10].
Absolute percent washout (APW) values are calculated 
by the formula:
HU at dynamicCT HU at delayed






A value ≥60% is diagnostic of an adenoma.
Relative percent washout (RPW) can be used when a non- 
contrast CT is not available and the dynamic enhanced val-
ues are compared to 15-min delayed scans. RPW is calculated 
by the formula:






A value ≥40% is diagnostic of adenoma.
Specificity for adenoma diagnosis using these washout 
threshold values is >90%.
A pitfall for CT adrenal washout are hypervascular metas-
tases from tumors such as renal cell carcinoma and hepato-
cellular carcinomas as they can have rapid washout similar to 
that adenomas [11].
More recently dual energy CT has been used to character-
ize lipid-rich adenomas using virtual unenhanced images. 
For adrenal masses >1 cm, the specificity for characterizing 
a lesion as benign was 100% in a small series of 42 patients 
with 51 adrenal masses, but subsequent studies have shown 
slightly lower specificity. However, the use of dual energy 
CT has not become mainstream due to limited use of dual 
energy scanners for this purpose worldwide [12–15].
Adenomas can be differentiated from metastases using 
chemical shift MRI [CSMRI] if the patient has an indeter-
minate adrenal mass on unenhanced CT and is allergic to 
iodinated contrast or in young patients, in whom radiation 
exposure is a concern, although with the use of low-dose 
CT techniques, this is less of an issue [16, 17]. Most adre-
nal adenomas contain sufficient intracellular lipid and lose 
signal on the out-of-phase (CSMRI) image compared to the 
spleen. Visual analysis is adequate in most cases to make 
this observation, but quantitative methods, such as the sig-
nal intensity index, are also useful and used routinely 
widely [18, 19].
However, a limitation of the technique is that metastases 
from primary malignancies clear cell renal carcinoma and 
hepatocellular carcinoma which contain intracellular lipid or 
fat can mimic adenomas [20–22].
More recently diffusion-weighted imaging has been used 
to try and differentiate between adenomas and malignant 
masses, but with limited success, as in most studies adeno-
mas and malignant lesions both demonstrated restricted dif-
fusion [23–26].
If the CT, MRI, or PET findings are equivocal, adrenal 
biopsy using CT guidance should be performed, particularly 
to stage in a patient with a malignancy with no other sites of 
metastatic disease, as this may determine whether surgical 
resection is a therapeutic option. The role of adrenal biopsy 
has evolved in the last few years; in addition to the above 
indication of an indeterminate adrenal mass, adrenal biopsy 
can also be used to confirm metastatic disease to the adrenal 
glands in patients with suspected solitary adrenal metastasis. 
CT-guided biopsy has been shown to be safe, with a diagnos-
tic accuracy of 96% and a 3% complication rate [27].
9.1.3  Evaluation of an Incidentally 
Discovered Adrenal Mass
With the continuing increased utilization of CT, the detection 
of the incidental adrenal masses has also increased, given the 
Key Points
• Adenomas can be differentiated from metastases 
using unenhanced CT and CSMRI in many 
instances.
• In most of the remaining patients, CT washout cal-
culations are more helpful than MRI to distinguish 
adenomas from non-adenomas.
• In oncology patients with indeterminate adrenal 
imaging findings, adrenal biopsy may be required 
to accurately stage the patient, and this determines 
optimal treatment.




high prevalence of adenomas in the general population 
(3–7%) [28–30]. In general, the overwhelming majority of 
incidentally discovered adrenal masses (incidentalomas) are 
benign, in a patient with no known malignancy [31]. An 
adrenal incidentaloma can be defined as “an unsuspected and 
asymptomatic mass (measuring ≥1 cm) detected on imaging 
exams obtained for other purposes.”
Risk factors for an incidental adrenal mass being 
malignant include lesion size, change in size, and his-
tory of malignancy. Morphology and features on con-
trast-enhanced CT have been used to distinguish benign 
from malignant masses, but their low sensitivity limits 
use in clinical practice [32]. For patients with no history 
of malignancy, most small (<4 cm) incidentally discov-
ered adrenal masses are benign, and an extensive and 
costly workup may not be justified. Endocrinologists may 
however recommend biochemical workup and imaging 
follow-up to exclude functioning adrenal tumors for all 
adrenal incidentalomas [33]. However, hyperfunctioning 
adrenal tumors rarely present as an “incidental” adrenal 
mass, so this practice is undergoing  reevaluation to justify 
continuing this approach, especially for small 1–2 cm size 
masses [34].
If an adrenal incidentaloma, regardless of size, has 
imaging features diagnostic of a benign lesion, such as a 
<10 HU on CT or loss of signal intensity when compared 
to spleen on opposed-phase/CSMRI [lipid-rich adenoma], 
presence of macroscopic fat [myelolipoma], or features of 
a simple cyst, no additional workup or follow up imaging 
is needed. In patients with a high density adrenal mass on 
unenhanced images and which demonstrates <10 HU 
change following contrast enhancement suggesting a diag-
nosis of adrenal hemorrhage, a follow up CT could be 
obtained to demonstrate interval change (decrease) in size 
and subsequent resolution to exclude the possibility of 
hemorrhage within an underlying mass lesion. Adrenal 
masses which have been stable for at least 1 year, when 
compared to prior imaging exams, are very likely benign 
and in general have no need for imaging follow-up. But if 
the lesion is enlarging or develops hemorrhage, etc., then 
suspicion for malignancy should be raised, and in patients 
with an underlying malignancy, it may be prudent to pro-
ceed to PET/CT or adrenal biopsy or resection. A common 
scenario is an adrenal incidentaloma which measures 
between 1 and 2 cm and >10HU on initial intravenous con-
trast-enhanced CT. What is the best way to proceed in this 
scenario? Although statistically, the lesion is most likely 
benign, it is essential to know if there is a history of malig-
nancy [31]. If there is no history of malignancy, one can 
opt to perform a follow-up unenhanced CT or CSMRI 
exam in 12 months, to determine stability of the lesion. For 
lesions >2 but <4 cm in size and with no history of malig-
nancy, a dedicated adrenal protocol CT is suggested to 
confirm benignity. If the lesion is indeterminate on the 
dedicated adrenal protocol CT, one may consider bio-
chemical evaluation and a follow-up CT in 6 months or 
laparoscopic resection.
However, if there is a history of malignancy without 
other findings of metastatic disease, and the imaging find-
ings are indeterminate then one can obtain a dedicated 
adrenal protocol CT [10, 31, 32, 34] or a PET/CT. If there 
are suspicious imaging features on contrast-enhanced 
CT (central necrosis, irregular margins etc.) [32], a PET/
CT (if not already performed) or adrenal biopsy are 
considerations.
In patients with a prior history of cancer and an adre-
nal mass of any size, and if there is no prior imaging to 
determine stability, one can consider a dedicated adrenal 
protocol or PET/CT. If the lesion does not behave like a 
typical adenoma, or does not show the findings of an ade-
noma on PET/CT, then a biopsy should be considered. A 
history of malignancy is an important risk factor for adre-
nal metastatic disease, as imaging features are typically 
indeterminate on routine portal venous phase contrast-
enhanced CT [31].
In patients with no history of cancer and an adrenal 
mass >4 cm in size, with no benign features, resection 
should be considered as this finding is suspicious for an 
adrenal cortical carcinoma; if there is a history of prior 
cancer, then a PET/CT scan and as indicated, a biopsy is 
recommended [35].
Past evidence suggests that adoption of these recommen-
dations has led to a more standardized approach to the inci-
dentally discovered adrenal mass [28]. An algorithm for the 
treatment of an adrenal incidentaloma published in the 
Journal of the American College of Radiology is shown in 
Fig. 9.1 [36].
9.2  Concluding Remarks
Most incidentally discovered adrenal masses are benign. But 
in the setting of a known malignancy, differentiation between 
a metastases and adenoma is essential to guide management. 
We have provided an algorithmic approach to evaluate and 
manage adrenal masses encountered in the most common 
clinical scenarios.
Key Points
• No additional workup usually needed for adrenal 
cyst, myelolipoma or adrenal hemorrhage due to 
trauma.
• An indeterminate mass >4 cm in patients with no 
history of a malignancy, is surgically removed.
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Diseases of the Upper GI Tract
Richard M. Gore and Marc S. Levine
10.1  Nonneoplastic Conditions
10.1.1  Gastroesophageal Reflux Disease
Early reflux esophagitis typically is characterized on double- 
contrast studies by granularity of the distal esophagus sec-
ondary to mucosal edema and inflammation [1]. Shallow 
ulcers appear as punctate, linear, or serpiginous barium col-
lections, sometimes associated with radiating folds [1]. This 
ulceration almost always extends proximally from the 
 gastroesophageal junction as a continuous area of disease, so 
ulcers that are confined to the upper or midesophagus should 
suggest another cause for the patient’s disease. Scarring from 
reflux esophagitis can lead to the development of reflux- 
induced (peptic) strictures, typically seen as smooth, tapered 
areas of distal esophageal narrowing or as asymmetric ring-
like strictures above a hiatal hernia [1].
10.1.2  Barrett’s Esophagus
Barrett’s esophagus is a premalignant condition in which the 
usual squamous epithelium in the distal esophagus is 
replaced my metaplastic columnar epithelium secondary to 
chronic reflux esophagitis. This condition develops in 10% 
of patients with reflux esophagitis and 20–40% with peptic 
strictures [1]. Barrett’s esophagus sometimes can be recog-
nized on barium studies by the development of a tapered or 
ringlike stricture in the midesophagus [1]. Other patients 
may develop a distinctive reticular pattern of the mucosa [2]. 
In the presence of a hiatal hernia and reflux, a high stricture 
or reticular pattern should be strongly suggestive of Barrett’s 
esophagus. Another recently reported finding of Barrett’s 
esophagus is a high Z line at the level of an elevated squamo-
columnar mucosal junction above long-segment columnar 
metaplasia [3].
10.1.3  Infectious Esophagitis
Candida esophagitis typically is manifested on double- 
contrast barium studies by multiple discrete linear or irregu-
lar plaquelike defects separated by normal mucosa [4]. 
Patients with AIDS occasionally may develop a more fulmi-
nant form of candidiasis characterized by a grossly irregular 
or shaggy esophagus secondary to trapping of barium 
between innumerable plaques and pseudomembranes [5]. 
Learning Objectives
• To review the key double-contrast upper GI exami-
nation features of benign infectious and inflamma-
tory esophagitis
• To identify the double-contrast barium features of 
the various gastritides
• To review the role of MDCT, endoscopic ultra-
sound, MR, PET/CT, PET-MR, and functional 
imaging in the staging and follow-up of esophageal 
cancer
• To understand the role of MDCT, endoscopic ultra-
sound, MR, PET/CT, PET-MR, and functional 
imaging in the staging and follow-up of gastric 
cancer
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In an immunocompromised patient with dysphagia or 
 odynophagia, these findings should be highly suggestive of 
Candida esophagitis. In contrast, herpes esophagitis usually 
is characterized by multiple small, discrete ulcers in the 
upper or midesophagus without associated plaque formation 
(Fig. 10.1) [6].
Patients with AIDS occasionally may develop CMV 
esophagitis, manifested by giant ulcers greater than 1 cm in 
size [7]. Because herpetic ulcers rarely become this large, 
giant ulcers should suggest CMV in patients with 
AIDS. Human immunodeficiency virus (HIV) has also been 
recognized as a cause of giant esophageal ulcers indistin-
guishable from those in CMV [8]. Unlike CMV ulcers, how-
ever, HIV ulcers may undergo rapid healing on treatment 
with oral steroids, so endoscopy is required to differentiate 
these infections.
10.1.4  Eosinophilic Esophagitis
Eosinophilic esophagitis (EoE) has been recognized as a 
chronic inflammatory disease causing dysphagia and 
recurrent food impactions in young men, who often have 
a history of allergies, asthma, or peripheral eosinophilia. 
EoE may be manifested on esophagography by segmental 
strictures, discrete ringlike indentations (the so-called 
ringed esophagus) [9], or a small-caliber esophagus with 
smooth, long-segment narrowing of virtually the entire 
thoracic esophagus (Fig. 10.2) [10]. Recently, lichen pla-
nus involving the esophagus has been recognized as 
another cause of a small-caliber esophagus indistinguish-
able from that in EoE [11]. Unlike EoE, however, lichen 
planus typically occurs in elderly women with a skin rash 
Fig. 10.1 Herpes esophagitis. Double-contrast esophagram shows 
multiple small, discrete ulcers both en face (black arrows) and in 
profile (white arrows) in the midesophagus. In the appropriate 
clinical setting, these findings are highly suggestive of herpes 
esophagitis
Fig. 10.2 Eosinophilic esophagitis with a small-caliber esophagus. 
Barium esophagram shows diffuse narrowing of the entire thoracic 
esophagus, which has a smooth, uniform contour. This was a young man 
with long-standing dysphagia and asthma. Lichen planus involving the 
esophagus may produce identical findings, but these patients tend to be 
elderly woman, often presenting with dysphagia and a skin rash
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and is not associated with allergies, asthma, or peripheral 
eosinophilia [11].
10.1.5  Drug-Induced Esophagitis
Drug-induced esophagitis is caused by various medications, 
including tetracycline, doxycycline, potassium chloride, 
quinidine, alendronate, and nonsteroidal anti-inflammatory 
drugs (NSAIDs) [12]. Affected individuals often ingest the 
medication with little or no water immediately before going 
to bed, so the medication lodges in the midesophagus, caus-
ing a focal contact esophagitis. Double-contrast studies may 
reveal a focal cluster of small, discrete ulcers in the mid-
esophagus indistinguishable from those in herpes  esophagitis 
[12], but the correct diagnosis usually is suggested by the 
clinical history.
10.1.6  Erosive Gastritis
Erosive gastritis is characterized on double-contrast studies 
by multiple punctate or slitlike collections of barium sur-
rounded by radiolucent halos of edematous mucosa [13]. 
The erosions tend to be located in the gastric antrum and 
often are aligned on the crests of the folds. NSAIDs are by 
far the most common cause of erosive gastritis, accounting 
for more than 50% of cases. Occasionally, however, NSAID- 
induced erosive gastritis may be manifested by multiple dis-
tinctive linear or serpiginous erosions that tend to be 
clustered in the gastric antrum or body, often near the greater 
curvature [14]. These erosions are thought to result from 
localized mucosal injury as the dissolving NSAID capsules 
collect by gravity in the most dependent portion of the stom-
ach. Whatever the explanation, detection of this finding 
should lead to careful questioning about recent NSAID use, 
and if confirmed, the offending medication should be 
withdrawn.
10.1.7  Helicobacter Pylori Gastritis
Helicobacter pylori gastritis can be diagnosed on barium 
studies by thickened folds in the antrum, body, or, less 
commonly, fundus of the stomach [15]. Other patients 
with H. pylori may have a polypoid form of gastritis char-
acterized by grossly thickened, lobulated folds, mimick-
ing the appearance of Ménétrier’s disease, lymphoma, or 
even a submucosally infiltrating carcinoma [15]. In these 
cases, endoscopy and biopsy are required for a definitive 
diagnosis.
10.1.8  Gastric Ulcers
Benign gastric ulcers classically appear en face as round or 
ovoid barium collections with a smooth, surrounding mound 
of edema and/or thin, straight folds radiating to the edge of 
the ulcer crater [16]. When viewed in profile, benign ulcers 
project beyond the gastric wall and are often associated with 
an ulcer mound or collar. In contrast, malignant ulcers appear 
en face as irregular craters in a discrete mass with nodularity 
or clubbing of adjoining folds [16]. When viewed in profile, 
malignant ulcers project inside the lumen within a mass that 
forms acute angles with the wall rather than the obtuse angles 
expected for a benign mound of edema [16].
Most benign ulcers are located on the lesser curvature or 
posterior wall of the gastric antrum of the body [16]. 
Occasionally, however, benign ulcers may occur on the 
greater curvature of the distal antrum, and nearly all of these 
ulcers are found to be caused by NSAIDs [16]. As NSAID- 
induced greater curvature ulcers enlarge, they can penetrate 
inferiorly via the gastrocolic ligament into the transverse 
colon, producing a gastrocolic fistula [17]. In today’s pill- 
oriented society, these NSAID-induced ulcers are the most 
common cause of gastrocolic fistulas.
10.2  Neoplastic Conditions
10.2.1  Esophageal Cancer
On double-contrast barium studies, early squamous cell car-
cinomas of the esophagus present as small sessile polypoid 
lesions with smooth or slightly lobulated contours; plaque- 
like lesions that often have flat, central ulcers that are best 
visualized in profile; or as superficial spreading lesions with 
a nodular appearance of the mucosa without a discrete mass. 
Advanced squamous cell carcinomas may appear infiltrative, 
ulcerative (Fig. 10.3), polypoid, or, less commonly, varicoid. 
Advanced carcinomas most commonly have an infiltrative 
appearance because they tend to grow circumferentially in 
the esophageal wall [18].
Early adenocarcinomas of the esophagus arising from 
Barrett’s mucosa can manifest as small sessile polyps, plaque-
like lesions, or superficial spreading lesions that cause focal 
nodularity of the mucosa without a discrete mass. These early 
cancers can also cause focal irregularity, flattening, or nodu-
larity in a pre-existing peptic stricture. Accordingly, early 
endoscopy and biopsy are necessary to exclude adenocarci-
noma whenever any of these suspicious features develop in a 
region of a peptic stricture. Advanced adenocarcinoma of the 
esophagus can appear infiltrating, polypoid, ulcerative, or, less 
commonly, varicoid on barium studies [18].
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Squamous cell carcinomas of the esophagus tend to be 
located in the upper or midthoracic esophagus and only rarely 
invade the adjacent stomach by contiguous spread. 
Adenocarcinomas of the esophagus develop primarily in the 
distal thoracic esophagus and have a marked tendency to 
invade the gastric cardia and fundus (Fig. 10.4). It may not 
always be possible to differentiate gastric adenocarcinoma of 
the gastric cardia invading the distal esophagus from a 
Barrett’s-related cancer arising from the distal esophagus [18].
Since a multimodality approach is presently used to treat 
esophageal cancer, a precise histologic diagnosis and highly 
accurate tumor staging are prerequisites for selecting the 
most suitable treatment options. This requires histologic 
classification of the tumor type, the exclusion of distant 
organ metastases, localization of the primary tumor in rela-
tion to the tracheobronchial tree, and determination of the 
penetration of the primary tumor through the esophageal 
wall into the surrounding tissues [19].
CT is useful in distinguishing between patients with early 
cancer (T1 and T2) who need further evaluation with EUS 
and those with T3 and T4 disease. For local staging of esoph-
ageal cancer using CT, 3 mm is considered the upper limit of 
normal mural thickness. The following comprise radiologic 
T stage criteria for esophageal cancer:
T1: focal or circumferential wall thickening of >3 and 
≤10 mm and/or intense enhancement of the esophageal 
wall, without stenosis, and the outer borders of the tumor 
are smooth.
T2: focal, polypoid, or diffuse circumferential thickening of 
the esophageal wall >10 and ≤15 mm and the outer bor-
ders of the tumor are either smooth or show stranding for 
less than one-third of the tumor extension.
T3: tumor appears symmetric or asymmetric, and markedly 
diffuse or circumferential wall thickening of ≥15 mm, 
with mild-to-severe stenosis, and marked stranding for 
over one-third of the tumor extension, or extensive blur-
ring of the outer border.
T4: tumor shows invasion into one of the adjacent structures: 
pericardium, the diaphragm, the pleura (T4a), the tra-
cheobronchial tree, or the aorta and spine (T4b) [20].
Lymphatic spread is found in 74–88% of patients with 
esophageal carcinoma. Accurate lymph node assessment for 
Fig. 10.3 Squamous cell carcinoma of the midesophagus. Double- 
contrast esophagram demonstrates a long, ulcerating, malignant appear-
ing esophageal stricture associated with an esophago-bronchial fistula 
(arrow). Note the dilation of the esophagus proximal to the neoplasm
Fig. 10.4 Adenocarcinoma of the gastroesophageal junction. Coronal 
reformatted CT image shows a partially obstructing mass at the gastro-
esophageal junction (white arrow). Notice the paraesophageal adenopa-
thy (yellow arrow)
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metastatic spread is challenging, even with PET/ 
MDCT. Diagnostic accuracy is improved if morphology, 
including size and shape, contrast enhancement pattern, and 
tracer uptake of lymph nodes are considered. N staging is as 
follows: N0, no regional lymph node metastasis; N1, 1–2 
positive regional lymph nodes; N2, 3–6 positive regional 
lymph nodes; and N3, ≥7 positive regional lymph nodes [21].
Hematogenous metastases from esophageal carcinoma 
may involve the liver, lungs, adrenal glands, kidneys, bones, 
and brain. Lymph node involvement outside the periesopha-
geal location is considered M1 disease [21].
10.2.2  Gastric Cancer
On double-contrast barium studies, Type I early gastric 
cancers typically appear as small protruded lesions in the 
stomach. Type II early gastric cancers are relatively flat 
lesions with elevated, superficial, or protruded compo-
nents. These lesions may present as plaque-like eleva-
tions, mucosal nodularity, shallow ulcers, or some 
combination of these findings. Occasionally, these lesions 
can be quite extensive, involving a large portion of the 
surface area of the stomach without invading beyond the 
submucosa. Type III early gastric cancers manifest 
as shallow ulcer craters with nodularity of the adjacent 
mucosa and clubbing or fusion of radiating folds due to 
infiltration of the adjoining folds by tumor. Advanced gas-
tric carcinomas usually appear on barium studies as pol-
ypoid, ulcerative, or infiltrative lesions [22].
As with esophageal carcinoma, precise histologic diagno-
sis and highly accurate tumor staging of gastric cancer are 
prerequisites for selecting the most suitable treatment 
options. In early advanced gastric cancers, the outer border 
of the stomach is smooth. The probability of transmural 
extension of the tumor (T3) is directly correlated with mural 
thickness. In transmural extension, the serosal contour 
becomes blurred, and strand-like areas of increased attenua-
tion may be seen extending into the perigastric fat. Tumor 
spread frequently occurs via ligamentous and peritoneal 
reflections to adjacent organs (T4). The liver may be invaded 
via the gastrohepatic ligament, the pancreas via the lesser 
sac, the spleen via the gastrosplenic ligament (Fig. 10.5), and 
the transverse colon via the gastrocolic ligament. The distal 
esophagus is directly involved by carcinoma of the cardia in 
about 60% of patients, whereas the duodenum is involved by 
carcinoma of the antrum in 13–18% of patients [22–24].
Lymphatic spread is found in 74–88% of patients with gas-
tric carcinoma because of the abundant lymphatic vessels in the 
stomach. The frequency of lymphatic metastases is related to 
the size and depth of penetration of the tumor. N staging depends 
on the number of positive perigastric lymph nodes (N1 1–5, N2 
6–15, and N3 >15 affected lymph nodes) [23, 24].
Hematogenous metastases from gastric carcinoma most 
commonly involve the liver because the stomach is drained 
by the portal vein. Less common sites include the lungs, 
adrenal glands, kidneys, bones, and brain. Lymph node 
involvement outside the perigastric location is considered 
M1 disease. Advanced cancers can develop peritoneal and 
ovarian (Krukenberg) metastases [24].
a b
Fig. 10.5 Adenocarcinoma of the stomach invading the gastrosplenic ligament and splenic hilum (arrows). This gastric neoplasm shows ulcer-
ation on the axial (a) and coronal (b) reformatted image
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10.2.3  Gastric Lymphoma
Lymphoma involves the stomach more frequently than any 
other portion of the gastrointestinal tract. Primary gastric 
lymphomas are confined to the stomach and regional lymph 
nodes (about 35% of gastrointestinal lymphomas) and are 
predominantly non-Hodgkin lymphomas of B-cell origin. 
Lymphoma of mucosa-associated lymphoid tissue (MALT) 
is a distinct type of extranodal lymphoma that is character-
ized by a relatively indolent clinical course and has a much 
better prognosis than gastric carcinoma, with overall 5-year 
survival rates of 50–60%. Although the clinical symptoms in 
high-grade lymphoma and MALT lymphoma may be simi-
lar, they differ in several aspects [25, 26].
High-grade B-cell lymphoma has a relatively aggressive 
course as opposed to the more indolent and favorable out-
come of MALT lymphoma. In high-grade gastric lympho-
mas, the extent of disease is usually greater at presentation, 
with involvement of adjacent organs and perigastric lymph 
nodes [25].
Lymphomas may involve any portion of the stomach. 
Transpyloric spread of tumor into the duodenum occurs in 
about 30% of patients. Despite extensive lymphomatous 
infiltration, the stomach usually remains pliable and disten-
sible without significant luminal narrowing. Early gastric 
lymphoma is confined to the mucosa and submucosa, with 
an average size of only 3.5 cm at diagnosis. Gastric lympho-
mas are usually advanced lesions with a mean diameter of 
10 cm. Most cases involve the antrum and body, although the 
entire stomach can be involved [24].
There are four gross pathologic types of gastric lym-
phoma [22]. Infiltrative gastric lymphomas manifest as focal 
or diffuse enlargement of gastric folds due to submucosal 
spread of tumor. One or more ulcerated lesions characterize 
ulcerative gastric lymphoma. Polypoid gastric lymphomas 
are characterized by intraluminal masses that may simulate 
polypoid carcinomas. Multiple submucosal nodules ranging 
in size between several millimeters and several centimeters 
characterize nodular gastric lymphoma.
CT is the primary imaging modality for pretreatment evalu-
ation of abdominal lymphoma. In patients with suspected gas-
tric lymphoma, CT provides depiction of gastric involvement 
and staging of generalized lymphoma in the abdomen and 
chest. Furthermore, CT may aid in early diagnosis of disease 
progression in patients undergoing therapy and follow-up for 
low-grade MALT lymphoma, which may progress to high-
grade B-cell lymphoma. The CT appearances of lymphoma 
and gastric carcinoma may be very similar.
10.2.4  Gastrointestinal Stromal Tumor (GIST)
GISTs have recently been recognized as the most common 
mesenchymal neoplasm of the gastrointestinal tract. Many 
but not all mesenchymal tumors previously diagnosed as 
leiomyomas, leiomyoblastomas, and leiomyosarcomas on 
are now considered GISTs on the basis of specific immuno-
histochemical criteria- c-kit positivity. The malignant vari-
ety of GISTs represents only about 3% of all malignant 
gastrointestinal tumors. Approximately 60–70% are found 
in the stomach. It is known that 10–30% of GISTs are 
malignant, and the risk of malignancy increases with extra-
gastric location, diameter greater than 5 cm, and extension 
into adjacent organ. Before and during surgery, in the 
absence of metastases, it is difficult to distinguish benign 
and malignant lesions. As with leiomyomas and leiomyo-
sarcomas, intramural endogastric (Fig. 10.6) and exogastric 
lesions can be distinguished [27, 28] on cross-sectional 
imaging studies.
10.2.5  Carcinoid Tumors
Carcinoid tumors of the stomach are rare and have three sub-
types, which have unique endoscopic and radiographic 
appearances. Type 1 gastric carcinoid tumors are associated 
with enterochromaffin-like cell hyperplasia, hypergastrin-
emia, and chronic atrophic gastritis, with or without perni-
cious anemia. Type 1 tumors generally represent benign 
disease. Nodal and hepatic metastases are very rare [29, 30]. 
Type 2 tumors are the least common type, representing 
5–10% of gastric carcinoid tumors. They are seen in the 
hypergastrinemic state of Zollinger-Ellison syndrome in 
association with multiple endocrine neoplasia (MEN) type 1. 
Approximately 30% of patients with MEN 1 have gastric 
carcinoid tumors. Type 2 tumors also arise from 
enterochromaffin- like cells in the setting of hyperplasia. 
These tumors are multicentric and variable in size but are 
prone to developing local lymph node metastases. The 
appearance of these tumors on CT and radiographs of the 
upper gastrointestinal tract can be striking because there are 
multiple masses in the setting of diffuse gastric wall thicken-
ing [29, 30]. Type 3 gastric carcinoid tumors are sporadic 
tumors and are not associated with a hypergastrinemic state. 
They represent about 13% of gastric carcinoid tumors. 
Unlike type 1 and 2 tumors, type 3 tumors are large, solitary 
tumors that may show ulceration and are more likely to be 
invasive with distant metastases. The likelihood of metasta-
sis is dependent on tumor size. Carcinoid syndrome may be 
seen in patients with hepatic metastases [29, 30].
When gastric carcinoid tumors are suspected, contrast 
material and water enhanced multidetector CT should be used 
to detect small mucosal masses. The discovery of polyps in a 
patient with chronic atrophic gastritis should alert the radiolo-
gist to the possibility of type 1 gastric carcinoid tumors. CT is 
necessary to properly assess type 2 (MEN 1 associated) and 
type 3 (sporadic) gastric carcinoid tumors, given the increased 
predisposition for nodal and hepatic metastases [29, 30].




Fig. 10.6 Gastric gastrointestinal stromal tumor. An ulcerating intra-
mural mass is identified in the greater curvature aspect of the proximal 
gastric body. (a) Double-contrast upper GI series. (b) Shaded surface 
display from a CT gastrography study. (c) Endoluminal view from a CT 
gastrography study. (d) Upper GI endoscopic view of the lesion
Key Points
• In the presence of a hiatal hernia and reflux, a high 
esophageal stricture or reticular pattern should be 
strongly suggestive of Barrett’s esophagus.
• Benign gastric ulcers classically appear en face 
as round or ovoid barium collections with a 
smooth, surrounding mound of edema and/or 
thin, straight folds radiating to the edge of the 
ulcer crater.
• Highly accurate tumor staging is a prerequisite for 
the selection of the most appropriate therapy of 
patients with upper gastrointestinal tract 
malignancies.
• Endoscopic ultrasound is more accurate for T stag-
ing than CT and MR in early upper gastrointestinal 
tract malignancies.
• PET/CT is recommended for staging locally 
advanced esophageal carcinoma.
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Magnetic Resonance Imaging 
of the Prostate in the PI-RADS Era
Bernd Hamm and Patrick Asbach
11.1  Introduction
Over the past years, continuing technical innovation in com-
bination with a broad research activity has resulted in a high 
diagnostic accuracy of magnetic resonance imaging (MRI) 
of the prostate. At the same time, the Prostate Imaging 
Reporting and Data System (PI-RADS) has standardized 
image acquisition and reporting and facilitated the commu-
nication of imaging findings to the urologist and can there-
fore be considered an obligatory key element in prostate 
MRI. This has had a tremendous impact on the diagnostic 
workup of patients with suspected prostate cancer, with MRI 
being incorporated in multiple prostate cancer guidelines 
(e.g., NICE, AUA, German S3-Guideline) by now. As a 
direct result, imaging-based targeted prostate biopsy has 
increased almost at the same speed, and urologists not only 
heavily rely on accurate interpretation of MRI of the prostate 
but actively claim high-quality MRI scans for their daily 
practice because prostate MRI has direct impact on their can-
cer detection rate. Furthermore, a paradigm shift is taking 
place in the urological community regarding the care of low- 
grade prostate cancer patients, where therapy is more and 
more replaced by active surveillance (AS). Prostate MRI 
plays an important role in AS not only during the initial 
assessment whether the patient is a candidate for AS but also 
during the surveillance of the disease.
Therefore, any abdominal and genitourinary radiologist if 
not already performing prostate MRI will subsequently be 
involved, and we forecast prostate MRI to be an indispens-
able diagnostic step for any patient with a clinical suspicion 
for prostate cancer or during surveillance of low-grade pros-
tate cancer in the near future.
11.2  PI-RADS
The European Society of Uroradiology (ESUR) has intro-
duced PI-RADS (Prostate Imaging Reporting and Data 
System) in 2012. An updated version (PI-RADS v2) was 
published in 2015 in collaboration with the American 
College of Radiology (ACR) and the AdMeTech Foundation. 
PI-RADS is not based on evidence from clinical research tri-
als rather than on expert knowledge; however, several studies 
have confirmed that the PI-RADS system improves the diag-
nostic accuracy of mpMRI. The overall rationale for imple-
mentation of PI-RADS was to “improve detection, 
localization, characterization, and risk stratification in 
patients with suspected cancer in treatment naïve prostate 
glands.” PI-RADS is currently not applicable to assess treat-
ment response in prostate cancer patients. The following 
specific definitions and aims regarding MR imaging and 
reporting are targeted by PI-RADS:
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• To understand the current role of prostate MRI for 
imaging-based targeted prostate biopsy, staging, 
and active surveillance
• To learn how to optimize the multiparametric pros-
tate MR imaging protocol
• To illustrate how to use the PI-RADS classification 
for prostatic lesion assessment
• To understand the need of structured reporting in 
communicating with the urologists
• To discuss the most common pitfalls in multipara-
metric MRI of the prostate
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11.2.1  Clinical Considerations
Timing of mpMRI after prostate biopsy does not necessarily 
need to be postponed since clinically significant cancer is 
likely in a location not altered by post biopsy hemorrhage 
when the biopsy was negative. For local staging of prostate 
cancer, a delay of a minimum of 6 weeks might be advanta-
geous. No specific patient preparation is necessary; however, 
the administration of a spasmolytic drug may be beneficial. 
Bowel cleaning is not recommended; however, the patient 
should evacuate the rectum if possible.
11.2.2  Technical Considerations
The field strengths of 1.5 and 3 T can both be adequate (even 
without an endorectal coil at 1.5 T) when the scan parame-
ters are tailored to small field-of-view imaging of the pros-
tate and contemporary scanner technology is used 
(specifically multichannel phased-array surface coils and 
high-performance gradients); however, 3 T is the preferred 
field strength (higher signal-to-noise ratio, shorter scan 
time).
Multiparametric MRI of the prostate should include the 
following sequences:
T2-weighted imaging: 2D turbo spin-echo sequence, slice 
thickness ≤3 mm (no interslice gap), and in-plane spatial 
resolution ≤0.7 mm (phase-encoding direction) x ≤ 0.4 mm 
(frequency-encoding direction).
Diffusion-weighted imaging (DWI): spin-echo EPI (echo 
planar imaging) sequence with fat saturation, slice thickness 
≤4 mm (no interslice gap), in-plane spatial resolution 
≤2.5 mm (phase- and frequency-encoding direction), and at 
least two b-values (low b-value of 50–100 s/mm2 and a high 
b-value of 800–1000 s/mm2) with consecutive calculation of 
an ADC map. If SNR allows, a very high b-value of 1400–
2000 s/mm2 should be measured. An alternative is to calcu-
late a high b-value, which is less SNR critical.
Dynamic contrast-enhanced (DCE) imaging: 2D or 3D 
gradient-echo sequence with a temporal resolution below 
10 s (preferably below 7 s) per acquisition, slice thick-
ness ≤ 3 mm (no interslice gap), and in-plane spatial resolu-
tion ≤2 mm (phase- and frequency-encoding direction).
Slice orientation and slice thickness should match for all 
mpMRI sequences to allow side-by-side comparison. Also, a 
large field-of-view sequence covering the pelvic lymph 
nodes and the skeleton should be acquired.
11.2.3  Assessment of Prostatic Lesions
One major key element of PI-RADS is scoring the likelihood 
of a prostatic lesion to be clinically significant prostate can-
cer on a 5-point Likert-type scale (Table 11.1).
Since several different definitions of clinically significant 
prostate cancer exist, PI-RADS defines it as “Gleason score ≥7 
(including 3+4 with prominent but not predominant Gleason 4 
component), and/or volume ≥0.5 cc, and/or extra prostatic exten-
sion (EPE).” The scoring system is based on typical imaging find-
ings on the respective multiparametric MR sequence (exact 
definitions according to PI-RADS, see Tables 11.2, 11.3 and 11.4; 
for examples, see Figs. 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 
11.8, 11.9, 11.10, 11.11, 11.12 and 11.13). For this purpose, 
typical examples for each score and sequence are included in the 
Table 11.1 PI-RADS classification (5-point Likert-type scale)
PI-RADS 1 Very low (clinically significant cancer is highly 
unlikely to be present)
PI-RADS 2 Low (clinically significant cancer is unlikely to be 
present)
PI-RADS 3 Intermediate (the presence of clinically significant 
cancer is equivocal)
PI-RADS 4 High (clinically significant cancer is likely to be 
present)
PI-RADS 5 Very high (clinically significant cancer is highly 
likely to be present)
Table 11.2 T2-weighted imaging
Score Peripheral zone (PZ) Transition zone (TZ)




2 Linear or wedge-shaped 
hypointensity or diffuse mild 






3 Heterogeneous signal intensity 
or non-circumscribed, rounded, 
moderate hypointensity, 
includes others that do not 
qualify as 2, 4, or 5
Heterogeneous signal 
intensity with obscured 
margins, includes others 
that do not qualify as  
2, 4, or 5
4 Circumscribed, homogenous 
moderate hypointense focus/
mass confined to prostate and 
<1.5 cm in greatest dimension
Lenticular or non- 
circumscribed, 
homogeneous, moderately 
hypointense, and <1.5 cm 
in greatest dimension
5 Same as 4 but ≥1.5 cm in 
greatest dimension or definite 
extraprostatic extension/
invasive behavior
Same as 4, but ≥1.5 cm in 
greatest dimension or 
definite extraprostatic 
extension/invasive behavior
Table 11.3 Diffusion-weighted imaging (DWI)
Score Peripheral zone (PZ) or transition zone (TZ)
1 No abnormality (i.e., normal) on ADC and high b-value DWI
2 Indistinct hypointense on ADC
3 Focal mildly/moderately hypointense on ADC and isointense/
mildly hyperintense on high b-value DWI
4 Focal markedly hypointense on ADC and markedly 
hyperintense on high b-value DWI; <1.5 cm in greatest 
dimension
5 Same as 4 but ≥1.5 cm in greatest dimension or definite 
extraprostatic extension/invasive behavior
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PI-RADS publication. The goal is to increase the diagnostic accu-
racy for detection of prostate cancer and to reduce the variability 
in image interpretation. Most preliminary studies report a good 
reader agreement which is higher for peripheral zone (PZ) lesions 
as compared to transition zone (TZ) lesions. Also, agreement is 
higher for PI-RADS score 4 and 5 compared to lower scores.
In the PI-RADS version 2, the diagnostic weighting of the 
multiparametric sequences has been changed compared to 
the first version. Now, a concept of a dominant sequence has 
Table 11.4 Dynamic contrast-enhanced (DCE) imaging
Score Peripheral zone (PZ) or transition zone (TZ)
Negative No early enhancement or diffuse enhancement not 
corresponding to a focal finding on T2-weighted and/or 
DWI or focal enhancement corresponding to a lesion 
demonstrating features of BPH on T2-weighted imaging
Positive Focal and earlier than or contemporaneously with 
enhancement of adjacent normal prostatic tissues and 




Fig. 11.1 (a–d) Normal peripheral zone. (a) Axial and (b) coronal 
T2-weighted sequence showing uniform hyperintense signal intensity 
of the peripheral zone (PI-RADS score 1). (c) Diffusion-weighted high 
b-value (calculated b = 1400 s/mm2) image and (d) ADC map (domi-
nant sequence for the peripheral zone) with no abnormality consistent 
with an overall PI-RADS score of 1
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Fig. 11.2 (a, b) Normal transition zone. (a) Axial and (b) coronal T2-weighted sequence (dominant sequence for the transition zone) showing 
homogeneous intermediate signal intensity of the non-enlarged transition zone (PI-RADS score 1)
a b
Fig. 11.3 (a–e) PI-RADS 2 changes of the peripheral zone. (a) Axial 
and (b) coronal T2-weighted sequence showing linear hypointensities 
in the bilateral peripheral zone (PI-RADS score 2). (c) Diffusion- 
weighted high b-value (calculated b = 1400 s/mm2) image shows no 
areas of increased signal intensity. (d) ADC map shows no focal 
hypointense areas (dominant sequence for the peripheral zone) in the 
peripheral zone (PI-RADS score 2). (e) DCE sequence shows no focal 
or early enhancement (DCE negative) consistent with an overall 
PI-RADS score of 2. Linear T2 hypointensities in the peripheral zone 
are a frequent finding and may represent changes related to chronic 
prostatitis or post biopsy scarring
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Fig. 11.4 (a–d) PI-RADS 2 findings of the transition zone in a patient 
with benign prostatic hyperplasia (BPH). (a) Axial and (b) coronal 
T2-weighted sequence (dominant sequence for the transition zone) 
showing multiple circumscribed heterogeneous encapsulated nodules 
(dark T2-rim) within the enlarged transition zone (overall PI-RADS 
score 2). (c) Diffusion-weighted high b-value (calculated b = 1400 s/
mm2) image shows no focal areas of moderately increased signal inten-
sity. (d) ADC map shows no focal hypointense areas (PI-RADS score 2)
a b






Fig. 11.5 (a–e) Protruded BPH node in the right anterior gland. (a) 
Axial and (b) coronal T2-weighted sequence (dominant sequence for the 
transition zone) showing a circumscribed heterogeneous encapsulated 
nodule (overall PI-RADS score 2). (c) Diffusion-weighted high b-value 
(calculated b = 1400 s/mm2) image shows increased signal intensity. (d) 
ADC map shows a focal hypointensity which is related to stromal BPH 
components which corresponds to the BPH nodule (therefore PI-RADS 
score of 2). (e) DCE sequence showing focal enhancement which cor-
responds to the lesion that demonstrates clear features of a BPH node 
(therefore DCE negative) consistent with an overall PI-RADS score of 2






Fig. 11.6 (a–e) PI-RADS 3 changes of the peripheral zone. (a) Axial and 
(b) coronal T2-weighted sequence showing heterogeneous non- 
circumscribed changes of the bilateral peripheral zone (PI-RADS score 3). 
(c) Diffusion-weighted high b-value (calculated b = 1400 s/mm2) image 
shows a mildly hyperintense signal intensity. (d) ADC map (dominant 
sequence for the peripheral zone) shows moderately hypointense changes 
in the bilateral peripheral zone (PI-RADS score 3). (e) DCE sequence 
shows no focal early enhancement (DCE negative) consistent with an 
overall PI-RADS score of 3. Randomized TRUS-guided prostate biopsy 
revealed mild chronic prostatitis with no evidence for prostate cancer






Fig. 11.7 (a–e) PI-RADS 3 changes of the transition zone in a patient 
with benign prostatic hyperplasia (BPH). (a) Axial and (b) coronal 
T2-weighted sequence (dominant sequence for the transition zone) 
showing heterogeneous signal intensity with obscured margins within 
the enlarged transition zone (overall PI-RADS score 3). (c) Diffusion-
weighted high b-value (calculated b = 1400 s/mm2) image shows mildly 
hyperintense signal intensity. (d) ADC map shows moderately hypoin-
tense areas (PI-RADS score 3). (e) DCE sequence shows diffuse 
enhancement not corresponding to a focal finding on any other sequence 
(DCE negative). Randomized TRUS-guided biopsy revealed no malig-
nancy; therefore, the findings can be attributed to BPH with predomi-
nantly stromal (T2 hypointense) components






Fig. 11.8 (a–e) PI-RADS 4 lesion in the peripheral zone. (a) Axial and 
(b) coronal T2-weighted sequence showing moderate diffuse (non- 
circumscribed) hypointensity of the bilateral peripheral zone (PI-RADS 
score 3). (c) Diffusion-weighted high b-value (calculated b = 1400 s/
mm2) image shows mildly hyperintense signal intensity in the right ante-
rior and lateral peripheral zone (PI-RADS score 3). (d) ADC map cor-
respondingly shows moderate hypointense signal intensity (dominant 
sequence for the peripheral zone) in the right anterior and lateral periph-
eral zone (PI-RADS score 3). (e) DCE sequence shows focal and con-
temporary enhancement (DCE positive) consistent with an upgrading to 
an overall PI-RADS score of 4. MRI/US fusion-guided biopsy revealed 
a Gleason 3 + 4 = 7 adenocarcinoma (PSA level was 6.9 ng/mL)






Fig. 11.9 (a–e) PI-RADS 4 lesion in the peripheral zone. (a) Axial and 
(b) coronal T2-weighted sequence showing a circumscribed 11 mm 
hypointense mass in the left lateral peripheral zone (PI-RADS score 4). 
(c) Diffusion-weighted high b-value (calculated b = 1400 s/mm2) image 
shows focal markedly hyperintense signal intensity of the mass. (d) 
ADC map (dominant sequence for the peripheral zone) correspond-
ingly shows focal markedly hypointense signal intensity of the mass 
(PI-RADS score 4). (e) DCE sequence shows focal and early enhance-
ment (DCE positive) corresponding to the focal mass seen on 
T2-weighted and DWI consistent with an overall PI-RADS score of 4. 
MRI/US fusion-guided biopsy revealed a Gleason 4 + 3 = 7 adenocar-
cinoma (PSA level was 8.1 ng/mL)





Fig. 11.10 (a–c) PI-RADS 4 lesion in the transition zone. (a) Axial 
T2-weighted sequence (dominant sequence for the transition zone) 
showing a circumscribed lenticular 14 mm hypointense mass in the left 
anterior transition zone with bulging of the prostatic capsule (PI-RADS 
score 4). (b) Diffusion-weighted high b-value (calculated b = 1400 s/
mm2) image shows focal markedly hyperintense signal intensity of the 
mass. (c) ADC map correspondingly shows focal markedly hypointense 
signal intensity of the mass (PI-RADS score 4). MRI/US fusion- guided 
biopsy revealed a Gleason 4 + 4 = 8 adenocarcinoma (PSA level was 
9.8 ng/mL). The patient had undergone a randomized TRUS- guided 
biopsy 3 months earlier with no evidence for malignancy. The anterior 
location is typical for adenocarcinoma missed by randomized biopsy; 
therefore, MRI is particularly useful in patients with negative random-
ized biopsy and persisting clinical suspicion for prostate cancer






Fig. 11.11 (a–e) PI-RADS 5 lesion in the peripheral zone. (a) Axial 
and (b) coronal T2-weighted sequence showing a circumscribed 18 mm 
hypointense mass in the right lateral peripheral zone (PI-RADS score 
5). (c) Diffusion-weighted high b-value (calculated b = 1400 s/mm2) 
image shows focal markedly hyperintense signal intensity of the mass. 
(d) ADC map (dominant sequence for the peripheral zone) correspond-
ingly shows focal markedly hypointense signal intensity of the mass 
(PI-RADS score 5). (e) DCE sequence shows focal and early enhance-
ment (DCE positive) corresponding to the focal mass seen on 
T2-weighted and DWI consistent with an overall PI-RADS score of 5. 
MRI/US fusion-guided biopsy revealed a Gleason 4 + 3 = 7 adenocar-
cinoma (PSA level was 11.2 ng/mL). Also note the wedge-shaped T2 
hypointensities in the left lateral peripheral zone which demonstrate 
moderately hypointense signal on the ADC map and no focal enhance-
ment (PI-RADS 3). On biopsy multifocal prostate cancer was diag-
nosed with Gleason 3 + 3 = 6 pattern in the left prostatic lobe




Fig. 11.12 (a–d) PI-RADS 5 lesion in the transition zone. (a) Axial 
and (b) coronal T2-weighted sequence (dominant sequence for the tran-
sition zone) showing a circumscribed lenticular 20 mm hypointense 
mass in the anterior transition zone with minimal bulging of the pros-
tatic capsule (PI-RADS score 5). (c) Diffusion-weighted high b-value 
(calculated b = 1400 s/mm2) image shows focal markedly hyperintense 
signal intensity of the mass. (d) ADC map correspondingly shows focal 
markedly hypointense signal intensity of the mass (PI-RADS score 4). 
MRI/US fusion-guided biopsy revealed a Gleason 4 + 3 = 7 adenocar-
cinoma (PSA level was 14.7 ng/mL)





Fig. 11.13 (a–c) Locally advanced prostate cancer with seminal vesi-
cle infiltration. (a) Axial T2-weighted sequence showing diffuse 
hypointensity of the entire prostate (zonal anatomy not visible) with 
extension into the bilateral seminal vesicles (PI-RADS score 5). (b) 
Diffusion-weighted high b-value (calculated b = 1400 s/mm2) image 
shows markedly hyperintense signal intensity of the entire prostate. (c) 
ADC map correspondingly shows markedly hypointense signal inten-
sity of the prostate (PI-RADS score 5). Randomized TRUS-guided 
biopsy revealed a Gleason 4 + 5 = 9 adenocarcinoma (PSA level was 
26.5 ng/mL)
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been introduced. The dominant sequence depends on the 
prostatic zone the lesion is located; therefore identification 
of the zonal anatomy is crucial. The area at the base of the 
prostate where the central zone borders the peripheral zone 
and the anterior gland where the anterior horn of the periph-
eral zone borders the transition zone and the anterior fibro-
muscular stroma might be challenging in this respect. The 
DWI sequence is the dominant sequence for the peripheral 
zone where most prostate cancers are located. The 
T2-weighted sequence is the dominant sequence for the tran-
sition zone. The dominant sequence defines the final 
PI-RADS score with the exception of PI-RADS 3 lesions, 
where for the peripheral zone the DCE sequence and for the 
transition zone the DWI sequence defines the final PI-RADS 
score (see Tables 11.5 and 11.6).
If a particular sequence cannot be acquired or is nondiag-
nostic due to artifacts (e.g., DWI when certain hip implants 
are present), it should be marked with “x.” In this situation, 
the following rules apply:
Assessment without DWI (applies to PZ and TZ): the 
T2-weighted sequences define the final PI-RADS score with 
the exception of PI-RADS 3—if the lesion is DCE negative, 
the final score remains 3; if the lesion is DCE positive, the 
final score is 4.
Assessment without DCE (only applies to the peripheral 
zone since DCE is not needed for transition zone scoring): 
the DWI score represents the final PI-RADS score.
11.2.4  Structured Reporting
A very important task of PI-RADS is to “simplify and stan-
dardize the terminology and content of radiology reports” 
and to “enhance interdisciplinary communications with 
referring clinicians.” A comprehensive mpMRI report should 
therefore include the following contents:
The volume of prostate should be reported according to 
the ellipsoid formula: maximum AP diameter x maximum 
transverse diameter x maximum longitudinal diameter × 0.52.
The aforementioned PI-RADS score is assigned to up to 
four intraprostatic lesions with a score ≥3. In case of multi-
ple lesions, an index lesion should be defined. The index 
lesion is the one with the highest PI-RADS score. In case 
multiple lesions qualify for the highest PI-RADS score, 
extraprostatic extension (EPE) outclasses lesion size. For 
each lesion a PI-RADS score is assigned to the series and the 
image number where the lesion is best visualized should be 
reported to assist the urologist in selecting optimal images 
for MRI/US fusion-guided prostate biopsy. The lesion size 
also needs to be reported. Measurement of each lesion is pre-
ferred on the axial images; the DWI sequence should be used 
for peripheral zone lesions and the T2-weighted images for 
transition zone lesions. If a lesion is not well delineated on 
the axial sequences, then another plain should be used.
Another crucial element of a full PI-RADS report is a sector 
map in which the lesions should be indicated, since this par-
ticularly enhances the communication with the urologist. For 
this matter, the prostate is subdivided into three axial heights, 
the base, the midgland, and the prostatic apex, respectively. The 
seminal vesicles should also be included for cases of extrapros-
tatic extension. The zonal anatomy (peripheral zone, transition 
zone, central zone, and anterior fibromuscular stroma) and the 
urethra should also be incorporated into the sector map.
11.3  Concluding Remarks
Comprehensive multiparametric MRI of the prostate should 
include lesion scoring and reporting according to the 
PI-RADS system. This will assist to achieve a high level of 
diagnostic accuracy and assure a thriving communication 
with the urologist.
Table 11.5 Peripheral zone (PZ)
DWI T2 DCE PI-RADS score
1 Any Any 1
2 Any Any 2
3 Any Negative 3
Positive 4
4 Any Any 4
5 Any Any 5
Table 11.6 Transition zone (TZ)
T2 DWI DCE PI-RADS score
1 Any Any 1
2 Any Any 2
3 ≤ 4 Any 3
5 4
4 Any Any 4
5 Any Any 5
Key Points
• Continuing technical innovation and broad research 
activity have resulted in a high diagnostic accuracy 
of MRI of prostate.
• Prostate MRI plays an important role for imaging- 
based targeted prostate biopsy.
• In patients undergoing active surveillance of pros-
tate carcinoma, MRI has become indispensable for 
initial assessment as well as during the surveillance 
of the disease.
• PI-RADS standardizes image acquisition and facili-
tates communication with the urologists. It is con-
sidered an obligatory key element in prostate MRI.
• Comprehensive multiparametric MRI of the pros-
tate should include lesion scoring and reporting 
according to the PI-RADS system.
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Small Bowel Disease
Andrea Laghi and Amy K. Hara
12.1  Techniques (US, CTE, MRE)
Ultrasonography (US), magnetic resonance (MR), and com-
puted tomography (CT) have a complementary role in the 
evaluation of small bowel disorders [1].
US is a powerful tool for bowel assessment in patients 
with known or suspected gut-related disease, especially in 
combination with oral (SICUS) [2] and intravenous (CEUS) 
contrast agents [3]. It is often the first imaging modality used 
in patients with undiagnosed abdominal pain [4]. Initial US 
evaluation of the gut should be performed in all four quad-
rants using curvilinear probe (3.5–5 MHz). The goal is to 
identify thickened bowel and/or ancillary findings of inflam-
mation (fluid collections, lymphadenopathy). Higher- 
frequency probe (7–12 MHz) provides better resolution of 
the bowel wall layers and surrounding tissues and can be 
subsequently used to evaluate regions of suspected bowel 
disease. Color Doppler US provides additional information 
regarding mural vascularity [5].
CT and MR evaluations of the small bowel require lumen 
distention, achievable by fluid administration after nasojeju-
nal intubation (CT/MR enteroclysis, CTE) or per os (CT/MR 
enterography, MRE). Enterography should be preferred, in 
the setting of inflammatory bowel disorders, due to less inva-
siveness and similar diagnostic accuracy compared to entero-
clysis. Usually for an average-size adult, the dose is around 
1500–2000 mL of enteral contrast agent, divided into three 
aliquots administered starting around 60 min before CT 
scanning to reduce patient’s discomfort [1, 6]. Spasmolytic 
agents should be administered intravenously immediately 
before the examination, in order to minimize motion arte-
facts [1]. Intravenous injection of contrast media is manda-
tory to depict mural enhancement pattern [1].
Advantages of MR imaging over computed tomography 
(CT) include high contrast resolution, lack of radiation expo-
sure, and use of intravenous contrast media with better safety 
profiles. MRE also allows dynamic assessment of small 
bowel peristalsis and distensibility of lumen narrowing, pro-
viding functional information [1].
Limitations of MR imaging include costs and variability 
in examination quality (related to patient cooperation and 
breath-holding ability), and its role in the emergency setting 
is still limited [6].
12.2  Normal Anatomy
The small bowel has an average length of 6 m (ranging 
between 3 and 10 m) and includes the duodenum, jejunum 
(proximal), and ileum (distal). It is attached at the posterior 
Learning Objectives
• To understand the role of different imaging modali-
ties in small bowel diseases
• To learn the most common CT findings in the emer-
gency setting, including small bowel obstruction 
and ischemia
• To learn the relevant CT and MR findings in the 
diagnosis of Crohn’s disease, according to different 
disease phenotypes
• To be aware of small bowel injury induced by non-
steroidal anti-inflammatory drugs (NSAID)
• To learn imaging findings in celiac disease
• To learn how to perform a differential diagnosis 
among different small bowel tumors
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abdominal wall thought the mesentery formed by the double 
fold of peritoneum. Its root extends from the left of L2 to the 
right sacroiliac joint and it is 15 cm long.
The duodenum is the first and shortest segment of the 
small intestine (20–30 cm) and continues into the jejunum at 
the duodenojejunal flexure, fixed to the retroperitoneum by 
ligament of Treitz. The jejunum occupies the left upper 
abdomen and constitutes about one third of the small bowel. 
One of the typical morphological finding in jejunum are the 
circular mucosal folds, known as valvulae conniventes or pli-
cae semilunaris, more prominent than in the ileum and easily 
depicted during an MRE or CTE. The ileum occupies the 
central and right lower part of the abdomen, and the ileocecal 
valve separates the small from large intestine.
Two main normal anatomical aspects should be consid-
ered during the evaluation of small bowel: wall thickness and 
caliber. The normal caliber of jejunal and ileal lumen, with-
out the administration of spasmolytic agents, must be 
<30 mm, and the wall thickness <3 mm [1].
12.3  Pathology
12.3.1  Emergency
US is often the first imaging method for undiagnosed abdom-
inal pain [4]. However, CT is considered the gold standard, 
offering a more comprehensive evaluation of emergency 
conditions. Small bowel obstruction (SBO), bowel hemor-
rhage, and ischemia are easily detected with CT.
SBO continues to be a substantial cause of morbidity and 
mortality. Adhesions, hernias, and malignancies account for 
more than 80% of all SBOs. The task of the radiologist is to 
determine its site, cause, and the presence or absence of 
complications such as ischemia or perforation. The hallmark 
of SBO is dilated small bowel (>3 cm) proximal to the site of 
obstruction with decompressed distal bowel. Air-fluid levels 
and string of beads sign (fluid-filled loops of bowel with a 
small amount of remaining gas trapped in folds between val-
vulae conniventes) may be identified. In high-grade obstruc-
tion, stasis and mixing of small bowel contents with gas 
creates the so-called “small bowel feces” sign, an appearance 
analogous to feces in colon [7] (Fig. 12.1).
The three main causes of mesenteric ischemia are arterial 
occlusion, venous occlusion, and poor cardiac output or 
hypovolemia. CT findings associated with ischemic bowel 
include bowel with thickening, mesenteric edema and fluid 
adjacent to bowel loops, abnormal decreased bowel wall 
enhancement, and pneumatosis with or without associated 
gas in mesenteric or portal veins.
Bleeding in the GI tract has many possible causes, includ-
ing ulcers, vascular malformations, and tumors. Active small 
bowel bleeding at multiphase CTE is observed as a gradual 
accumulation of contrast material within the bowel lumen [8].
12.3.2  Inflammatory
12.3.2.1  Crohn’s Disease (CD)
One of the most common inflammatory diseases of the small 
bowel is Crohn’s disease (CD) which can involve the entire 
gastrointestinal tract from the mouth to the anus, most com-
monly affecting the ileocecal region (approximately 50% of 
cases), followed by the ileum (30%) and colon (20%) [9]. 
Perianal disease is present in 20% of CD patients at initial 
presentation. CD exhibits skip lesions with transmural 
inflammation of the bowel wall, deep ulcerations at endos-
copy [10], granulomas, and focal crypt irregularity on histol-
ogy [9].
Cross-sectional imaging of the small bowel with CTE or 
MRE is performed to identity the presence, length, and 
severity of inflammation as well as to identify complications 
such as fistulas, abscesses, and obstruction [11]. CTE and 
MRE have similar performance for diagnosing CD [12]. CT 
is more widely available and less time consuming than MR, 
but MR spares radiation exposure which can be considerable 
over time [11].
CD phenotypes include quiescent, active inflammatory, 
stricturing, and penetrating. Due to the chronic and relapsing 
nature of CD, these phenotypes often coexist (Fig. 12.2a). A 
primary responsibility of the radiologist is to communicate if 
there are signs of active inflammation such as mural enhance-
ment, perienteric inflammation, bowel wall thickening/
edema, dilated vasa recta, ulcerations, and restricted diffu-
sion [13]. As these findings are nonspecific and can be seen 
with a wide variety of other disease processes, the pattern of 
bowel wall involvement can be helpful. Asymmetric bowel 
wall involvement that prefers the mesenteric side of the 
bowel wall predominantly is a pattern that is specific for CD 
and not in other disease processes.
Chronic changes of CD include bowel wall fibrosis, stric-
tures, obstruction, and chronic mesenteric venous occlusion. 
Thus, in addition to identifying signs of active inflammation 
that could lead to medical therapy, the radiologist must report 
findings that could result in surgical intervention such as 
strictures with upstream bowel dilations >3 cm, fistulas, 
frank perforation, and abscesses [13].
12.3.2.2  NSAID Enteropathy
Nonsteroidal anti-inflammatory drugs (NSAID) [14] can 
induce small bowel injury, primarily through direct mucosal 
injury, resulting in ulcers and eventually characteristic 
 circumferential strictures/diaphragms. Clinically, patients 
can present with obscure GI bleeding with iron deficiency 
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anemia, abdominal pain, and bowel obstruction. The gold 
standard for detecting NSAID enteropathy is capsule endos-
copy and balloon enteroscopy. Treatment includes endo-
scopic dilatation, stricturoplasty, or resection.
These strictures can be challenging to detect at CTE, 
MRE, and barium exams as they are typically short segment 
and weblike (Fig. 12.2b) rather than longitudinal strictures 
seen with CD. Unlike CD, the bowel wall involvement is 
typically circumferential and does not prefer the terminal 
ileum. These strictures are commonly multifocal and, 
depending on the presence of active inflammation, may or 
may not present with bowel thickening and increased mural 
enhancement. Without increased mural enhancement and 
upstream bowel dilatation, a small bowel diaphragm can be 
difficult to differentiate from a peristaltic contraction or 
underdistention. In these cases, multiphasic imaging and 
optimized bowel distention is useful.
Diagnoses that can simulate NSAID enteropathy at imaging 
are strictures due to radiation, CD, potassium chloride tablets, 
and eosinophilic gastroenteritis. The diagnosis can be narrowed 
by the clinical history, bowel location, and other associated 
radiologic features. For example, fistulas or fatty deposition 
would favor CD or involvement of pelvic small bowel loops 
only favor radiation injury in a patient with that clinical history.
12.3.2.3  Celiac Disease
Celiac disease [15] is an inflammatory small bowel disease 
triggered by gluten ingestion and typically resulting in diarrhea 
predominant symptoms but can be asymptomatic and detected 




Fig. 12.1 A 55-year-old man with SBO caused by adhesive bands sec-
ondary to a prior laparotomy. Contrast enhanced coronal CT reforma-
tion shows dilated fluid-filled small bowel (arrow in a) with 
decompressed distal small bowel (arrowhead) consistent with obstruc-
tion. Peritoneal fluid is identified in axial images (arrow in b and c) both 
in upper and lower abdomen. Obstruction point (arrowhead in d) is 
identified at the point of transition, immediately below a dilated bowel 
segment filled with gas bubbles mixed with particulate matter (asterisk 
in c) (feces sign)
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The diagnosis is confirmed by biopsy which shows intraepithe-
lial lymphocytes, crypt hyperplasia, and villous atrophy. A sub-
set of patients may have persistent symptoms even with gluten 
avoidance leading to a diagnosis of refractory celiac disease 
(RCD). Type 2 RCD is associated with enteropathy associated 
T-cell lymphoma (EATL) leading to higher mortality.
Imaging features of celiac disease at cross-sectional 
imaging and barium exams include reversal of the jejunal- 
ileal fold pattern (decreased jejunal folds and increased ileal 
folds) (Fig. 12.2c), intussusception, dilated small bowel, and 
bowel lymphoma. Additional associated findings at CT/MR 
are mesenteric/retroperitoneal adenopathy and hyposplen-
ism. Findings of active inflammation as seen in CD can also 
be present with celiac disease including mural enhancement, 
bowel wall thickening, and dilated vasa recta.
12.3.3  Small Bowel Tumors
Small bowel tumors account for 3–6% of all GI neoplasms 
and 1–3% of all GI malignancies [16]. The most common 
subtypes are adenocarcinoma (30–45%), neuroendocrine 
tumors (20–40%), lymphoma (10–20%), and sarcomas (10–
15%) [17] (Fig. 12.3). Small bowel tumor incidence has been 
rising for unclear reasons, although the mortality rate is sta-
ble and 5-year survival has been improving [18].
Adenocarcinoma (ACA) is the most common primary 
malignancy of the small bowel, follows the adenoma- carcinoma 
sequence and typically arises in the proximal small bowel. Risk 
factors for ACA include conditions associated with chronic 
inflammation such as CD, celiac disease,  ileostomy or 
 duodenal/jejunal bypass surgery, as well as syndromes such as 
Peutz-Jeghers and familial polyposis. At imaging, ACA classi-
cally has an apple-core appearance associated with bowel 
obstruction and adenopathy. If it is an intraluminal polypoid 
mass, it can predispose to intussusception. It typically enhances 
more than lymphoma but less avidly compared to carcinoid 
and GI stromal tumors [19].
Carcinoid neuroendocrine tumors (NET) are the second 
most common primary small bowel malignancy. Unlike 
ACA, NET most commonly arise in the ileum, are multifocal 
in 15–35% of cases and hypervascular. These tumors 
 commonly metastasize to mesenteric lymph nodes resulting 
in the classic calcified mesenteric mass with associated des-
moplastic response, tethering and obstructing adjacent bowel 
loops, and causing vascular engorgement. Nuclear studies 
with 68Gallium Dotatate or Indium −111 octreotide, soma-
tostatin analogues, can be used to detect the primary tumor 
as well as metastatic disease [20].
Lymphoma is the third most common small bowel malig-
nancy and can be the primary site or a site of secondary involve-
ment. The distal ileum is the most common location because it 
has the most lymphoid tissue. Most cases are  non- Hodgkin 
B-cell lymphoma although T-cell lymphoma is more common 
in celiac disease and occurs in the jejunum. At imaging, lym-
phoma can have a wide variety of presentations from mucosal 
nodules to circumferential bowel wall thickening with aneurys-
mal dilatation to a large exocentric mass [19].
GI stromal tumors arise from the interstitial cells of Cajal, 
intestinal pacemaker cells that line the GI tract [21]. They are 
initiated by mutations in KIT, a tyrosine kinase growth factor 
receptor, which allows the cells to grow and divide 
a b c
Fig. 12.2 Inflammatory bowel diseases. (a) Crohn’s disease showing 
complex enteroenteric fistula involving the terminal ileum (arrow), 
active inflammation of involved bowel loops, and strictures with small 
bowel dilatation. (b) NSAID enteropathy with multiple weblike stric-
tures (arrows) and small bowel dilatation. (c) Celiac disease with 
decreased jejunal folds (arrow), increased ileal folds (arrowhead), and 
superior mesenteric vein thrombosis (dotted arrow)
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 abnormally. Thus, they can be treated by tyrosine kinase 
inhibitors such as imatinib mesylate. These tumors can have 
a wide variety of imaging appearances, presenting as a 
 homogeneously hypervascular enhancing small bowel mass 
to a large hypoenhancing exophytic cavitary mass. They are 
typically large at presentation as they don’t commonly cause 
bowel obstruction, unlike ACA and NET. Surgical resection 
is typically the treatment of choice. Target therapies with 
tyrosine kinase inhibitors are used if not surgically resectable 
or to prevent recurrence/metastases. PET/CT can be used to 
evaluate treatment response as size criteria alone can under-
estimate response.
12.4  Concluding Remarks
Diagnostic imaging and in particular cross-sectional modali-
ties (US, CT, and MR) have a critical and complementary 
role in diagnosis and management of small bowel diseases. 
Radiologists should be aware of advantages and disadvan-
tages of each imaging test in order to choose the best option, 
considering the specific small bowel disease and the patient’s 
characteristics (age, gender, clinical status). A deep knowl-
edge of the different entities involving the small bowel is 
also critical in order to reach a correct diagnosis and to pro-
vide the necessary information for patient management.
a b
c d
Fig. 12.3 Small bowel tumors at CT. (a) Adenocarcinoma (arrow) 
with mild enhancement and associated small bowel obstruction. (b) 
Carcinoid (arrow) with mesenteric mass, associated bowel obstruction, 
desmoplastic response, and vascular engorgement. (c) Jejunal lym-
phoma (arrow) with bowel wall thickening and preservation of the 
lumen (aneurysmal dilatation). (d) GI stromal tumor (arrow) with typi-
cal lobulated, homogenous hypervascular appearance without bowel 
obstruction
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Take-Home Messages
• A small bowel loop is considered normal when cali-
ber is <30 mm and wall thickness <3 mm.
• US is a powerful diagnostic test for bowel assess-
ment in patients with known or suspected gut-
related disease, especially in combination with the 
administration of oral and/or intravenous contrast 
agents.
• CT is the imaging modality of choice in the emer-
gency setting (i.e., small bowel occlusion, ischemia, 
and, in some circumstances, bleeding).
• MR is the preferred imaging modality in inflamma-
tory bowel diseases (IBD) because of multipara-
metric approach, evaluation of bowel motility, and 
lack of radiation exposure.
• In IBD, cross-sectional imaging is performed to 
identity the presence, length, and severity of inflam-
mation as well as to assess complications such as 
fistulas, abscesses, and obstruction.
• Imaging features of celiac disease at cross-sectional 
imaging and barium exams include reversal of the 
jejunal- ileal fold pattern (decreased jejunal folds 
and increased ileal folds), intussusception, dilated 
small bowel, and bowel lymphoma.
• Small bowel tumors account for 3–6% of all GI neo-
plasms and 1–3% of all GI malignancies; in order of 
frequency, they are adenocarcinoma (30–45%), neu-
roendocrine tumors (20–40%), lymphoma (10–
20%), and sarcomas (10–15%).
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Emergency Radiology of the Abdomen 
and Pelvis: Imaging of the Non- 
traumatic and Traumatic Acute 
Abdomen
Jay P. Heiken, Douglas S. Katz, and Yves Menu
13.1  Imaging Techniques
13.1.1  General Considerations
Acute abdominal and pelvic pain is often non-specific, and 
even under the best of circumstances, physical examination 
findings and laboratory investigations may not reveal a diag-
nosis, which is why the radiologist has such a major role in 
the evaluation of these patients. Because of their substantial 
limitations compared with cross-sectional imaging examina-
tions, abdominal radiographs have a limited role but are still 
obtained selectively, primarily to evaluate suspected bowel 
obstruction and/or perforation. Multiple studies have demon-
strated the superiority of CT as well as its impact on patient 
management for imaging the acute abdomen, whether in the 
trauma or non-trauma setting. Conventional radiographs 
include supine and upright views, as well as lateral decubitus 
views. Multi-detector CT, as noted, is the primary imaging 
examination for evaluation of adult patients with acute 
abdominal pain, as well as for patients of all ages following 
acute abdominal and pelvic trauma.
13.1.2  CT
The use of CT in patients with an acute abdomen requires 
careful attention to protocol. In suspected or known uroli-
thiasis, if rupture of an abdominal aortic aneurysm (AAA) is 
suspected, or if there is a suspected non-traumatic hemor-
rhage, then generally no intravenous (IV) contrast is admin-
istered for initial CT evaluation. In most other cases of 
non-traumatic acute abdominal and pelvic pain, IV contrast 
is generally indicated. Typically, 2–3 mL per second of an 
appropriate per weight amount of iodinated contrast is 
administered through a peripheral IV catheter, and portal 
venous phase images are acquired from the dome of the dia-
phragm to the inferior aspect of the symphysis pubis, with 
routine image reconstruction in the transaxial plane using 
3 mm slice thickness and 2 mm intervals. Thinner sections 
can be generated in selected cases, but coronal reformations 
should be created routinely by the CT technologists, sent to 
PACS, and reviewed by the radiologist. Sagittal (or other) 
reformations may be helpful in selected cases, especially in 
patients with bowel obstruction. The data set should be 
reviewed using routine abdominal windows, bone windows, 
and lung windows (e.g., to look for extraluminal gas and for 
pneumothorax at the lung bases in trauma patients). Protocols 
Learning Objectives
• To distinguish the roles of ultrasound, computed 
tomography, and magnetic resonance imaging in 
evaluating traumatic and non-traumatic emergen-
cies of the abdomen and pelvis.
• To discuss the differential diagnosis of acute 
abdominal and pelvic disorders that present with 
diffuse abdominal pain and with pain in each 
abdominal quadrant.
• To evaluate the imaging findings in acute non-trau-
matic disorders of the abdomen and pelvis.
• To evaluate the imaging findings after blunt or pen-
etrating abdominal trauma.
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can be modified by the radiologist, in conjunction with the 
referring physician, for specific situations. For example, a 
CT angiography protocol can be used for evaluation of sus-
pected bowel ischemia, with thin-section arterial and then 
routine portal venous phase images acquired.
On post-contrast CT images, hyperattenuating areas can 
correspond to contrast enhancement or hematoma. Similarly, 
some calcifications can mimic contrast enhancement. To 
avoid this ambiguity, some centers recommend acquisition 
of images using dual energy to allow the reconstruction of 
virtual unenhanced images whenever necessary. However, 
the need for dual energy CT acquisition would have to be 
anticipated, as it is not routinely performed.
In the trauma setting, IV contrast should be given to all 
patients if possible, but oral contrast is not given (although 
combined water-soluble oral and rectal contrast may be indi-
cated in selected patients with penetrating trauma, to evalu-
ate for colonic injury). Trauma CT protocols vary depending 
on the practice and the specific situation and are often com-
bined with CT imaging of other portions of the body. In gen-
eral a single acquisition is obtained in the late arterial/early 
portal venous phase, which is then immediately checked by 
the radiologist. If there are any substantial abnormalities on 
these images, or if initial plain radiography of the pelvis 
demonstrates fractures, then a delayed (and ideally relatively 
low dose) CT acquisition through the area(s) of interest can 
be performed, to sort out the nature of injuries (i.e., whether 
a pseudoaneurysm versus an area of active vascular hemor-
rhage is present; or CT cystography can be performed in sus-
pected bladder injury).
Oral contrast is used less frequently or not at all in an 
increasing number of practices, for a variety of reasons, in 
patients undergoing CT for non-traumatic abdominal and 
pelvic pain. The yield of oral contrast has been questioned, 
administration of such contrast adds time and minor expense, 
the contrast does not always reach the distal bowel, and sub-
tle bowel wall pathology may be obscured. However, other 
practices prefer to give oral contrast for CT of suspected 
appendicitis and/or when the patient has non-specific abdom-
inal pain. For imaging of suspected solid organ abnormali-
ties, and for suspected urinary tract and gynecologic 
pathology, oral contrast is not indicated. In suspected high- 
grade small bowel obstruction or in the setting of mesenteric 
ischemia or gastrointestinal bleeding, positive oral contrast 
is contraindicated.
Increased attention has recently been paid to the radiation 
exposure from diagnostic CT examinations. Although CT 
appropriately remains the workhorse examination for the 
acute abdomen, radiation dose reduction strategies should be 
employed routinely, including the use of mAs reduction and, 
if available, iterative reconstruction in conjunction with radi-
ation dose reduction (such as lowering the kVp in thin 
patients). Multiple CT phases should be acquired only when 
needed. For patients requiring repeat cross-sectional imag-
ing examinations, alternative strategies, particularly MRI, 
should be strongly considered whenever feasible.
13.1.3  Ultrasound
Ultrasound (US) is the initial imaging examination of choice 
for patients with suspected acute cholecystitis and acute 
gynecological abnormalities. It is also the primary method 
for evaluating pregnant women and pediatric patients with 
acute abdominal or pelvic pain, in most clinical situations. 
Although somewhat less sensitive and specific than CT for 
appendicitis in adult patients, US is a very good first imaging 
examination when employed by experienced radiologists 
(and technologists). It also can be used to evaluate the bowel 
wall (in patients with a body habitus permitting such evalua-
tion) and has a role for rapid triage of trauma patients. A 
variety of probes and techniques are routinely employed, 
including Doppler imaging and graded compression for right 
lower quadrant evaluation.
13.1.4  Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) has a growing role in the 
imaging of pregnant women with abdominal pain who have 
undergone a nondiagnostic US examination. In a variety of 
mostly retrospective, small- to medium-sized studies, MRI 
has been shown to have high accuracy in the evaluation of 
appendicitis (Fig. 13.1) and has utility for identification and 
evaluation of alternative conditions, including other bowel 
Fig. 13.1 Acute cholecystitis. Ultrasound image demonstrates moder-
ate distention of the gallbladder with wall thickening, sludge, and 
stones, including one impacted in the gallbladder neck (arrow)
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pathology (such as Crohn disease), and for urinary and bili-
ary tract pathology. Non-contrast sequences are obtained at 
1.5 Tesla (or lower), with an emphasis on fast, multi-planar 
gradient echo/T2-weighted sequences.
13.2  Acute Pain in an Abdominal Quadrant
The differential diagnosis in a patient with an acute abdomen 
is greatly influenced by the nature and location of the pain. 
Therefore, the imaging strategies localized to each of the 
four abdominal quadrants will be discussed first, followed by 
pain which is diffuse or localized to the flank or the epigas-
tric region.
13.2.1  Right Upper Quadrant
Pain from gallstones, particularly acute cholecystitis, is by 
far the most common group of disorders to present with 
acute right upper quadrant pain. Other differential diagnostic 
considerations include hepatitis from a variety of etiologies, 
liver abscess, and rarely a ruptured liver mass (usually hepa-
tocellular adenoma or carcinoma).
US is the imaging examination of choice for evaluation of 
acute right upper quadrant pain. It is an accurate examination 
for diagnosing or excluding acute cholecystitis. Sonographic 
findings include gallstones, a sonographic Murphy’s sign, 
wall thickening of 3 mm or greater, and pericholecystic fluid/
inflammatory changes (Fig. 13.1). The more these findings 
are present, particularly gallstones combined with a sono-
graphic Murphy’s sign, the more likely acute cholecystitis is 
present. Isolated gallbladder wall thickening may be due to a 
variety of etiologies in addition to acute cholecystitis.
Recent publications have shown that CT and MRI also are 
relatively accurate imaging examinations for cholecystitis, 
although the findings may be more subtle compared with 
sonography, especially early on. In our experience, patients 
with non-specific abdominal pain and the eventual diagnosis 
of cholecystitis may be sent for CT on a relatively frequent 
basis rather than for sonography, and radiologists need to be 
aware of the potential for establishing or suggesting this diag-
nosis based on the initial CT findings, which are very similar 
to those on sonography, although pericholecystic inflamma-
tory changes may be more obvious on CT and MRI. If the CT 
findings suggest cholecystitis but are not definitive, US can 
then be performed. CT also is an excellent examination for 
demonstrating complications and severe forms of cholecysti-
tis, including perforation/abscess formation, hemorrhage, gas 
(in diabetic patients with emphysematous cholecystitis), and 
wall gangrene. The CT findings of a stone lodged in the gall-
bladder neck or cystic duct and areas of absent wall enhance-
ment have been shown to correlate with the need for an open 
rather than a laparoscopic cholecystectomy. CT is also accu-
rate in differentiating cholecystitis from gallbladder cancer, 
which sometimes is challenging.
US, CT, and MRI are all accurate examinations for the 
diagnosis (and follow-up) of liver abscesses (Fig. 13.2), 
which usually are pyogenic but which also may be amebic. 
US usually demonstrates a round or oval hypoechoic mass or 
masses, which may contain low-level echoes. Occasionally a 
hepatic abscess may simulate a solid (or partially solid) 
a
b
Fig. 13.2 Hepatic abscess. 48-year-old man with right upper quadrant 
abdominal pain, fever, and leukocytosis. Transaxial (a) and coronal (b) 
contrast-enhanced CT images demonstrate a large fluid attenuation 
mass in the right hemiliver with a thick enhancing wall and septations. 
A drainage catheter was placed, and cultures grew Streptococcus 
anginosus- constellatus-intermedius group
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hepatic mass on cross-sectional imaging examinations (espe-
cially with certain Klebsiella species). Pyogenic liver 
abscesses may be idiopathic or may result from seeding from 
infection in the biliary tract, from the luminal gastrointesti-
nal tract or from the portal/mesenteric venous system. An 
enhancing wall and a peripheral zone of edema are common 
on CT and MRI, but are not universally present.
Spontaneous rupture of a hepatocellular carcinoma with 
associated hemoperitoneum is a frequent complication in 
countries with a high incidence of this tumor, but is very 
uncommon in Western countries (less than 2% of cases). 
Hepatocellular carcinoma usually is highly vascular, and 
tumor necrosis with associated hepatic capsular rupture and 
rupture of vessels within the tumor is the presumed etiology. 
The differential diagnosis includes spontaneous hemorrhage 
within a hepatic adenoma or a hepatic metastasis. Patients 
present with acute pain and blood loss. Rapid diagnosis and 
therapy are essential. Transcatheter embolization is the treat-
ment of choice.
13.2.2  Left Upper Quadrant
Although infrequent, acute left upper quadrant pain is 
most often caused by splenic infarction or splenic abscess 
(e.g., secondary to bland or septic emboli to the spleen) 
(Fig. 13.3), but may also occur in the setting of acute gas-
tric disorders including gastritis and ulcer. Generally CT is 
performed first, although US may occasionally be the first 
imaging examination in such patients. The diagnosis of 
gastric pathology is best established by endoscopy, 
although patients may present with left or right upper 
abdominal pain, and with other non-specific signs and 
symptoms, and CT may reveal the diagnosis when it is not 
clinically suspected. CT findings include focal or diffuse 
gastric wall thickening, increased mucosal enhancement, 
submucosal edema, and perigastric inflammatory changes. 
Focal ulceration with or without perforation also may be 
identified, which is generally of benign but occasionally of 
malignant etiology.
Splenic infarction may be focal and less commonly 
global. Other etiologies of splenic infarction include marked 
splenomegaly with outgrowth of the splenic blood supply 
and pancreatitis. Typical infarcts are wedge-shaped and 
hypoattenuating on CT. Most splenic abscesses are second-
ary to hematogenous dissemination of infection and are seen 
primarily in immunocompromised individuals and IV drug 
abusers. On CT, splenic abscesses demonstrate low attenua-
tion centrally with an enhancing rim and occasionally have 
central gas. Spontaneous splenic rupture can occur in patients 
with splenomegaly caused by hematologic malignancy or 
viral infection (e.g., mononucleosis).
13.2.3  Right Lower Quadrant
Appendicitis is the most frequent cause of acute right lower 
quadrant pain and the most commonly encountered diagno-
sis leading to surgery. Other disorders that can present with 
acute right lower quadrant pain include Crohn disease, right- 
sided colitis or diverticulitis, and, in women, pelvic inflam-
matory disease, ovarian cysts (and their complications, 
including rupture, hemorrhage, and torsion), and other 
obstetric and gynecologic conditions. Less common causes 
include omental infarction (which also can present with 
upper or mid right abdominal pain), epiploic appendagitis, 
and small bowel diverticulitis (ileal or Meckel’s).
Preoperative cross-sectional imaging continues to play an 
important role in the diagnosis or exclusion of appendicitis, 
as well as in the identification of complications or alternative 
diagnoses. At most centers, even when the clinical presenta-
tion is typical (in up to one-third of patients, it is not), CT 
usually is obtained to confirm the diagnosis and to serve as a 
surgical road map (Fig. 13.4). The most specific CT finding 
is a thick-walled, dilated, fluid-filled appendix (occasionally 
containing gas), which may have one or more liths. Contrast- 
enhanced CT often demonstrates “stratification,” in which 
the individual layers of the appendiceal wall can be identi-
fied, with mucosal hyperenhancement and submucosal 
edema. As the disorder progresses, there is increasing inflam-
mation of the adjacent fat, especially in the retroperitoneal 
planes. Findings indicative of perforation include periappen-
diceal abscess, extraluminal gas or lith(s), a defect in the 
appendiceal wall, and associated small bowel obstruction. 
Determination of the severity of appendicitis is increasingly 
important as treatment strategies continually evolve. Surgery 
Fig. 13.3 Splenic abscess. 73-year-old man with left upper quadrant 
pain, fever, and leukocytosis. Transaxial contrast-enhanced CT image 
shows a gas-containing fluid collection in the spleen. A drainage cath-
eter was placed percutaneously, and cultures grew Escherichia coli
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should be performed emergently for severe forms of 
 appendicitis, but alternative options that are increasingly 
used at some centers include delayed surgery, either the next 
day or on an outpatient basis, and medical treatment with 
imaging follow-up.
Opacification of the entire appendiceal lumen is a help-
ful finding to exclude appendicitis, if oral contrast is admin-
istered; however, as noted, some institutions/practices have 
eliminated the routine use oral contrast for CT of the acute 
abdomen. Regardless of the specific CT protocol used, 
interpretation depends in part on the experience of the 
 interpreting radiologist. In a minority of cases, particularly 
in early and subacute/chronic appendicitis, the imaging 
findings can be subtle. It should be noted that the appendix 
can be larger than 6 mm in transverse diameter and can still 
be normal on CT, if other findings of appendicitis are 
absent. In the evaluation of suspected appendicitis in chil-
dren (Fig. 13.5) (and in selected nonpregnant women of 
childbearing age), US is considered the initial examination 
of choice, if available, although CT has a higher accuracy. 
Demonstration of a swollen, non-compressible appendix 
>7 mm in diameter, with a target configuration (and with 
pain corresponding to the site of the appendix), is the pri-
mary US criteria. An appendicolith or multiple appendico-
liths may be identified.
In pregnant women, appendicitis has a more variable pre-
sentation, and diagnosis is more challenging with all cross- 
sectional imaging modalities. US remains the initial imaging 
examination, despite its poor sensitivity and specificity in 
this clinical setting. Non-contrast MRI (Fig. 13.6) is being 
used increasingly in such patients after nondiagnostic US 
and has demonstrated high accuracy for diagnosis and exclu-
sion of appendicitis and for identification of alternative diag-
noses. CT should be reserved as a third-line examination, 
used only if needed.
A potential pitfall of image interpretation in patients with 
suspected acute appendicitis is the occurrence of “secondary 
appendicitis.” In patients with adjacent inflammatory pro-
cesses such as enteritis or pelvic inflammatory disease, the 
appendix may be inflamed secondarily as an extension of the 
regional process. Differentiation between secondary and 
 primary appendicitis may be difficult as some thickening of 
adjacent bowel loops, including the terminal ileum, may 
occur in cases of “primary appendicitis.”
The CT findings of right-sided diverticulitis are similar to 
those of the more common left-sided diverticulitis, including 
an inflamed diverticulum, adjacent diverticula, colonic wall 
thickening, and pericolonic inflammatory changes. Localized 
inflammation may be substantial. When considering a diag-
nosis of cecal diverticulitis, it is important to identify a nor-
mal appendix. Microperforation may occur, but more 
substantial complications, which are common in left-sided 
diverticulitis, including abscess formation, fistula, and 
obstruction, are highly unusual in right-sided diverticulitis.
Crohn disease often is first evaluated with CT; however, 
because patients with known Crohn disease usually are 
young and require serial imaging, follow-up imaging with 
MR enterography has become increasingly important to 
reduce radiation exposure (Fig. 13.7). Cross-sectional imag-
ing permits evaluation of wall thickening and enhancement; 
changes of the adjacent fat, vessels, and lymph nodes; and 
assessment of complications, including formation of 
abscesses, strictures, and fistulas.
a
b
Fig. 13.4 Acute appendicitis. Transaxial (a) and sagittal (b) contrast- 
enhanced CT images demonstrate a dilated, thick-walled, fluid-filled 
appendix (small arrows) with an appendicolith (large arrow) at the 
appendiceal orifice
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13.2.4  Left Lower Quadrant
Diverticulitis of the sigmoid or descending colon is a very 
common disorder in middle-aged and older patients, but 
also can affect young individuals. CT is the examination of 
choice, which is typically performed with IV contrast, with 
or without oral or rectal contrast. Other protocols include 
non-contrast CT. In uncomplicated disease, the CT (or MR) 
findings are the same as with right colonic diverticulitis. 
Patients with redundancy of the sigmoid colon may present 
with midline or right lower quadrant pain. CT also demon-
strates complications, including microperforation/extralu-
minal gas (Fig. 13.8), fistula/abscess formation, and unusual 
complications such as venous thrombosis, liver abscess, uri-
nary tract obstruction, and adnexal involvement. Recent 
data suggest that only selected patients identified with what 
is believed to be left colonic diverticulitis on CT require 
follow- up optical colonoscopy to exclude underlying carci-
noma (i.e., those with CT findings that are atypical and/or 
complicated).
Other diagnostic considerations in patients presenting 
with left lower quadrant pain include colitis of a variety of 
etiologies, including infection (especially from C. difficile, in 
the correct clinical setting) and ischemia; functional colonic 
disorders (especially constipation and also obstruction from 
a variety of other etiologies); urinary tract infection; and 
gynecologic disease.
Epiploic appendagitis is a relatively common, self- limiting 
condition, in which an appendage of fat along the external 
aspect of the colon, left side much more common than right, 
undergoes torsion, with subsequent venous thrombosis. CT 
findings include a swollen, ovoid, 1.5–3.5 cm  fat- containing 
focus with peripheral thickening and associated inflamma-
tion. The adjacent colon is usually normal or nearly normal.
13.3  Gynecologic Disorders
US is the primary imaging examination in females with suspected 
gynecologic pathology. A human chorionic gonadotropin (HCG) 
level should be checked emergently in all women of childbearing 
age with acute non-traumatic abdominal and pelvic pain to 
exclude ectopic or incidental pregnancy. MRI is being used 
increasingly as a problem-solving examination after pelvic US and 
Fig. 13.6 Acute appendicitis. 30-year-old woman who is 21 weeks 
pregnant with right lower quadrant pain. Transaxial T2-weighted unen-
hanced MR image shows a thick-walled retrocecal appendix (large 
arrow) with surrounding inflammation (small arrows)
a b c
Fig. 13.5 (a–c) Ultrasonography of acute appendicitis in a 12-year-old girl. Oblique and transverse views show a swollen appendix (diameter 
10 mm), with a target configuration
J. P. Heiken et al.
129
for follow-up. However, because women with acute gynecologic 
disorders often present with non-specific signs and symptoms, 
CT is frequently ordered to evaluate their abdominal pain. 
Therefore radiologists interpreting CT of the acute abdomen 
and pelvis must be familiar with the findings of a wide vari-
ety of gynecologic disorders that may present emergently. 
CT also can be used selectively as a problem-solving tool in 
patients with known or suspected gynecologic disorders.
If ovarian torsion is suspected prospectively, pelvic US is 
performed emergently. However, CT and MR findings also are 
characteristic, are similar to US findings, and may complement 
US if the sonographic examination is initially equivocal. 
Radiologists must maintain a high index of suspicion for ovar-
ian torsion as the clinical presentation is variable; the possibil-
ity of torsion should be raised if the imaging findings suggest 
a
b
Fig. 13.7 Crohn disease. 55-year-old woman with abdominal pain, 
diarrhea, and gastrointestinal bleeding. Transaxial (a) and coronal (b) 
contrast-enhanced T1-weighted images with fat suppression demon-
strate ileal wall thickening, mucosal hyperenhancement, submucosal 
edema, and mesenteric vascular engorgement indicative of disease flair
a
b
Fig. 13.8 (a, b) Perforated sigmoid diverticulitis. (a) Axial CT image 
demonstrates tiny bubbles of extraluminal gas within the left subphrenic 
space (arrows, 1) and hepatic pedicle (arrow, 2). (b) Coronal CT refor-
mation shows thickened sigmoid colon, with associated diverticular 
disease, inflammation of the adjacent fat, and thickening of the root of 
the sigmoid mesocolon. Note the tiny bubble of extraluminal gas 
(arrow) within the hepatic pedicle
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or strongly point to this diagnosis. Cross-sectional imaging 
findings include an enlarged, edematous ovary, with or without 
an associated cyst or mass (most commonly a teratoma), devia-
tion of the adnexal structures to the contralateral side, deviation 
of the uterus to the side of torsion, twisting of the adnexal/vas-
cular structures, decreased ovarian vascularity, multiple periph-
eral ovarian follicles, inflammation of the adjacent fat, and 
ascites which may be high attenuation due to blood.
Ovarian cysts are very common and may be complicated 
by hemorrhage. Associated hemoperitoneum, if present, 
usually is self-limited. The differential diagnosis of a hemor-
rhagic ovarian cyst is endometrioma. It is particularly critical 
to check the HCG level in a woman with otherwise unex-
plained hemoperitoneum, to ensure that a ruptured ectopic 
pregnancy is not present.
Pelvic inflammatory disease (PID) is common and has a 
broad spectrum of findings and presentations. If PID is known 
or suspected, US is done first. However, CT may be initially 
performed if the diagnosis is not known and the clinical presen-
tation is non-specific (Fig. 13.9). The most common causative 
organisms are gonococcus and chlamydia. Because PID most 
commonly results from ascending infection, it usually involves 
both adnexa. In the earlier stages of PID, there may be no find-
ings or subtle findings on cross-sectional imaging. There may 
be swelling of the ovaries and/or fallopian tubes, abnormal 
enhancement of the adnexal structures, and mild adjacent 
edema. In later stages, tubo-ovarian abscesses and/or hydrosal-
pinx/pyosalpinx may be identified, and adjacent organs also 
may be involved in complicated cases. Imaging findings include 
thickening and increased enhancement of the dilated, tortuous 
fallopian tube(s), a septated mass in the ovary or ovaries, and 
adjacent edema. Other presentations of PID include endometri-
tis, cervicitis, and Fitz-Hugh-Curtis syndrome in which peri-
hepatitis leads to increased enhancement of the liver edge.
Other acute gynecologic disorders that can be identified 
on cross-sectional imaging examinations include less 
 common forms of PID (e.g., actinomycosis), endometritis, 
ovarian vein thrombosis (typically following cesarean 
 section), uterine rupture following delivery, gynecologic 
tumors, and complicated uterine leiomyomas (e.g., hemor-
rhage/degeneration, torsion, and acute prolapse).
13.4  Acute Abdomen with Diffuse Pain
Any disorder that involves a large portion of the gastrointes-
tinal tract or irritates the peritoneum can cause diffuse 
abdominal pain. The most common disorder is gastroenteri-
tis, in which the CT findings often are normal or may show 
mild bowel wall thickening and increased intraluminal fluid. 
Patients with colitis have varying degrees of colonic wall 
thickening/edema, with inflammation of the adjacent fat. 
Other important disorders that present with diffuse abdomi-
nal pain include bowel obstruction and ischemia.
13.4.1  Bowel Obstruction
Bowel obstruction is a very frequent cause of abdominal pain 
in the emergency setting. Small bowel obstruction (SBO) 
usually is due to adhesions (more commonly in patients with 
previous surgery, but occasionally in patients without prior 
surgery) and less commonly due to a hernia (external or 
internal), obstructing tumor, perforated appendicitis, inflam-
matory bowel disease, or complicated diverticulitis. Less 
common etiologies include gallstone ileus, intussusception, 
intramural small bowel hematoma, and radiation enteritis. 
a
b
Fig. 13.9 Pelvic inflammatory disease. 27-year-old woman with lower 
abdominal pain, fever, and leukocytosis. Transaxial (a) and coronal (b) 
contrast-enhanced CT images show hydrosalpinx (small arrows) and a 
thick-walled fluid collection (large arrows) in both adnexa
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Large bowel obstruction (LBO) is most commonly due to 
colorectal carcinoma, but diverticulitis and sigmoid or cecal 
volvulus also are important etiologies.
Bowel obstruction usually is diagnosed on clinical 
grounds and then confirmed and further evaluated as needed 
by imaging, typically with CT, with or without initial plain 
radiographs. However, not infrequently the diagnosis of 
bowel obstruction is not clear or known clinically, and 
obstruction is established on the basis of imaging. CT reveals 
the presence or absence of obstruction, as well as the site, 
level, and cause of obstruction, and permits identification of 
associated ischemia (Fig. 13.10). In SBO, the radiologist 
should search for the transition zone between the dilated 
proximal small bowel and the collapsed distal small bowel. 
There often is a segment of small bowel containing feces- 
like material, just proximal to the transition zone. Review of 
multi-planar CT reformations is important to help identify 
the site of transition, which may be difficult to find conclu-
sively on review of transaxial images alone. In a minority of 
cases, CT reveals a closed-loop SBO (Fig. 13.10), which 
usually requires emergency surgery. In this situation, two 
points along the course of the small bowel are obstructed at 
a single site, usually associated with an adhesive band or her-
nia. Less commonly, closed-loop SBO may be due to volvu-
lus of the small bowel.
SBO needs to be differentiated from LBO and from ileus 
and motility disorders involving the small and/or large 
bowel. Ileus of the small and/or large bowel is common after 
abdominal surgery and has multiple etiologies. In LBO, CT 
demonstrates distension of the colon to the point of obstruc-
tion, with collapse of the colon. The small bowel may dem-
onstrate varying degrees of associated dilation. Colonic 
volvulus should be readily identified (Fig. 13.11), particu-
larly on review of multi-planar reformations. A variety of CT 
signs have been reported, and volvulus may be complicated 
by ischemia and subsequent perforation. Marked dilation of 
most or all of the colon may be seen in toxic megacolon from 
a variety of etiologies, as well as in “pseudo-obstruction,” the 
latter of which also can lead to subsequent volvulus. A very 
common cause of abdominal pain in emergency department 
patients is constipation, which may be of varying degrees of 
severity, usually without an associated focal obstructing 
lesion. Other motility disorders, such as scleroderma and 
Fig. 13.10 Closed-loop small bowel obstruction. 62-year-old man 
with metastatic colon cancer who presented with severe abdominal 
pain, nausea, and vomiting. Transaxial contrast-enhanced CT image 
shows a fluid-filled, distended loop of small bowel in the left mid- 
abdomen. Mesenteric edema and mild wall thickening indicate bowel 
ischemia. Note the two adjacent collapsed segments of small bowel 
(arrows), where the loop of small bowel had entered an internal hernia
a
b
Fig. 13.11 (a, b) Cecal volvulus. Transverse CT image (a) and coronal 
CT reformation (b) demonstrate a markedly dilated cecum (C) located 
in the midline and left lower abdomen and upper pelvis. The arrow 
points to the area of colonic twisting. Note the dilated small bowel 
loops, due to the proximal colonic obstruction
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administration of anticholinergic or opioid medications, also 
may lead to the performance of CT, in patients presenting 
with acute abdominal pain.
One of the most important responsibilities of the radiolo-
gist in the case of acute bowel obstruction is to help deter-
mine if the patient should undergo surgery or conservative 
management. Today, more than 50% of patients with bowel 
obstruction do not undergo surgery. Imaging criteria for sur-
gical intervention include findings indicative of bowel isch-
emia (see Sect. 13.4.2) or a closed-loop obstruction.
13.4.2  Bowel Ischemia
Bowel ischemia has a variety of etiologies, including arterial 
thrombosis or embolism, venous thrombosis, hypoperfusion, 
and vasculitis. Occlusive disease involves the mesenteric arter-
ies, most commonly the superior mesenteric artery (Fig. 13.12), 
whereas bowel ischemia secondary to venous thrombosis is 
much less common. The only direct CT (or MRI) sign of vas-
cular impairment of the bowel is diminished wall enhance-
ment, whereas increased bowel wall enhancement is seen in a 
wide variety of disorders, including in a subset of patients with 
bowel ischemia due to reactive hyperemia, loss of autoregula-
tion, or compromised venous outflow. Other cross-sectional 
imaging findings include direct visualization of embolus or 
thrombus in the mesenteric arterial circulation or thrombus in 
the mesenteric venous circulation. Bowel distension and wall 
edema are non-specific findings that may be identified in isch-
emia, but also may be present in various infectious, inflamma-
tory, or immunologic conditions and in primary bowel 
obstruction. Nonocclusive acute mesenteric ischemia usually is 
due to hypoperfusion secondary to severe cardiac disease; gen-
eralized decreased caliber of the arterial circulation is present.
a c
b
Fig. 13.12 Acute bowel ischemia secondary to superior mesenteric 
artery thrombosis. 52-year-old man with 4-day history of severe diffuse 
abdominal pain. Transaxial (a, b) and sagittal curved planar reformat-
ted (c) contrast-enhanced CT images demonstrate thrombosis of the 
superior mesenteric artery (large white arrow). Note the bowel pneuma-
tosis (small black arrow) and gas within the mesenteric veins (small 
white arrow) indicative of bowel ischemia
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Bowel ischemia also may be secondary to bowel obstruc-
tion, particularly a closed-loop SBO, but may also be identi-
fied secondary to large bowel obstruction or volvulus. Focal 
or regional bowel wall thickening due to edema and hemor-
rhage may be seen on CT, with decreased bowel wall 
enhancement and edema adjacent to the affected bowel. With 
frank infarction, pneumatosis, portal/mesenteric venous gas, 
peritonitis/ascites, and free gas can be found.
13.4.3  Gastrointestinal Perforation
Gastrointestinal perforation usually causes localized pain 
initially, which becomes more diffuse if peritonitis devel-
ops. Perforation due to peptic ulcer disease (Fig. 13.13) or a 
necrotic neoplasm has become less frequent, due to earlier 
diagnosis and improved therapy (Fig. 13.12a). However, 
perforation resulting from endoscopic procedures has 
increased in incidence. Perforation of the small bowel is 
relatively uncommon, but may be secondary to a foreign 
body, diverticulitis, or trauma, among other possibilities. 
Perforation of the colon is more frequent and can occur 
when the colon becomes markedly distended proximal to an 
obstructing lesion (e.g., tumor, volvulus) or when the 
colonic wall is friable (e.g., diverticulitis, ischemia, ulcer-
ative colitis, tumor).
Pneumoperitoneum can be recognized by gas under the 
diaphragm on an upright chest radiograph or an upright or 
lateral decubitus abdominal radiograph. Detection of subtle 
pneumoperitoneum often is difficult. CT is the examination 
of choice in suspected bowel perforation as is much more 
sensitive for the identification of such perforations com-
pared with plain radiographs and can be used to identify the 
source of perforation in the vast majority of such cases. 
Viewing the CT images using lung window settings 
improves demonstration of small amounts of extraluminal 
gas. Examining all three orthogonal planes (axial, sagittal, 
and coronal) improves the sensitivity for detection of small 
volume pneumoperitoneum. The sagittal plane is especially 
helpful as a minimal amount of gas in the umbilical area 
may be very difficult to see under the transverse mesocolon 
on axial images.
Identifying the cause of perforation may be difficult. The 
first step is to determine if the perforation is in the upper or 
lower abdomen. Some simple rules are helpful. If the pneu-
moperitoneum is localized only under the transverse meso-
colon, the perforation likely is of colonic origin. If gas 
accumulates in the lesser omentum and along the left portal 
vein in the liver hilum, gastroduodenal perforation is likely. 
If gas is found in the lesser sac, gastroduodenal perforation is 
almost certain. In cases of abundant pneumoperitoneum, 
localizing the site of perforation may be difficult.
Gas from retroperitoneal bowel perforation typically has 
a more mottled appearance and initially may be contained 
locally. As with intraperitoneal perforation, it is more readily 
identified and its etiology more clearly defined on 
CT. Diagnostic considerations include a perforated duodenal 
ulcer, complicated diverticulitis, perforated colon cancer, 
and iatrogenic perforation.
13.4.4  Acute Abdomen with Flank or 
Epigastric Pain
Acute flank pain or upper abdominal pain that radiates to the 
back most commonly is a manifestation of retroperitoneal 
pathology, particularly ureteral colic, acute pancreatitis, and 
ruptured abdominal aortic aneurysm (AAA). If AAA rupture 
is suspected, or if retroperitoneal (or other site of hemor-
rhage) is suspected, then an emergency non-contrast CT is 
performed. An additional CT acquisition with IV contrast to 
evaluate the vascular anatomy in more detail and to deter-
mine if there is ongoing active hemorrhage usually is 
obtained as part of the same examination.
Fig. 13.13 Perforated gastric ulcer. 26-year-old man with left upper 
quadrant pain, fever, and leukocytosis. Coronal CT image shows an 
ulcer (large arrow) along the lesser curvature of the stomach with sur-
rounding wall thickening. Note free intraperitoneal gas (small arrows) 
and large pelvic abscess (asterisk)
13 Emergency Radiology of the Abdomen and Pelvis: Imaging of the Non-traumatic and Traumatic Acute Abdomen
134
13.4.5  Urinary Colic
The lifetime incidence of an obstructing ureteral calculus is 
estimated at upward of 12%. The clinical diagnosis often is 
not initially clear (and CT with IV contrast may therefore be 
obtained). For evaluation of known or suspected urolithiasis, 
non-contrast CT is the imaging examination of choice. It is 
extremely accurate for the identification of urinary tract cal-
culi, as well as for stone sizing, determination of overall 
stone burden, identification of complications, and demon-
stration of alternative or additional significant diagnoses (in 
upward of 10–15% of cases).
Virtually all urinary tract stones are radiopaque, regardless 
of their specific chemical composition. The non- symptomatic 
side acts as an intrinsic control, as bilateral ureteral calculi are 
rare. Secondary signs of obstruction, including hydronephro-
sis, hydroureter, renal swelling, and perinephric and periure-
teric edema, are present in 95% of patients with a ureteral 
stone (Fig. 13.14). Coronal reformations are routinely used 
and may help the radiologist distinguish between a ureteral 
calculus and an adjacent phlebolith. Phleboliths, which are 
calcifications in veins, increase in incidence with age, usually 
are located lateral and posterior to the ureter, and typically 
have a “tail” or “comet” sign, whereas most ureteral calculi 
are surrounded by a rim of soft tissue. In patients who present 
with symptoms of renal colic but do not have a ureteral calcu-
lus, CT demonstrates a wide variety of alternative diagnoses 
in a substantial minority of such patients.
CT is used to determine management of patients with uro-
lithiasis, as almost all ureteral calculi <5 mm, especially if 
distally located, will pass spontaneously with conservative 
treatment (unless there is concurrent infection, in which case 
more aggressive management usually is indicated). Renal 
calculi frequently are found concurrently with ureteral cal-
culi and occasionally may be the source of pain. Repeat CT, 
for short-term follow-up and for additional episodes of colic, 
should be used selectively, especially in younger patients, 
and attention should be paid to reducing radiation dose. In 
very selected situations, repeat CT with IV contrast is indi-
cated, for evaluation of suspected superinfection or to clarify 
an equivocal alternative diagnosis.
13.4.6  Acute Pancreatitis
Pancreatitis is common and has a broad spectrum of presenta-
tions and outcomes. On initial clinical evaluation, pancreatitis 
frequently is confused with other disorders, and amylase and 
lipase levels may either be pending or not obtained. Therefore 
it is important for the radiologist to identify pancreatitis, usu-
ally on CT but occasionally on sonography, when the diagno-
sis is not suspected clinically. The vast majority of cases are 
due to gallstones or alcohol abuse. Less common etiologies 
include trauma, interventional pancreatobiliary procedures, 
medications, elevated triglycerides, congenital anomalies 
(i.e., pancreas divisum, annular pancreas, absent dorsal pan-
creas), and underlying tumor. Less common presentations 
include chronic pancreatitis, autoimmune pancreatitis, and 
paraduodenal (groove) pancreatitis.
A routine CT protocol is used when pancreatitis is not 
specifically suspected, but a tailored protocol can be used 
when it is suspected or for follow-up of known pancreatitis. 
Specifically, no oral contrast is given, or water is used as a 
neutral oral contrast agent. IV contrast is administered, if not 
contraindicated, to assess for necrosis, to characterize fluid 
collections, and to identify vascular complications including 
venous thrombosis and pseudoaneurysm formation. Imaging 
is performed in a late arterial (“pancreatic”) phase. CT find-
ings range from a normal or nearly normal pancreas with 
mild focal or diffuse peripancreatic inflammation to marked 
pancreatic edema and associated necrosis (Fig. 13.15). In the 
initial few days, CT findings do not necessarily correlate 
with patient outcome, but later in the patient’s course, the CT 
findings have greater prognostic significance.
a b c
Fig. 13.14 (a–c) Right-sided urinary colic. Axial CT image (a) and coronal (b) and oblique sagittal (c) CT reformations show dilatation of the 
proximal right urinary tract, due to a ureteral calculus
J. P. Heiken et al.
135
There are two main types of acute pancreatitis: interstitial 
edematous versus necrotizing. The revised Atlanta classifica-
tion system attempts to better characterize the disease  process, 
to standardize terminology—including the description of 
cross-sectional imaging findings—and to provide better corre-
lation with prognosis. Other CT scoring systems also are in use 
to characterize the findings of pancreatitis and provide prog-
nostic information. In the revised Atlanta classification system, 
in the first 4 weeks, there may be acute peripancreatic fluid 
collections (APFCs) associated with interstitial edematous 
pancreatitis versus acute necrotic collections (ANCs) associ-
ated with necrotizing pancreatitis, the latter of which can be 
pancreatic and/or peripancreatic and which may be sterile or 
infected. After 4 weeks, APFCs usually resolve, but can 
become pseudocysts (which may be sterile or infected), 
whereas ANCs may evolve into areas of walled-off necrosis 
(WON), which may be pancreatic and/or peripancreatic and 
which may be sterile or infected.
CT-guided aspiration is very useful when indicated, to dis-
tinguish sterile from infected necrosis/fluid collections. 
Additionally, MRI should be strongly considered when follow-
 up imaging is needed, to reduce radiation exposure, as these 
patients often require multiple repeat examinations in the short 
term and may also have repetitive episodes of pancreatitis.
13.5  Imaging of Abdominal and Pelvic 
Trauma
13.5.1  Blunt Abdominal Trauma
MDCT has become the primary imaging examination for 
evaluating blunt abdominal trauma and has replaced diagnos-
tic peritoneal lavage (DPL) in almost all circumstances. US 
plays an important role in the detection of hemoperitoneum in 
hemodynamically unstable patients. The intra- abdominal 
injuries expected after blunt abdominal trauma depend upon 
the mechanism of injury, whether or not a restraint device was 
used, and patient body habitus. Knowledge of the common 
patterns of injury resulting from different types of motor 
vehicle collisions (frontal, lateral, and rear impact; sideswipe, 
rollover, etc.) and other traumatic events aids identification of 
specific types of injuries, but a discussion of these factors is 
beyond the scope of this chapter.
13.5.2  Imaging Techniques
Intravenous contrast enhancement for MDCT is critical to 
enable detection of abdominal and pelvic injuries. As noted 
above, mages generally are obtained in the portal venous 
phase of enhancement (approximately 65–80 s after admin-
istration of 100–150 mL injected at 3–5 mL per second). 
Arterial phase images may be helpful in some severely 
injured patients to demonstrate vascular injuries of the solid 
organs that may not be apparent on the portal venous phase 
images and to characterize areas of active extravasation as 
arterial versus venous. When injuries are suspected on the 
portal venous phase images, 5–10-min delayed images are 
helpful to detect injuries of the urinary tract and to further 
characterize solid visceral organ injuries that involve the vas-
culature. Patients with suspected bladder injury should 
undergo CT cystography. Oral contrast material is no longer 
administered at almost all trauma centers for patients with 
blunt abdominal trauma.
Focused assessment with sonography for trauma (FAST) 
is a limited abdominal ultrasound examination designed 
primarily to identify peritoneal fluid. A six-point examina-
tion generally is performed using a 3.5 MHz sector trans-
ducer. Images of the right subphrenic space (above the 
*
Fig. 13.15 Evolution of acute interstitial edematous pancreatitis (a) to 
acute necrotizing pancreatitis (b). 34-year-old man with abdominal pain. 
(a) Transaxial contrast-enhanced CT image shows diffuse edema of the 
pancreas and peripancreatic fluid. (b) Transaxial contrast- enhanced CT 
image obtained 2 weeks later shows necrosis of the pancreatic tail which 
is now replaced by an acute necrotic collection (asterisk)
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liver), left subphrenic space (above the spleen), hepatorenal 
fossa, perisplenic space (at the inferior margin of the 
spleen), peritoneal recess of the pelvis, and pericardium are 
recorded. Although FAST has been shown to be 86% sensi-
tive for detection of abdominal injuries requiring surgery, 
liver and spleen injuries are not always associated with 
hemoperitoneum, and a negative FAST does not exclude an 
intra- abdominal injury. On the other hand, patients with a 
positive FAST do not always require surgery. Therefore, 
hemodynamically stable patients with a positive FAST 
should undergo MDCT for staging of their injuries. In addi-
tion, FAST is not reliable for assessment of the 
retroperitoneum.
13.5.3  Pneumoperitoneum
On MDCT, pneumoperitoneum may consist of free gas 
beneath the anterior abdominal wall or small bubbles of gas 
trapped between leaves of the mesentery or within peritoneal 
recesses. Review of images using lung window settings can 
be helpful in identifying small amounts of intraperitoneal 
gas. In the setting of trauma, pneumoperitoneum is highly 
suggestive of bowel perforation. A localized collection of 
gas may be identified adjacent to the site of bowel perfora-
tion. It is important to keep in mind that pneumoperitoneum 
is not always present on CT scans of patients with docu-
mented bowel perforation. In addition, pneumoperitoneum 
occasionally may be present in patients without bowel injury, 
secondary to multiple other potential causes including baro-
trauma, intraperitoneal spread of air from a large pneumo-
thorax, or DLP.
13.5.4  Peritoneal Fluid
In trauma patients, peritoneal fluid most commonly repre-
sents blood resulting from injury to the liver, spleen, bowel, 
or mesentery. In most patients hemoperitoneum has an atten-
uation value ranging from 20 to 45 HU or greater (Fig. 13.16); 
however, in up to one-quarter of patients, hemoperitoneum 
has an attenuation value less than 20 HU. Blood located adja-
cent to the source of hemorrhage often is partially clotted and 
higher in attenuation (the “sentinel clot” sign), which can be 
helpful in identifying the site of bleeding. Free peritoneal 
fluid in the absence of direct signs of solid or hollow visceral 
injury may be problematic, especially in men. However, 
recent studies have shown that small amounts of simple peri-
toneal fluid are found in up to 5% of male blunt trauma 
patients in the absence of hollow or solid organ injury. 
Therefore, immediate surgical intervention is not mandated in 
such patients, but careful review of the CT images for subtle 
injuries and hospital admission with close clinical follow-up 
and repeat CT if necessary are recommended.
13.5.5  Splenic Injuries
The spleen is the most commonly injured abdominal organ 
in blunt trauma. In the large majority of cases, splenic inju-
ries can be managed nonsurgically. The need for surgical 
intervention is based on patient factors, clinical findings, 
and the CT-based splenic injury scale developed by the 
American Association for the Surgery of Trauma (AAST) 
(Table 13.1). The AAST splenic injury scale takes into 
account the size and location of splenic lacerations and 
hematomas. Higher- grade injuries (generally AAST grade 
III and higher) more often require surgical therapy; how-
ever, this grading scale has been shown to be a relatively 
poor predictor of the success of nonsurgical management. 
More recently an MDCT- based splenic injury grading sys-
a
b
Fig. 13.16 (a, b). Hemoperitoneum due to mesenteric injury from 
motor vehicle collision. Transaxial CT image (a) demonstrates high- 
attenuation fluid (arrow) adjacent to small bowel loops. Increased atten-
uation within the mesenteric fat (arrowhead) is due to a mesenteric 
contusion. Coronal image (b) shows blood layering dependently within 
the peritoneal cavity
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tem (Table 13.2) has been proposed, which takes into 
account additional CT features of splenic trauma including 
the presence of active hemorrhage (Fig. 13.17), a pseudoan-
eurysm, or an arteriovenous (AV) fistula. Active hemor-
rhage appears as a localized area of hyperattenuation within 
the injured splenic parenchyma, which persists and grows 
larger on delayed images. In contradistinction, a pseudoan-
eurysm or AV fistula washes out on delayed phase images. 
Some trauma specialists now advocate the acquisition of 
arterial phase CT images of the abdomen, in addition to the 
portal venous and delayed phase images after blunt trauma, 
because not all vascular injuries of the spleen are identified 
on portal venous and delayed phase images. Further study is 
required to validate this proposal.
13.5.6  Hepatic Injuries
Hepatic injuries are only slightly less common than splenic 
injuries and more frequently involve the right lobe. As with 
Table 13.1 American Association for the Surgery of Trauma (AAST) 
Splenic Injury Scale
Injury grade and 
type Description
I
Hematoma Subcapsular, <10% surface area
Laceration Capsular tear, <1-cm parenchymal depth
II
Hematoma Subcapsular, 10–50% of surface area or 
intraparenchymal hematoma <5-cm diameter
Laceration 1–3 cm parenchymal depth; does not involve 
trabecular vessels
III
Hematoma Subcapsular hematoma, >50% surface area or 
expanding; ruptured subcapsular or 
intraparenchymal hematoma; intraparenchymal 
hematoma >5 cm or expanding
Laceration >3-cm parenchymal depth or involves trabecular 
vessels
IV
Laceration Laceration, involves segmental or hilar vessels, 
producing major devascularization (>25% of 
spleen)
V
Laceration Completely shattered spleen
Vascular Hilar vascular injury that devascularizes spleen
Note: Increase by one grade (up to grade III) for multiple injuries. 
Adapted from Moore et al. (1995), with permission




I Subcapsular hematoma <1-cm thick; laceration <1-cm 
parenchymal depth; parenchymal hematoma <1-cm 
diameter
II Subcapsular hematoma 1- to 3-cm thick; laceration 1- to 
3-cm parenchymal depth; parenchymal hematoma 1- to 
3-cm diameter
III Splenic capsular disruption; subcapsular hematoma <3-cm 
thick; laceration <3-cm parenchymal depth; parenchymal 
hematoma <3-cm thick
IVA Active intraparenchymal or subcapsular splenic bleeding; 
splenic vascular injury (pseudoaneurysm or arteriovenous 
fistula); shattered spleen
IVB Active intraperitoneal bleeding
Adapted from Marmery et al. (2007), with permission
a
b
Fig. 13.17 Splenic laceration. Transaxial (a) and coronal (b) contrast- 
enhanced CT images show a splenic laceration with contrast extravasa-
tion (arrow) and intraperitoneal bleeding (grade IVB)
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splenic injuries, the majority of blunt liver injuries are suc-
cessfully managed nonoperatively. The AAST liver injury 
scale (Table 13.3) is commonly used to assess the severity of 
hepatic injuries. Lacerations appear as linear or branching 
areas of hypoattenuation that frequently travel along vascu-
lar planes. Perihilar lacerations may be associated with bili-
ary tract injuries. As with the AAST splenic injury scale, the 
AAST liver injury scale has limitations in guiding clinical 
management. Additional useful CT findings include exten-
sion of the injury to the major hepatic veins (Fig. 13.18), the 
presence of active bleeding into the peritoneal cavity, and the 
presence of large volume hemoperitoneum. Extension to the 
major hepatic veins usually requires surgery to control hem-
orrhage, and active bleeding into the peritoneum often can be 
treated with endovascular interventions.
13.5.7  Bowel and Mesenteric Injuries
Injuries to the hollow viscera and mesentery occur in only 
approximately 5% of patients with blunt abdominal trauma, and 
the CT findings may be subtle; however, identification of bowel 
and mesenteric injuries is critical, as delay in diagnosis increases 
the morbidity and mortality from peritonitis and sepsis. The 
bowel segments affected most commonly are the proximal jeju-
num and the distal ileum. The most specific signs of bowel 
injury are focal discontinuity of the bowel wall (transection), 
extraluminal oral contrast (when administered), pneumoperito-
neum, and retropneumoperitoneum. Less specific (but more 
frequently encountered) signs of bowel trauma include focal 
wall thickening, abnormal bowel wall enhancement, mesenteric 
stranding, and free intraperitoneal fluid. The association of a 
focal bowel abnormality with adjacent or free fluid increases the 
likelihood that bowel injury is present. The most specific signs 
of mesenteric injury are active extravasation from a mesenteric 
vessel (Fig. 13.19), mesenteric hematoma, and abrupt termina-
tion or beading of mesenteric vessels. Small isolated mesenteric 
hematomas do not always require immediate surgery and can be 
managed with observation. Larger hematomas and mesenteric 
vascular injuries have a higher risk of subsequent bowel isch-
emia and usually require surgical repair.
In the setting of trauma, the combination of diffuse thicken-
ing and hyperenhancement of the bowel generally is not an indi-
cation of direct bowel injury but is a component of the 
hypoperfusion complex (Fig. 13.20), which is seen in trauma 
patients who have persistent hypovolemia after initial intrave-
nous fluid resuscitation. Other CT features of the hypoperfusion 
complex include collapse of the inferior vena cava, flattening of 
the renal veins, decreased caliber of the aorta, delayed nephro-
grams, increased enhancement of the adrenal glands, decreased 
enhancement of the spleen, and pancreatic enlargement with 
peripancreatic and retroperitoneal edema. These findings usu-
ally are reversible with additional fluid resuscitation.
13.5.8  Pancreatic Injuries
Pancreatic injuries typically occur after blunt trauma to the 
upper abdomen. Pancreatic contusions appear as focal areas 
of hypoattenuation or enlargement, whereas lacerations are 
linear low attenuation defects that may be superficial or 
Fig. 13.18 Grade V liver laceration. Transaxial CT image shows a 
large ill-defined area of hypoattenuation surrounding the central hepatic 
blood vessels





Hematoma Subcapsular, <10% surface area
Laceration <1 cm in depth
2
Hematoma Subcapsular, 10–50% of surface area; 
intraparenchymal hematoma <10 cm in diameter
Laceration 1–3 cm in depth or <10 cm in length
3
Hematoma Subcapsular, >50% surface area or expanding; 
ruptured subcapsular or parenchymal hematoma; 
intraparenchymal hematoma >10 cm or expanding
Laceration >3-cm parenchymal depth
4
Laceration Parenchymal disruption involving 25–75% of hepatic 
lobe or one to three Couinaud segments in a single 
lobe
5
Laceration Parenchymal disruption involving >75% of hepatic 
lobe, or more than three Couinaud segments in a 
single lobe
Vascular Juxtahepatic venous injuries (i.e., retrohepatic vena 
cava and/or central major hepatic veins)
6
Vascular Hepatic avulsion
Adapted from Moore et al. (1995), with permission
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extend completely through the pancreas, resulting in transec-
tion (Fig. 13.21). Lacerations that involve more than 50% of 
the pancreatic thickness usually cause pancreatic ductal 
injury. Indirect signs of pancreatic injury include fluid in the 
peripancreatic fat or transverse mesocolon and thickening of 
the left anterior renal fascia. The injured pancreas may 
appear normal at CT in the first 12 hours after trauma. 
Therefore a 24–48-h repeat CT is warranted in patients who 
subsequently develop abdominal pain.
Magnetic resonance cholangiopancreatography (MRCP) 
may be useful to document noninvasively injury of the 
main pancreatic duct; however, endoscopic retrograde 
 cholangiopancreatography (ERCP) may be necessary for 
diagnosis. Although some patients with pancreatic ductal 
injury may be successfully treated with endoscopic pancre-
atic duct stenting, most require surgical repair.
13.5.9  Urinary Tract Injuries
As with the liver and spleen, an AAST grading system classifies 
the severity of renal trauma based on the size and location of 
renal lacerations and hematomas (Table 13.4). Most renal inju-
ries are treated conservatively, with surgical intervention 
reserved for collecting system disruptions and vascular injuries 
(Fig. 13.22). Delayed CT images are necessary to assess the 
integrity of the collecting system. Avulsion of the renal pedicle, 
characterized on CT as very poor or absent enhancement of the 
kidney, carries a high risk of renal devascularization. Rupture of 
the urinary bladder is a complication of pelvic trauma. Patients 
with gross hematuria or pelvic fractures should undergo CT cys-
tography. Intraperitoneal rupture requires surgical repair, 
whereas extraperitoneal rupture can be treated conservatively. 
However, there may be combined intraperitoneal and extraperi-
toneal bladder rupture in some trauma patients.
13.5.10  Diaphragmatic Injuries
Diaphragmatic injuries are caused by sudden increase in 
intra-abdominal pressure from blunt abdominal trauma. CT 
findings include diaphragmatic discontinuity, herniation of 
abdominal viscera into the thorax, constriction of herniated 
abdominal contents through a diaphragmatic defect, and 
dependent position of the herniated viscera along the poste-
rior chest wall (dependent viscera sign). Multiplanar CT 
imaging can be helpful in identifying diaphragmatic 
injuries.
13.5.11  Vascular Injuries
Abdominal aortic injuries in high-speed motor vehicle colli-
sions can be life-threatening. Obvious findings include large 
retroperitoneal hematoma and active extravasation. More 
subtle injuries include pseudoaneurysm, intimal flap, and 
thrombosis. Thoracic aortic transection usually requires 
emergency surgical repair, preferably utilizing endovascular 
techniques, but selected less severe aortic injuries can be 
watched closely initially without repair. Abdominal aortic 
injuries most commonly result from high-speed motor vehi-
cle collisions in which the aorta is compressed between a lap 
belt and the lumbar spine. It is important to note that a sub-
stantial amount of blood loss in the retroperitoneum may be 
clinically occult and will not be detected with 
FAST. Extraperitoneal hemorrhage in the pelvis often is 
a
b
Fig. 13.19 Severe mesenteric injury. 81-year-old man who suffered 
blunt abdominal trauma from a fall. Transaxial (a) and coronal (b) 
contrast- enhanced CT images demonstrate a large mesenteric hema-
toma with extravasation from a mesenteric artery (arrows)
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associated with pelvic fractures. CT angiography is useful in 
this setting to evaluate for active extravasation, which can be 
treated in most cases with endovascular embolization.
13.5.12  Penetrating Abdominal Trauma
The need for surgery after a stab wound depends upon the 
location and depth of penetration. Wounds in any location 
that penetrate the peritoneum require surgical exploration 
because of the likelihood of bowel injury. Anterior wounds 
that penetrate the deep fascia usually require laparoscopy 
or laparotomy because of the possibility of bowel injury. 
In contradistinction, posterior stab wounds that penetrate 
the deep muscular fascia may be confined to the paraspinal 
muscles and may not be deep enough to penetrate the perito-
neum, thus not necessitating surgical exploration. CT with 
intravenous, oral, and rectal contrast is useful in determin-
ing the depth of wound penetration and in identifying organ 
injury, retroperitoneal hematoma, and hemoperitoneum.
Gunshot wounds are much more complex injuries that 




Fig. 13.20 Hypoperfusion complex. 42-year-old woman with acute blood loss. Transaxial (a) and coronal (b, c) contrast-enhanced CT images 
show diffuse edema, bowel wall thickening, collapse of the inferior vena cava, and hyperenhancement of the adrenal glands
J. P. Heiken et al.
141
or radiographs indicate that the bullet might have crossed 
bowel, laparoscopy or exploratory laparotomy is indicated, 
and CT is not necessary. Similarly, patients who are hemody-
namically unstable require surgical exploration. In the remain-
der of patients who are hemodynamically stable, CT is 
effective in delineating the path of the bullet and identifying 
solid and hollow organ injuries. Solid organ injuries are staged 
using the AAST criteria. Findings of bowel perforation includ-
ing pneumoperitoneum and extraluminal leakage of orally or 
rectally administered contrast material require surgical explo-
ration; however, small perforations of bowel may be very dif-
ficult to diagnose with CT. If CT demonstrates peritoneal fluid 
or the bullet path crossing bowel in the absence of pneumo-
peritoneum or contrast leakage, surgical exploration is 
indicated.
Fig. 13.21 Pancreatic laceration. Transaxial CT image demonstrates a 
linear hypoattenuating defect (arrow) extending through the tail of the 
pancreas. The pancreatic tail is surrounded by fluid





Contusion Microscopic or gross hematuria, with normal 
urologic studies
Hematoma Subcapsular nonexpanding, without parenchymal 
laceration
II
Hematoma Nonexpanding perirenal hematoma confined to 
renal retroperitoneum
Laceration <1-cm parenchymal depth of renal cortex, without 
urinary extravasation
III
Laceration >1-cm parenchymal depth of renal cortex, without 
collecting system rupture or urinary extravasation
IV
Laceration Parenchymal laceration extending through renal 
cortex, medulla, and collecting system
Vascular Main renal artery or vein injury, with contained 
hemorrhage
V
Laceration Completely shattered kidney
Vascular Avulsion of renal hilum, which devascularizes the 
kidney
Adapted from Moore et al. (1989), with permission
a
b
Fig. 13.22 (a, b) Deep (grade III) renal laceration with active extrava-
sation. Transaxial CT images (a, b) show a deep laceration of the left 
kidney that extends to the renal hilum. Arrows indicate active extravasa-
tion. A large hematoma surrounds the kidney and displaces it anteriorly
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Take-Home Messages
• Imaging of non-traumatic abdominal and pelvic 
pain, as well as imaging of acute abdominal and 
pelvic trauma, continues to evolve.
• CT, using a variety of protocols, remains the main-
stay for imaging acute traumatic as well as non-
traumatic conditions, especially in adults, although 
US frequently is used as the first examination in 
children and in the non-trauma setting, with subse-
quent CT utilized in children when necessary.
• MRI has a growing role, especially for follow-up 
examinations in the non-trauma setting and for initial 
imaging or following US in pregnant patients and in 
pediatric patients, to reduce radiation exposure.
• Close cooperation with the referring physician imme-
diately prior to imaging remains essential for rapid 
and accurate diagnosis, as the character and location 
of the patient’s pain, and other considerations, 
strongly influence the specific imaging examination(s) 
performed and the protocol(s) utilized, as well as the 
resulting imaging differential diagnosis.
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Diseases of the Pancreas
Thomas K. Helmberger and Riccardo Manfredi
Modern cross-sectional imaging with high spatial and 
 contrast resolution allows a perfect delineation of the pan-
creas in its retroperitoneal home. The organ typically pres-
ents itself with a length between 12 and 15 cm and a diameter 
at the head area of about 2.5 cm, at the body of about 2 cm, 
and at the tip of the pancreatic tale of about 1.5 cm. 
Anatomically, the pancreatic head is defined as the area to 
the right of the left border of the superior mesenteric vein, 
the body as the area between the left border of the superior 
mesenteric vein and the left border of the aorta, and the tail 
as the area between left border of the aorta and the hilum of 
the spleen. The normal pancreatic duct ranges between 
1.5 mm at the tail to 3 mm at the head.
Usually (ca. 60% of cases) the pancreatic main duct (duct 
of Wirsung), the duct of Santorini, and the common bile duct 
join together within the pancreatic head, entering the duode-
num via the papilla of Vater.
Several conditions that affect the function and integrity of 
the pancreas, as developmental anomalies, neoplastic and 
inflammatory diseases will be discussed.
14.1  Developmental Anomalies 
of the Pancreas
During embryogenesis, the pancreas is formed from a larger, 
dorsal bud (tail, body, parts of the head) and a small, ventral 
bud (rest of the head). The ventral bud migrates downwards 
dorsal from the dorsal bud. During the union of the both 
buds, the main pancreatic duct within the ventral bud ends 
via the duct of Santorini in the minor papilla. This duct gets 
then reduced to an accessory duct, whereas the main pancre-
atic duct of the dorsal bud merges with the duct of the former 
ventral bud ending in the major papilla [1, 2]. The disturbed 
union of the two buds can cause three major anomalies.
Pancreas divisum, a non-union anomaly of the pancreas, 
is found in autopsy studies with a frequency of 1–14% and is 
characterized by the separate drainage of the main pancreatic 
duct via the duct of Santorini into the minor papilla and of 
the duct of Wirsung into the major papilla. Only 1% of indi-
viduals with pancreas divisum will develop unspecific 
abdominal symptoms (abdominal discomfort, most likely 
caused by recurrent episodes of mild pancreatitis). 
Therefore—without real proof—some authors consider pan-
creas divisum a promoting factor for pancreatic tumors based 
on recurrent and lately chronic focal pancreatitis [3].
In pancreas annulare, the non-migration of the ventral bud 
of the pancreas causes the ventral and dorsal bud forming a 
ring around the duodenum. This rare anomaly (estimated 
prevalence 0.01%) can be associated with other birth deformi-
ties as congenital duodenal atresia, mesenterium commune, 
oral facial defects, and Down’s syndrome. Clinical signs are 
determined by stenosis and occlusion of the duodenum.
To reveal a union/migration anomaly of the pancreas, in 
most of the cases, MRCP will add the crucial information of 
the distorted duct configuration.
Learning Objectives
• To understand typical imaging criteria to identify 
and differentiate solid and cystic pancreatic struc-
tural changes and neoplasia.
• To understand the limitations of imaging in com-
plex pancreatic diseases and to appreciate the 
importance of additional clinical information.
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The generally asymptomatic ectopic pancreatic tissue can 
be found in the stomach, duodenum, and ileum, very rarely 
in Meckel’s diverticulum, gall bladder, bile duct, and spleen, 
whereas autopsy studies reveal a frequency between 0.6 and 
15%. Typically, pancreatic ectopic tissue is detected by 
endoscopy.
Total agenesis of the pancreatic gland, hypoplasia of the 
pancreas (partial agenesis), congenital pancreatic cysts (dys-
ontogenetic cysts, hamartosis), multiple congenital cysts 
associated with von Hippel-Lindau disease (cysts also in the 
liver and kidneys), and also cystic degenerative transforma-
tion of the pancreas in cystic fibrosis are in general rare and 
are identified by MRI, as well as by sonography and CT, 
based on the partial or complete missing of the organ or by 
solitary or multiple cysts [2, 4].
14.2  Pancreatic Neoplasms
Pancreatic tumors can be classified according to their cellu-
lar origin, enzymatic activity, and benign or malignant poten-
tial. The most recent WHO classification (2010, revised 2012 
and 2017) divides pancreatic tumors into primary epithelial 
and mesenchymal tumors, lymphomas, and secondary 
tumors; from a clinical-practical point of view, tumorlike 
lesions can be added (Table 14.1). In clinical reality, many of 
the rare and very rare tumors have no specific imaging 
appearance and can be differentiated only pathologically.
14.2.1  Pancreatic Carcinoma
Pancreatic ductal adenocarcinoma—most of the various sub-
types of pancreatic carcinoma can be differentiated only by 
histo- and immunopathology—accounts for 85–95% of all 
malignant pancreatic tumors (15–20% in gastrointestinal malig-
nancies, 3% in all carcinomas). In general, the tumors are located 
predominantly in the pancreatic head (60–70%; body, 15% and 
tail, 5%). A multifocal or diffuse tumor spread is uncommon. 
The prognosis is poor, since most tumors are detected late in an 
advanced stage of spread. An early metastatic spread along peri-
vascular, ductal, lymphatic, and perineural pathways is promoted 
by the absence of a true capsule around the organ.
For detection, staging, and follow-up after treatment, endo-
scopic ultrasound, contrast-enhanced CT, MRI, and FDG/PET 
Key Point
• The majority of pancreatic anomalies are asymp-
tomatic. MRI and MRCP are superior in identifying 
the structural variants and to exclude suspected 
neoplastic conditions.
Table 14.1 Classification of pancreatic lesions modified according to 
WHO classification, pancreas (modified according to [5] and the 2017 
update for neuroendocrine tumors [6])
Epithelial tumors
Benign Acinar cell cystadenoma




Pancreatic intraepithelial neoplasia, grade 3 
(PanIN-3)
Intraductal papillary mucinous neoplasm 
(IPMN) with low- or intermediate-grade 
dysplasia
Intraductal papillary mucinous neoplasm 
(IPMN) with high-grade dysplasia
Intraductal tubulopapillary neoplasm (ITPN)
Mucinous cystic neoplasm (MCN) with low- or 
intermediate-grade dysplasia
Mucinous cystic neoplasm (MCN) with 
high-grade dysplasia
Malignant lesions Ductal adenocarcinoma
  Adenosquamous carcinoma
  Mucinous adenocarcinoma
  Hepatoid carcinoma
  Medullary carcinoma, NOS
  Signet ring cell carcinoma
  Undifferentiated carcinoma




Intraductal papillary mucinous carcinoma 














neuroendocrine tumors (PanNEN G1/G2/G3)
  Pancreatic neuroendocrine microadenoma
  Nonfunctioning pancreatic neuroendocrine 
tumor







  Serotonin-producing tumors with and 
without carcinoid syndrome
  ACTH-producing tumor with Cushing 
syndrome
Pancreatic neuroendocrine carcinoma (PanNEC 




  Mixed ductal-neuroendocrine carcinoma
  Mixed acinar-neuroendocrine carcinoma
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may be applied, with endoscopic ultrasound having the high-
est accuracy in detecting small pancreatic head and periampul-
lary tumors and FDG/PET in detecting distant metastatic 
spread. Nevertheless, CECT and MRI provide a sufficient and 
comprehensive display of the primary tumor and its sequelae 
with an accuracy of about 90% and even more [7–9].
The imaging appearance of common pancreatic adeno-
carcinoma is determined by its typically dense, fibrous, low- 
vascularized stroma resulting in low soft-tissue density in 
CT and low signal on T1-weighted and T2-weighted MRI 
and no or only minor contrast enhancement (Fig. 14.1) which 
makes the tumors best delineable to the normal glandular 
parenchyma on CE imaging.
The pancreatic duct may be involved depending on the pri-
mary tumor localization within the pancreas ranging from no 
duct involvement at all in peripheral tumor, over segmental 
obstruction due to intraductal tumor invasion (duct penetrating 
sign), to obstruction of both the pancreatic and common bile 
duct (double duct sign) in pancreatic head tumors. The relation 
between tumor and ducts is noninvasively seen best on MRCP.
Assessing potential invasive local growth, metastatic 
spread to the local and regional lymph nodes, to the liver, and 
to the vascular invasion, completes staging of pancreatic 
malignancies.
Not well-defined tumor margins and blurred surroundings 
are still a challenge for every imaging modality since micro-
scopic local invasive peritumoral spread and an inflammatory 
desmoplastic reaction can often not be differentiated causing 
over- or underestimation of the T-stage of the tumor [10].
At the time of diagnosis of the primary, about two thirds of 
the patients will present distant metastases (lymph node 
metastases 40%, hematogenous metastases of the liver 40%, 
peritoneal metastases 35%) which will be detected with accu-
racies above 90% by CE-MRI and FDG/PET/CT [11, 12]. 
Non-resectability in pancreatic cancer is determined by vascu-
lar encasement of the superior mesenteric artery, celiac trunk, 
hepatic or splenic artery, and peripancreatic veins, which is 
very likely if a vessel circumference is encased more than 50% 
(typical signs: decreased vessel caliber, dilated peripancreatic 
veins, teardrop shape of superior mesenteric vein present).
14.2.2  Other Tumors of Ductal Origin
This heterogeneous group of tumors embrace cystic neo-
plasms, tumors neuroendocrine components, and a variety of 
very rare tumors as pancreatoblastoma and solid pseudopap-
illary neoplasm.
14.3  Cystic Neoplasm
In modern high-resolution imaging, pancreatic cysts are a 
common finding by MRI (~20%) and CT (~3%). Due to the 
slightly increased risk of malignancy in incidental cysts, 
mainly in the younger than 65 of years, incidentally found 
pancreatic cysts have to be assessed carefully without exag-
gerating unnecessary therapeutical consequences [13, 14].
14.3.1  Serous Cystadenoma
Serous cystic neoplasms are accounting for about 50% of all 
cystic tumors including serous cystadenomas, serous oligo-
cystic adenomas, cystic lesions in von Hippel-Lindau syn-
drome, and rarely serous cystadenocarcinomas [15, 16].
The most common subtype is the benign serous cystade-
noma (microcystic type), typically in elderly women (60–
80 years of age). In most cases, the lesion is located in the 
pancreatic head, composed of multiple tiny cysts, separated 
by thin septae. Spotty calcifications and a central stellate 
nidus might be present (Fig. 14.2).
About 10% of all serous cystic tumors present as an oligo-
cystic variant with only a few cysts of 2–20 mm diameter and 
a higher prevalence in men (30–40 years).
The rare cystadenocarcinomas are usually large at clinical 
presentation already with local invasive growth and metasta-
ses to lymph nodes and liver.
The diagnosis of serous cystic lesions of the pancreas by 
imaging is ruled by the proportion of small cysts and septae with-
out contrast enhancement that may create an almost solid impres-
sion in CT, whereas the cystic components still can be best 
Key Point
• Pancreatic adenocarcinoma is the most common 
malignancy of the pancreas. CT and MRI are the 
established imaging tools for primary diagnosis, 










Desmoplastic small round cell tumor
Perivascular epithelioid cell neoplasm
Lymphomas Diffuse large B-cell lymphoma (DLBCL), NOS
Secondary tumors Metastases












Fig. 14.2 (a–c) Serous cystadenoma. (a) Axial T2-weighted turbo spin 
echo image (TR/TE 4500/102) shows a multicystic microcystic neo-
plasm of the head of the pancreas (arrows). (b) On axial fat- saturated 
volumetric T1-weighted gradient echo image (TR/TE 4.86/1.87 ms) 
during the portal venous phase of the dynamic study following 
Gd-chelate administration, serous cystadenoma shows enhancement of 
and lack of a peripheral wall. (c) On the coronal MRCP image single- 
shot RARE (TR/TE ∞/110 ms), serous cystadenoma is responsible of 
compression of the main pancreatic duct with upstream dilatation
a b
Fig. 14.1 (a, b) Adenocarcinoma of the head of the pancreas locally 
invasive. (a) Axial contrast-enhanced computed tomography (CT) dur-
ing the pancreatic phase shows a hypovascular focal pancreatic lesion 
of the head, responsible of infiltration of the main pancreatic duct with 
obstructive chronic pancreatitis and infiltration of the peripancreatic fat 
(arrow). (b) Axial contrast-enhanced computed tomography (CT) dur-
ing the portal venous phase shows infiltration of the posterior peripan-
creatic fat
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appreciated by MRI. Even if the tumors can grow rather large the 
mismatch of tumor size, missing both ductal involvement and 
secondary signs of malignancy will direct to the right diagnosis.
For the differentiation of oligocystic adenomas from 
mucinous cystic tumors, IPMN, or walled-off cysts tumor 
localization, an “empty” clinical history and normal ducts in 
MRCP can be helpful [17, 18].
14.3.2  Mucinous Cystic Neoplasm (MCN)
Mucin-producing cystic tumors, typically in middle-aged 
women (f:m = 19:1), are characterized by a missing connec-
tion to the pancreatic ducts and the histological presence of 
an ovarian-like stroma. In comparison to SCN, MCN is less 
frequent (10% of all cystic pancreatic lesions) in general 
asymptomatic, detected as solitary, large lesions arising in 
the body and tail of the pancreas (95%), and composed of 
only few cysts with pronounced septae. Since the cysts may 
contain mucinous, hemorrhagic, necrotic, jellylike content, 
they may present intermediate and higher densities and sig-
nal intensities on CT and MRI, whereas T2-weighted MRI 
displays the true cystic structure of the tumor the best. 
Nodular enhancement of the septae is indicating potential 
malignancy which occurs in up to 30% of MCN [17, 18].
14.3.3  Intraductal Papillary Mucinous 
Neoplasm (IPMN)
Due to increased detection rates by high-resolution imaging, 
IPMN is considered the most common cystic neoplasm of 
the pancreas, seen more often in men than in women.
IPMNs may affect the main duct (28%), side branches 
(46%), or both duct components (26%) based on a mucin- 
producing neoplasm arising from the ductal epithelium. The 
side-branch type can be found as a solitary or multifocal duct 
dilatation all over the pancreas and may also form a system of 
cystic dilated ducts that may mimic a microcystic appearance 
as in SCN. Segmental or general dilatation is typical for the 
main duct type creating a chronic pancreatitis- like appear-
ance. In such cases patients’ history is the crucial differential 
diagnostic information. Since the main duct-type IPMN has a 
low malignant potential, at least a thorough follow-up regi-
men should be recommend in nonsurgical cases {Lana, 2016 
#1140;Lee, 2017 #1137}.
14.4  Other Neoplasm
14.4.1  Neuroendocrine Tumors
The WHO (2010, last modification 2017) classified these 
tumors mainly according to their grading (well, moderately, 
poor differentiated) and their hormonal activity (PanNEN, 
pancreatic neuroendocrine neoplasm), as well as the Ki67 
proliferative index.
In general, these tumors are rare and account for about 
5–7% of all pancreatic tumors with the most common sub-
types being insulinoma, glucagonoma, and nonhormonal 
active tumors. Imaging features of various PanNEN are often 
rather similar, making immunohistochemical staining a cru-
cial issue, particularly when a specific hormone release is not 
the leading clinical sign (Fig. 14.3) [19].
14.4.1.1  Insulinoma
The presentation of insulinomas—the most common PanNEN 
(60%)—is determined by hyperinsulinism (Whipple’s triad: 
starvation attack, hypoglycemia after fasting, and relief by IV 
dextrose). The majority of tumors are solitary (95%) and 
small (<2 cm) and hypervascularized with a peripherally pro-
nounced enhancement and localized in the pancreatic body 
and tail [20].
14.4.1.2  Gastrinoma
Gastrinoma is the second most common PanNEN (20–30%) 
clinically associated with the Zollinger-Ellison syndrome 
(peptic ulcer disease, diarrhea) due to the massively elevated 
gastrin blood levels. At detection, the tumors present with a 
moderate size (mean 3 cm, ranging from 0.1–20 cm) and in 
half of the cases with multiple nodules. The vast majority of 
gastrinomas will arise within the gastrinoma triangle deter-
mined by the confluence of the cystic and common bile duct, 
the junction of the second and third portions of the duodenum, 
and the junction of the neck and body of the pancreas. On 
imaging, gastrinomas are revealed as mainly solid tumors with 
intermediate densities and signal intensities on both CT and 
MRI with moderate to strong contrast enhancement. Even if 
about 60% of the tumors are malignant, extensive metastatic 
spread is rare [21].
14.4.2  Other Rare Pancreatic Neoplasm
Beside the above displayed neoplasms, there is still a wide 
variety of pancreatic tumors which—in general—can be dif-
ferentiated only by specific immunohistological staining. 
This tumors comprise a number of variably differentiated 
neuroendocrine tumors including mixed neuroendocrine- 
nonneuroendocrine tumors, mostly without functional activ-
ity, rare malignant pancreatoblastoma in children (a large, 
Key Point
• MRI is the superior imaging method allowing the 
detailed characterization of cystic lesions and neo-
plasia of the pancreas.
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encapsulated tumor in the pancreatic head often associated 
with elevated alpha-fetoprotein levels and metastases to liver 
and lymph nodes), acinar cell carcinoma (relatively large 
tumors in elderly men with an imaging appearance similar to 
pancreatic adenocarcinomas and potential excessive release 
of serum lipase followed by focal panniculitis and polyar-
thritis as diagnostic hint), and solid pseudopapillary tumor 
(of mainly young women (frequently incidental tumor in 
women 20–30 years of age; m: f = 1:10; large,  heterogenous 
tumor of uncertain dignity) and occasionally children) [22].
Mesenchymal tumors (sarcoma, cystic dermoid, lymph-
angioma, leiomyosarcoma, hemangiopericytoma, heman-
gioma, malignant fibrous histiocytoma, lymphoepithelial 
cysts, primary lymphoma) and secondary tumors (sec-
ondary lymphoma, metastases) of the pancreas are very 
rare and may be identified due to specific imaging fea-
tures such as peripheral nodular enhancement on dynamic 
imaging or high signal intensity in T1- and T2-weighted 
imaging in, e.g., hemangioma or lipoma; otherwise clini-




Fig. 14.3 (a–d) Small neuroendocrine neoplasm. (a) Axial 
T1-weighted gradient echo image (TR/TE 180/4.66 ms) with fat satura-
tion shows a neuroendocrine neoplasm that appears hypointense com-
pared to adjacent pancreatic parenchyma (arrow). (b) Axial T2-weighted 
turbo spin echo image (TR/TE 4500/102) shows a small neuroendo-
crine neoplasm that appears hyperintense compared to adjacent paren-
chyma (arrow). (c) On the axial fat-saturated volumetric T1-weighted 
gradient echo image (TR/TE 4.86/1.87 ms) during the pancreatic phase 
of the dynamic study following Gd-chelate administration, the neuroen-
docrine neoplasm appears hyperintense during compared to adjacent 
pancreatic parenchyma (arrow). (d) On Axial diffusion-weighted image 
(b = 1000), the neuroendocrine neoplasm shows restricted diffusion 
(arrow)
Key Point
• PanNEN comprises a complex group of neoplasia 
which can be identified usually by imaging—beside 
very small tumors. Nevertheless, without clinical 
information and immunohistopathological correla-
tion, a precise diagnosis is not possible. In malignant 
transformation, the mismatch between tumor size 
and missing secondary signs of malignant spread as 
common in pancreatic cancer can be helpful.
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14.5  Inflammatory Diseases 
of the Pancreas
14.5.1  Acute and Chronic Pancreatitis
Especially in the Western world, the incidence of inflamma-
tory diseases of the pancreas is increasing. The most com-
mon causes are biliary stone disease and alcohol abuse; 
nevertheless, more and more other causes as metabolic syn-
drome and systemic inflammatory diseases are identified as 
promoting factors. Depending on the type and severity of the 
inflammatory process, no mild or extensive morphological 
and functional deterioration is seen.
In general, the task of imaging is to monitor substantial 
structural changes and complications in acute pancreatitis, such 
as parenchymal integrity vs. necrosis, peripancreatic inflam-
mation, subtle and substantial fluid collections, formation of 
pseudocysts and walled-off cysts, and vascular and ductal 
affections (Fig. 14.4), and to assist in the clinical outcome 
prognosis together with the clinical assessment [23–25].
In chronic pancreatitis, differentiation of long-term 
parenchymal and ductal changes from similar changes 
caused by neoplasms—e.g., focal or complete duct dilation, 
focal parenchymal lesions, and cystic degeneration—is 
mandatory to rule out complications and potential pancre-
atic cancer (Fig. 14.5). Perfusion MRI, DWI, and FDG/PET 
can be helpful in such cases. Nevertheless, the common 
clinical presentation with chronic abdominal pain in chronic 
pancreatitis does not correlate very well with imaging find-
ings [26–30].
a b
Fig. 14.4 Acute severe pancreatitis. At the patient’s admission, 
contrast- enhanced CT during the venous phase (a) displayed a fuzzy 
contour of the pancreatic gland together with peripancreatic exsudation 
(arrow). Note the hypo- and hyperdense hepatic lesions (arrow heads). 
A control scan 10 days later (b) revealed an almost normal gland with 
resorption of the peripancreatic fluid. However, there was an area with 
a lack of enhancement representing focal necrosis (large arrow). In the 
liver, one lesion turned out to be a hemangioma (arrow) while the other 
two lesions were small abscesses
a b
Fig. 14.5 Chronic pancreatitis. Cystic degeneration of the pancreatic head (a) together with irregular dilatation of the pancreatic main duct (b) in 
MRI (fast SE T2). Note the similar imaging appearance to other cystic lesions of the pancreas
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14.5.2  Autoimmune Pancreatitis
In comparison to gallstone or alcohol-associated pancreati-
tis, autoimmune pancreatitis (AIP) is a rare disease in which 
the pathophysiological understanding has evolved signifi-
cantly over the last years. The most common form, type 1 
AIP, is associated with IgG4-related diseases. Type 2 AIP is 
a different, even rarer entity and may be associated to chronic 
inflammatory bowel disease [31, 32].
Both diseases have a similar clinical presentation with 
unspecific upper abdominal pain, obstructive jaundice, further-
more weight loss, and endo- and/or exocrine pancreatic insuf-
ficiency. Clinically, there is an overlap with pancreatic 
carcinoma, which cannot be solved by imaging alone, since AIP 
may provide diffuse (“sausage”-like) or focal (“mass- forming”) 
enlargement of the gland together with segmental or focal duct 
strictures or dilatation. In consequence, the task of imaging and 
further parameters as serology and histology is the differentia-
tion of both entities to guide each to the appropriate therapy and 
to avoid the small number but unnecessary pancreatectomies.
The International Association of Pancreatology defined 
diagnostic consensus criteria (Table 14.2) which provide a 
high accuracy in identifying an AIP. Both types of AIP 
 usually present an excellent response to steroid therapy; 
however, in type 1 AIP, 60% of patients will have relapse. 
Over the last years, the body of knowledge in AIP was grow-
ing significantly; nevertheless, data for the long-term course 
and potential complications are still scarce (Fig. 14.6).
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Table 14.2 Consensus criteria in type 1 and type 2 AIP (modified acc. to Shimosegawa et al. [33], Beyer et al. [34] and O’Reilly et al. [35]; L 
level, ERP endoscopic retrograde pancreatography, IgG4-RD IgG4-related disease, IBD inflammatory bowel disease, GEL granulocytic epithelial 
lesions)
Type 1 AIP Type 2 AIP
Synonym Lymphoplasmacellular sclerosing pancreatitis (LPSP) Idiopathic ductal-centric pancreatitis (IDCP)
Incidence 0.9/100.000
Das heißt Weihnachten 6. Jahrzehnt es… Sie
Online leerzeichen Nach der Restauration Ich gehe! Bin ich jetzt gehen Hör mir verweilen und ich komm die Rechnung bitte Sieben 
jetziger Sicht drei Tage krank 3 Wochen krank Mehrfamilienhaus Ich will Risikoabschätzung Wie Computer? Aber vergessen Gegen dass 
damit der immerhin schon sind wir es ist irgendwie doch noch fristlos Selbst Der beste Weg herr valgus mir sagen welchen Fall
Geographic 
frequency sieche
EU/USA 50%, Asia 95% EU/USA 50%
Age (years) 50–70 30–50
Sex M (75%) » F M = F
Consensus criteria of the International Association of Pancreatology [33]
Cardinal criteria Level 1 Level 2 Level 1 Level 2
Imaging: 
parenchyma
Typical: diffuse enlargement (“sausage sign”), 
delayed (interstitial) enhancement (sometimes 
capsule-like, nodular enhancement)
Indeterminate: focal 






(sometimes capsule- like, 
nodular enhancement)
Indeterminate: focal 
enlargement with delayed 
enhancement
Atypical: hypodense in 
CT, duct dilatations, 
atrophy
Imaging: pancreatic 




Long (>1/3 of duct length) or multiple strictures 
without proximal (upstream) dilatation
Segmental/focal strictures 
with proximal (upstream) 
dilatation (<5 mm)
Long (>1/3 of duct length) 




with proximal (upstream) 
dilatation (<5 mm)
Serology IgG4 > 2 × upper limit IgG4 1–2 × upper limit – –
Other organ 
involvement (OOI)
IgG4-related disease (RD) (50%) No association with IgG4-RD
≥3 histological findings in other organs:




– IgG4-positive cells (>10/HPF)
≥1 radiological finding:
– Segmental/multiple bile duct strictures
– Retroperitoneal fibrosis
IgG4-RD (ca. 60%):
– Chronic sclerosing sialadenitis (14–39%)
–  IgG4-associated cholangitis (IAC) (12–47%)
–  IgG4-associated tubulointerstitial nephritis and 
renal parenchymal lesions (35%)




–  Chronic inflammatory bowel disease (0.1–6%)
Bile duct involvement plus 
both:
–  Lymphoplasmacytic 
cellular infiltrates without 
granulocytes
–  IgG4-positive cells (>10/
HPF)
or ≥1 criterion (imaging or 
clinical exam):
–  Symmetric enlarged 
salivary glands
  –Renal involvement
–  Histological and/or clinical diagnosis of inflammatory 
bowel disease (16%)
– Involvement of proximal bile duct possible
– Involvement of thyroid possible
Histology (Trucut 
biopsy or resection, 
FNB not suitable)
Periductal lymphoplasmacellular infiltrations, inflammatory, cell-rich stroma
3 of 4 criteria
– Storiform fibrosis
– Obliterative phlebitis
– Prominent lymphatic follicles
– IgG4-positive plasma cells
2 of 4 criteria
– Storiform fibrosis
– Obliterative phlebitis
–  Prominent lymphatic 
follicles
–  IgG4-positive plasma 
cells
–  GEL with or without 
granulocytic acinar 
infiltration
No or few (10 < 10 HPF) 
IgG4-positive plasma cells
–  Granulocytic and 
lymphoplasmacytic 
acinar infiltrate
–  No or few (>10 HPF) 
IgG4-positive plasma 
cells
Response to steroids Rapid (≤ 2 weeks) response to therapy with significant improvement in imaging
Relapse post steroids 20–60% <10%
Diagnosis based on 
criteria
Type 1 AIP Type 2 AIP
Definitive Histo L1 + imaging L1/2
Imaging L1 + other criteria L1/2
Imaging L2 + ≥ 2 criteria L1
Steroid Response + Bildgebung L2 + 3 Kriterien L1 oder 4  
Kriterien L2
Imaging L1/2 + histo L1 or IBD + histo L2 + response 
to steroids
Probable Imaging L2 + other criteria L2 Imaging L1/2 + histo L2 + IBD + response to steroids





Fig. 14.6 Autoimmune pancreatitis type 1. Well-demarcated focal 
enlargement of the pancreatic tail on CT (a, b). Note the slightly 
reduced perfusion in the early parenchymal phase (a). Low signal 
intensity on T2-weighted MRI (c) and diffusion restriction on DWI 
ADC map (d) reveals the lymphoplasmacytic infiltration with fibrotic 
components in contrast to edema in “usual” pancreatitis. After 6 weeks 
therapy with steroids, note the significant atrophy of the pancreatic tail 
on T2-weighted (e) and CE T1-weighted MRI (f)
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Key Point
• Acute and chronic pancreatitis are common dis-
eases, whereas the diagnosis is ruled by the clinical 
history and/or presentation. Imaging adds the cru-
cial information on the severity and complications 
of the disease. In AIP imaging findings contribute to 
the cardinal criteria; however, imaging alone is not 
suitable to establish the diagnosis in AIP.
14.6  Concluding Remarks
Pancreatic lesions encompass a wide variety of anatomical 
variants as well as benign and malignant neoplastic and 
inflammatory diseases. The specific anatomical position of the 
gland allows only limited insight by ultrasound and endos-
copy. Therefore, cross-sectional imaging by CT and MRI is of 
ample importance in assessing the pancreas and related disor-
ders, allowing for a very high accuracy in depicting structural 
alterations of the parenchymal and ductal components of the 
gland. In the majority of clinical-diagnostic situations, there is 
no significant difference between the two imaging modalities 
with respect to diagnostic efficacy. However, MRI will reveal 
its superiority particularly in conditions where the assessment 
of ductal and intra- and  peripancreatic cystic structures as well 
as subtle parenchymal changes is pivotal.
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The Pediatric Gastrointestinal Tract: 
What Every Radiologist Needs to Know
Emily A. Dunn, Øystein E. Olsen, 
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15.1  Imaging Techniques
15.1.1  Plain Film Radiography 
and Fluoroscopy
Conventional radiography remains the first-line imaging in 
most hospitals for infants and children presenting with sus-
pected gastrointestinal pathology.
Fluoroscopy is particularly useful when evaluating dynamic 
processes such as gastrointestinal motility. Fluoroscopy can 
also be used for guiding procedures/interventions such as for-
eign body removal and intussusception reduction.
15.1.2  Ultrasound
Ultrasound (US) is one of the most valuable imaging tools 
for the initial evaluation of gastrointestinal disease, due to its 
high-resolution, real-time capability, wide availability and 
acceptance, and lack of ionizing radiation and because it 
rarely requires sedation. There are two key factors for suc-
cess: (1) knowing how to deal with children of all ages and 
(2) using high-end US equipment/high-frequency probes.
15.1.3  Computed Tomography
In children, CT should be used with caution and is usually 
reserved for troubleshooting equivocal findings made in the 
initial diagnostic workup of acutely and critically sick children. 
CT is consequently often performed as first-line imaging for 
emergent indications, such as blunt and penetrating trauma. As 
a general rule, only one acquisition is needed, and multiphase 
contrast enhanced sequences should be avoided.
15.1.4  Magnetic Resonance Imaging
MRI is rarely used in the first-line evaluation of gastrointes-
tinal pathology; however, it may serve as an adjunct in chal-
lenging/unequivocal cases. In children, MRI is typically 
performed in the assessment of intestinal pathology such as 
inflammatory bowel disease and appendicitis, focal and dif-
fuse disease of the abdominal viscera, and diseases of the 
biliary tree.
15.2  Intestinal Obstruction
In neonates and young children, there is no radiographic 
“signature” for the large and small bowel. Plain film radio-
graphs of the normal newborn demonstrate swallowed air 
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reaching the rectum by 24 h of life. In a clinically obstructed 
newborn, the number of dilated loops (“dilated” meaning 
roughly wider than the vertebral interpedicular space) may 
be more helpful. Whether there is one gas bubble (gastric 
outlet obstruction), a double bubble (duodenal obstruction), 
3–4 bubbles/loops (other high small bowel obstruction), or 
more (low obstruction), the bowel gas pattern can help 
decide which contrast study is appropriate. A bowel gas pat-
tern suspicious for a high obstruction may be assessed fur-
ther with an upper GI contrast study. A bowel gas pattern 
suggesting a low obstruction should be followed by a con-
trast enema.
15.3  Neonatal Obstruction
Neonatal intestinal obstruction can be classified by location, 
with “high” obstructions occurring through the level of the 
proximal jejunum and “low” obstructions occurring after the 
proximal jejunum. Etiologies of neonatal intestinal obstruc-
tion are commonly congenital. In most cases, a fluoroscopic 
contrast study is required.
The differential diagnosis for high intestinal obstruction 
includes atresia of the esophagus, stomach, duodenum and jeju-
num, duodenal stenosis from annular pancreas, duodenal web, 
and malrotation possibly complicated by midgut volvulus.
The differential diagnoses for low intestinal obstruction 
include ileal and colonic atresia, anorectal malformation, 
meconium ileus, colonic dysmotility syndromes, and 
Hirschsprung’s disease. Congenital abdominopelvic cysts or 
masses can cause both high and low (usually partial) 
obstruction.
An understanding of clinical presentation as well as the 
expected postnatal bowel gas progression throughout the 
abdomen on radiographs can help to detect the level of 
obstruction [1].
Esophageal atresia (Fig. 15.1) is a clinical diagnosis. If 
the diagnosis is established, then any gas in the gastrointesti-
nal system distal to the esophagus on plain radiographs 
means there is also a tracheoesophageal fistula. Radiology 
has a greater role in the follow-up of these children. Fistulae 
may recur, and the contrast esophagogram is the imaging test 
of choice for diagnosis of recurrence; this is performed by 
trained operators as there is a considerable aspiration risk. 
a b c
Fig. 15.1 Esophageal atresia and tracheoesophageal fistula represent 
a spectrum of anomalies believed to result from abnormal formation 
and separation of the embryological foregut. These anomalies range 
from isolated EA to isolated TEF. Classification of congenital tracheo-
esophageal anomalies depends on the presence and location of the fis-
tulous communication between both structures. (a) Radiograph of a 
newborn with isolated esophageal atresia (no fistula) shows no bowel 
gas distally. Those with isolated EA may have polyhydramnios in 
utero, and at birth, there is failure of passage of the orogastric tube 
beyond the level of the atresia. (b) Radiograph of a newborn with 
esophageal atresia and a fistula between the airway and the distal 
atretic segment demonstrates gas in the gastrointestinal tract despite 
failure to pass a feeding tube. (c) Fluoroscopic image in an infant with 
isolated tracheoesophageal fistula (arrow) following instillation of 
water-soluble contrast medium in the esophagus
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For suspected anastomotic stricture, contrast swallow is per-
formed. There is almost always relative narrowing at the 
anastomosis, so it is a functional holdup which suggests a 
potential need for dilatation [2, 3]. Esophageal atresia may 
be observed as part of the VACTERL association. Additional 
anomalies should be actively searched for.
Duodenal obstruction (Fig. 15.2) may have several 
causes. In duodenal atresia the classic radiographic findings 
are a double bubble and no distal intestinal gas. Duodenal 
atresia is thought to result from failure or incomplete recana-
lization of the intestine in utero.
Annular pancreas is caused by failed migration of the anla-
gen, and it may be evident sonographically (or with CT/MRI). 
Duodenal stenosis and duodenal web cause partial obstruction 
and may be difficult to distinguish. The classic sign of a web 
on a contrast study is the “windsock sign” [4, 5].
Malrotation with midgut volvulus (Fig. 15.3) is a surgical 
emergency in the neonate as well as in infants and children. 
The failed intestinal rotation manifests as a right-sided/mid-
line low duodenojejunal flexure and a high cecum. This is 
associated with a short mesenteric root, which predisposes 
for volvulus. The normal position of the duodenojejunal flex-
ure is at the height of the pylorus and to the left of the mid-
line, at least as far as the left vertebral pedicles. Volvulus is 
suggested by bilious vomiting and is verified by the finding 
of a spiraling outline of a malrotated duodenum/proximal 
jejunum on the contrast study [6, 7]. On US a whirlpool of 
vessels is typically seen.
Small bowel atresia and stenosis (Fig. 15.4) are relatively 
common causes of complete and incomplete obstruction in 
the neonate. Multiple atresias may coexist; the etiology is 
thought to be in utero mesenteric vascular accidents. Accurate 
diagnosis is critical, since early surgical invention is usually 
performed. Bilious vomiting may be observed in those with 
obstruction beyond the level of the pancreatic ampulla. The 
typical findings of atresia on contrast enema are a small-cal-
iber (unused) colon and distal small bowel and the inability 
to reflux contrast into dilated small bowel loops (distinguish-
ing it from meconium ileus; see below) [4, 5].
Meconium ileus (Fig. 15.5) has a very high association 
(>80%) with cystic fibrosis. The distal ileum is impacted with 
sticky meconium. The findings on contrast enema are similar 
to those in small bowel atresia except that when contrast 
refluxes into the ileum, it outlines pellets of meconium, and it 
is usually possible to eventually fill dilated small bowel loops. 
In uncomplicated cases, (repeated) contrast enemas using 
water soluble contrast material are used therapeutically to 
soften and wash out meconium pellets. Both meconium ileus 
and intestinal atresias may be complicated by in utero bowel 
necrosis/perforation and meconium peritonitis [8, 9].
a b
Fig. 15.2 Duodenal obstruction (complete or partial) is commonly 
caused by duodenal atresia, duodenal stenosis, duodenal web, annular 
pancreas, and midgut volvulus. (a) Radiograph of a 12-hour-old new-
born with prenatally diagnosed duodenal atresia. Abdominal radio-
graph shows the “double bubble” appearance of the air-distended 
stomach and proximal duodenum and no gas distally. These findings 
suggest duodenal obstruction. It should be noted that annular pancreas 
and midgut volvulus may produce a similar radiographic appearance. 
(b) Newborn with vomiting. The first and second portions of the duode-
num are distended. A curvilinear filling defect is observed at the transi-
tion point (arrows), representing the “windsock” appearance of the 
duodenal web
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a b
Fig. 15.3 Intestinal malrotation results from incomplete rotation and 
fixation of the bowel in utero, with the duodenojejunal junction and 
cecum lying closer. This shortening of the mesenteric pedicle predis-
poses to midgut volvulus, in which the abnormally fixed bowel loops 
twist about the axis of the superior mesenteric artery and may obstruct 
the duodenum. While malrotation with midgut volvulus may occur at 
any age, the great majority present within their first month and many 
within their first week. Midgut volvulus can lead to intestinal ischemia 
necessitating bowel resection. Emergent and accurate imaging diagno-
sis is therefore critical. Bilious vomiting and abdominal distention in a 
newborn infant should raise the suspicion for an obstruction distal to the 
ampulla of Vater, and imaging should be pursued. Radiographs are nor-
mal in many cases of malrotation, and a fluoroscopic upper gastrointes-
tinal series, which is considered the gold standard for diagnosis, should 
be performed in highly suspect cases. (a) Malrotation with midgut vol-
vulus. In the case of malrotation with midgut volvulus, contrast mate-
rial fails to pass beyond the obstructed third portion of the duodenum. 
(b) Malrotation with midgut volvulus in the setting of an incomplete 
obstruction. There is corkscrew configuration of contrast within the 
twisted midgut bowel loops
a b
Fig. 15.4 Ileal atresia is thought to result from mesenteric vascular 
events in utero. (a) Radiograph of a newborn infant with ileal atresia 
shows distention of multiple bowel loops throughout the abdomen, sug-
gesting a low obstruction. (b) Fluoroscopic contrast enema in the same 
child demonstrates a typical “microcolon” (unused colon) and retro-
grade filling of non-dilated distal ileum to the level of the atresia 
(arrow). More proximal bowel loops are distended and air filled
E. A. Dunn et al.
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Colonic atresia is exceedingly rare, and the diagnosis is 
often made clinically (vomiting and failure to pass meco-
nium) on plain radiographs (no gas in the rectum). Contrast 
enema reveals failed reflux of contrast proximal to the level 
of the colonic atresia [10].
In Hirschsprung’s disease (Fig. 15.6), intermuscular and 
submucosal nerve plexuses are absent due to arrested migra-
tion of intestinal ganglion cells, producing a functional 
intestinal obstruction. Since this migration occurs from 
proximal to distal large bowel, the aganglionic segment 
extends proximally from the anus. The typical clinical pre-
sentation is delayed passage of meconium in the neonate 
beyond 24 h of age.
Most affected patients demonstrate short-segment 
involvement, in which the transition point between normal 
and aganglionic bowel is located in the rectosigmoid colon. 
Rarely, the entire colon may be involved. Meconium/fecal 
impaction, a zone of transition from dilated to non-dilated 
bowel, and abnormal peristalsis of the affected colon seg-
ment with “sawtooth” appearance of the wall are classical 
findings at contrast enema. Very short-segment agangliono-
sis lacks a clear transition zone and is therefore difficult to 
diagnose radiologically. Hirschsprung’s disease can only be 
definitively diagnosed by rectal (suction) biopsy [4, 11].
Functional immaturity of the colon, small left colon, and 
meconium plug syndrome (Fig. 15.7) are entities with con-
siderable overlap. The risk is greater in babies of diabetic 
mothers. Radiologically there is a relatively smaller left 
colon and proximal meconium impaction. It is difficult to 
make a categorical diagnosis as similar findings may be seen 
in Hirschsprung’s disease [12, 13].
Anorectal malformation is a clinical diagnosis. These 
malformations are classified as “high” or “low” depending 
on the location of the distal-most bowel segment relative to 
the puborectalis sling, with high lesions terminating above 
and low lesions terminating below this level. The role of 
radiology is to assess the length of the atretic anorectal seg-
ment and to map the fistula(e) [14].
15.4  Intestinal Obstruction in the Older 
Neonate and Infant
In older infants and children, obstruction may be related to 
other etiologies, such as adhesions, hypertrophic pyloric ste-
nosis, intussusception, incarcerated intestinal hernia, appen-
dicitis, sigmoid volvulus, and Meckel’s diverticulum. Plain 
film radiographs can occasionally suggest the level of 
obstruction in older infants and children. In many cases, 
however, ultrasound and, occasionally, CT or MRI may be 
necessary to reach the diagnosis.
Hypertrophic pyloric stenosis (Fig. 15.8) classically pres-
ents with forceful “projectile” vomiting and failure to gain 
weight in an infant. The diagnosis is made sonographically 
a b
Fig. 15.5 Meconium ileus represents obstruction of the distal ileum by 
viscous, impacted meconium pellets. There is a high association with cystic 
fibrosis (presenting symptom in 15% of neonates with CF). (a) Fluoroscopic 
contrast enema demonstrates contrast opacification of a “microcolon” 
(unused colon due to proximal obstruction). Contrast has refluxed into the 
distal ileum (arrowheads) and outlines numerous impacted meconium pel-
lets. (b) Abdominal radiograph demonstrates punctate calcifications scat-
tered throughout the abdomen, suggestive of meconium peritonitis which 
can occur with intestinal atresias as well as meconium ileus, and results 
from perforation of meconium-containing bowel
15 The Pediatric Gastrointestinal Tract: What Every Radiologist Needs to Know
162
where the typical findings are (1) thickened muscularis 
(>4 mm); (2) elongated pylorus (>15 mm), with redundant 
mucosa occasionally protruding into the antrum of the stom-
ach; (3) gastric hyperperistalsis; and (4) persistent closed 
pyloric channel after a test feed. A contrast meal is rarely 
indicated except in a few equivocal cases [15].
Incarcerated intestinal hernia is a surgical emergency. 
The presentation and imaging findings are similar to those in 
adults.
Congenital abdominopelvic masses (Fig. 15.9) comprise 
a spectrum of abnormalities where gastrointestinal obstruc-
tion is relatively unusual. Sacrococcygeal masses (e.g., germ 
cell tumors, such as teratomas, or anterior meningoceles) 
may cause rectal obstruction. A cystic obstructive mass 
should raise suspicion for meconium pseudocyst or enteric 
duplication cyst. Duplication cysts may occur anywhere 
along the gastrointestinal tract and may have a relatively 
thick layered wall (akin to bowel) and a mucus-fluid level. 
Differential diagnoses for abdominal cystic lesions that are 
rarely obstructive include choledochal, mesenteric, and ovar-
ian cysts, renal cystic dysplasia, and hydroureter [16].
15.5  Intestinal Obstruction in the Infant 
and Older Child
Ileocolic intussusception (Fig. 15.10) is a surgical emergency, 
usually occurring in infants and toddlers with maximum inci-
dence at just under 1 year of age. The typical presentation is 
with abdominal pain, bloody stools, and a palpable mass. A 
clear cause (i.e., a “lead point,” such as a mesenteric lymph 
node, lymphoid hyperplasia, duplication cyst, mural inflam-
mation caused by Henoch-Schonlein  purpura, or Meckel’s 
diverticulum) may or may not be  established. The sono-
graphic diagnosis is fairly straightforward with the finding of 
a concentric doughnut shape in the transverse plane and sand-
wiching of the involved bowel segments (the “pseudokidney” 
sign) in the longitudinal plane [17].
Long-standing intussusception, trapped fluid in the 
involved segments, and trapped lymph nodes are thought to 
be associated with lower success rates for reduction with 
pressurized gas or fluid.
Colonic volvulus results from twisting of the colon around 
its mesenteric root and is a rare cause of obstruction in chil-
dren. In children, cecal volvulus is more common compared 
with volvuli occurring in the sigmoid and transverse colon. 
Fig. 15.7 Functional immaturity of the colon, along with meconium 
plug and small left colon, represent syndromes of colonic dysmotility. 
Those affected typically present with delayed passage of meconium. 
There is a reported increased incidence in babies with mothers who are 
diabetic or who have received magnesium sulfate during pregnancy for 
preeclampsia. This image from a contrast enema reveals a small caliber 
of the descending and sigmoid colon, which are filled with meconium, 
proximal dilatation, and a normal-caliber rectum
Fig. 15.6 A fluoroscopic contrast enema in a 2-day-old with biopsy- 
proven Hirschsprung’s disease shows a small-caliber rectum with mild 
distention of more proximal large bowel loops. Note the “sawtooth” 
appearance of the aganglionic segment (arrowheads), which reflects 
irregular contractions
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a b
Fig. 15.8 Hypertrophic pyloric stenosis is an acquired obstruction of 
the gastric outlet, characterized by elongation of the antropyloric chan-
nel and thickening of the pyloric muscularis with varying degrees of 
mucosal hypertrophy. Infants typically present with non-bilious, pro-
jectile vomiting and occasionally a palpable hypertrophied pyloric 
“olive.” Hypertrophic pyloric stenosis is usually not present at birth. 
Infants usually present with symptoms at 2–12 weeks of age. The diag-
nosis is made sonographically. (a) High-frequency ultrasound examina-
tion of the antropyloric region shows thickening of the muscularis layer 
to more than 3 mm (arrowheads) and elongation of the pyloric channel 
to more than 15 mm in length (dashed line). Dynamic imaging can 
detect the presence or absence of transit through the pyloric channel 
and may also identify hyperperistaltic gastric waves (asterisk) in the 
presence of a gastric outlet obstruction. Redundant pyloric mucosa may 
protrude into the gastric lumen (arrow), producing the “antral nipple 
sign.” (b) High-frequency detailed ultrasound often demonstrates stria-
tion within the thickened muscularis (between calipers)
a b
Fig. 15.9 Duplication cysts represent closed congenital duplicated 
segments of any part of the gastrointestinal tract and may be diagnosed 
incidentally or as a result of obstruction. (a) Coronal reformat of com-
puted tomography scan following oral and intravenous contrast medium 
administration demonstrates a small bowel duplication cyst (arrow-
head). (b) Sagittal sonogram shows a cyst posterior to the urinary blad-
der (u). The diagnosis of a rectal duplication cyst is readily made by 
demonstrating a bowel wall appearance of the cyst wall (arrowheads)
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Clinical presentation includes abdominal pain, vomiting, and 
distention. Depending on the type of twist, plain films may 
demonstrate marked distention of the colon and/or air-fluid 
levels resembling either a “bird’s beak” or “coffee bean.” CT 
demonstrates the “swirling” appearance of the sigmoid mes-
entery and its vasculature. While clinical and imaging find-
ings are suggestive, sigmoid volvulus remains an often 
missed diagnosis which can be complicated by bowel isch-
emia, gangrene, perforation, shock, and even death [18–20].
Henoch-Schonlein purpura is an acute small-vessel vas-
culitis in young children typically involving the skin, kid-
neys, synovium, and bowel. Sonographically there is 
nonspecific mural inflammation [21].
15.6  Infectious, Ischemic, 
and Inflammatory Intestinal 
Pathology
Necrotizing enterocolitis (Fig. 15.11) is the most common gas-
trointestinal emergency in the newborn. The etiology of NEC 
is incompletely understood and is thought to involve multiple 
factors, including immaturity of the blood-gut barrier, early 
feeding, and bacterial colonization which ultimately lead to 
hemorrhagic and ischemic necrosis of the intestines. NEC 
typically occurs in preterm neonates especially with very low 
birthweight and less commonly term or late preterm neonates 
with congenital cardiac disease or Hirschsprung’s disease. 
Although somewhat insensitive, plain films may demonstrate 
intestinal pneumatosis, portal venous air, and pneumoperito-
neum. Intestinal ultrasound has proven useful in the diagnosis 
of NEC and may demonstrate the presence of free fluid and 
abnormal bowel peristalsis, increased wall thickness, echo-
genicity, and vascularity and may suggest impending compli-
cations such as perforation. Additionally, US has been shown 
to detect small amounts of intramural and portal venous “air 
bubbles” not demonstrated on plain film [22, 23].
Acute appendicitis is the most common surgical indica-
tion in children. Appendicitis results from obstruction of the 
appendix which leads to distention, mucosal ischemia, bac-
terial overgrowth, inflammation, and potentially wall com-
promise and perforation. Early diagnosis is therefore 
essential in order to avoid such complications. US is the ini-
tial test of choice due to its lack of ionizing radiation and is 
optimal for imaging children. With an experienced sonogra-
pher and use of graded compression technique, US is highly 
sensitive and specific for the diagnosis of appendicitis and its 
complications and approaches the accuracy of CT. Use of 
MRI in the diagnosis of appendicitis is increasing, particu-
larly for children with equivocal ultrasound [24, 25].
a b
Fig. 15.10 Intussusception, most commonly ileocolic, has peak inci-
dence in late infancy and presents with abdominal distention and bloody 
stools. (a) Radiographs may show, as in this example, a well-defined 
opacity (arrows) representing the invaginate. (b) Ultrasound is diagnos-
tic showing a typical doughnut configuration (arrowheads) of the tele-
scoping bowel segments with trapped mesenteric fat (hyperechoic 
content)
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Inflammatory bowel disease may be seen at any age, but 
early-onset disease is often more complex with associated 
immunological disorders. In older children and adolescents, 
the clinical picture and the imaging characteristics are more 
similar to those in adults. Conventional fluoroscopic contrast 
follow-through is rarely indicated. Both ultrasound and MR 
enterography are excellent for assessing the macroscopic dis-
ease: bowel wall thickening, mesenteric inflammation, mes-
enteric lymphadenopathy, hyperemia, and fistulation [26].
Meckel’s diverticulitis is inflammation of a Meckel’s 
diverticulum, an omphalomesenteric remnant containing 
gastric/pancreatic mucosa. Abdominal pain and melena are 
typical symptoms. The diagnosis is extremely difficult to 
make with radiographs and cross-sectional imaging alone, 
which are often insensitive. 99mTc-pertechnetate scintigra-
phy is typically diagnostic [27].
15.7  Gastrointestinal Trauma
Accidental and non-accidental traumas, particularly blunt 
trauma, are common causes of morbidity and mortality in 
children. Clinical and laboratory findings may suggest 
injury to the hollow and solid abdominal viscera, necessitat-
ing imaging follow-up. CT performed with intravenous con-
trast provides superb detail of vascular, solid organ, 
intestinal, and musculoskeletal anatomy, thus making it the 
imaging of choice in stable children presenting with trauma. 
US may be used in unstable patients and is especially help-
ful in the detection of hemoperitoneum. The liver, spleen, 
and kidneys are among the most common solid organ inju-
ries observed in accidental trauma. In non-accidental 
trauma, the liver and pancreas are the most commonly 
injured solid organs. Intestinal injury is uncommon overall, 
yet occurs with more frequency in non-accidental versus 
accidental trauma.
Children with compensated shock following initial 
resuscitation efforts may demonstrate characteristic 
abdominal CT findings known as the hypoperfusion com-
plex, which includes collapse of the aorta and inferior vena 
cava and hyperenhancement of the adrenals, kidneys, mes-
entery, and bowel walls. These findings signal impending 
hemodynamic collapse, and their immediate recognition is 
critical [28–30].
a b
Fig. 15.11 Necrotizing enterocolitis is a clinical diagnosis but may 
nevertheless have typical radiological features. (a) Abdominal radio-
graph demonstrates thick-walled gas-distended bowel loops with intra-
mural gas seen as linear lucencies (arrowheads) and portal venous gas 
(arrows). (b) Intramural gas demonstrated sonographically as a string 
of hyperechoic “pearls” (arrowheads) in the bowel wall
Take-Home Messages
• The differential diagnosis for neonatal high intestinal 
obstruction includes atresia of the esophagus, stom-
ach, duodenum and jejunum, duodenal stenosis from 
annular pancreas, duodenal web, and malrotation with 
midgut volvulus.
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• The differential diagnoses for neonatal low intestinal 
obstruction include ileal and colonic atresia, anorec-
tal malformation, meconium ileus, colonic dysmotil-
ity syndromes, and Hirschsprung’s disease.
• Congenital abdominopelvic cysts may lead to high 
or low intestinal obstruction.
• In older infants and children, intestinal obstruction 
may be related to adhesions, pyloric stenosis, intus-
susception, incarcerated intestinal hernia, appendi-
citis, sigmoid volvulus, and Meckel’s diverticulum.
• Radiographic findings of NEC including free, intra-
mural, and portal venous air are classic yet infre-
quently observed. Ultrasound improves sensitivity.
• In the hands of an experienced sonographer and 
with use of graded compression technique, sensitiv-
ity and specificity of intestinal ultrasound for acute 
appendicitis approaches that of CT.
• Contrast enhanced CT is the imaging standard in 
the evaluation of stable children with blunt or pen-
etrating trauma.
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Diseases of the Colon and Rectum: CT 
Colonography
C. Dan Johnson and Perry J. Pickhardt
The public health need for colorectal cancer screening is 
compelling. Colorectal cancer is common, accounting for 
approximately 50,000 deaths yearly in the USA [1]. The 
benign precursor adenoma can be detected by several differ-
ent imaging techniques, and, if removed, can prevent malig-
nant transformation. The approximately 10-year polyp dwell 
time allows ample opportunity for patients to be screened 
and polyps detected and removed. Potentially, under ideal 
screening circumstances, an entire class of cancers could be 
prevented. Unfortunately, barriers exist to ideal screening, 
including suboptimal performance of many existing colorec-
tal screening tests, reluctant compliance by patients to follow 
recommended screening guidelines, and variable insurance 
coverage of examination charges. In many ways, CT colo-
nography (CTC) approaches an ideal screening test by 
addressing issues and problems inherent with other tech-
niques. This syllabus will highlight many key issues for CT 
colonography today.
16.1  Technique
Proper technique at CT colonography is imperative for high 
performance. The three main steps include preparation, CT 
scanning, and interpretation.
16.1.1  Preparation
 1. Dietary restriction. Preparation begins with a recommen-
dation for patients to consume clear liquids or a low- 
residue diet for at least 1 day prior to beginning the 
cathartic bowel preparation. Although this step is opti-
mal, it can be skipped if patients are following the subse-
quent instructions carefully.
 2. Stool tagging. 10–20 mL of barium or iodinated contrast 
material is administered orally for three meals prior to 
beginning the cathartic preparation. This contrast agent 
mixes with stool and ideally is evacuated with the cathar-
tic preparation. Residual stool will contain high- 
attenuation contrast and can be easily discriminated from 
soft tissue attenuation polyps. Some prefer to perform 
stool tagging after the cathartic agent, but before fluid 
tagging.
 3. Cathartic. The cathartic preparation can be performed 
with a number of different formulations including poly-
ethylene glycol electrolyte solution and magnesium 
citrate or bisacodyl tablets. Phospho-soda agents are not 
recommended because of prior issues with renal insuffi-
ciency and sodium retention. Bisacodyl tablets require 
the patient to be well hydrated for the purgation process 
to be successful. Bisacodyl tablets are easy to consume 
and well tolerated by patients. Polyethylene glycol elec-
trolyte solution provides the cleanest colon, but some 
patients find it more difficult to consume in its entirety.
 4. Fluid tagging. Following the cathartic preparation, the 
small bowel will continue to secrete soft tissue attenuation 
fluid into the colon. This fluid can obscure immersed pol-
Learning Objectives
• To implement proper technique for obtaining a 
high-quality CT colonography examination
• To educate others regarding the safety and perfor-
mance of CT colonography
• To participate in a quality improvement program 
related to CT colonography
• To recognize difficult-to-detect lesions at CT 
colonography
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yps. Tagging of this fluid is accomplished by drinking 
60 ml of iodinated contrast material (either hyperosmolar 
or iso-osmolar) at bedtime, on the day before the exam. 
The high attenuation tagging allows inspection of the 
immersed portions of the colon wall and visualization of 
any colon lesions within this fluid.
 5. Insufflation. The colon must be fully distended with 
air or carbon dioxide for optimal visualization at 
CT. Commercially available insufflation devices are avail-
able instilling C02 at a predefined rate and pressure. Excess 
intraluminal colonic pressure during a colonic contraction 
will result in venting of gas into the room—thereby reduc-
ing patient discomfort and the risk of perforation. As the 
pressure is reduced, the machine automatically refills the 
colon. Turning the patient on the CT table is helpful in 
creating a well-distended colon.
 6. Spasmolytics [2]. The use of spasmolytics is controver-
sial. Although it has not been shown to improve image 
quality, there are some that believe the exam is more com-
fortable for patients [3].
16.1.2  CT Scanning
Acquisition of CT data using thin collimation and isotropic 
reconstruction intervals will result in high-quality images in any 
desired plane. The colon and rectum data should be acquired in 
a single breath-hold, using a low-dose technique. Generally, we 
use a 1 mm collimation, reconstructing every 0.8 mm, 50 mAs. 
Optimally, new reconstruction software should be employed to 
enable ultralow-dose acquisition. Ideally, average patients should 
receive an effective dose equivalent of less than 5 mSv [4].
16.1.3  Interpretation
There are two main ways to interpret a CTC examination: 
either a primary 2D with 3D problem-solving or primary 3D 
with 2D problem-solving approaches. Both methods have 
been shown to have equal effectiveness. Most authorities 
advocate that each exam should have both a 2D and 3D 
review. Small polyps are more easily detected with a 3D 
(endoluminal) review, whereas obstructing cancers and flat 
lesions are better detected with a 2D review. There is no 
proven difference between software manufacturers in lesion 
detection [5] (Fig. 16.1).
16.2  Performance
The performance of CT colonography has undergone exhaus-
tive testing. The Department of Defense (DoD) trial by Pickhardt 
et al. demonstrated sensitivity similar to colonoscopy [6], but 
concerns were raised that community practices might not be 
able to achieve these results. The National CT Colonography 
Trial findings were similar to the Pickhardt’s trial and have reas-
sured many groups [7] that the test can be performed with high 
accuracy in both academic and private practice settings.
Training and preferably testing of radiologists are require-
ments for optimal reader performance [8]. Participation in a 
dedicated training program is recommended. These training 
sessions should provide enough time for the radiologist to 
become facile with a specific colonography software package 
and experience interpreting at least 50 proven cases. Polyp 
detection testing will allow individuals an opportunity to 
assess if additional training is needed before clinical imple-
mentation. In order to continue to improve reader perfor-
mance, it is recommended that patients who are undergoing 
both CTC and subsequent colonoscopy be reviewed retrospec-
tively to assess for CTC false-positive and false- negative 
detections. This quality improvement review offers a rich 
experience for learning and gaining expertise, confidence, and 
competence. Strict adherence to state-of-the art CTC protocol 
requirements is also recommended including stool and fluid 
tagging regimens, mechanical insufflation of the colon, thin-
section data acquisition, and low-dose CT techniques [9]. It is 
clear that meticulous attention to all aspects of the examina-
tion and interpretation is required to achieve the best results.
16.3  Acceptance
Today, nearly 40 million US adults age 50 or older have not 
undergone a sigmoidoscopy or colonoscopy within the pre-
vious 10 years or had used a fecal occult blood test (FOBT) 
home test kit within the preceding year [10]. The major dis-
incentive for patients undergoing a full structural colorectal 
examination is the laxative purgation [11]. Work is being 
done to reduce the burden of laxation either with the use of a 
partial colon preparation [12] or without cathartic prepara-
tion [13]. Although not considered standard of care, evidence 
from feasibility trials is promising and may translate to better 
patient acceptance in the future.
Despite a full cathartic bowel preparation, the advantages of 
CTC include the lack of required sedation and intravenous line 
placement, a quick return to work following the examination, 
and the convenience of no driving restrictions following the test.
The disadvantage of CTC includes the fact that if a sig-
nificant polyp is identified, patients must undergo colonos-
copy and polypectomy. If same-day colonoscopy is not 
offered, then the patient must undergo a second bowel prepa-
ration, spend another day away from work, and experience 
added worry and inconvenience. In a screening population 
(including false-positive interpretations), the prevalence of 
patients being referred from CTC to colonoscopy for polyp-
ectomy is 12% when a 6 mm threshold is applied [6, 7]. This 
translates into an 88% chance that an individual patient will 
C. Dan Johnson and P. J. Pickhardt
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not require a second procedure—thereby mitigating con-
cerns for redundancy. Those with a high likelihood of polyps 
may best be triaged to colonoscopy screening.
16.4  Safety
The main risk for patients at CTC is the risk of colorectal 
perforation. The symptomatic perforation rate has been esti-
mated to be 1:20,000 examinations and likely safer among 
screening patients [14]. In contrast, colonoscopy perforation 
rates have been recorded to be in the range of 1:1000 [15], 
often but not always related to biopsy procedures. Bleeding 
can also follow colonoscopy intervention and is more com-
mon than perforation.
Radiation risk from a CTC examination has been of pub-
lic concern. It is unfortunate that the risk associated with the 
low radiation dose required for CTC has been misunder-
stood. The standard dose at CTC represents about 25–50% 
of the dose used for a standard body CT examination. This 
a b
c d
Fig. 16.1 Unsuspected colon cancer in 56-year-old asymptomatic 
woman undergoing CTC screening. Transverse (a) and coronal (b) 2D 
images from CTC show a bulky soft tissue mass in the right colon 
(arrowheads). 3D endoluminal CTC image (c) correlates with the image 
from subsequent same-day colonoscopy (d)
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results in an average dose of approximately 2.5–5 mSv, 
 similar to annual environmental exposures in many locales 
that is without known adverse health effects. The doses at 
CTC can be reduced significantly even further using new 
noise reduction software (iterative reconstruction). The real 
risk of this small dose is unknown, but the Health Physics 
Society has stated that doses in this range are associated with 
risks for the development of radiation-induced cancer that 
are either too small to measure or are nonexistent [16]. Even 
if a very small risk is assumed from radiation exposure at CT, 
it must be balanced against the risk of developing colon can-
cer (1:13) and the risks of other alternative procedures 
including colonoscopy [17].
16.5  Extracolonic Findings
Extracolonic abnormalities are common in patients of 
screening age [18, 19]. Although lifesaving findings can be 
identified, most incidental findings are of little clinical sig-
nificance but can potentially increase the cost of care if 
additional testing and treatment are recommended. A prag-
matic approach to these findings is needed. Radiologists 
should only recommend follow-up studies for those find-
ings most likely to be of clinical significance. Clinicians 
will be grateful if additional testing is minimized and for 
those that might benefit from additional studies to include 
recommendations for optimal follow-up within the radio-
logic report.
16.6  Individual Responsibility
Maintaining high-quality interpretations is a responsibility 
that each individual, each practice, and our specialty should 
assume. The ACR has established a national CTC database 
within the National Radiology Data Registry (NRDR) [20]. 
Selected process and outcome metrics can be quickly entered 
online and compared to national benchmarks. These mea-
sures include process metrics related to the CT technique and 
the adequacy of patient preparation, outcome metrics related 
to colon perforation, true positive and false-positive rates for 
large (≥1 cm) polyps, and the prevalence of significant extra-
colonic findings. Practices seriously interested in providing 
the best care should be encouraged to participate in this data 
registry and manage their practice so benchmark metrics are 
achieved.
A spirit of cooperation between radiologists and gastroen-
terologists is needed for optimal patient care. Guidelines will 
need to be jointly developed for the proper use of colonogra-
phy and colonoscopy and for processes to efficiently transfer 
patients with polyps to colonoscopy. Those practices that are 
able to do this effectively will offer patients a service of high 
value and will likely find themselves very busy.
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Key Point
• CT colonography is a well-validated examination 
and should be available clinically. Radiologists 
committed to performing the examination to the 
highest quality must obtain the education and 
equipment needed. We have an obligation to edu-
cate and to collaborate with referring physicians on 
the correct use of the technique. We must be vigi-
lant that extracolonic findings are properly reported 
so that only highly suspicious lesions have recom-
mended additional follow-up testing. Lastly, a com-
mitment to incorporate ongoing quality measures 
within your daily practice will ensure that patients 
continue to receive the highest standards of care. 
Radiology has an exciting opportunity to serve the 
public and potentially reduces the incidence of a 
common cancer killer.
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Focal Liver Lesions
Wolfgang Schima, Dow-Mu Koh, and Richard Baron†
17.1  Introduction
Multidetector computed tomography (MDCT) and mag-
netic resonance (MR) imaging provide noninvasive insights 
into liver anatomy and the pathophysiology of liver dis-
eases, which allows for better disease diagnosis, monitoring 
of disease evolution and treatment response, as well as for 
guiding treatment decisions. Understanding the application 
of different imaging techniques is critical for the manage-
ment of focal liver lesions. In the current climate of chal-
lenging health economics, the most appropriate and cost 
effective modality should always be utilized. For liver imag-
ing, ultrasonography (US) is widely available, noninvasive, 
and often used in the community for disease screening but 
has unfortunately limited diagnostic sensitivity and specific-
ity. Contrast- enhanced MDCT remains the modality of 
choice for routine liver imaging. MR imaging is still used 
largely as a problem- solving tool when MDCT or US is 
equivocal or if there is concern for malignancy in high-risk 
populations.
In this chapter, we will highlight imaging of focal liver 
lesions, focusing on the use of MDCT and MR imaging for 
disease detection and characterization. The reader should 
learn how to optimize CT and MR imaging in his/her own 
practice, understand how to apply and interpret CT and MR 
imaging for the management of focal liver lesions, and 
appreciate the expanding role of liver-specific MR contrast 
agents for lesion characterization.
17.2  MDCT Imaging Techniques
MDCT allows imaging to be performed in multiple planes. 
Using a 64-plus-detector-row system, the entire liver can be 
scanned within 1–4 s using a submillimeter detector configura-
tion allowing for high-quality multiplanar reconstructions 
(MPR) [1]. When viewed axially, reconstructed sections of 
2.5–3 mm thickness with an overlap of 0.5–1 mm are usually 
used in clinical practice. Thinner slices do not improve lesion 
conspicuity because of increased image noise [2] that can 
decrease diagnostic specificity [3]. The amount of contrast mate-
rial administered can be calculated by a patient’s weight, but 
0.5 g iodine/kg b.w. is typical (i.e., 1.7 mL/kg b.w. at 300 mg/
mL). The total amount of iodine administered determines the 
quality of the portal venous imaging phase, with the aim of 
increasing the liver attenuation by 50 HU after contrast injection 
[4]. To achieve good arterial phase imaging, a relatively high 
contrast medium injection rate of 4–5 mL/s is recommended [5]. 
On the other hand, studies have shown that a fixed injection 
 duration of 30 s (meaning that the injection rate will differ 
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according to patient’s weight) also provides consistent image 
quality.
The timing of the image acquisition in relation to con-
trast media administration depends on whether imaging is 
required during early arterial phase (for arterial anatomy 
only), late arterial phase (for hypervascular tumor detection 
and characterization), or venous phase (for follow-up imag-
ing and hypovascular tumor detection). For the detection 
and characterization of focal liver lesions, late arterial 
phase imaging (with a delay of aortic transit time plus 
15–18 s) [6, 7] and a venous phase scan (20–30 s interscan 
delay or with fixed delay of ~60–70 s) are performed. 
However, the use of combinations of these imaging phases 
also depends on specific indications [8]. Automated meth-
ods of measuring arterial enhancement (aortic transit time) 
on CT, often termed bolus tracking, have replaced the use 
of fixed scan-delay times because it provides better coinci-
dence of scanning with peak enhancement of liver tumors 
(in the late arterial phase) and the liver parenchyma (in the 
venous phase).
Different techniques for dose reduction and optimization 
of image quality are now widely in use: automatic exposure 
control by tube current (mA) modulation, selection of lower 
tube potential (kVp), and adaptive dose shielding to mini-
mize overscanning in the z-axis, to name a few. Conventional 
filtered back projection (FBP), the standard CT image 
reconstruction technique for many years, has given way to 
iterative reconstruction (IR). IR uses loop-wise raw data 
correction to reduce image noise, thus allowing imaging to 
be performed at reduced kVp or mAs, with lower radiation 
dose but comparable image quality. All major manufactur-
ers now provide iterative reconstruction techniques 
(SAFIRE, ADMIRE, Siemens; iDose, IMR, Philips; ASIR, 
MBIR, GE Healthcare; AIDR, AIDR 3D, Toshiba) [9]. 
Stepwise IR reduces CT noise levels. However, high levels 
of IR may induce a pixelated (plastic-like) image texture 
and may render image quality unacceptable [10]. A substan-
tial dose reduction of 38–55% is possible with IR without 
compromising image quality [11–13] (Fig. 17.1). In recent 
years, dual-energy and spectral CT technique has emerged, 
where the utilization of dual-source or polychromatic X-ray 
beams and the differential attenuation of such beams of dif-
ferent energies in tissues are applied to improve the detec-
tion of hypervascular hepatocellular carcinomas [14] or for 
the quantification of hepatic iron content [15]. However, 
dual- energy CT technology is still not widely employed in 
clinical practice despite potential merits, in part because of 
the post- processing time required to generate the appropri-
ate images.
17.3  MR Imaging Technique
MR imaging of the liver can now be performed at both 1.5 
and 3.0 T; the latter has significantly improved in image 
quality due to advancements in both imaging hardware and 
software. MR examination of the liver should include unen-
hanced T1-weighted and T2-weighted sequences, as well as 
contrast-enhanced sequences. Specific acquisition sequences 
vary by manufacturer, patient compliance, and the clinical 
question being addressed.
a b c
Fig. 17.1 Dose reduction using iterative reconstruction techniques at 
MDCT. (a) Normal dose MDCT in the venous phase (120 kVp, ref. 
mAs 230) reconstructed with standard filtered back projection shows 
colorectal liver metastases. (b) Image appearance (120 kVp, ref. mAs 
150) using iterative reconstruction (SAFIRE level 3) is slightly differ-
ent in general, due to reduced image noise. The lesions are shown with 
the same conspicuity. Patient dose is reduced by 36%. (c) At higher 
iterative reconstruction levels (SAFIRE level 5), the image appearance 
is pixelated (“plastic-like”), especially seen at the liver parenchyma and 
the perirenal fat
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In- and opposed-phase (or out-of-phase) T1-weighted 
imaging is recommended for maximal tumor detection and 
for characterization of fat containing tumors and the pres-
ence of steatosis. T1-weighted MRI can be now performed 
using a 3D DIXON technique, which can generate in-phase, 
out-of-phase, water-only, and fat-only images of the whole 
liver volume in a single breath-hold acquisition. The resul-
tant water-only images have been shown to improve the uni-
formity of fat suppression at 3 T, compared with conventional 
spectral fat suppression technique [16]. The use of the 
DIXON images for dynamic contrast-enhanced acquisition 
has also been shown to improve the detection of hepatocel-
lular carcinoma compared with standard fat-suppressed 
sequences.
Another useful recent implementation is non-Cartesian 
radial T1-weighted imaging, which allows 3D volume 
T1-weighted imaging of the liver to be performed in free 
breathing. This allows good quality T1-weighted of the liver 
to be obtained in patients with poor breath holding (e.g., 
elderly, breathless adults, or young children) (Fig. 17.2), espe-
cially during dynamic contrast-enhanced acquisitions [17]. 
T2-weighted pulse sequences with fat suppression provide 
better lesion contrast than nonfat-suppressed sequences and 
are also widely used.
Diffusion-weighted imaging (DWI) has become a stan-
dard technique in liver imaging, and it is now available on all 
scanners. In general, DWI depends upon the microscopic 
mobility of water, called Brownian motion, in tissue. Water- 
molecule diffusion (and thus the measured signal intensity) 
depends on tissue cellularity, tissue organization, integrity of 
cellular membranes, and extracellular space tortuosity. 
Usually, lower water diffusion is found in most solid tumors, 
which are attributed to their high cellularity [18]. Thus, DWI 
is helpful for detecting liver solid focal liver lesions [19–21]. 
By performing diffusion-weighted imaging using two or 
more b-values, we can quantify the apparent diffusion coef-
ficient (ADC) of liver tissues. Benign focal liver lesions have 
been shown to have higher ADC value than malignant liver 
lesions, although there is significant overlap [22]. 
Nonetheless, quantitative ADC values may be useful to sup-
port lesion characterization and for identifying early tumor 
response to treatment, which is currently being investigated.
Imaging after the administration of intravenous contrast 
agents remains the cornerstone for liver MR imaging. Of 
these, nonspecific extracellular gadolinium contrast medium 
is still most widely used. Following the intravenous (IV) 
bolus injection of extracellular gadolinium-based contrast 
agents, dynamic imaging (using volumetric T1-weigthed 
imaging) is performed in characterizing lesion, detecting 
lesion, evaluating tumor response to therapy, and detecting 
marginal recurrences after tumor ablation.
Liver-specific (or hepatobiliary) MR contrast agents are 
available and have specific roles in the management of focal 
liver lesions. These include gadobenate dimeglumine 
(MultiHance®, Bracco) and gadoxetic acid (Primovist® or 
Eovist®, Bayer Healthcare). Liver-specific MR contrast 
agents are also usually administered IV as a bolus, as with 
nonspecific gadolinium chelates for dynamic imaging. 
However, imaging is also performed at a delayed liver- 
specific or hepatobiliary phase, the timing of this differs 
according to the contrast agent. These liver-specific agents 
are taken up into hepatocytes to varying extent (gadobenate 
dimeglumine 4–5%; gadoxetic acid ~50%), resulting in avid 
T1 enhancement of the liver parenchyma in the hepatobiliary 
a b
Fig. 17.2 Radial acquisition technique. Colorectal liver metastases. 
Hepatobiliary phase imaging performed at 20 min after gadoxetate con-
trast administration using (a) free breathing radial acquisition fat- 
suppressed gradient echo and (b) breath-hold volume interpolated 
fat-suppressed gradient echo technique. Note that the free-breathing 
acquisition in this patient resulted in better delineation of the smaller 
liver metastases as T1 hypointense lesions against the enhancing liver 
parenchyma (arrows)
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phase, which is performed at 20 min for gadoxetic acid and 
about 1–2 h for gadobenate dimeglumine after contrast 
administration. Liver-specific contrast agents have been 
shown to improve the detection of liver metastases [23–26], 
especially when used in combination with diffusion-weighted 
MR imaging.
17.4  Benign Hepatic Lesions
17.4.1  Cysts
Simple hepatic cysts are common, occurring in 5–14% of the 
general population. As they are usually asymptomatic, they 
are detected incidentally on US, CT, or MR imaging. On CT, 
hepatic cysts are well circumscribed and typically show 
attenuation values similar to water (0–15 HU), although 
smaller cysts may show higher attenuation values due to par-
tial volume effects. Cysts should not show mural thickening, 
nodularity, or contrast enhancement. Small cysts (≤3 mm in 
size) may pose a diagnostic challenge in the cancer patient 
on CT as they are too small to fully characterize and stability 
on follow-up imaging is important to reassure. Nonetheless, 
the majority of small hypodense liver lesions even in the 
oncology patient are usually benign.
On MR imaging examinations, cysts are well-defined, 
homogeneous lesions that appear hypointense on 
T1-weighted images and markedly hyperintense on 
T2-weighted images. Their marked hyperintensity on 
T2-weighted imaging provides greater confidence toward the 
diagnosis of small cysts on MRI.
17.4.2  Hemangioma
Hemangioma is the most common benign liver tumor. On 
US, liver hemangioma appears circumscribed, well-defined, 
hyperechoic, and associated with distal acoustic enhance-
ment. Small hemangiomas usually appear homogeneous, but 
larger hemangiomas (>4 cm) can show a heterogeneous 
appearance.
On CT, hemangiomas are well-defined hypodense masses. 
They are hypointense on T1-weighted and markedly hyper-
intense on T2-weighted imaging, sometimes with a lobular 
contour. Hyperintensity on T2-weighted MRI helps to dif-
ferentiate hemangiomas from other solid neoplasms [27, 28]. 
At a relatively long T2 echo time (140 ms or longer), a 
homogeneously bright lesion is characteristic of a benign 
lesion, such as a cyst or hemangioma. Exceptions include 
cystic or mucinous metastases, gastrointestinal stromal 
tumor (GIST), and neuroendocrine tumor metastases.
Hemangiomas show three distinctive patterns of enhance-
ment at CT/MRI (type I to III) [29], where there is character-
istically enhancement that closely follows the enhancement 
of blood pool elsewhere [30]. Small lesions (up to ~2 cm) 
may show immediate and complete enhancement in the arte-
rial phase, with sustained enhancement in the venous and 
delayed phases (type I, “flash filling”) [31] (Fig. 17.3). On 
delayed imaging, the enhancement usually fades to a similar 
extent as the blood pool. The most common enhancement 
pattern is peripheral nodular discontinuous enhancement, 
which progressively fill-in over time (type II). Larger lesions 
(>5 cm) or lesions with central thrombosis/fibrosis may lack 
central fill-in (type III) (Fig. 17.4). When evaluated using 
liver-specific contrast agents, the appearance of hemangio-
mas in the dynamic arterial and venous phases is similar to 
that with nonspecific gadolinium chelates. However, in the 
delayed phase, after 3 min, there may be “pseudowashout” 
(hypointensity) due to early hepatocellular enhancement of 
liver parenchyma (Fig. 17.5). In the hepatobiliary phase, 
hemangiomas may appear hypointense to the parenchyma, 
thus mimicking liver metastases. In this instance, DWI may 
help to differentiate between hemangioma and other solid 
lesions, as the apparent diffusion coefficient (ADC) of 
uncomplicated hemangiomas is significantly higher (typi-
cally >1.70 × 10−3 s/mm2) than in malignant solid lesions 
[22, 32].
17.4.3  Focal Nodular Hyperplasia
Focal nodular hyperplasia (FNH) is a benign lesion that 
can cause confusion when incidentally detected during 
abdominal imaging. On ultrasound, the lesion is usually 
isoechoic or slightly hypoechoic [33] to liver, but appears 
hypoechoic in patients with diffuse hepatic steatosis. 
Typically, FNH demonstrates a lobular contour, which is 
uncommon in malignant lesions. A central scar is present 
in about 67% of larger lesions and about 33% of smaller 
lesions [34]. The central scar in FNH is usually hyperin-
tense on T2-weighted images, with a comma-shaped or 
spoke-wheel appearance, which can be distinguished from 
fibrolamellar HCC, where the central scar, when present, 
is predominately low signal intensity on T2-weighted 
MR. Color/power Doppler US may show blood flow 
within the scar [35].
FNH is isodense or minimally hypodense on unenhanced 
and equilibrium-phase post-contrast CT and may be only 
suspected because of the presence of mass effect on adjacent 
vessels. On unenhanced T1- and T2-weighted MR images, 
FNH returns signal intensity similar to hepatic parenchyma 
but is usually slightly different on either T1- or T2-weighted 





Fig. 17.3 Hemangioma type 1. Liver-specific MR contrast agent. A 
45-year-old woman with incident lesion (arrows) in the right lobe of the 
liver. This appears as (a) high signal intensity on T2-weighted imaging 
and (b) low signal intensity on T1-weighted imaging and (c–e) shows 
uniform enhancement on dynamic T1-weighted contrast-enhanced 
imaging, isointense to the vascular signal at all phases. The lesion 
appears (f) hypointense in the hepatobiliary phase of gadoxetic acid- 
enhanced MRI
a b c
Fig. 17.4 Hemangioma type 3: nonspecific gadolinium chelate. (a–c) 
T1-weighted dynamic enhanced T1-weighted GRE in the (a) arterial 
and (b) portal venous and (c) delayed phase shows nodular peripheral 
enhancement of the lesion with centripetal filling. There is incomplete 
enhancement of the lesion
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images. Due to the prominent arterial vascular supply, FNH 
demonstrates marked homogenous enhancement during the 
arterial phase of contrast-enhanced CT/MR imaging, which 
becomes rapidly isodense/isointense to liver parenchyma in 
the portal venous phase [34]. The central scar often showed 
delayed enhancement (Fig. 17.6) [33] because of its vascular 
component. Another key feature is that other than the scar, 
FNH are usually homogeneous in appearance compared with 
the heterogeneous appearance encountered in fibrolamellar 
HCC.
Using liver-specific MR contrast agents, FNH fre-
quently shows enhancement on delayed images after 
administration of hepatobiliary contrast agents (such as 
gadoxetic acid or gadobenate dimeglumine) because of the 
presence of normal biliary ductules within the lesion and 
the expression of OATP receptors (Fig. 17.6). However, 
the uptake of hepatobiliary contrast agents within FNH 
may be rarely heterogeneous or absent [36]. Nonetheless, 
a recent meta-analysis showed that the lesion T1 isointen-
sity or hyperintensity at delayed hepatobiliary phase MRI 
has a high sensitivity (91–100%) and specificity (87–
100%) for diagnosing FNH [36]. This feature can be help-
ful for differentiating FNH from hypervascular metastases 
or hepatic adenomas (HCA) and hepatocellular carcino-
mas (HCC) (which do not usually take up liver- specific 
agents) [31, 37]. However, it should be noted that some 
HCAs (particularly inflammatory HCA and beta- catenin- 
activated HCA) and HCC can appear isointense or hyper-
intense at delayed imaging after hepatobiliary contrast 
media administration. While differentiating FNH from 
variants of HCA remains challenging, it has been sug-
gested that the presence of contrast washout (i.e., lesion 
hypointensity compared to liver parenchyma) of HCC in 
the portal venous or transitional phase of dynamic contrast 
enhancement can be used to distinguish between HCC 
(that shows contrast uptake in the hepatobiliary phase) and 
FHN nodules. The majority of FNH tend to remain static 
in size, although FNH may increase in size on follow-up 
(3–11%), although oral contraceptives do not appear to 




Fig. 17.5 Hemangioma type 3: liver-specific MR contrast agent. (a) 
T2-weighted TSE shows a large lobulated lesion of very high signal 
intensity. (b–d) Dynamic gadoxetic acid-enhanced imaging shows 
peripheral nodular enhancement in the arterial (b) and venous phases 
(c). In the hepatobiliary phase (d) there is marked hypointensity of the 
lesion due to lack of hepatocellular uptake in the lesion and enhance-
ment of surrounding liver parenchyma
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17.4.4  Hepatocellular Adenoma
Hepatocellular adenoma (HCA) is uncommon, but has an 
association with oral contraceptive and anabolic steroid 
usage. Histologically, HCA is composed of cells resembling 
normal hepatocytes but lacking bile ducts, which distin-
guishes them from FNH [39].
The imaging features of HCA are heterogeneous and var-
ied. HCA are often hypervascular and may appear heteroge-
neous due to the presence of fat, necrosis, or hemorrhage 
[39, 40]. T1-weighted chemical shift or DIXON imaging is 
useful for detecting intratumoral fat, while the presence of 
high T1-signal before contrast administration will raise the 




Fig. 17.6 FNH. Incidental lesion in the left lobe of the liver (arrows). 
(a) Pre-contrast T1-weighted image shows an isointense lesion with a 
central hypointense scar, which shows minimal mass effect upon adja-
cent vasculature. (b) Arterial phase T1-weighted contrast-enhanced 
image shows hypervascularity of the lesion. (c) T1-weighted delayed 
phase imaging after contrast shows that the lesion is now predominantly 
isointense to the liver but with late enhancement of the (vascular) cen-
tral scar. The enhancement pattern is typical for FNH. (d) Hepatobiliary 
phase imaging of another FNH: homogenous uptake of the liver- specific 
MR contrast agent, the spoke-wheel central scar is typically not 
enhanced
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familiar with the differential diagnoses of fat containing 
focal liver lesions on MRI, which include focal fat infiltra-
tion, HCA (particularly the HNF1A inactivating subtype), 
hepatocellular carcinoma (usually well differentiated), angi-
omyolipoma, lipoma, teratoma, and liver metastases from fat 
containing malignancies (e.g., liposarcomas). The presence 
of intratumoral fat helps to narrow the differential diagnosis 
of a hypervascular lesion, as hemangioma can be excluded 
and metastases and FNH rarely contain fat.
On dynamic contrast-enhanced CT or MR, adenomas 
usually show marked arterial-phase enhancement, with rapid 
transition to either iso- or hypoattenuating/intense to hepatic 
parenchyma on portal venous phase imaging. Our under-
standing of the molecular aberrations associated with HCA 
has improved our understanding of HCA subtypes, which is 
linked to risk factors, histological features, clinical presenta-
tion, and imaging appearances [41, 42]. The latest molecular 
classification categorizes HCA into the following six sub-
groups: HNF1A-inactivated HCA, inflammatory HCA, 
CTNNB1-mutated HCA in exon 3, CTNNB1 mutated in 
exon 7 and 8 HCA, sonic hedgehog HCA, and unclassified 
HCA [43, 44].
What is important for radiologists? Inactivating mutations 
of hepatocyte nuclear factor 1 alpha (HNF1A) are observed 
in 40–50% of HCA. HNF1A-inactivated HCA usually con-
tains fat as evidenced by diffuse and homogenous signal loss 
on chemical shift T1-weighted imaging (Fig. 17.7). They 
return variable T2 signal. At contrast-enhanced T1-weighted 
MRI, they are hypervascular, often with contrast washout in 
the portal venous or delayed phase. They are typically 
hypointense on hepatobiliary-phase MRI using liver-specific 
contrast medium. HNF1A-inactivated HCAs have a very low 
risk of malignant transformation.
Inflammatory HCA accounts for 35–45% of HCA cases. 
Obesity and a history of oral contraceptives intake are risk 
factors for their development. Inflammatory HCA appear 
strongly hyperintense on T2-weighted MRI, which may be 
diffuse or rim-like in the periphery of the lesion (Atoll sign). 
Intralesional fat is uncommon and, when present, is often 
patchy or heterogeneous. On contrast-enhanced imaging, 
there is usually intense arterial enhancement, with persistent 
enhancement on delayed phase imaging (Figs. 17.8 and 
17.9). Although the majority of inflammatory HCA are 
hypointense on hepatobiliary phase using liver-specific con-
trast media, about 30% may appear iso- or hyperintense. 
Inflammatory HCA may also harbor activating mutations of 
b-catenin in exon 3 and are therefore at risk of malignant 
transformation.
Mutations of catenin b1 (CTNNB1) in exon 3 (coding for 
b-catenin) are seen in 10–15% of HCA. These are associated 
with a higher risk of malignant transformation. By contrast, 
a subset of HCA (5–10%) is associated with mutations of 
CTNNB1 in two hot spots in exon 7 and 8, which does not 
confer an increased risk of malignancy. These variants of 
HCA do not have typical imaging features and may be diffi-
cult to differentiate from HCC or FNH. HCA with mutations 
of catenin b1 may also show contrast uptake in the hepatobi-
liary phase of MRI using liver-specific contrast media.
Activation of sonic hedgehog pathway occurs in approxi-
mately 5% of HCA. As these are relatively uncommon, the 
spectrum of imaging features associated with these is yet to 
be fully described. Nonetheless, these lesions have a higher 
propensity to undergo spontaneous hemorrhage. About 7% 
of HCA remains unclassified. These do not have typical clin-
ical or imaging appearances.
Overall, the imaging features at MRI, including their 
appearances using liver-specific MR contrast agents (gado-
benate, gadoxetic acid) are helpful in distinguishing between 
FNH and HCA. In the hepatobiliary phase of contrast 
enhancement, FNH typically show contrast uptake, whereas 
NHF1A-inactivated HCA and the majority of other HCA 
subtypes do not [44]. Of note is that diffusion-weighted MRI 
has little value in helping to distinguish between HCA and 
FNH or HCC because of the substantial overlap in the ADC 
values.
17.4.5  Biliary Hamartomas (Von Meyenburg 
Complex)
Bile duct hamartomas are congenital malformations of the 
ductal plate without connections to the bile ducts. They are 
usually discovered incidentally at abdominal imaging. 
Although of no clinical significance, they can mimic dis-
seminated small liver metastases in the patient with cancer. 
Biliary hamartomas are typically small (5–10 mm in size) 
and usually widely distributed in both lobes of the liver. On 
ultrasound, they appear as small hyperechoic or hypoechoic 
lesions and can demonstrate ringing artifacts (comet tail 
appearance). On CT, they appear as small cystic lesions of 
round, oval, or irregular shape without contrast enhance-
ment, although thin rim enhancement may sometimes be 
present, thus mimicking hypovascular liver metastases [40]. 
When enhancement is present, it is usually very thin (≤2 mm) 
and observed only on equilibrium-phase images, related to 
the fibrous component of the lesions [45]. On MRI, biliary 
hamartomas appear low signal intensity on T1-weighted 
imaging and high signal intensity on T2-weighted imaging 
(Fig. 17.10). They are best observed on maximum intensity 
projections MRCP sequences as high signal intensity foci 
without connection to or associated abnormalities of the 
intrahepatic ducts. Occasionally, bile duct hamartomas can 
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be very large, up to 20 cm, and be symptomatic from internal 
hemorrhage or pressure on adjacent structures [46]. 
Differential diagnoses of biliary hamartomas include peribil-
iary cysts (predominantly perihilar distribution in patients 
with liver parenchymal disease), polycystic disease, and 
Caroli’s disease (cysts communicate with bile ducts and are 
associated with bile duct abnormalities). They can also 
mimic liver abscesses in the appropriate clinical setting.
17.4.6  Hepatic Abscess and Echinococcus
The appearances of hepatic abscesses on imaging depend 
on etiology (peribiliary abscesses tend to be small and scat-
tered adjacent to the biliary tree; hematogenous distribution 
via the hepatic artery or via the portal vein in appendicitis 
or diverticulitis tends to lead to larger lesions diffusely 
spread in the liver). US reveals a cystic lesion with internal 
a b
c d
Fig. 17.7 Adenoma (HNF1A subtype). (a) T1-weighted in-phase GRE 
image demonstrates a very large mass in a young woman. The mass is 
inhomogeneous and shows bright spots. (b) There is typical signal 
intensity drop on the opposed-phase image indicative of intratumoral 
fat. (c) The T2-weighted TSE shows moderate hyperintensity. (d) On 
the gadoxetic acid-enhanced images in the hepatobiliary phase, there is 
little to no enhancement





Fig. 17.8 Adenoma: inflammatory type. (a–c) Arterial (a) venous (b) phase CT shows strong and progressive contrast enhancement of the lesion, 
which retains enhancement in the delayed phase (c), which is typical for peliotic changes in inflammatory adenoma
a b c
d e f
Fig. 17.9 Adenoma (inflammatory type) in a young female presenting 
with vague upper quadrant pain. (a) In- and (b) opposed-phase T1-weighted 
imaging shows no significant intralesional fat. The nodule is (c) mildly 
hyperintense on T2-weighted imaging. (d–f) Pre-contrast, post-contrast 
arterial phase, and delayed phase images show avid arterial enhancement, 
which persists. Surgical resection confirmed an inflammatory adenoma
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echoes. On CT, hepatic abscesses are hypodense lesions 
with capsules that may show enhancement (Fig. 17.11); 
cluster sign may be noted when multiple abscesses are 
present [47]. CT appearance of hepatic abscess is nonspe-
cific and can be mimicked by cystic or necrotic metastases. 
Hence, appropriate clinical and laboratory corroboration is 
vital toward making the right radiological diagnosis. 
Though present in only a small minority of cases, central 
gas is highly specific for abscess. On MR imaging, hepatic 
abscesses are hypointense relative to liver parenchyma on 
T1-weighted images and markedly hyperintense on 
T2-weighted images, often surrounded by a local area of 
slight T2 hyperintensity representing perilesional edema, 
which may also show increased enhancement after contrast 
administration.
Amebic liver abscess is nonspecific. It usually appears as 
a solitary, hypodense lesion, with an enhancing wall that 
may be smooth or nodular, and is often associated with an 
incomplete rim of edema. With MR imaging, lesions are 
hypointense on T1-weighted images and heterogeneously 
hyperintense on T2-weighted images [48].
On CT scan, involvement of liver by Echinococcus granu-
losus (hydatid cyst) can manifest as unilocular or multilocu-
lar cysts with thin or thick walls and calcifications, usually 
with daughter cysts seen as smaller cysts, with septations at 
the margin of or inside the mother cyst (i.e., this appearance 
is quite different from a “usual” multicystic tumor). On MR 
imaging, the presence of a hypointense rim on T1- and 
T2-weighted images and a multiloculated appearance are 
diagnostic features.
17.5  Malignant Primary Tumors
17.5.1  Hepatocellular Carcinoma
HCC is the most common primary liver cancer, with the 
highest incidence in Asia and the Mediterranean. In European 
countries, HCC is found mostly in patients with chronic liver 
disease (particularly hepatitis B or C, liver cirrhosis, or 
hemochromatosis). At histopathology, HCC is characterized 
by abnormal hepatocytes arranged in trabecular and sinusoi-
dal patterns. Lesions may be solitary, multifocal, or diffusely 
infiltrating.
There is wide varying appearances of HCC on imaging. 
An early HCC occurring within at risk population is typi-
cally small (<3 cm) and has a homogenous appearance. By 
contrast, late presentation disease (including tumor in non- 
cirrhotic patients) is characterized by more advanced dis-
ease, presenting as a larger heterogeneous lesion. US is 
frequently used for disease screening and surveillance of cir-
rhosis patients. The appearance of HCC on US is variable, 
with iso-, hypo-, or hyperechogenicity (increased echo-
genicity is often due to intratumoral fat). Smaller lesions are 
typically homogeneous and larger lesions heterogeneous. A 
surrounding fibrous capsule is often present and characteris-
tic for HCC, appearing as a hypoechoic rim surrounding the 
lesion.
On unenhanced CT images, most HCCs are hypo- or 
isodense (the latter particularly if small). The presence of 
intratumoral fat can lower CT attenuation and is sugges-
tive of primary hepatocellular tumors in the appropriate 
clinical settings. Due to their altered and predominant arte-
rial supply, HCCs enhance avidly in the arterial phase of 
contrast enhancement, becoming iso- or hypodense with 
the liver parenchyma in the portal venous phase of 
enhancement. Delayed phase images show most HCC 
lesions as hypodense compared with surrounding liver. 
The washout of contrast in these tumors is a diagnostic 
characteristic of HCC (Fig. 17.12). Small HCCs may have 
a nodule-in-nodule appearance on CT and MR images, 
especially when the disease develops within a regenerative 
or dysplastic nodule (Fig. 17.13). At MR imaging, such a 
nodule can exhibit higher signal intensity on T2-weighted 
images and display hypervascularity on arterial-phase 
images.
Multiphase imaging after contrast administration on CT 
helps to optimize the detection and characterization of 
HCC. Late arterial-phase imaging is the most sensitive for 
detecting small lesions [6, 49, 50]. A venous phase is 
always necessary for tumor detection/characterization and 
Fig. 17.10 Biliary hamartomas (von Meyenburg complex). A middle-
aged woman was referred to MRI following an ultrasound examination. 
There are multiple foci of high T2-weighted signal within the liver, 
 suggestive of biliary hamartomas
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assessment of venous structures (Fig. 17.12), as well as 
other abdominal organs. The delayed phase imaging (e.g., 
at 2–3 min) can occasionally help to detect a lesion that 
may be missed [51]. Much more important is that it can 
help to make a firm diagnosis of HCC by showing typical 
lesion contrast washout, if it had not been present in the 
portal venous phase [52]. Unenhanced images are impor-
tant for identifying hyperdense siderotic nodules and for 
detecting hypodense intratumoral fat. Unenhanced images 
are also useful for tumor follow-up after chemoemboliza-
tion or after tumor ablation. For these reasons, a three- to 
four-phasic MDCT protocol is utilized at most centers to 
evaluate HCC.
The reliance on focal hypervascularity in the arterial 
phase can lead to false-positive diagnosis of HCC [53]. 
Transient focal enhancement of liver parenchyma during 
arterial phase, also termed transient hepatic attenuation dif-
ferences (THAD), can lead to a false diagnosis of HCC. In 
cirrhotic patients, transient focal enhancement is most often 




Fig. 17.11 Abscesses. (a) Typical large subcapsular abscess with an 
air-fluid level and a reactive pleural effusion. (b, c) Another patient with 
fever and right upper quadrant pain. T1-weighted contrast-enhanced 
images in the (b) arterial and (c) portal venous phase demonstrate mul-
tiple ring-enhancing lesions in both lobes of the liver. In the arterial 
phase, there is also associated increased parenchyma enhancement sur-
rounding many of the lesions. The appearance is consistent with multi-
ple hepatic abscesses
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ately early focal areas of portal venous distribution enhance-
ment in the liver. THAD are usually peripherally located in 
the liver, appear wedge shaped, and may be poorly circum-
scribed. Subcapsular lesions that do not exhibit mass effect 
or a round nature should be carefully evaluated before sug-
gesting the diagnosis of HCC. THAD are not associated with 
lesion hypodensity in the portal venous or delayed phases of 
contrast enhancement.
The combination of hyperdensity on arterial-phase images 
combined with washout to hypodensity on venous- or 
delayed phase images, although not sensitive (33%), is 
highly specific (100%) for the diagnosis of HCC [54] 
(Fig. 17.11). However, a small proportion of HCC can be 
isovascular or hypovascular compared with the liver, which 
can be difficult to diagnose. The typical MR imaging  features 
of larger HCC include a fibrous capsule/ pseudocapsule, 
intratumoral septa, daughter nodules, and tumor thrombus 
(Fig. 17.14) [55]. These lesions are often heterogeneous in 
appearances (mosaic architecture) on both CT and MR [56]. 
Whereas most large HCC are hyperintense on T2-weighted 
images, smaller lesions, measuring even 3–4 cm, can appear 
isointense or hypointense. On T1-weighted images, HCC 
shows variable signal intensity relative to hepatic paren-
chyma. A tumor capsule/pseudocapsule may be seen on 
T1-weighted and, less commonly, as hypointense on 
T2-weighted imaging.
Conventional gadolinium contrast imaging in HCC paral-
lels the features described for CT, with characteristic early 
peak contrast enhancement and delayed phase tumor con-
trast washout of the nodular solid components, as well as late 
T1 enhancement of the capsule/pseudocapsule. Liver- 
specific MR contrast agents (gadoxetic acid or gadobenate 
Fig. 17.12 HCC: quadruple-phasic CT for detection and characteriza-
tion. (a) Non-contrast CT shows liver cirrhosis and splenomegaly. In 
segment 4, a lesion is only faintly seen. (b) In the late arterial phase, a 
hypervascular HCC is depicted in segment 4 (arrow). (c) In the venous 
phase, the lesion is not visible. (d) The delayed phase scan reveals 
washout of the lesion, which is now hypoattenuating (arrow). The com-
bination of arterial hypervascularity and washout is a very specific sign 
of malignancy






Fig. 17.13 HCC with nodule-in-nodule appearance. (a) Unenhanced 
CT shows a siderotic (hyperattenuating) large nodule, which contains a 
low-density (non-siderotic) focus (arrow). (b) On T1-weighted GRE 
opposed-phase image, the marginal nodule shows low signal intensity 
(arrow). (c) The large nodule shows siderosis on T2-weighted TSE 
images, but the marginal focus displays higher SI. (d, e) Dynamic 
gadolinium- enhanced T1-weighted GRE images show (d) arterial 
hypervascularity of the malignant focus (arrow) and (e) washout in the 
equilibrium phase
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dimeglumine) can be administered to provide arterial, portal 
venous, and equilibrium-phase imaging but has the added 
advantage of revealing additional characteristics at the 
delayed hepatobiliary phase of contrast enhancement. HCC 
typically do not show contrast retention of liver-specific 
 contrast medium in the hepatobiliary phase, which can add 
confidence toward the detection and characterization of HCC 
(Fig. 17.15) [57]. It has been shown that using gadoxetic 
acid-enhanced MRI can improve the detection of small or 
early HCCs, as it is superior for detecting HCC measuring 
<1–2 cm in size compared with CT [58]. In addition, subcen-
timeter lesions detected by gadoxetic acid-enhanced MRI 
are likely to be or can transform to become HCC within a 
short interval [59]. Hence, several evolving guidelines for 
the imaging evaluation of HCC are incorporating the role of 
liver-specific contrast media for the diagnosis of subcentime-
ter HCC. Subcentimeter HCC may be treated by locoregional 
therapy, thus avoiding the morbidity and mortality associated 
with radical surgery.
However, it is important to note some potential pitfalls 
of using liver-specific contrast media for HCC evaluation. 
Some benign regenerating nodules may appear hypointense 
at the hepatobiliary phase of contrast enhancement, 
although the majority appears isointense of the liver [60]. 
In addition, some well-differentiated or moderately differ-
entiated HCC may appear isointense or hyperintense on 
delayed images due to higher levels of OATP1B3 and 
MRP3 receptor expression. For this reason, the use of ancil-
lary imaging features at MRI can improve the confidence of 
HCC diagnosis. These include mild to high T2 signal inten-
sity and impeded diffusion on high b-value DWI. The use 
of liver-specific contrast agents may also help toward the 
identification of isoenhancing or hypoenhancing HCC that 
do not show typical hypervascularity in the arterial phase of 
contrast enhancement. With regard to the use of diffusion-
weighted MRI for HCC evaluation, higher b-value (e.g., 
800 s/mm2) DWI may help in the identification of disease, 
particularly if the suspected nodule also demonstrates typi-
cal vascularity pattern at contrast- enhanced MRI. Because 
of background liver  cirrhosis, higher-grade/poorly differen-
tiated HCC are more likely to show impeded diffusion and 
lower ADC values compared with low-grade/well-differen-
tiated HCC.
To summarize, many MR characteristics are often associ-
ated with HCC (arterial-phase hyperintensity, T2 hyperinten-
sity, venous- or equilibrium-phase washout, lack of 
hepatobiliary MR contrast agent uptake on hepatobiliary 
phase images, and restricted diffusion on high-b-value DWI). 
However, for each of these findings, there is only ~60–80% 
sensitivity, and benign lesions show these findings in 16–65% 
of cases, depending on finding, contrast agent used, and 
series reported [60, 61]. Based on data from numerous stud-
ies, the American Association for the Study of Liver Disease 
(AASLD) and the European Association for the Study of the 




Fig. 17.14 Diffuse HCC in the right lobe with tumor thrombus in the 
portal vein. (a) Arterial phase and (b) venous phase T1-weighted GRE 
shows inhomogeneous enhancement and expansion of the portal vein. 
There is inhomogeneous enhancement of the right lobe, but no definite 
tumor is seen. (c) DWI shows a solid mass in the entire intrahepatic 
portal vein and part of the tumor in the right lobe
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diagnosis of HCC in patients with chronic liver disease [62]. 
Lesions more than 1 cm that demonstrate arterial-phase 
hypervascularity and venous- or delayed phase washout are 
triaged for treatment with a diagnosis of HCC. If only one of 
the two findings are present, then the guidelines require 
obtaining a different modality with contrast imaging to 
determine whether these findings can be verified. If the 
lesion remains atypical, then biopsy is recommended. If a 
suspected lesion is less than 1 cm, the AASLD and EASL 
guidelines recommend repeating the examination at 3-month 
intervals, using the same imaging technology used to detect 
the lesion, to determine whether there is growth or changing 
in character. In following up patients with chronic liver dis-
ease, development of a new nodule with any of the MR sig-
nal abnormalities discussed above should be considered 
worrisome for HCC, even if they do not meet the AASLD 
[63] criteria for noninvasive diagnosis. These criteria were 
developed to be specific but are only approximately 70% 
sensitive [60]. It is essential for radiologists to also document 




Fig. 17.15 HCC: MRI with liver-specific contrast agent (gadoxetic 
acid). (a) Axial T1-weighted GRE shows an encapsulated slightly 
hyperintense mass in the dome of the liver. (b) Gadoxetic acid-enhanced 
image shows strong enhancement in the arterial phase. (c) In the hepa-
tobiliary phase after 20 min, the lesion shows hypointensity due to lack 
of hepatocellular uptake
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as treatment for these patients varies depending on these fac-
tors. It is also important to document whether vascular inva-
sion or distant metastasis is present.
17.5.2  Fibrolamellar HCC
Fibrolamellar HCC (FL-HCC) is a less aggressive tumor 
with a better prognosis than typical HCC. It consists of 
malignant hepatocytes separated into cords by fibrous 
strands. On CT, FL-HCC appears as a large, well-defined 
vascular mass with lobulated surface and often a central scar 
and calcifications in up to 70% of cases [64, 65]. On MR 
imaging, FL-HCC are typically hypointense on T1- and 
hyperintense on T2-weighted images, with the central scar 
being hypointense on both sequences (Fig. 17.16). This is in 
contrast to the scar of FNH, which is most often hyperintense 
on T2-weighted images. The fibrous central zones of both 
FNH and FL-HCC show delayed retention of CT and extra-
cellular gadolinium MR contrast agents. By comparison with 
FNH, the contrast enhancement in FL-HCC is usually het-
erogeneous compared with the often homogeneous contrast 
enhancement pattern of FNH.
17.5.3  Cholangiocellular Carcinoma
Cholangiocellular carcinoma (CCC) is the second most com-
mon primary malignancy of the liver. Intrahepatic CCC orig-
inates from the intralobular bile ducts (in contrast to hilar 
CCC, which arises from a main hepatic duct or from the 
bifurcation). Intrahepatic CCC often presents late as a large 
mass [66]. According to the growth characteristics, CCC is 
classified as mass forming, periductal infiltrating, or intra-
ductal growing, with the mass-forming type being most 
common in intrahepatic CCC [66]. At CT and MR imaging, 
lesions tend to be hypodense at unenhanced CT and hypoin-
tense on T1-weighted images, with peripheral enhancement 
at dynamic contrast-enhanced studies [67]. Delayed phase 
CT/MR imaging (after 5–15 min) may show enhancement 
homogeneously or in the center of the lesion due to its rich 
fibrous stroma, which is suggestive of the diagnosis of CCC 
[68]. Interestingly, the central fibrotic stroma often shows 
signal suppression on diffusion-weighted MRI and return 
relatively high ADC value (Fig. 17.17). Periductal infiltra-
tive CCC causes early segmental dilatation of bile ducts in a 
stage when the tumor itself may be difficult to discern [67]. 
In addition, there are morphologic features that can suggest 
the diagnosis of CCC. Peripheral lesions often demonstrate 
overlying capsular retraction due to their scirrhous, fibrous 
matrix (Fig. 17.18). Dilated intrahepatic bile ducts proximal 
to an intrahepatic CCC can also provide clues to the diagno-
sis, as biliary obstruction is usual with intrahepatic metasta-
ses (with the exception of colorectal cancer [69].
17.6  Rare Primary Liver Tumors
17.6.1  Biliary Cystadenoma/
Cystadenocarcinomas
These tumors present a similar appearance and morphology as 
their mucinous counterparts in the pancreas and occur usually 
in women. Even when benign, these tumors have a propensity 
for malignant degeneration, and any such tumor should be con-
sidered as potentially malignant. They appear as unilocular or 
 multilocular cystic masses, with the typical anechoic and 
hypoechoic US appearance and near water-like attenuation 
a b
Fig. 17.16 Fibrolamellar HCC. (a) Arterial phase MDCT shows het-
erogeneously enhancing mass in the left lobe (arrows) with low attenu-
ation central fibrous scar with calcifications (arrowheads). (b) 
T2-weighted MRI shows large left lobe mass (arrows) with heteroge-
neous appearance and mild to moderately increased signal intensity. 
Fibrous central scar is of very low signal intensity (arrowheads)
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 contents on CT, with peripheral soft tissue nodularity and tra-
versing septations. The greater presence of papillary excres-
cences, soft tissue nodularity or septations, are associated with 
a higher risk of malignancy [70]. The cystic areas show vari-
able signal intensity at T1-weighted MRI, including being 
hyperintense to liver related to its proteinaceous content. 
Coarse calcifications may be observed at US and CT in both 
cystadenoma and cystadenocarcinoma and is not a sign of 
benignity.
17.6.2  Hepatic Angiosarcoma
Hepatic angiosarcoma is a rare tumor. There is a strong asso-
ciation with prior exposure to carcinogens such as vinyl 
chloride and Thorotrast, as well as in patients with hemo-
chromatosis. However, in the majority, the tumor is idio-
pathic. Pathologically, angiosarcoma presents as large, 
solitary masses or with multiple tumor nodules of varying 
size, which contain multiple vascular channels.
a b
Fig. 17.17 Hilar cholangiocarcinoma: elderly man with progressive 
jaundice. (a) Contrast-enhanced T1-weighted image in the arterial 
phase shows dilatation of the intrahepatic ducts, which extend to the 
hepatic hilum. On the (b) 10 mins’ delayed image, the tumor demon-
strates late enhancement, which allows better delineation of the tumor 
(arrows) from the surrounding hepatic parenchyma
a b
Fig. 17.18 Peripheral cholangiocarcinoma. (a) Contrast-enhanced CT in the arterial phase demonstrates a multicentric hypovascular mass with 
capsular retraction (arrow). (b) Delayed phase demonstrated typical late enhancement due to fibrous matrix
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The imaging appearance of angiosarcoma is often non-
specific, appearing hypodense on unenhanced CT, hypoin-
tense on T1-weighted MR imaging, and mildly hyperintense 
on T2-weighted imaging (although if prominent sinusoidal 
vascular spaces are present, these can appear of homoge-
neous and very high T2-weighted signal intensity). Following 
iodinated or gadolinium-based contrast administration, most 
lesions show nonspecific heterogeneous enhancement. 
Potentially problematic, however, are those tumors with 
prominent sinusoidal vascular spaces, because they can 
mimic the appearance of benign hemangioma on CT and 
MRI. The high MR T2-weighted signal in such lesions fur-
ther compounds this problem. In most such cases, however, 
careful evaluation will show that the tumoral enhancement 
does not follow characteristics of blood pool at all phases or 
that there are other features, such as multiple lesions, that 
make the diagnosis of hemangioma unlikely [71, 72].
17.6.3  Epithelioid Hemangioendothelioma
Epithelioid hemangioendothelioma (EHE) is a rare tumor of 
vascular origin, not to be confused with infantile hemangioen-
dothelioma, which is a very different tumor. These hepatic 
tumors are characterized by multiple, peripheral-based lesions 
that progressively become confluent masses. In addition to the 
unusual peripheral liver distribution, a key characteristic fea-
ture is the presence of overlying capsular retraction, due to the 
presence of fibrosis and scarring [73]. The CT attenuation or 
MR signal intensity characteristics are nonspecific, although 
occasional tumoral calcifications may be seen. Contrast 
enhancement with CT or MR gadolinium chelates often shows 
a central zone of decreased enhancement with marked periph-
eral enhancement (Fig. 17.19). The reverse pattern has also 
been observed with a central area of increased enhancement 
and peripheral decreased enhancement. Concentric zones of 
marked enhancement have also been reported. A visible 
branch of the portal or hepatic vein terminating at the periph-
ery of these lesions t (lollipop sign) has also been described, 
although this is not pathognomonic of the disease [74]. Lesions 
often become confluent and may grow large enough to replace 
nearly the entire liver parenchyma.
17.7  Hepatic Metastases
At US, liver metastases can appear hypoechoic, isoechoic, 
or hyperechoic. On dynamic contrast-enhanced CT, most 
metastases appear hypovascular and hypodense relative to 
liver parenchyma on the portal venous phase (Fig. 17.20). 
Hypervascular metastases are most commonly seen in 
renal cell carcinoma, neuroendocrine tumors, sarcomas, 
and breast tumor patients (Fig. 17.20). These tumors are 
best seen in the arterial phase and may become isodense 
and difficult to detect at the later phases of contrast 
enhancement. At MR, metastases are usually hypointense 
on T1-weighted and hyperintense on T2-weighted images 
[75]. Peritumoral edema makes lesions appear larger on 
T2-weighted images and is highly suggestive of a malig-
nant mass [76]. High signal intensity on T1-weighted 
sequences is typical for melanoma metastases due to the 
paramagnetic nature of melanin. Some lesions may have a 
central area of hyperintensity (target sign) on T2-weighted 
images, which corresponds to central necrosis. DWI with 
high b-values (e.g., 600–800) is very helpful for detecting 
small liver metastases, which may otherwise escape detec-
tion (Fig. 17.21). On dynamic contrast- enhanced MR 
imaging, metastases demonstrate enhancement character-
istics similar to those described for CT. Metastases may 
demonstrate a hypointense rim compared with the center 
of the lesion on delayed images (peripheral washout sign), 
which is highly specific for malignancy. It has been shown 
in colorectal cancer that the combination of using DWI, 
together with liver-specific contrast media, enhanced MRI 
results in the highest diagnostic accuracy for the detection 
of liver metastases (Fig. 17.22) [77].
17.8  Differential Diagnosis of Focal Liver 
Lesions
The approach to characterizing a focal liver lesion seen on 
CT begins with determining its density. If the lesion shows 
near water density, is homogenous in character, and has 
Fig. 17.19 Epithelioid hemangioendothelioma. Contrast CT (portal 
venous phase) shows multiple predominantly peripheral-based 
hypodense lesions. Note that some of the lesions show a laminated 
appearance (arrows). Early development of capsular retraction is pres-
ent with flattening of the capsule overlying some of the lesions 
(arrowheads)
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sharp margins, then a cyst should be considered and can be 
confirmed with US, equilibrium-phase CT, or even MR 
imaging (T2 bright and non-enhancing post-gadolinium), 
which can ensure there are no solid components or mural 
wall lesions. However, the radiologist should be familiar 
with the imaging features of other cystic lesions that can 
mimic simple cysts.
When evaluating solid focal liver lesions, disease charac-
terization is largely reliant on observing the rate and pattern 
of contrast enhancement. If a lesion shows peripheral and 
nodular enhancement, with the density of enhancing portions 
showing the same general levels of blood vessels in the arte-
rial, venous, and delayed phases, a hemangioma can be con-
fidently diagnosed. Arterially hypervascular enhancing 
a b
Fig. 17.20 Metastases. (a) Contrast-enhanced MDCT in the arterial phase demonstrates several predominantly hypervascular liver metastases of 
neuroendocrine cancer of the pancreas. (b) Contrast-enhanced MDCT in the venous phase shows typical hypovascular colorectal metastases
a b
Fig. 17.21 Value of diffusion-weighted MRI for detection of small 
metastases. (a) Contrast-enhanced MRI shows one small metastasis in 
the right lobe (arrow). There is a subtle hypointensity in the right lobe 
in a subcapsular location. (b) DWI clearly shows that there is an addi-
tional metastasis (arrows)
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lesions include FNH, HCA, HCC, and metastases from 
neuroendocrine tumors, melanoma, renal cell carcinoma, 
and breast cancer. In general, HCC is considered in a set-
ting of cirrhosis or chronic liver disease. FNH is most 
likely in young women with a non-cirrhotic liver and if the 
lesion is homogeneous and near-isodense/near-isointense on 
unenhanced CT/MR imaging with a central T2-weighted 
hyperintense scar.
By comparison, thick, irregular, heterogeneous enhance-
ment or the presence of peripheral washout at the delayed 
phase suggests a malignant mass, such as metastases, CCC, 
or even HCC. In particular, delayed enhancement is a feature 
of CC due to is fibrotic stroma.
Liver-specific MR contrast has been shown to improve 
the characterization of FNH and HCA, increase the detec-
tion of suspicious focal lesions in patients with liver cir-
rhosis, as well as the identification of small focal liver 
lesions.
DWI is also now routinely performed in liver imaging. 
Its main clinical benefit is the detection of focal liver 
lesions, which may be missed on conventional and con-
trast-enhanced imaging sequences. Quantitative ADC 
measurements can support the characterization of focal 
liver lesions, with higher ADC values (e.g., 
>1.7 × 10–3 mm2/s) favoring benign lesions [22]. However, 
the use of ADC value should be made with the knowledge 
of the scanner ADC repeatability, as well as in collabora-
tion with all other imaging findings because of the signifi-





Fig. 17.22 Colorectal liver metastases at gadoxetic acid-enhanced MRI. 
(a) Unenhanced T1-weighted MRI shows two hypointense lesions in seg-
ments 6/7 and 4. (b) The T2-weighted TSE image shows the lesions to be 
moderately hyperintense. (c) The gadoxetic-enhanced T1-weighted GRE 
image in the hepatobiliary phase shows two additional small subcapsular 
metastases (arrows) not seen on unenhanced MRI or MDCT (not shown)
Take-Home Messages
• Contrast-enhanced liver MDCT for detection and 
characterization of focal masses should be at least 
biphasic, with a quadruple-phasic protocol being 
recommended for HCC detection and characteriza-
tion in cirrhotic patients.
• MRI protocol should routinely include dynamic 
contrast- enhanced pulse sequences and DWI.
• Liver-specific MR contrast agents are recom-
mended for evaluation of patients with potentially 
resectable colorectal liver metastases.
• Liver-specific MR contrast agents are helpful for 
characterization of FNH and adenoma and may 
increase the reader confidence in HCC 
characterization.
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18.1  Cervical Cancer
18.1.1  Epidemiology and Diagnosis
Cervical cancer is the fourth most common malignancy 
among women worldwide [1, 2]. Most cases and deaths 
occur in developing countries, whereas in developed coun-
tries widespread cytology-based screening has led to a sharp 
decline in incidence [1, 3].
The main risk factor is chronic human papillomavirus 
(HPV) infection [1, 3]. Thus, cervical cancer can be effec-
tively prevented with HPV vaccines and HPV DNA-based 
screening [1]. Abnormal cytology or positive high-risk 
HPV test should prompt colposcopy and cervical biopsy. 
Squamous cell carcinoma comprises 70–80% and adenocar-
cinoma 20–25% of cases [1].
18.1.2  Initial Staging and Management
Cervical cancer is staged using the International Federation 
of Gynecology and Obstetrics (FIGO) classification [4]. It is 
the only gynecologic malignancy staged clinically owing to 
high prevalence in developing countries. Lymph node (LN) 
status, a major prognostic factor, is excluded from FIGO 
staging as clinical detection is not possible [1]. Cross- 
sectional imaging is not accepted for formal assignment of 
FIGO stage but is used routinely in developed countries to 
guide treatment decisions [1, 5]. Treatment selection is 
determined by tumor stage and presence/location of LN 
metastases (Fig. 18.1).
18.1.3  MRI and Initial Staging
MRI is the method of choice to evaluate locoregional extent 
(Table 18.1) [6, 7]. Small field-of-view T2-weighted imag-
ing in the sagittal and short-axis planes is the mainstay of 
staging MRI (Fig. 18.2) [6]. Diffusion-weighted imaging 
(DWI) in conjunction with T2-weighted imaging improves 
delineation of tumor margins. Dynamic contrast-enhanced 
imaging (DCE) is used largely in research for prognosis and 
response assessment.
18.1.3.1  Stage I: Cervix-Confined Disease
Stage IA is microscopic in size. Stage IB is visible clinically 
and is divided based on size into IB1 (≤4 cm) and IB2 
(>4 cm). The tumor has intermediate signal intensity (SI) on 
T2-weighted imaging and shows diffusion restriction. Intact 
rim of low-SI fibrous cervical stroma around the tumor indi-
cates cervix-confined disease (Fig. 18.3) [6]. Fertility preser-
vation (LN assessment + cone/trachelectomy) is possible for 
patients with ≤Stage IB1 (Table 18.2) [8, 9].
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Fig. 18.1 Diagram (adapted 
from [6]) highlights the role 
of MRI and PET/CT to assess 
disease extent and guide 
treatment decisions in patients 
with new diagnosis of cervical 
cancer
Table 18.1 Suggested MRI protocol to stage cervical and endometrial cancer [7]
Sequences Planes
Field of view 
(FOV) Assessment/detection of
T1-weighted imaging Axial Large FOV,
Kidneys to pubic 
symphysis
• Pelvic and para-aortic LNs
• Bones
T2-weighted imaging Axial Pelvis, small FOV • Hydronephrosis
• Pelvic sidewall invasion
• Adnexal involvement
Sagittal Pelvis, small FOV Cervical cancer
• Endocervical extent
Endometrial cancer
• Depth of myometrial invasion
Both
• Cervical stromal invasion
• Vaginal involvement
Short-axis plane perpendicular to cervix (cervical cancer) 
or endometrium (endometrial cancer)
Pelvis, small FOV Endometrial cancer
• Depth of myometrial invasion
Both
• Cervical stromal invasion
• Parametrial invasion
DWI
B = 0, ≥800




Pelvis, small FOV •  Adjunct to T2-weighted imaging to 
assess tumor extent
• Increase in LN conspicuity
Optional for cervical 
cancer
• Vaginal gel: Upper vaginal invasion
• Endovaginal coil: Small tumors prior to fertility preservation
• Long-axis plane T2-weighted imaging + DWI (parallel to cervix)
– Endocervical extent




• Long-axis plane T2-weighted imaging + DWI (parallel to endometrium)
– Depth of myometrial invasion
– Cervical stromal invasion
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18.1.3.2  Stage II: Cervical + Upper Vaginal 
Disease ± Parametrial Invasion
Stage IIA invades the upper vagina (upper two-thirds) but 
not the parametrium. Similar to Stage IB, it is divided into 
IIA1 (≤4 cm) and IIA2 (>4 cm). Vaginal invasion is diag-
nosed when intermediate-SI tumor disrupts low-SI vagina on 
T2-weighted imaging. A horizontal line drawn at the bladder 
base on sagittal T2-weighted imaging divides the vagina into 
upper and lower portions (Fig. 18.2).
Stage IIB invades the parametrium. Complete loss of low- 
T2 SI stromal ring does not always indicate parametrial 
 invasion. Parametrial invasion is present if tumor disrupts low-
SI stroma AND causes spiculated/nodular tumor-parametrial 
interface ± encases parametrial vessels (Fig. 18.4) [6]. 
DWI + T2-weighted imaging improve specificity for detecting 
parametrial invasion [10]. Accurate diagnosis is important as 
parametrial invasion indicates concurrent chemotherapy and 
radiation (CCRT) as treatment of choice (Fig. 18.1).
18.1.3.3  Stage III: Pelvic Sidewall Invasion, 
Lower Vaginal Involvement, 
Hydronephrosis, or Nonfunctional 
Kidney
Stage IIIA invades the lower vagina. Stage IIIB extends 
to the pelvic sidewall ± causes hydronephrosis. Tumor 
Upper vagina
Lower vagina
Fig. 18.2 Drawing illustrates orientations of short-axis planes to stage 
endometrial cancer (solid line oriented perpendicular to endometrium) 
and cervical cancer (dashed line oriented perpendicular to endocervical 
canal). Double line is drawn at the bladder base/urethral junction and 
divides the vagina into upper and lower portions
a b
Fig. 18.3 52-year-old woman with Stage IB1 cervical adenocarci-
noma. Sagittal T2-weighted imaging (a) and short-axis T2-weighted 
imaging (b) demonstrate 1.8 cm tumor with intermediate SI on 
T2-weighted imaging. Tumor involves partial thickness of cervical 
stroma with intact low-SI stromal ring (arrow) ruling out parametrial 
invasion
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within 3 mm of iliac vessels or obturator internus, 
piriformis, or levator ani muscles indicates sidewall inva-
sion [6].
18.1.3.4  Stage IV: Bladder/Rectal Mucosal 
Invasion or Extension Beyond 
the Pelvis
Stage IVA invades the bladder/rectal mucosa; invasion is 
present when intermediate-SI tumor disrupts low-SI mus-
cle wall and extends into the mucosa on T2-weighted imag-
ing. Bullous edema alone (high-SI mucosa) does not mean 
Stage IVA [6]. Stage IVB is indicated by the presence of 
Table 18.2 Selection criteria for conservative management of women 
with ≤ Stage IB1 lesions and desire for fertility
Eligibility criteria
    •  Squamous cell carcinoma, adenocarcinoma, or adenosquamous 
carcinoma
    • Tumor size ≤2 cm
      – Some centers ≤4 cm
    • Tumor-to-internal os distance ≥1 cm
      – Some centers ≥0.5 cm
    • Cervical stromal invasion <50%
      – Some centers, any depth
    • Cervix-confined disease
      – Absence of parametrial invasion or LN metastases
a b
c
Fig. 18.4 35-year-old woman with Stage IIB cervical squamous cell 
carcinoma. Sagittal T2-weighted imaging (a), short-axis T2-weighted 
imaging (b), and fused T2-weighted imaging + DWI (c) demonstrate 
5.2 cm tumor involving the lower uterus, upper vagina (arrow), and 
parametrial regions. There is nodular interface between the tumor and 
parametrium (arrow). Also note right internal iliac LNs (arrowhead)
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distant metastases (including LN metastases beyond the 
pelvis).
18.1.4  PET/CT and Initial Staging
LN metastases impact prognosis and treatment. On MRI 
(and CT) short-axis diameter ≥ 1 cm is a main diagnostic 
criterion but yields low-to-moderate sensitivity because 
metastases to normal-sized LNs remain undetected 
(Fig. 18.5) [11]. LNs show high SI on DWI, increasing their 
conspicuity (Fig. 18.4); however, DWI is not used to distin-
guish benign from malignant LNs due to overlap in ADC 
values [10]. PET/CT improves N and M staging and is rec-
ommended for Stage ≥ IB2 disease (Fig. 18.5) [5, 12].
18.1.5  Evaluation During and After Initial 
Treatment
After radical hysterectomy, imaging is obtained if recur-
rence is suspected clinically [1, 5]. After fertility-sparing 
surgery, MRI is recommended at 6 months and annually 
thereafter [5].
MRI and PET/CT are useful for radiotherapy (RT) plan-
ning. For example, RT field is extended to para-aortic regions 
if para-aortic LN metastases are present on pretreatment 
PET/CT (Figs. 18.1 and 18.5) [1, 5], and mid-treatment MRI 
allows adjustment of brachytherapy dose based on volume/
location of residual tumor [13, 14].
Low-SI stroma on T2-weighted imaging indicates tumor- 




Fig. 18.5 Same patient as in Fig. 18.4. Axial T2-weighted imaging and 
PET/CT images show 0.5 cm short-axis FDG-avid left para-aortic LN 
(a, b). (c) Baseline axial PET/CT image through the pelvis demon-
strates FDG-avid cervical tumor and right internal iliac LN (arrow). (d) 
Complete resolution of FDG avidity after CCRT
18 Malignant Diseases of the Uterus
202
6 months after CCRT [6]. Thus, PET/CT obtained 
3–6 months after CCRT is useful. Absent FDG avidity indi-
cates low risk of recurrence; diminished FDG avidity signi-
fies moderate risk; and unchanged, increased, or new 
FDG-avid foci indicate persistent disease (Fig. 18.5) [15]. 
The role of DWI and DCE to assess response is an area of 
active research [10, 13].
18.1.6  Evaluation of Recurrence
Recurrent cervical cancer has similar imaging features as 
primary lesions [6]. In the absence of prior pelvic RT, local-
ized recurrence may be approached with CCRT. Radical sur-
gery is the only potential cure in previously irradiated pelvis. 
MRI and PET/CT are essential to determine eligibility and 
tailor the extent of surgery [16].
18.1.7  Future Directions
PET/MRI may offer a “one-stop-shop” approach to the eval-
uation of cervical cancer in both primary and recurrent set-
tings [17].
18.2  Endometrial Cancer
18.2.1  Epidemiology and Diagnosis
Endometrial cancer is the sixth most common malignancy 
among women worldwide and the most common gyneco-
logical cancer in developed countries [2]. Incidence has 
steadily increased, primarily due to increased longevity and 
obesity in developed countries. Approximately 75% of cases 
occur in postmenopausal women and >90% present with 
postmenopausal bleeding. As such, most patients are diag-
nosed at an early stage with 5-year survival rates >90% in 
this subgroup [18].
Initial evaluation includes pelvic ultrasound (US) 
and pipelle endometrial biopsy or dilatation and curet-
tage. Thresholds of endometrial thickness of 4–5 mm 
in postmenopausal women detect endometrial cancer 
with a sensitivity of up to 95% and a specificity of 77% 
[19]. Endometrial cancer is traditionally subdivided into 
two types based on biological behavior: type 1 tumors 
are estrogen-dependent and include FIGO grades 1 and 
2 endometrioid adenocarcinomas, while type 2 tumors 
include serous papillary carcinomas, clear cell adenocar-
cinomas, carcinosarcomas, and FIGO grade 3 endometri-
oid adenocarcinomas [18]. Type 2 tumors are not estrogen 
dependent, present at a higher stage, and behave more 
aggressively.
18.2.2  Initial Staging and Management
Endometrial cancer is staged surgically using the FIGO sys-
tem [4]. The standard surgical staging procedure consists of 
total abdominal hysterectomy, bilateral salpingo- 
oophorectomy, LN dissection, peritoneal washing, and 
omental biopsies. FIGO stage correlates well with prognosis, 
but preoperative staging remains important, since early- 
stage/low-grade tumors may be treated with minimally inva-
sive surgery and may not require LN dissection [20, 21].
18.2.3  MRI and Initial Staging
MR imaging is the modality of choice to determine the depth 
of myometrial invasion, which correlates with tumor grade, 
LN metastases, and 5-year survival (Table 18.1) [22]. Small 
field-of-view high-resolution imaging in the sagittal and 
short-axis planes is the mainstay of MRI staging (Fig. 18.2) 
[6]. The combination of T2-weighted imaging, DCE, and 
DWI offers the best diagnostic accuracy [23, 24].
MRI with its high-spatial resolution and larger field of 
view has a particular advantage over endovaginal US in the 
setting of bulky tumors, advanced stage, and concomitant 
benign disease, i.e., adenomyosis and LMs.
18.2.3.1  Stage I: Uterine-Confined Disease
Stage IA is confined to the endometrium or inner half of the 
myometrium, i.e., <50% myometrial thickness involvement 
(Fig. 18.6). Stage IB extends to the outer half of the myome-
trium (≥50%) (Fig. 18.7). The tumor has intermediate-to- 
low SI on T2-weighted imaging, is hypointense to 
myometrium on later phases of DCE, and shows restricted 
diffusion. However, small tumors may be iso- or only mini-
mally hypointense relative to the normal endometrium and 
may be hypervascular relative to the endometrium early on 
after contrast administration. A partially intact, low-SI junc-
tional zone around the tumor indicates the absence of deep 
myometrial invasion.
18.2.3.2  Stage II: Cervical Stromal Invasion
Stage II invades and disrupts the low-SI cervical stroma on 
T2-weighted imaging. Polypoid extension of the tumor into 
the endocervical canal or endocervical mucosal invasion is 
not sufficient to assign Stage II. Tumor extension beyond the 
cervix into the parametrium requires a radical hysterectomy.
18.2.3.3  Stage III: Invasion of Uterine Serosa, 
Adnexa, Vagina, and/or Pelvic or 
Para-Aortic Lymph Nodes
Stage IIIA invades the uterine serosa appearing as an area of 
intermediate SI on T2-weighted imaging with loss of normal 
rim enhancement of the outer myometrium on DCE. Direct 





Fig. 18.6 62-year-old woman with Stage IA endometrioid adenocarci-
noma (grade 2) of the endometrium. Short-axis (a) T2-weighted imag-
ing, (b) B1000 DWI, and (c) delayed post gadolinium 3D T1-weighted 
imaging demonstrate an endometrial-based tumor (thick arrow) at the 
level of the fundus and right cornua. There is partial invasion of the 





Fig. 18.7 76-year-old woman with Stage IB endometrioid adenocarci-
noma (grade 3) of the endometrium. Short-axis (a) T2-weighted imag-
ing, (b) B1000 DWI, and (c) delayed post gadolinium 3D T1-weighted 
imaging demonstrate a large tumor (thick arrow) invading the deep 
myometrium. There is a thin rim of intact outer myometrium (thin 
arrow) along the left aspect of the uterus excluding serosal 
involvement
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tumor spread to the adnexa or ovarian metastases is consid-
ered Stage IIIA disease. It is important but challenging to 
differentiate synchronous ovarian lesions from metastases to 
the ovaries. Type 2 tumors have a higher pretest probability 
of advanced disease, and therefore a meticulous search for 
advanced tumor extent is required in this subgroup.
Stage IIIB involves the vagina either by contiguous spread 
or metastatic involvement.
Stage IIIC is diagnosed when there is pelvic (Stage IIIC1) 
and/or para-aortic (Stage IIIC2) LN metastatic involvement. 
The use of a 1 cm short-axis cutoff value results in a high speci-
ficity but poor sensitivity (range, 36–89.5%) for predicting LN 
metastases [6]. A cutoff value of 0.8 cm increases the sensitiv-
ity albeit at the cost of specificity. In practice, given that endo-
metrial carcinoma is staged surgically, it is important to provide 
the size and detail the location of LNs exceeding 0.5–0.6 cm in 
short-axis. The role of DWI and ADC to assess LNs is the same 
as described for cervical cancer [10]. PET/CT improves N and 
M staging; however, PET/CT is currently not part of standard 
of care for initial staging of endometrial cancer.
18.2.3.4  Stage IV: Bladder/Rectal Mucosal 
Invasion or Extension Beyond 
the Pelvis
Please refer to section “MRI and Initial Staging of Cervical 
Carcinoma,” as the findings are the same for endometrial and 
cervical carcinoma.
18.2.4  Evaluation of Recurrence
Recurrent endometrial cancer has a similar imaging appear-
ance as the primary tumor. Risk factors for recurrence 
include advanced stage at presentation, high-grade disease, 
and lymphovascular invasion. More than 80% of recurrences 
occur within 3 years of initial treatment with LNs (46%) and 
the vaginal vault (42%) being the most common sites. MRI 
is useful to evaluate surgical resectability of pelvis-confined 
recurrent disease, while PET/CT is helpful to exclude distant 
and LN metastases [6, 16].
18.3  Uterine Sarcomas
18.3.1  Epidemiology and Presentation
Uterine sarcomas are rare aggressive tumors originating from 
mesenchyme and comprising <3% of uterine corpus tumors 
[6, 21]. Leiomyosarcoma (LMS) is the most common histo-
logic subtype, followed by endometrial stromal sarcoma 
(ESS) and undifferentiated uterine sarcoma. ESS is subdi-
vided into low- and high-grade ESS based on differences in 
histopathology and clinical outcomes [21]. Carcinosarcoma 
was previously categorized as uterine sarcoma but is now 
classified as high-grade endometrial carcinoma [6, 21].
Uterine sarcomas arise de novo and have no biologic link 
to LM [25]. Prompt radical surgery is the standard of care for 
uterine sarcomas [21]. In contrast, symptomatic LM can be 
approached with traditional surgery (hysterectomy, myo-
mectomy) or newer minimally/noninvasive strategies (embo-
lization, ablation, medical therapy). The latter do not yield 
histologic diagnosis, highlighting the need for precise initial 
diagnosis [26].
Uterine sarcoma and LM manifest with similar symp-
toms. Large size and rapid growth are unreliable signs of 
malignancy [25]. Growth of uterine mass after menopause 
and elevated LDH, particularly LDH isozyme type 3, should 
be viewed as suspicious for LMS [25]. Endometrial sam-
pling may aid diagnosis of uterine sarcoma, but sensitivity is 
limited due to myometrial origin [21, 25].
18.3.2  Role of Imaging
MRI is the imaging method of choice if uterine sarcoma is 
suspected clinically or if intervention is planned for symp-
tomatic LM (to map tumors and exclude sarcoma) [26].
No single MR feature can reliably distinguish uterine sar-
coma (including LMS) from atypical LM (degeneration or 
histologic variants). Combined MR features may suggest cor-
rect diagnosis including a single large uterine mass with hem-
orrhage (high SI on T1-weighted imaging), heterogeneous 
high SI on T2-weighted imaging, infiltrative/nodular borders 
on T2-weighted imaging, and central necrosis [27]. Uterine 
sarcoma also demonstrates rapid early enhancement of solid 
components on DCE and restricted diffusion (Fig. 18.8) [27]. 
Diffusion restriction alone is insufficient for diagnosis because 
it may be observed with LM, especially cellular LM [27].
ESS often demonstrates distinct MR features that aid 
diagnosis including an ill-defined myometrial mass with 
endometrial component, wormlike low-SI bands on 
T2-weighted imaging (normal myometrium compressed by 
tumor), and contiguous extension along the fallopian tubes, 
periuterine vessels, and pelvic ligaments [6].
Key Points
• MRI excels at locoregional staging of cervical and 
endometrial cancer for treatment stratification, 
while PET/CT improves N and M staging in uterine 
malignancies.
• MRI facilitates patient selection prior to fertility preser-
vation for early stage cervical and endometrial cancers.
• MRI aids the characterization of clinically sus-
pected uterine sarcoma.
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Benign Diseases of the Colon 
and Rectum (incl. CT colonography)
Thomas Mang and Philippe Lefere
19.1  Introduction
Diagnostic imaging of the colon and the rectum has under-
gone a remarkable evolution over the last few decades. 
Routine cross-sectional imaging techniques, such as stan-
dard abdominal CT scans, provide the possibility to evaluate 
the course of the colon for mural and extracolonic changes. 
With the introduction of CT colonography (CTC) to the clin-
ical routine, a noninvasive and safe diagnostic test for imag-
ing the endoluminal aspect of the entire colon became 
available. CTC has been shown to be as accurate as optical 
colonoscopy (OC) for the detection of advanced colonic neo-
plasia, including advanced adenomas and cancers [1]. Since 
its performance is clearly superior to that of the barium 
enema, it is now recommended as the radiological method of 
choice for the detection of colorectal neoplasia [2, 3]. The 
barium enema is no longer recommended for this indication. 
Indeed, the role of the barium enema in daily radiological 
imaging has been fading over the last several years due to the 
emerging use of endoscopic techniques. Today, OC repre-
sents the diagnostic and therapeutic gold standard in colonic 
imaging. CTC has become a valuable complementary diag-
nostic tool to OC, serving as an alternative colonic screening 
test, and it represents the method of choice in patients with 
incomplete colonoscopy or with contraindications to colo-
noscopy [3].
The purpose of this contribution is to focus on benign 
conditions of the colon and rectum that can be detected dur-
ing CTC and routine cross-sectional imaging techniques.
19.2  Benign Colonic Findings Seen at CTC
19.2.1  Benign Mucosal Colonic Polyps
Polyps are the most common benign lesions of the colon. In 
addition to malignant tumors, polyps are the main targets of 
CTC. According to the Paris classification, they are catego-
rized by their morphologic appearance as sessile, peduncu-
lated, or flat [4]. On CTC, polypoid findings of the colon are 
characterized by their outer morphology, their internal struc-
ture and attenuation characteristics, and their mobility 
between the supine and prone patient positions [5].
A sessile polyp (0-Is) presents as a round, oval, or lobu-
lated intraluminal filling defect, with a base that is equal to or 
larger than its vertical height (Fig. 19.1).
A pedunculated polyp (0-Ip) presents with a round, oval, 
or lobulated polyp head that is connected to the mucosa by a 
stalk. On 2D planar images, colorectal polyps typically show 
a homogeneous internal structure with a soft tissue attenua-
tion. Polyps arise from the colonic wall. Therefore, they 
maintain their intraluminal position when the prone and 
supine scanning positions are compared. This criterion may 
help to differentiate true polyps from untagged residual stool 
that is not attached to the colonic wall and that shows a posi-
tional movement. Pedunculated polyps, however, may show a 
Learning Objectives
• To illustrate the spectrum of benign conditions of 
the colon and rectum, seen at CT colonography and 
conventional cross-sectional imaging
• To learn how to characterize and differentiate 
benign polypoid and stenotic filling defects with 3D 
and 2D CT colonography imaging criteria
• To discuss both specific and unspecific cross-sec-
tional imaging criteria of various infectious and 
noninfectious inflammatory conditions of the colon
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considerable positional shift between the supine and prone 
acquisitions because of their stalk (Fig. 19.2). This so-called 
pseudo mobility may cause confusion with the untagged 
stool, showing true mobility, i.e., a pseudo-stool appearance.
Flat or non-polypoid lesions are morphologically character-
ized by their low elevation compared to their width (Fig. 19.3). 
On CTC, non-polypoid lesions are defined as lesions that mea-
sure 6 mm or larger above the surrounding mucosa, with a 
height of 3 mm or less [6]. Endoscopically, they are categorized 
according to their predominant direction of growth, which 
defines their morphology: flat elevated (0-IIa), truly flat (0-IIb), 
and depressed flat (0-IIc). Non- polypoid lesions are generally 
less common than their polypoid counterparts.
On CTC, they are less conspicuous than polypoid lesions. 
On endoluminal 3D views, flat lesions present as a plaque- 
like elevation of the colonic wall, with a smooth or nodular 
surface. A flat lesion, located on a semilunar fold, typically 
leads to a circumscribed thickening of the fold. On 2D pla-
a b
c d
Fig. 19.1 (a–d) Sessile oval polyp located in the ascending colon. (a) 
The endoluminal 3D view shows a round polypoid lesion (arrow) (b) 
The corresponding prone axial 2D image shows the homogeneous soft-
tissue density (arrow) of the lesion. (c) The corresponding supine endo-
luminal 3D view shows a horizontal fluid layer (arrowheads). No polyp 
is seen. (d) The supine axial 2D image shows that the lesion (arrow) is 
submerged unter tagged residual fluid (arrowhead)
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nar views, flat lesions typically appear as circumscribed, 
plaque- like wall thickening with a homogeneous soft-tissue 
attenuation [5]. Flat lesions with a central depression have 
been shown to have a higher risk for malignancy. Flat lesions 
are frequently covered by tagged residue, which may aid 
detection. This is called “contrast coating” [7].
Larger non-polypoid tumors, spreading over ≥1 cm (on 
CTC ≥ 3 cm), are laterally spreading tumors (LSTs). An 
older, commonly used term is a “carpet lesion.” They are an 
important subset of flat lesions, with a predilection for the 
cecum and the rectum. They typically present with advanced 
histological features. Based on their surface appearance, they 
are endoscopically categorized as granular or non-granular 
types [8].
On CTC, they typically present with a broad-based flat 
morphology, with a size ≥3 cm. They may exceed 3 mm in 
Fig. 19.2 Large pedunculated polyp located in the sigmoid colon. (a) 
The prone endoluminal 3D view shows the polyp head (arrow), con-
nected to the mucosa by its stalk (arrowhead). A small mucus tear is 
attached to the polyp head (asterisk). (b) The corresponding prone sag-
ittal 2D image shows the soft tissue dense polyp head (arrow) located 
on the anterior sigmoid wall. It is connected by the stalk (arrowhead) to 
the dorsal sigmoid wall. (c) The corresponding supine endoluminal 3D 
view and (d) sagittal 2D image show that the polyp head (arrow) moves 
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height but are still flat and may have superficially raised 
edges. Surface coating with oral contrast material is fre-
quently seen [9] (Fig. 19.4).
Correct CTC size measurement is important because the 
size of a polyp, as measured by the radiologist, has a direct 
influence on the selection of the appropriate therapeutic 
a b
Fig. 19.3 (a, b) A 12 mm slightly elevated flat lesion with a central 
depression. (a) The endoluminal 3D image shows a flat slightly ele-
vated filling defect with a central depression (arrow), located on a haus-
tral fold adjacent to the ileocecal valve (arrowhead). (b) The 
corresponding sagittal 2D view shows a flat elevation of the bowel wall 
leading to a plaque-like soft tissue thickening of the haustral fold. Note 
the slight central depression at the center of the lesion (arrow)
a b
Fig. 19.4 (a, b) Laterally spreading tumor of the mixed granular type 
in the rectum. (a) The endoluminal 3D view shows a flat irregular filling 
defect with a nodular surface (arrow). (b) The corresponding axial 2D 
image shows a nodular wall thickening with soft tissue attenuation 
(arrow). The lesion is covered by a small amount of tagged fluid
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 procedures. There is general consensus that all polyps mea-
suring 6 mm or larger need to be reported, and endoscopic 
polypectomy should be recommended [3, 6]. Polyps smaller 
than 6 mm are frequently ignored. For sessile and flat polyps, 
the greatest diameter is measured, which is most often at the 
base of the lesion. For pedunculated lesions, only the largest 
diameter for the polyp head should be measured, excluding 
the stalk [6].
19.2.2  Benign Submucosal Tumors
19.2.2.1  Lipomas
Lipomas are the most common submucosal tumors in the 
colon. They are typically between 1 and 3 cm in size. A lipoma 
can have a sessile, pedunculated, or even flat morphology. On 
endoluminal 3D views, they present as filling defects, typi-
cally with a smooth surface. A correct diagnosis is obtained 
with 2D views: lipomas typically have a homogeneous fatty 
attenuation. Often, a thin mucosal stripe covering the fatty tis-
sue is seen. Since lipomas are relatively soft lesions, they may 
change their shape when the position of the patient is changed 
(Fig. 19.5). Lipomas are benign. No diagnostic or therapeutic 
investigation is needed. Large lipomas, however, can be symp-
tomatic and lead to intussusceptions [10].
19.2.2.2  Rare Submucosal Tumors
Lymphangiomas are rare benign lesions which may be sim-
ple, cavernous, or cystic. In case of the cystic type, the lesion 
appears with a cystic morphology on 2D views. However, 
whenever the finding is ≥6 mm on OC, it is necessary to 
exclude a true neoplastic lesion. There is a wide range of 
other submucosal tumors that are typically very rare, includ-
ing leiomyoma, hemangioma, and ganglioneuroma. These 
cannot be differentiated from adenomatous polyps or tumors 
based on CT imaging criteria [10].
19.2.2.3  Pneumatosis Cystoides Coli
Pneumatosis coli is a rare entity with intramural collec-
tions of gas. The primary type is benign and self-limiting. 
The secondary type is related to bowel wall necrosis. It 
usually requires immediate treatment according to the 
clinical presentation. On CTC, the primary type has been 
reported as a rare finding. Primary pneumatosis coli pres-
ents with pseudopolypoid filling defects on endoluminal 
3D views, corresponding to submucosal cystic or linear 
pockets of air. Two-dimensional views reveal the pathog-
nomonic air attenuation on these findings. Primary pneu-
matosis coli is a totally innocuous, asymptomatic, and 
self-limiting “complication,” which requires no further 
medical action [11].
a b
Fig. 19.5 (a, b) Lipoma in the ascending colon. (a) The endoluminal 
3D view shows a large polypoid lesion with smooth appearance (arrow). 
(b) The corresponding axial 2D image shows the homogeneous fat tis-
sue density (arrow) of the lesion, covered by a thin mucosal stripe con-
firming its submucosal origin (asterisk)
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19.2.2.4  Endometriosis
Endometriosis is a condition related to the growth of the 
endometrium outside the uterus. Colonic involvement 
occurs mostly in the rectosigmoid and rarely in the cecum. 
This occurs via peritoneal implants of endometrial tissue. 
These implants may develop trans-serosal growth with sub-
mucosal extension. From there, intraluminal extension may 
occur in a small number of patients. According to the grade 
of invasion, CTC shows different aspects. With serosal/sub-
mucosal infiltration, there is mural thickening, which leads 
to a marginal luminal filling defect, showing a smooth delin-
eation (Fig. 19.6). In case of extension to the mucosa, the 
wall becomes irregular and ends in a polypoid lesion or 
mass [12].
19.2.3  Anatomy-Related Findings
19.2.3.1  Segmental Colonic Spasm
Colonic spasm is a physiological narrowing of the intestinal 
lumen due to muscular contraction of the colonic wall that 
can simulate circular stenotic tumors. The degree of colonic 
distension and the intraluminal aspect of the colon also 
depend on the muscular contraction of the taenia coli. 
Optimal colonic distension prevents spasms and possible 
false-positive findings. In the sigmoid, the taenia is more or 
less subtle. When contracted, they cause the narrowed lumen 
to be round, with smoothly thickened folds without over-
hanging edges. In the descending colon, the taenia becomes 
slightly more prominent with, in contraction, a slightly more 
triangular aspect of the colonic lumen. In the transverse and 
ascending colon, the triangular shape of the lumen is obvi-
ous. However, the folds are not distorted, and there is usually 
no shoulder formation, which is typical of malignancy. Due 
to redistribution of intracolonic gas, the spasm will fre-
quently either change in morphology or even disappear 
between the supine and prone acquisitions [5].
19.2.3.2  Flexural Pseudotumor
The colon presents with many loops and flexures. At each 
flexure, the structure at the inner side is more compressed 
than that on the outer side. This can cause complex structures 
that consist of crowded and thickened colonic folds. This 
thickening is accentuated by the pericolic fat and its vascular 
structures. On 2D planar views, this may lead to an apparent 
wall thickening that may be mistaken for a colonic mass. 
Therefore, such thickening is referred to as a flexural pseu-
dotumor. Such pseudolesions can become real tumor mimics 
in case of a flexure over an acute angle with the convergence 
of many folds. A comparison of both acquisitions will help 
to detect any change in appearance. A thorough analysis of 
the appearance on 3D and 2D images is helpful to exclude a 
tumoral process. The pseudolesion most frequently consists 
of a convergence of many folds that show regular smooth 
contours on endoluminal 3D views. On 2D views, pericolic 
fat is sometimes demonstrated in the thickened fold [13].
Fig. 19.6 (a, b) Endometriosis implant in the sigmoid colon. (a) The endoluminal 3D view shows a flat intraluminal filling defect with a smooth 
delineation (arrows). (b) The corresponding axial 2D image shows a homogeneous soft tissue dense lesion (arrow) infiltrating the colonic wall
a b
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19.2.4  The Anorectal Region
For the evaluation of the rectum, it is important to inspect the 
anal margin. This is done by turning the virtual camera to the 
anus. In this part of the rectum, several benign and/or tumor- 
like conditions are possible [5, 13, 14].
19.2.4.1  The Hypertrophied Anal Papilla
The hypertrophied anal papilla is a frequent finding. It is a 
papillary projection of a rectal column (Morgagni) and 
appears as a fibrous white polyp of any size at OC. On CTC, 
it is impossible to differentiate from a true polyp, necessitat-
ing rectoscopy in case of a polypoid structure ≥6 mm.
19.2.4.2  Internal Hemorrhoids
Internal hemorrhoids are varicosities of the superior hemor-
rhoidal plexus. They arise at the anal margin and are a very 
frequent finding (±50% of patients). They typically appear as 
smooth filling defects surrounding the rectal catheter with 
thin folds converging toward the catheter. On rare occasions, 
they may have a polypoid appearance.
19.2.4.3  Other Findings
The rectal varix is a dilated submucosal vein that causes a long, 
serpiginous filling defect. It is important to be aware of its exis-
tence, as, on rare occasions, polyps may also have a serpiginous 
aspect. A venous bleb is a small venous malformation that may 
present with a polypoid morphology and mimic true polypoid 
lesions. However, usually they are <5 mm.
19.2.5  The Cecum
The cecum has a complex topography including the ileocecal 
valve and the appendix. As with the rectum, its CTC exami-
nation requires specific attention [15–17].
19.2.5.1  The Ileocecal Valve
The normal ileocecal (IC) valve consists of twofolds (upper 
and lower lip), converging at both sides in a prominent fold, 
the frenulum. When examining the cecum, it is always essen-
tial to identify the IC valve and check its anatomic appear-
ance, excluding polyps and cancers located on the valve. The 
normal IC valve, however, may show some pseudotumoral 
aspects that should not be confused with colonic pathology.
19.2.5.2  Lipomatous Transformation
Lipomatous transformation refers to fatty infiltration of both 
lips of the IC. The IC valve is typically enlarged and may 
have a dome-like appearance. Correct characterization of 
this benign anatomical variant is obtained by assessing the 
typical fat attenuation (0/−100 H.U.) in an abdominal win-
dow setting.
19.2.5.3  Papillary Transformation
Papillary transformation is less frequently observed than the 
normal labial appearance. The papillary IC valve is caused 
by protrusion of the terminal ileum into the IC valve. This is 
considered a normal functional status, with the IC valve pre-
venting fluid reflux from the colon into the ileum. A papil-
lary IC valve is recognized by a bulbous or polypoid 
morphology and a smooth surface. It may also appear slightly 
distorted and presents as a bulky, mass-like lesion. In such 
cases, the diagnosis is not always straightforward. Most 
often, this condition is characterized by a smooth delineation 
of the IC valve with some fatty infiltration on 2D images. 
The appearance frequently changes with dual acquisition 
(i.e., supine-prone). However, any accumulation of soft tis-
sue should raise the suspicion for neoplasia.
19.2.5.4  The Appendix
As the appendix is part of the colon, it is necessary to inspect 
it. On endoluminal 3D views, the orifice of appendix is iden-
tified as a small orifice or depression frequently located in 
the vicinity of small fold. On 2D planar views the appendix 
presents as a thin-walled tubular structure, which may be 
filled with air or tagged fluid. Any global or focal wall thick-
ening should prompt further investigation to rule out malig-
nancy (appendectomy). Tumoral conditions of the appendix 
are rare and are frequently asymptomatic [18].
19.2.5.5  Mucocele of the Appendix
An appendiceal mucocele corresponds to a mucus-dilated 
appendix. It typically appears as a tubular cystic lesion in the 
course of the appendix and may present with a mural calcifi-
cation. This may correspond to a simple mucocele (retention 
cyst) or a hyperplastic mucocele (hyperplastic polyp) in 
5–20% of cases, to mucinous cystadenoma in 63–84%, and 
to mucinous cystadenocarcinoma in 11–20%. Rarely, it cor-
responds to endometriosis. A mucocele can protrude into the 
cecal lumen and presents as a polypoid lesion on endolumi-
nal 3D views (Fig. 19.7) [19]. A malignant cause has to be 
excluded by surgery.
19.2.5.6  Inverted Appendiceal Stump
Following inversion-ligation appendectomy, which is an 
older appendectomy technique, an appendiceal stump may 
be seen as a polypoid lesion in the region of the expected 
appendiceal orifice. It presents as a round smooth polypoid 
filling defect at the site of the appendiceal orifice with a 
homogeneous soft-tissue attenuation. This postsurgical pol-
ypoid finding cannot be differentiated from a true colonic 
polyp based on CT imaging criteria. If there is uncertainty 
concerning previous appendectomy, OC should be recom-
mended, the same as for any polypoid lesion ≥6 mm. 
Furthermore, on rare occasions, a polyp or malignancy may 
develop in the stump [20].
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19.2.6  Diverticular Disease
Diverticular disease is the most common disease of the colon 
in the Western population, with a frequency of about 30% at 
age 50 and more than 50% at age 60. It is mostly located in 
the sigmoid colon. In its early stage, diverticular disease is 
characterized by myochosis: a triad of muscular wall thick-
ening, shortening of the taenia, and luminal narrowing. This 
results in restricted colonic distensibility with prominent and 
narrow stranding semilunar folds and deep haustrations, with 
shortening of the interhaustral segments (concertina appear-
ance). On endoluminal 3D views, there is restricted mucosal 
visualization behind and between the prominent semilunar 
folds (blind spots). Dedicated 3D inspections are required, 
which involve turning the virtual camera around to visualize 
the backside of the folds and the interhaustral segment. To 
improve colonic distension, the use of hyoscine-N- 
butylbromide is justified [6]. Distension can also be improved 
by repositioning the patient to the right or left lateral decubi-
tus position, with an additional low-dose CT scan of the 
affected segment.
With progression of myochosis, the diverticula appear 
and the semilunar folds become more prominent. On 2D 
images, the diverticula are characterized by gas-filled out-
pouchings on the colonic wall. On endoluminal 3D views, 
they appear as a well-defined complete dark ring that may 
simulate a small sessile polyp lesion. Polyps, in contrast, 
often present with an incomplete or vague ring shadow when 
viewed en face. Two-dimensional views make differentiation 
of diverticula and polyps straightforward. Diverticular dis-
ease gives rise to pseudopolypoid lesions [21].
19.2.6.1  The Diverticular Fecalith
Diverticula are often impacted with fecal residue that can 
protrude through the neck of the diverticulum into the colonic 
lumen. This causes a polypoid filling defect on endoluminal 
3D views, with a pathognomonic aspect on 2D views: the 
diverticular fecalith almost invariably presents as a round 
structure with a hyperdense ring and a hypodense center cor-
responding to an air occlusion [22]. It can protrude from the 
diverticulum into the colonic lumen. Diverticular fecaliths 
can be the source of inflammation that leads to focal 
diverticulitis.
19.2.6.2  The Inverted Diverticulum
A diverticulum may invert into the colonic lumen. Although 
infrequent, radiologists need to be aware of this possibility. 
On endoluminal 3D views, the inverted diverticulum mimics 
a true polyp with, on 2D planar views, mostly an air or fat 
inclusion. Sometimes, a central umbilication can be 
distinguished.
19.2.6.3  Chronic Diverticular Disease  
or Stenosing Cancer
Patients with repetitive episodes of acute diverticulitis may 
develop chronic diverticular disease, a common reason for 
a b
Fig. 19.7 (a, b) Mucocele of the appendix. (a) The endoluminal 3D 
view of the partially fluid-filled cecum showing a broad-based polypoid 
intraluminal filling with a smooth surface (arrow). (b) The correspond-
ing axial 2D image shows a cystic structure, causing a subtle extrinsic 
impression on the colonic lumen (arrow). The lesion had a thin mural 
calcification (open arrowhead) and was contiguous with the appendix
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incomplete OC. CTC is the method of choice to complete the 
colonic evaluation. However, differential diagnosis between 
chronic diverticular disease and a stenosing cancer can be 
challenging. Each entity presents with imaging characteris-
tics which, unfortunately, are not entirely specific. 
Interference of signs is quite frequent. Features, characteris-
tic of chronic diverticular disease and malignant tumor, are 
presented in Table 19.1. Studies comparing both entities con-
cluded that it seems reasonable that the presence of divertic-
ula in the affected segment, together with wall thickening 
over a rather long segment, thickening of the local fascia 
(fascia sign) without lymphadenopathy, cone-shaped or 
tapered margins, and the preserved more or less thickened 
colonic folds, is likely indicative of chronic diverticular dis-
ease. Conversely, the absence of diverticula in the thickened 
segment and thickening of the local fascia, a more prominent 
wall thickening with a short extension, shoulder formation or 
overhanging edges, and a completely distorted or fold pat-
tern are more likely indicative of a stenosing colonic cancer 
[23, 24].
19.2.7  Postoperative Colon
According to the surgical technique used (end-to-end or 
side-to-end), the anastomosis will have a different morphol-
ogy. The anastomosis should show a smooth transition, 
with, occasionally, a subtle, smooth, circumferential ridge, 
or a web-like appearance. On 2D views, the surgical staples, 
if used, are easily identified. Sometimes, the staples pro-
trude into the colonic lumen, causing a tiny luminal filling 
defect on 3D views that can be easily identified on 2D views 
by its high internal density. Polypoid granulation tissue as 
well as inflammatory and hyperplastic polyps may develop 
at the anastomosis. These findings will present with the 
same imaging features as adenomatous polyps. In the post-
operative period, fibrosis may develop, causing a pseudotu-
moral narrowing at the anastomosis [25]. Therefore, any 
increase of soft tissue at the site of, or adjacent to, the anas-
tomosis should raise the suspicion for tumor recurrence, 
indicating OC.
19.3  Inflammatory Diseases of the Colon
In addition to benign polypoid and stenotic findings and their 
pitfalls, several other benign colonic conditions may be 
encountered with diagnostic imaging techniques. They 
include a wide range of inflammatory diseases, including 
diverticulitis, chronic inflammatory bowel diseases (CIBDs), 
infectious and noninfectious colitis, as well as mechanical 
colonic obstruction and perforation. In almost all of these 
acute conditions, CTC is contraindicated since the distension 
of the colon with gas may lead to colonic wall perforation. 
For these indications, standard cross-sectional imaging is the 
method of choice. Furthermore, some of these entities 
require histologic workup to achieve a correct diagnosis or 
identification of dysplasia.
Table 19.1 CT colonography imaging characteristics suggestive of chronic diverticular disease in the left column, and a stenosing colonic cancer 
in the right column
Findings suggesting chronic diverticular disease Findings suggesting a stenosing colonic cancer
1. Long segment ≥10 cm 1. Shorter segment
2. Milder wall thickening (<2 cm) 2. Wall thickening ++ (≥2 cm)
3. Cone-shaped aspect, tapered margins 3. Shoulder formation, overhanging edges
4. Preserved folds 4. Completely distorted fold pattern
5. Diverticula in the thickened segment 5. No diverticula in the thickened segment
6. Pericolic fat infiltration 6. Pericolic tumor infiltration
7. Thickened local facia 7. No thickened local facia
8. No pericolic lymphadenopathy 8. Pericolic lymphadenopathy
Note that these signs overlap each other, making an exact diagnosis difficult and sometimes impossible. However, the absence of diverticula within 
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In the large bowel, inflammation typically leads to bowel wall 
thickening, with or without mural stratification, which is the abil-
ity to distinguish the different layers of the colonic wall on cross-
sectional imaging [26, 27]. Various inflammatory bowel diseases 
differ in their primary location within the GI tract, length of seg-
mental involvement, degree of wall thickening, mural enhance-
ment pattern, and extraintestinal involvement.
19.3.1  Diverticulitis
Inflammation of diverticula leads to symptomatic diverticuli-
tis, which occurs, in two-thirds of cases, in the sigmoid colon. 
This can affect a single or a few adjacent diverticula, called 
focal diverticulitis, or the entire colonic segment. If a single 
diverticulum is inflamed, there is focal, edematous mural 
thickening, typically surrounding a stool-impacted diverticu-
lum, with increased mural enhancement and focal pericolonic 
fat stranding [28]. Imaging findings of acute colonic diverticu-
litis are cone-shaped inflammatory wall thickening, involving 
a long segment (>10 cm), and increased mural contrast 
enhancement, as well as submucosal edema. Acute inflamma-
tion is typically accompanied by pericolic fat stranding and 
fluid at the root of the mesentery (Fig. 19.8). The presence of 
diverticula is pathognomonic. Their absence makes diverticu-
litis unlikely [29]. Complications that may develop are perico-
lic abscess, contained or free perforation, hemorrhage, fistula 
formation, and post-inflammatory stenosis. The most impor-
tant differential diagnosis for diverticulitis is colon cancer. In 
contrast, extensive wall thickening with short extension 
(<5 cm), especially with shoulder formation and pericolonic 
lymph nodes, is suspicious for neoplasms [30].
19.3.2  Colonic Involvement in Chronic 
Inflammatory Bowel Disease
Within the group of CIBD, Crohn’s disease (CD) and ulcer-
ative colitis (UC) represent the most important conditions. 
OC with biopsy is the examination of choice to evaluate 
colonic involvement in CIBD, specifically for the detection 
of colonic dysplasia, and to differentiate between an inflam-
matory stenosis and cancer. Standard abdominal CT is indi-
cated for the detection of acute complications. CTC is not 
indicated and may be an option only in patients with incom-
plete OC in chronic inactive disease.
19.3.2.1  Ulcerative Colitis
Ulcerative colitis is an inflammatory bowel disease limited to 
the mucosa and submucosa of the colon. The disease typi-
cally begins in the rectum and continuously extends proxi-
mally to involve parts of the colon or the entire colon. In 
10–40% of cases, the distal ileum is also inflamed, which is 
referred to as backwash ileitis.
Early, subtle, and inflammatory mucosal changes, such as 
the granular pattern of the mucosa or tiny punctuate ulcers, 
may be beyond the current spatial resolution of modern 
cross-sectional imaging.
Progression of the disease leads to mucosal hyperemia 
and submucosal edema, which then result in thickening and 
stratification of the wall, accompanied by increased pericolic 
vascularity. Increased ulceration and pseudopolyps appear, 
and the mucosa becomes friable. Typically, the outer contour 
of the affected colonic wall is regular and smooth (Fig. 19.9). 
Lymph node enlargement is only slight. The appearance of 
abscess or fistula formation is uncommon.
Subacute and chronic forms lead to thickening and rigid-
ity of the wall. Narrowing of the colonic lumen and fore-
shortening of the colon may occur. The bowel loses its 
haustral pattern, which can result in a tubular “lead pipe” 
appearance. Post-inflammatory polyps may be present. The 
deposition of submucosal fat in the large bowel is found in 
up to 61% of cases and may result in additional wall thicken-
ing and, consequently, in luminal narrowing. As a result of 
inflammation, there may be proliferation of the pericolic/rec-
tal fat, resulting in widening of the presacral space.
The most severe complication is the toxic megacolon, 
which appears in up to 5% of cases and carries the risk of 
perforation and peritonitis. The risk development of colorec-
tal cancer increases with the extent and the duration of the 
disease [28, 29, 31].
Fig. 19.8 Acute diverticulitis. The contrast-enhanced axial CT image 
shows wall thickening of the sigmoid colon (arrow) with adjacent 
inflammatory stranding of the pericolic fat tissue. Note the fluid collec-
tion representing abscess formation (arrowhead)
T. Mang and P. Lefere
217
19.3.2.2  Crohn’s Disease
Crohn’s disease may involve segments of the whole GI tract. 
However, Crohn’s disease most often affects the terminal 
ileum and the proximal colon. Unlike ulcerative colitis, 
Crohn’s disease typically affects the GI tract in a discontinu-
ous way (so-called skip lesions), and the inflammatory pro-
cess is transmural in nature.
CT usually misses the early stages of Crohn’s disease. With 
progression of the disease, distinct mural thickening and lumi-
nal narrowing occur. In the acute stage of the disease, wall 
thickening presents with mural stratification mostly related to 
submucosal edema. The degree of contrast enhancement of the 
bowel wall correlates with the severity of the disease. Compared 
to ulcerative colitis, the outer contour of the colonic wall is 
irregular. As a result of the hyperemia from the inflammatory 
process, the local mesenteric vessels are dilated and widely 
spaced. This has been described as the “comb sign,” indicating 
disease activity (Fig. 19.10). A progressive increase in higher-
density pericolic fat is called fibrofatty proliferation, resulting 
in separation of the bowel loops. Usually, multiple mesenteric 
lymph nodes, measuring <10 mm in the short-axis diameter, 
are present. Extensive, intersecting linear transverse and longi-
tudinal ulcerations can result in the so-called cobblestone pat-
tern. With progression of the disease, the transmural 
inflammation is accompanied by irreversible fibrosis. On cross-
sectional imaging, this presents with a loss of mural stratifica-
tion, with mural thickening and homogeneous attenuation [28, 
29, 31].
Frequent complications are fistula, abscesses, adhesions, 
and stenosis, leading to bowel obstruction. Fistula can appear 
as ill-defined soft tissue bands extending either to another part 
of the gastrointestinal tract or to the skin. Abscesses are most 
frequently associated with the penetrating type of Crohn’s 
disease, affecting the small bowel with or without the colon. 
Stenosis in Crohn’s disease shows, in many cases, circular, 
cone-shaped wall thickening with increased contrast enhance-
ment and involvement of a longer segment. In other cases, 
short stenosis with wall thickening and abrupt shoulders at 
the proximal and distal end occur, which renders differentia-
tion from malignant stenosis impossible. Perforations are 
uncommon and usually contained. Conglomerate masses are 
present if there is involvement of multiple bowel segments or 
a large bowel segment with fistulization and abscess forma-
tion. There is a slightly increased risk of developing colorec-
tal cancer and lymphoma as a complication of the disease. 
These neoplasms mostly affect the small bowel. The presence 
of lymph node enlargement >10 mm in the short-axis diame-
ter should raise the suspicion of malignancy.
19.3.3  Infectious Colitis
Inflammation of the colon can be caused by bacterial, viral, 
fungal, or parasitic infection. The diagnosis of infectious 
Fig. 19.9 Ulcerative colitis. The contrast-enhanced axial CT image 
shows continuous wall thickening of the sigmoid colon with mural 
stratification (arrow). Note that the outer contour of the colon is regular 
and smooth
Fig. 19.10 Crohn’s disease. The contrast-enhanced coronal CT image 
shows mural thickening of the transverse colon with dilated mesenteric 
vessels (comb sign) and fistula formation to the ascending colon (arrow-
head). Note the inflammatory mural enhancement of small bowel loops
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colitis is readily achieved, based on the typical presentation 
of GI symptoms. Stool culture may be required to identify 
specific organisms. In general, most of these diseases are 
self-limiting, and dedicated imaging is not required for diag-
nosis. However, cross-sectional imaging may be required to 
assess the extent, the severity, and the potential complica-
tions of the disease.
Radiologic imaging features are not specific for a particular 
microorganism. Infectious colitis presents with diffuse colonic 
wall thickening, frequently with a so-called target appearance 
caused by mural stratification. This phenomenon is caused by 
mucosal CM enhancement and submucosal edema. Colonic 
air-fluid levels may be present. Extracolonic changes may 
include pericolonic fat stranding as well as ascites.
The affected colonic segment may suggest a specific 
organism. For instance, colonic infection with shigella or 
salmonella is limited to the right colon, while diffuse involve-
ment may be seen with CMV and E. coli. Gonorrhea, herpes 
virus, and C. trachomatis typically involve the rectosigmoid 
area (Fig. 19.11) [32, 33].
19.3.3.1  Pseudomembranous Colitis
Pseudomembranous colitis (PMC) is an acute infectious 
colitis that results from an unopposed bacterial overgrowth 
of Clostridium difficile, typically following broad-spectrum 
antibiotic therapy or chemotherapy. Bacterial enterotoxins 
lead to superficial ulceration and subsequent formation of 
pseudomembranes. Often, the whole colon is involved; how-
ever, both the rectosigmoid colon and the right colon may be 
affected in isolation.
Typical imaging findings include marked circumferential 
diffuse colonic wall thickening, caused by distinct mucosal 
and submucosal edema. The edema leads to a typical low 
attenuation aspect of the colonic wall. Wall thickening is 
more pronounced than in other types of colitis. After IV CM 
administration, mucosal and serosal enhancement reveals a 
target enhancement pattern, consisting of three concentric 
rings of different attenuation. Edematous thickening of the 
haustral outpouchings, as well as semilunar folds, leads to 
the appearance of an accordion on longitudinal cross- 
sectional (accordion sign). Pericolonic changes include fat 
stranding and, often, ascites (Fig. 19.12). Potential complica-
tions include toxic megacolon and colonic perforation [34].
19.3.4  Noninfectious Colitis
This summarizes a colonic inflammatory involvement related 
to either a heterogeneous range of disorders or secondary to 
medical treatment.
19.3.4.1  Ischemic Colitis
Ischemic colitis is a disease of elderly patients with atheroscle-
rotic disease, hypotension, or heart failure. Vascular insuffi-
ciency and ischemia can lead to a secondary inflammation of 
the colon. Low-flow states and nonocclusive vessel disease are 
a b
Fig. 19.11 (a, b) Rectal syphilis mimicking rectal cancer. (a) The 
contrast-enhanced axial CT image shows a large circumferential mass- 
like rectal structure of with soft tissue density suggestive for a rectal 
carcinoma (arrow). (b) Axial T2-weighted image of the rectum reveals 
a mural stratification caused by hyperintense, oedematous thickening of 
the submucosal layer, indicating an inflammatory process
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most common and typically lead to ischemic colitis in water-
shed areas at the splenic flexure and the rectosigmoid junction. 
The left colon is more frequently affected than the right colon. 
Imaging findings are nonspecific and may include mural 
thickening associated with submucosal edema. A target sign 
may be present. Following the acute event, fibrosis may lead to 
chronic strictures of the colonic lumen (Fig. 19.13) [29].
19.3.4.2  Neutropenic Colitis
Neutropenic colitis, also referred to as typhlitis, is a necrotiz-
ing inflammation of the cecum, ascending colon, and 
 sometimes the terminal ileum seen in immunocompromised 
patients with severe neutropenia. It is caused by the transmu-
ral invasion of various microorganisms, including bacteria, 
virus, or fungi, without an inflammatory reaction. Imaging 
findings include a marked circumferential mural thickening 
of the right colon, typically the cecum, with distinct submu-
cosal edema. Pneumatosis indicates the severity of the dis-
ease. Pericolonic fat stranding is a common finding. 
Complications include wall necrosis and perforation [29].
19.3.4.3  Graft-Versus-Host Disease
In graft-versus-host disease (GvHD), after allogenic bone 
marrow transplantation, donor lymphocytes attack the host 
tissues. GvHD is more frequently present in the small bowel 
but may also affect the colon. Imaging findings are nonspe-
cific and include mural thickening associated with submuco-
sal edema, which also affects mucosal enhancement (target 
sign). Typically, longer bowel segments are affected. 
Engorged mesenteric vascularization, fat stranding, and asci-
tes may be present. In chronic stages, submucosal edema is 
replaced by fat tissue [35]. Clinical history leads to the spe-
cific diagnosis.
19.3.4.4  Drug-Induced Colitis
Drug-induced injury to the colon most frequently presents as 
colitis [36]. Cancer treatment with chemotherapeutics may 
lead neutropenic enterocolitis, pseudomembranous colitis, 
or pneumatosis intestinalis [37, 38]. With the introduction of 
new anticancer drugs, such as checkpoint inhibitors, a new 
range of potential side effects from these therapies has been 
encountered. Checkpoint inhibitor-induced (e.g., 
ipilimumab- associated) colitis may occur in melanoma 
patients under immunotherapy (Fig. 19.14). On cross- 
sectional imaging, it may present as mild, diffuse, bowel- 
wall thickening, with fluid-filled colonic distention, and 
mesenteric vessel engorgement. It can also present as seg-
mental colitis in the sigmoid colon in an area of pre-existing 
diffuse diverticulosis [39].
Long-term abuse of nonsteroidal anti-inflammatory drugs 
(NSAIDs) can induce colitis [40]. NSAID-induced colitis 
typically affects the right colon, with diffuse or segmental 
inflammation and ulcerations, as well as diaphragm-like 
fibrotic strictures. CT imaging findings are nonspecific, and 
wall thickening may simulate malignancy. Diaphragm-like 
strictures in the right colon on CTC may raise the suspicion 
for an inflammatory cause. A clinical history of NSAID 
abuse and an ischemic appearance at pathohistology leads to 
the diagnosis.
Fig. 19.12 Pseudomembranous colitis. The contrast-enhanced axial 
CT image shows marked mural thickening with intense enhancement of 
the mucosa and distinct submucosal edema of the entire colon (target 
sign) (arrow). Note the ascites
Fig. 19.13 Ischemic colitis. The contrast-enhanced axial CT image 
shows mural thickening of the descending (arrow) and sigmoid colon 
(arrowhead)
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19.3.4.5  Radiation Colitis
Since radiation therapy is often given for pelvic disease, the 
sigmoid colon and rectum are most commonly affected. 
Acute radiation injury, within 8 weeks after treatment, is 
typically self-limited and treated symptomatically. It is 
diagnosed clinically and does not require imaging. Imaging 
findings include nonspecific wall thickening and inflamma-
tory stranding in the affected segments. In chronic radiation 
injury, 6–12 months after treatment, which results from 
radiation-induced endarteritis, smooth wall thickening and 
fibrosis may narrow the colonic lumen. Strictures and fistu-
las are possible complications. Increased pelvic fat may be 
present [29, 37].
19.3.5  Epiploic Appendagitis
Epiploic appendagitis is an uncommon inflammatory/isch-
emic process that results from torsion with infarction or 
spontaneous venous thrombosis of the appendices epiploi-
cae. Patients may present clinically with sudden, focal 
abdominal pain, indistinguishable from diverticulitis or 
appendicitis. CT is diagnostic, typically showing an ovoid 
1.5–3.5 cm fat-containing pericolic lesion with stranding of 
the surrounding fat tissue (Fig. 19.15). A central hyperdense 
“dot” can be identified within the lesion that corresponds to 
the thrombosed vein. Chronically, an infarcted epiploic 
appendix may calcify. Epiploic appendagitis is a self- limiting 
condition and does not require invasive intervention [41].
Fig. 19.14 Severe ipilimumab-associated colitis in a patient with met-
astatic melanoma. The contrast-enhanced coronal CT image shows 
marked thickening of the left colon with pericolic fat stranding and 
mesenteric vessel engorgement (arrow). Note the liver metastasis
Fig. 19.15 Epiploic appendagitis. The contrast-enhanced coronal CT 
image shows a round fat containing pericolic lesion with stranding of 
the surrounding fat tissue (arrow). A central hyperdense “dot” within 
the lesion corresponds to the thrombosed vein
Take Home Messages
• Cross-sectional imaging techniques have become 
the most important radiologic tool for the evalua-
tion of diseases of the colon and rectum.
• CTC is a reliable technique for the detection and 
classification of polypoid and stenotic lesions of the 
colon.
• At CTC, the most important imaging features to 
characterize a finding are morphology, internal struc-
ture and attenuation characteristics, and mobility. 
Inflammatory conditions of the colon represent a het-
erogeneous spectrum of diseases, showing, however, 
a considerable overlap of their imaging criteria.
• Radiologic differentiating features at standard 
cross-sectional imaging include the primary loca-
tion within the GI tract, length of segmental involve-
ment, degree of wall thickening, mural enhancement 
pattern, pericolonic and extraintestinal findings.
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Urinary Obstruction, Stone Disease, 
and Infection
Refky Nicola and Christine O. Menias
20.1  Urinary Infection
20.1.1  Introduction
Urinary tract infection is the most common urologic ailment, 
reported to affect 150 million patients annually worldwide. 
The diagnosis is usually based on clinical symptoms and uri-
nalysis. In general, imaging is not necessary for the diagno-
sis of uncomplicated urinary tract infections in adult patients. 
However, diagnostic imaging can play an important role in 
the evaluation of patient’s infections who do not respond to 
antibiotic treatment in the first 72 h. It also helps to look for 
structural abnormalities of the urinary tract, which guide 
appropriate medical or surgical therapy. Various imaging 
modalities, including ultrasound (US), computed tomogra-
phy (CT), and magnetic resonance imaging (MRI), are use-
ful in the diagnosis and depiction of urinary tract infections. 
This section highlights the imaging features of acute pyelo-
nephritis, renal and perinephric abscess, pyonephrosis, 
emphysematous pyelonephritis, xanthogranulomatous 
pyelonephritis, and renal tuberculosis, using multimodality 
approach.
20.1.2  Ultrasound
Ultrasound (US) is a readily available imaging modality to 
serve as the initial modality in the evaluation of patients 
who have the clinical diagnosis of pyelonephritis. US 
serves as a good screening modality to evaluate for struc-
tural anatomic anomalies or complications of urinary tract 
infection, such as hydronephrosis and obstructive uropathy. 
Gray-scale imaging features of pyelonephritis include renal 
enlargement, hydronephrosis, loss of renal sinus fat due to 
edema, loss of corticomedullary differentiation, areas of 
hypoperfusion on color Doppler, and abscess formation [1]. 
There may be changes in the renal echogenic pattern and 
the involved kidney which can be either hyperechoic or 
hypoechoic. The urinary bladder may also be evaluated in 
this setting and can show amount of residual urine volume, 
presence of bladder wall thickening, or potentially a stone. 
However, ultrasound is limited in its ability to differentiate 
calcification from gas within the collecting system or 
parenchyma, visualization of small abscesses, and peri-
nephric extension of infection which are all common in 
early infections. In one study, ultrasound findings were 
noted in only 24% of patients, while other studies report 
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• To review the pathogenesis of urinary infection, 
obstruction, and stones
• To discuss the imaging features of acute urologic 
infections such as renal abscess, acute pyelonephri-
tis, and emphysematous pyelonephritis or chronic 
infections such as renal tuberculosis
• To illustrate the imaging of struvite or infection 
stones as well as highlight their complications
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only 20% of patients [2, 3]. However, new techniques such 
as tissue harmonics have showed sensitivity and specificity 
of 97% and 80% [3].
20.1.3  CT Technique
CT is the preferred imaging modality for the evaluation of 
complicated pyelonephritis because it provides both physi-
ologic and anatomic detail and identifies both extrarenal 
and intrarenal pathology [4]. An unenhanced CT is excel-
lent for identifying gas in the urinary tract, stones, hemor-
rhage, and dilatation of the urinary tract [5]. Regions of 
higher attenuation on non-contrast CT are associated with 
hemorrhage, while areas of lower attenuation represent 
edema. Following intravenous contrast administration, 
pyelonephritis manifests as “wedge shaped” or linear 
regions of decreased enhancement that spans from the renal 
sinus to the renal cortex. The excretory phase, obtained 
between 3 and 5 min after the administration of contrast, 
should be performed in suspected urinary obstruction [2]. 
CT also can evaluate for additional features of renal inflam-
mation and its complications, including inflammation of 
the perinephric fat, thickening of Gerota’s fascia, and 
abscess formation.
20.1.4  Acute Renal Infection
20.1.4.1  Acute Pyelonephritis
CT is indicated when complications of renal infection are 
suspected. Predisposing conditions, including urinary cal-
culi, neurogenic bladder, immune system compromise, dia-
betes, IV drug abuse, or chronic debilitating disease, 
increase the risk of complications that require intervention. 
Most urinary tract infections are caused by gram-negative 
bacilli, but the incidence of fungal and tuberculous infec-
tions is rising. Acute pyelonephritis is a multifocal infection 
of one or both kidneys, which can result from either hema-
togenous spread or from ascending infection from the blad-
der and usually resolves after appropriate antibiotic therapy. 
Adults who fail to improve should be imaged to detect 
complications.
CT signs of acute bacterial infection of the kidneys 
include wedge-shaped areas of decreased parenchymal 
enhancement due to decreased blood flow caused by 
edema. A striated pattern of linear alternating increased 
and decreased attenuation (“striated nephrogram”) on 
enhanced scans is classic [6]. This differential enhance-
ment is contributed by various factors, namely, tubular 
obstruction by inflammatory debris, interstitial edema, and 
vasospasm which tend to decrease the flow of contrast 
through tubules [7, 8].
20.1.5  Acute Renal/Perirenal Abscess
Untreated or inadequately treated pyelonephritis can lead to 
suppuration, liquefaction, and parenchymal necrosis that 
eventually leads to abscess. Patients at risk of abscess forma-
tion include those with diabetes, chronic diseases, immuno-
compromised state, urinary tract obstruction, and intravenous 
drug abusers. Renal abscesses tend to be solitary and may 
decompress into the perinephric space or collecting system. 
On US, they usually are hypoechoic with through transmis-
sion, mobile debris, and occasional air pockets and on color 
Doppler lack internal flow. US is less sensitive in determining 
the presence and extent of perinephric extension relative to 
CT; however, it is an appropriate modality for follow-up imag-
ing to look for response to treatment and as a guide for percu-
taneous drainage. CT demonstrates a fluid collection with an 
enhancing rim which may contain gas. Large abscesses usu-
ally require catheter or surgical drainage (Fig. 20.1). Extension 
of infection into the perirenal space is common, and perirenal 
abscesses may develop. Extra- parenchymal collections can 
extend to the psoas muscle, pelvis, or groin [4, 6].
20.1.6  Emphysematous Pyelonephritis
Emphysematous pyelonephritis is a severe life-threatening 
necrotizing type of pyelonephritis that develops in mostly 
diabetics (90%), but also in immunocompromised patients, 
Fig. 20.1 Renal Abscess in a 37-year-old female with HIV and fever. 
Axial contrast-enhanced CT image of the left kidney shows a complex 
peripherally enhancing fluid collection and associated perinephric 
stranding. Subsequent drained fluid grew Staphylococcus aureus
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and patients with urinary obstruction. Gas is produced from 
metabolism of glucose by gram-negative bacteria. CT shows 
gas in the renal parenchyma in addition to signs of renal 
inflammation. The most common gas-forming organisms are 
E. coli, Klebsiella pneumoniae, and Proteus mirabilis which 
are also the same organisms associated with struvite stones. 
US shows an enlarged kidney with nondependent echoes 
(gas) in the parenchyma or collecting system, with “dirty 
shadowing” that helps differentiate from stones. US is 
 limited in evaluating the extent of the disease. CT is the 
imaging modality of choice for emphysematous pyelone-
phritis with findings of parenchymal enlargement and 
destruction without or with abscess formation, small streaks 
of gas, or fluid collections [4, 9, 10].
Emphysematous pyelonephritis is classified into two 
types based on imaging features and prognosis.
Type 1 emphysematous pyelonephritis is renal parenchy-
mal destruction with streaky or mottled areas of gas without 
an extrarenal fluid collection. Type 2 is renal or perirenal 
fluid collections that are directly associated with a loculated 
gas or gas within the collecting system. The mortality for 
type 1 and type 2 is 69% and 18%, respectively.
20.1.7  Pyonephrosis
Pyonephrosis is an acute infection with pus within an 
obstructed collecting system. Renal destruction is rapid, and 
urgent drainage of the collecting system is required. The 
obstruction can be due to tumor, stricture, sloughed papilla, 
tumor, or stones. If patients are left untreated, patients may 
develop loss of renal function and septic shock [11, 12]. US 
features include dilatation of the pelvicalyceal system, inter-
nal collecting system fluid-fluid levels, echogenic debris, and 
occasionally dirty echoes of gas. CT features may show a 
dilated but thick-walled collecting system, distended with 
high attenuation pus-filled fluid, and thinning of the renal 
cortex, and typically source of obstruction.
20.1.8  Renal Tuberculosis
Tuberculosis (TB) remains the leading global cause of death 
from infectious disease [4]. The urinary tract is the most 
common extra-pulmonary site of infection and results from 
hematogenous dissemination in 15–20% of cases [4]. The 
rise of tuberculosis within developed countries is caused by 
the spread of HIV (human immunodeficiency viral) infection 
and antibiotic-resistant strains of mycobacterium. The uri-
nary tract may be involved even though chest radiographs do 
not show evidence of TB. Multiple caseous granulomas form 
in the cortex because of its favorable blood supply. These 
may remain dormant or reactivate, spreading organisms to 
the tubules, resulting in papillary necrosis. Progressive infec-
tion will eventually destroy the kidney. The common imag-
ing findings of renal tuberculosis are due to papillary necrosis 
which is followed by parenchymal destruction. Parenchymal 
lesions lead to corticomedullary scarring and renal contour 
scarring. Pelvoinfundibular stricture, cortical low- attenuation 
lesions, scarring, and papillary necrosis and calcifications 
are findings which are all associated with renal tuberculosis 
[13, 14]. Calcification is very commonly seen and varies 
from granular, amorphous, and curvilinear which can replace 
segments or the entire renal parenchyma resulting in the end 
stage “putty kidney” [14].
20.2  Urinary Stones and Obstruction
20.2.1  Introduction
The most common cause of urinary obstruction in the emer-
gent setting is urolithiasis, but chronic urinary obstruction 
has multiple etiologies such as lymphadenopathy or retro-
peritoneal fibrosis. Also, the patients with a history of uro-
thelial, cervical, prostate, or colon carcinoma are also 
susceptible to chronic urinary obstruction due to neoplastic 
obstruction [15]. Therefore, the role of the radiologist is piv-
otal in differentiating between acute and chronic urinary 
obstruction because an accurate diagnosis is essential in 
avoiding serious complications such as sepsis or chronic 
renal insufficiency.
20.2.2  Epidemiology
Urolithiasis has become a problem which transcends geogra-
phy, culture, and gender. Approximately, 1.2 million 
Americans are affected each year. About 12% of men and 
5% of women will develop urolithiasis during their lifetime. 
However, the prevalence is estimated to be higher in more 
developed countries [16–20]. Stone disease is also one of 
America’s costliest health issues, accounting for approxi-
mately $2 billion annual health-care dollars [21].
20.2.3  Stone Composition
There are several dietary, hereditary, and environmental fac-
tors which play an integral role in stone disease, such as hyper-
calciuria, renal tubular acidosis, and chronic diarrhea and gout 
[20]. The composition of most upper urinary tract stones is 
either calcium (i.e., calcium oxalate dehydrate, calcium oxa-
late monohydrate, calcium phosphate), struvite, or uric acid 
with calcium being the most common. Less common compo-
sitions include protein matrix, cystine, brushite, or stones due 
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to drug-related therapies such as indinavir. Even though most 
stones are visible on CT, the struvite stones and uric acid 
stones are radiolucent on radiography [22]. Due to the differ-
ence in composition of renal stones, there is a wide variation 
in the attenuation on multidetector CT. For example, calcium 
monohydrate and brushite measure 1700–2800 HU, calcium 
phosphate 1200–1600 HU, cystine 600–1100 HU, struvite 
600–900 HU, and uric acid 200–450 HU [23–25].
The importance of identifying the stone composition is 
directly related to management. Uric acid stones are man-
aged with medical therapy. Cystine- and calcium-based 
stones cannot be easily fragmented with shock wave litho-
tripsy (SWL) [22].
20.2.4  Clinical Perspective
The most common complaint in patients with urolithiasis is 
acute flank pain which is eventually relieved with the pas-
sage of the stone. If the stone is lodged at the ureteropelvic 
junction (UPJ), the pain will radiate to the groin. However, if 
the stone is located distally at the ureterovesical junction 
(UVJ), it will cause suprapubic discomfort and voiding 
urgency. Pain typically radiates to the testis or labium [26]. 
In addition, patients will complain of vomiting, nausea, and 
microscopic hematuria. However, staghorn calculus which is 
caused by urease-producing bacteria such Proteus mirabilis, 
Pseudomonas aeruginosa, Klebsiella pneumoniae, and E. 
coli can manifest as a recurrent urinary tract infection instead 
of an obstruction [20]. If there is an infection and an 
obstructed collecting system, patients can present with sepsis 
[27]. Microscopic or macroscopic hematuria can occur 
regardless of urinary obstruction. Usually, a urinalysis and 
complete blood count is done to evaluate for infection.
20.2.5  CT Technique
Since 1995 unenhanced MDCT is the primary modality of 
choice in the evaluation of patients with renal colic and 
accounts for 20% of all CT examinations which are per-
formed for acute abdominal pain. Thin (1–3 mm) reconstruc-
tion sections are helpful for detection of small stones. 
However, 5 mm MDCT with 3 mm coronal reformatted 
images has been found to improve stone detection while 
maintaining radiation dose benefits [28]. A tube potential of 
100–120 kvp and automatic tube current modulation is per-
formed  with a tube current of 80 to 500 mAs. Typically, 
intravenous contrast administration is not required for the 
evaluation of renal calculi at CT.
Unlike MDCT which uses a single energy source, dual- 
energy CT (DECT) allows for acquisition of CT images at 
two different energies. With MDCT, stone composition is 
difficult to assess since there is significant overlap in attenu-
ation for each of the stone subtypes. By comparing the atten-
uation of a stone at two different energy levels, the mystery 
of the stone’s composition is somewhat mitigated. For exam-
ple, this becomes particularly useful in differentiating uric 
acid from calcium-based stones, since both have similar 
attenuation coefficient on single-energy CT [26].
20.2.6  Struvite Stone and their Complications
Struvite stones, which are also known as infection stones, are 
composed of magnesium ammonium phosphate and com-
prise 15–20% of all renal calculi. Struvite stones develop 
more frequently in a patient with urinary stasis or recurrent 
urinary tract infections. Struvite stones with superimposed 
pyelonephritis are caused by bacteria entering the renal 
tubules and inciting an inflammatory response which 
involves the tubules and renal interstitium [7]. CT is useful in 
assessing intra- and extrarenal inflammation such as gas, cal-
culus, and hemorrhage [4]. CT shows the inciting staghorn 
calculus with superimposed pyelonephritis with wedge- 
shaped areas of decreased enhancement corresponding to the 
striated nephrogram and perinephric stranding [7, 8]. 
Another complication is pyonephrosis, which is a dilated, 
obstructed, and infected collecting system. Struvite calculi 
can obstruct the pelvicalyceal system with superimposed 
infection and can lead to significant morbidity if not ade-
quately treated.
20.2.7  Xanthogranulomatous Pyelonephritis
Xanthogranulomatous pyelonephritis is a rare form of 
chronic pyelonephritis which develops from chronic 
obstruction due to struvite/infected renal stones resulting in 
a chronic granulomatous inflammatory response and even-
tual destruction and replacement of the renal parenchyma, 
by lipid-laden macrophages. The most common inciting 
organisms are E. coli and Proteus mirabilis which are 
organisms associated with struvite/infection stones. XGPN 
classically presents in mid-aged female patients with recur-
rent urinary tract infection, diabetes, or obstructing urinary 
stones [2, 5]. XGPN may involve the entire kidney (diffuse) 
or related to an obstructed upper or lower pole (focal), 
which at times is difficult to differentiate from tumor or 
abscess.
20.2.8  Imaging of XGPN
US features of XGPN are nonspecific and include focal or 
diffuse enlargement of the kidney with renal cortical thin-
ning, and echogenicity within the calyces, and typically a 
large UPJ stone with posterior acoustic shadowing due to 
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the stone, obscuring detail of the kidney. Contrast-enhanced 
CT is the modality of choice in the evaluation of XGPN; 
however, MR serves as a useful alternative when IV contrast 
cannot be administered. CT may show an enlarged kidney 
replaced with low-attenuation dilated/blown-out calyces 
resulting in renal cortical thinning, resulting in the classic 
“bear paw sign” [4]. These blown-out calyces are thought to 
represent dilated calyces filled with hemorrhage, debris, or 
pus (Fig. 20.2). XGPN results in a non-functioning enlarged 
kidney, with typically a large central staghorn/infected stru-
vite stone that fails to excrete on the excretory phase [4] 
(Fig. 20.3). Extrarenal extension of XGPN is often present 
with inflammatory changes and abscess that track from the 
kidney and dissect through the posterior flank, psoas mus-
cle, and adjacent viscera like the liver and spleen.
20.2.9  Renal Replacement Lipomatosis
Another end-spectrum complication of long-standing stone 
disease is complete destruction and atrophy of the renal 
sinus, perinephric space, and hilum with subsequent fatty 
replacement, known as renal sinus or replacement lipomato-
sis (RRL) [29]. In the most extensive form of RRL, there is 
total atrophy of the renal parenchyma and complete fibro-
fatty replacement. RRL is typically unilateral and linked to 
renal stones in 76–79% and results from severe renal atrophy 
or destruction due to chronic stone disease, chronic pyelone-
phritis, and renal tuberculosis [29]. US findings may demon-
strate a large hyperechoic fatty mass which may suggest the 
diagnosis; however, parenchymal and renal sinus fat deposi-
tion may not be well visualized on ultrasound, and the echo-
genicity of fat may obscure detection of its associated stone. 
CT is the modality of choice, to confirm the end stage renal 
atrophy and fatty proliferation in the renal sinus and peri-
nephric space, and helps differentiate RRL from fat- 
containing neoplasms.
20.3  Concluding Remarks
Ultrasound and CT play an important role in the evaluation of 
patients who present with acute urinary tract infection, obstruc-
tion, and stone disease. Familiarity with the pathogenesis, 
imaging features, and treatment of these entities can aid radio-
logic diagnoses and guide appropriate patient management.
Fig. 20.2 XGPN in a 56-year-old female with flank pain and urinary 
tract infection. Axial contrast-enhanced CT image shows an enlarged 
non-functioning left kidney with blown-out calyces and “bear paw” 
appearance, with a large central staghorn struvite/infection stone. 
Subsequent nephrectomy specimen confirmed XGPN
Fig. 20.3 Staghorn calculus in a 68-year-old female with flank pain. 
Coronal non-contrast CT image in bone windows shows a large stone 
filling in the right renal pelvocalyceal system with a staghorn appear-
ance consistent with an infection stone. Stone analysis subsequently 
showed struvite/magnesium ammonium phosphate. Note the subtle 
perinephric inflammatory stranding
Take-Home Message
• Ultrasound and CT play an important role in the 
evaluation of patients who present with acute uri-
nary tract infection, obstruction, and stone disease. 
Familiarity with the pathogenesis, imaging features, 
and treatment of these entities can aid radiologic 
diagnoses and guide appropriate patient 
management.
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Diffuse Liver Disease: Cirrhosis, Focal 
Lesions in Cirrhosis, and Vascular  
Liver Disease
Khoschy Schawkat and Caecilia S. Reiner
21.1  Cirrhosis
21.1.1  Imaging of Pre-stages of Cirrhosis
With the growing epidemics of diabetes, obesity, and meta-
bolic syndrome, the prevalence of nonalcoholic fatty liver 
disease (NAFLD) is rising worldwide. NAFLD has become 
one of the most common causes of chronic liver disease. It is 
commonly classified into two phenotypes, nonalcoholic fatty 
liver (NAFL) and nonalcoholic steatohepatitis (NASH). The 
need for noninvasive screening and monitoring protocols 
with imaging as an alternative to liver biopsy to define thera-
peutic targets and treatment end points in NASH is emerging 
with growing burden of NAFLD. Significant advances in 
magnetic resonance imaging (MRI) allow quantification of 
hepatic steatosis by measuring the proton-density fat fraction 
(PDFF) of MRI-visible protons bound to fat divided by all 
protons in the liver (bound to fat and water) with chemical 
shift imaging. The technique acquires multiple images at 
echo times optimally spaced for fat and water separation and 
T2* signal decay correction. Several studies proved that 
MRI-PDFF is a robust, quantitative, accurate, and reproduc-
ible noninvasive biomarker for the assessment of NAFLD 
[1–4].
The next step in the cascade of diffuse liver disease is the 
development of liver fibrosis commonly on the basis of ste-
atohepatitis or hepatitis B or C. Quantification of hepatic 
fibrosis is either possible with ultrasound (US)-based or MR 
elastography (MRE). MRE can be accomplished with most 
MR scanners by adding hardware to generate mechanical 
waves. Increased rigidity caused by collagen deposition can 
be visualized by modified phase-contrast pulse sequences. 
The stiffness generated from the wave propagation informa-
tion can be depicted on cross-sectional elastogram images. 
Several studies have demonstrated a high diagnostic accu-
racy of MRE (AUC 0.90–0.98, 95% CI 0.84–0.94) for iden-
tifying clinically significant fibrosis (stage 2 or higher) 
(Fig. 21.1) with advantages of MRE over US-based elastog-
raphy [5–9].
21.1.2  Imaging of Cirrhosis
Cirrhosis as a common endpoint of chronic liver disease is 
characterized by progressive fibrosis of the liver parenchyma 
with ongoing regeneration. Cirrhosis is most commonly the 
result of hepatitis B and C or chronic alcoholism; other 
causes are metabolic, biliary, and cryptogenic diseases. At an 
early stage of cirrhosis, the liver may appear normal. With 
disease progression, heterogeneity and surface nodularity 
are observed. Because of the unique ability of the liver to 
regenerate in cirrhosis, the liver harbors a spectrum of hepa-
tocellular nodules, most of which are regenerative. Due to 
Learning Objectives
• To know MR techniques useful to quantify liver ste-
atosis and fibrosis
• To recognize the characteristic and atypical 
contrast- enhancement pattern of hepatocellular 
carcinoma
• To discuss the MR imaging appearance of focal 
lesions in the cirrhotic liver and the use of the stan-
dardized reporting system LI-RADS
• To learn about HCC mimics and diffuse vascular 
liver disease causing liver parenchyma alteration
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the ongoing distortion of the liver parenchyma, the liver sur-
face appears smooth, nodular, or lobular in most of the cases. 
Caudate lobe hypertrophy is the most characteristic morpho-
logic feature of liver cirrhosis [10]. Alteration of blood flow 
results in typical morphologic abnormalities such as seg-
mental hypertrophy involving the lateral segments of the left 
lobe (segment 2, 3) and segmental atrophy affecting the right 
lobe (segment 6, 7) and medial segment of the left lobe (seg-
ment 4). Other typical findings include enlargement of hilar 
periportal space, the right posterior notch sign, and general-
ized widening of the interlobar fissures. Less typical distri-
bution of segmental atrophy and hypertrophy is seen in 
primary sclerosing cholangitis, where the distribution fol-
lows in part the distribution of the bile duct involvement, 
and, for example, atrophy of segments 2 and 3 or 5 and 7 
may be seen. In 25% of cirrhosis, the liver shape and contour 
appears normal on CT or MRI.
Lymph adenopathy can appear in the liver hilum and peri-
pancreatic region, which may mimic neoplastic lymph 
nodes, if the lymph nodes are large. Portal hypertension due 
to increased vascular resistance at the level of the hepatic 
sinusoids causes complications such as ascites and develop-
ment of portosystemic shunts at the lower end of the esopha-
gus and at the gastric fundus, via periumbilical veins and left 
gastric vein. Other shunts include splenorenal collaterals, 
hemorrhoidal veins, and abdominal wall and retroperitoneal 
collaterals [10]. These collateral veins are seen as enhancing 
tortuous vessels. The typical nodular liver contour and liver 
shape of cirrhosis as well as its vascular complications can 
be seen on ultrasound, CT, or MRI. MRI very well depicts 
fibrotic bands between regenerative nodules as T2 hyperin-
tense and progressively or delayed enhancing structures.
21.2  Focal Lesions in Cirrhotic Liver
21.2.1  Regenerative Nodules
Regenerative nodules are present in a cirrhotic hepatic envi-
ronment surrounded by fibrous septa and result from con-
tinuous injury to the liver parenchyma resulting usually in 
cirrhosis. They play a role in the stepwise carcinogenesis of 
HCC, most frequently through dedifferentiation, which 
occurs in the following order: regenerative nodule, low- 
a b c
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Fig. 21.1 Imaging pre-stages of cirrhosis. 53-year-old male patient 
with chronic hepatitis C, genotype C. Histology proved moderate 
inflammatory activity (METAVIR A2) and portal fibrosis (METAVIR 
F3, Ishak 4). (a) Axial T1-weighted post-contrast magnetic resonance 
(MR) image in the portal venous phase does not show features of liver 
cirrhosis. No signal drop of the liver parenchyma is observed from the 
in-phase (b) to the out-of-phase gradient-dual-echo sequence (c). 
(d) Axial proton-density fat fraction map from a gradient multi-echo 
sequence with automated liver segmentation showed normal liver fat 
content (mean ± SD: 5.0 ± 0.8%). (e) Diffusion-weighted axial image 
with a b-value of 800 s/mm2 shows increased signal of the liver paren-
chyma. (f) Stiffness map from MR elastography demonstrated increased 
stiffness of 4.9 ± 0.6 kPa corresponding to advanced fibrosis
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grade dysplastic nodule, high-grade dysplastic nodule, and 
HCC. Most regenerative nodules do not progress in the 
dedifferentiation process. They are macronodular (≥9 mm) 
or micronodular (3–9 mm). MR imaging demonstrates 
regenerative nodules with greater sensitivity than other 
imaging modalities; these nodules are visualized in only 
25% of unenhanced CT scans and approximately in 50% of 
MR images [11]. Regenerative nodules are usually iso- to 
hypointense on T2-weighted images. Variable signal inten-
sity on T1-weighted images is due to lipid, protein, or copper 
content leading to a T1-weighted hyperintense appearance or 
iron deposition in the so-called siderotic nodules leading to a 
hypointense appearance on T1-weighted images. The most 
usual appearance on T1-weighted images is isointense. 
Using extracellular gadolinium-containing contrast agent, 
regenerative nodules appear hypointense in the arterial and 
portal venous phase and isointense during equilibrium and 
delayed phases. After administration of hepatobiliary- 
specific contrast material, regenerative nodules enhance to 
the same degree as adjacent liver because they have normal 
hepatocellular and phagocytic functions [12].
21.2.2  Dysplastic Nodules
Dysplastic nodules are regenerative nodules that contain 
atypical hepatocytes, measuring at least 1 mm, not meeting 
histologic criteria for malignancy. They are classified as low- 
or high-grade dysplastic nodules. High-grade dysplastic 
nodules are considered premalignant and are characterized 
by moderate cytologic and architectural atypia to a degree 
insufficient to render a diagnosis of HCC. The differentiation 
between a regenerative nodule and a low-grade dysplastic 
nodule is difficult due to similar appearance on MRI with 
iso- to hypointense appearance on T2-weighted images and 
iso- or hyperintense appearance on T1-weighted images. 
Dysplastic nodules are rarely detected on CT. Dysplastic 
nodules usually are hypovascular and do not show hyperen-
hancement with extracellular contrast agents. In high-grade 
dysplastic nodules, arterial vascularization can increase lead-
ing to arterial hyperenhancement on imaging. Using 
hepatocyte- specific MR contrast agents, dysplastic nodules 
show variable signal intensity in the hepatocyte-specific 
phase. With progressing dedifferentiation, the nodules lose 
their ability to take up the hepatocyte-specific contrast agent 
(Gd-EOB-DTPA) and appear hypointense in the hepatobili-
ary phase. These hepatobiliary hypointense dysplastic nod-
ules may be mistaken for HCC. Dysplastic nodules may also 
instead lose the ability to excrete the hepatocyte-specific 
contrast agent and appear iso- or hyperintense on hepatobili-
ary phase images. Hypovascular cirrhotic nodules with 
hypointense appearance in the hepatobiliary phase carry a 
significant risk of transforming into hypervascular HCC with 
a pooled overall rate of 28% (95% CI, 22.7–33.6%). The size 
of the hypovascular nodule is a second risk factor for hyper-
vascular transformation with nodules ≥9 mm in size show-
ing a higher risk [13].
The earliest definitive sign of dysplastic nodule dediffer-
entiation is the “nodule within a nodule” appearance which 
is a dysplastic nodule harboring a focus of HCC, occurring in 
approximately 6% of patients with dysplastic nodules. 
However, it is believed that the majority of dysplastic nod-
ules do not progresses to an HCC.
21.2.3  Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common 
cancer worldwide, and its incidence is rising occurring most 
frequently in patients with cirrhosis or chronic viral hepati-
tis. HCC occurs as a solitary lesion (in half of the cases) and 
as multiple lesions or diffuse. It differs from most malignan-
cies because it is commonly diagnosed on the basis of imag-
ing features alone without histological confirmation in the 
setting of cirrhosis. A multiphasic contrast material-enhanced 
study is used (either CT or MR imaging) to set the radiologic 
diagnosis of HCC. The nodules that are suspicious for HCC 
during surveillance are new nodules that measure more than 
1 cm or nodules that enlarge over a time interval. Following 
hepatocarcinogenesis, regenerative nodule dedifferentiates 
to dysplastic nodules and then to hepatocellular carcinoma. 
The vascular supply of HCC is mainly arterial though neoan-
giogenesis supplied by abnormal, unpaired hepatic arteries. 
Characteristically, HCC enhances during the arterial phase 
because of its blood supply. In the portal venous and equilib-
rium phase, the surrounding liver parenchyma becomes rela-
tively hyperattenuated, and the lesion is perceived to be 
hypoattenuated because of its lack of portal venous supply 
corresponding to the so-called washout effect (Fig. 21.2). 
The third characteristic feature is pseudocapsule enhance-
ment in the equilibrium phase. The diagnosis of HCC can be 
made from a single imaging study when this characteristic 
enhancement patterns—that is, arterial phase hyperenhance-
ment and venous or delayed phase washout—are present. 
These noninvasive criteria can only be applied to cirrhotic 
patients [14]. About 70% of HCCs show these characteristic 
enhancement features of hypervascular HCCs, while the 
other 30% either do not show washout appearance or are 
hypovascular HCCs. When looking at HCCs 1 cm in size or 
less, only about 47% show typical enhancement features. 
When using Gd-EOB-DTPA, about 90% demonstrate 
hypointensity on hepatobiliary phase images and 10% dem-
onstrate iso- or hyperintensity. Especially in hypovascular 
HCCs, which are difficult to diagnose with extracellular con-
trast agents, the hepatocyte-specific contrast agent 
 (Gd-EOB- DTPA) is useful. Among the hypovascular HCCs, 
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97% demonstrate hypointensity on hepatobiliary phase 
images (Fig. 21.3) [15]. In dynamic phases the contrast 
enhancement of typical, hypervascular HCCs with 
hepatocyte- specific contrast agent is comparable to extracel-
lular contrast agents. In delayed phase (2–4 min after con-
trast administration), the washout may appear more 
pronounced because the surrounding liver parenchyma pro-
gressively takes up the contrast agent. The pseudocapsule 
appearance may be less visible due to background liver 
enhancement.
21.2.4  Cholangiocellular Carcinoma
Intrahepatic cholangiocellular carcinoma (ICC) is the second 
most common primary hepatic tumor and accounts for 
10–20% of all primary hepatic tumors. Recently, cirrhosis 
and viral hepatitis C and B have been recognized as risk fac-
tors for cholangiocarcinoma, especially for the intrahepatic 
type [16]. Radiologic features of cholangiocarcinoma such 
as progressive contrast enhancement from arterial to venous 
and late phase and arterial or both arterial and venous rim 
a b c
Fig. 21.2 Multifocal HCC. 69-year-old patient with biopsy-proven 
metabolic toxic liver cirrhosis. (a) Axial T2-weighted magnetic reso-
nance image demonstrates an iso- to slightly hyperintense lesion in the 
caudate lobe and multiple confluent lesions in the left liver lobe (white 
arrow) with early enhancement in the arterial phase (b) and washout 
with peripheral enhancement (pseudocapsule appearance) in the equi-
librium phase (c). With the typical appearance, the lesions can be cate-
gorized as LI-RADS 5 lesions
a b c
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Fig. 21.3 Hypovascular HCC. 60-year-old male patient with chronic 
hepatitis B and Child C cirrhosis. Initial imaging study (a–c) showed a 
focal hypovascular lesion (arrow) in liver segment 5 and 8 without con-
trast enhancement (Gd-EOB-DTPA) in the arterial (a), portal venous 
(b), and hepatocyte-specific phase (c) consistent with an atypical hypo-
vascular HCC. No treatment was performed, and the follow-up study 
3 months later (d–f) shows progression of the tumor (arrow) with inva-
sion into the portal vein
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enhancement can help differentiate ICC from HCC in the 
cirrhotic liver [17] (Fig. 21.4). Mixed hepatocellular cholan-
giocarcinoma has emerged as a distinct subtype of primary 
liver cancer [16, 18]. A strong enhancing rim and irregular 
shape on gadoxetic acid-enhanced MRI favors mixed 
hepatocellular- cholangiocellular carcinoma, and lobulated 
shape, weak rim and targeted appearance favors a mass- 
forming intrahepatic cholangiocarcinoma [16, 19].
21.2.5  Standardized Reporting Approach
Given the spectrum of focal liver lesions in stepwise hepato-
carcinogenesis ranging from regenerative nodules to poorly 
differentiated HCC and the overlap in imaging features 
between the different steps, a definite diagnosis of a benign 
or malignant lesion in the cirrhotic liver is often not possible. 
Furthermore, a great variety in nomenclature of imaging fea-
tures of cirrhotic nodules is used. To overcome these difficul-
ties, the Liver Imaging Reporting and Data System 
(LI-RADS) has recently been developed, which is a compre-
hensive system for standardized interpretation and reporting 
of computed tomography (CT) and magnetic resonance 
(MR) examinations performed in patients at risk for HCC. It 
uses a standardized nomenclature and provides a diagnostic 
algorithm that uses imaging features to categorize the obser-
vations seen in patients at risk for HCC along a spectrum 
from benign to malignant. Liver lesions in these patients are 
rated for their risk of being an HCC. LI-RADS 1 category 
observations are those that demonstrate imaging features 
diagnostic of a benign entity, e.g., cyst and hemangioma. 
LI-RADS 2 category observations are those that are proba-
bly benign, such as a hemangioma with an atypical enhance-
ment pattern or a probably benign cirrhotic nodule. Major 
features including arterial-phase enhancement, lesion diam-
eter, washout appearance, capsule appearance, and threshold 
growth are imaging features used to categorize LI-RADS 3 
(indeterminate probability of HCC), LI-RADS 4 (probably 
HCC), and LI-RADS 5 (definitely HCC) lesions. LI-RADS 
5 lesions have typical imaging features diagnostic for HCC 
(Fig. 21.2) [20].
21.3  Diffuse Vascular Liver Disease
21.3.1  Arteriovenous Shunts
Intrahepatic arterioportal shunts are communications 
between the hepatic arterial system and a portal vein or 
between hepatic arteries and hepatic veins which can be 
either at the level of the trunk, sinusoids, or peribiliary 
venules. In a cirrhotic liver, they can occur spontaneously, 
represent pseudolesions, and subsequently resolve. 
Secondary shunts may be posttraumatic, postbiopsy, or 
a b c
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Fig. 21.4 Cholangiocellular carcinoma in cirrhosis. 63-year-old male 
patient with chronic hepatitis C and Child A cirrhosis. (a) Axial 
T2-weighted magnetic resonance (MR) image shows features of cir-
rhosis with a focal hyperintense mass in the liver segment 2/4a with 
inhomogeneous signal intensity. (b–e) Corresponding axial gradient- 
echo T1-weighted images acquired before and after administration of 
hepatocyte-specific contrast agent (Gd-EOB-DTPA): (b) on pre- 
contrast image, the lesion is hypointense; (c) in the arterial phase, the 
lesions shows rim enhancement, which persists in the portal venous 
phase (d); (e) in hepatocyte-specific phase, the lesion is hypointense. (f) 
Axial-fused image of fluoro-18-deoxyglucose (FDG) positron- emission 
tomography and computed tomography shows peripheral FDG uptake 
favoring cholangiocellular carcinoma over hepatocellular carcinoma, 
which was histologically confirmed
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instrumentation. On imaging they appear as small, periph-
eral, nonspherical enhancing foci, which become isoattenu-
ating to the liver in the portal venous phase. It may be 
difficult to distinguish an arterioportal shunt from a small 
hepatocellular carcinoma. Repeating imaging after 6 months 
usually helps distinguishing these entities and demonstrates 
resolution or stability of an arterioportal shunt or growth of 
an HCC.
21.3.2  Portal Venous Thrombosis
A thrombus in the portal vein can be either bland or through 
venous invasion from adjacent malignancies. Several causes 
lead to thrombosis of the portal vein system such as cirrho-
sis, hypercoagulable states, trauma, or abdominal tumors 
[21]. Disruption of the portal venous endothelium can occur 
in intra-abdominal inflammatory processes such as chronic 
inflammatory bowel disease, schistosomiasis, and pylephle-
bitis leading to portal venous thrombosis [11]. After acute 
occlusion numerous periportal collaterals can develop 
within 6–20 days even if partial recanalization of the throm-
bus develops, representing cavernous transformation of the 
portal vein [22] (Fig. 21.5), also known as portal cavernoma 
(PC). At ultrasound it appears as a mass of veins in the porta 
hepatis with hepatopetal flow that lacks the normal respira-
tory variation of the portal vein [21, 22]. PC represents a 
portoportal collateral pathway that substitutes for a throm-
bosed portal vein. The veins are usually insufficient to 
bypass the entire splenomesenteric inflow, and signs of por-
tal hypertension such as splenomegaly frequently coexist 
[23]. On contrast-enhanced CT or MR scans, inhomoge-
neous, peripheral, patchy areas of high attenuation can be 
seen during the hepatic arterial phase. This pattern of perfu-
sion occurs because the central regions of the liver are better 
supplied by the cavernous portal vein than are the peripheral 
regions; therefore, a peripheral increase in arterial inflow 
develops [23]. Portal biliopathy (PB) is defined as the pres-
ence of biliary abnormalities in patients with non-cirrhotic/
nonneoplastic extrahepatic portal vein obstruction (EHPVO) 
and PC (Fig. 21.5). The pathogenesis of PB is due to the 
compression of bile ducts by PC and/or to ischemic damage 
secondary to an altered biliary vascularization in EHPVO 
and PC [24].
21.3.3  Budd-Chiari Syndrome
Budd-Chiari syndrome is defined as lobar or segmental 
hepatic venous outflow obstruction at the level of the inferior 
vena cava (IVC, type 1) or at the level of the hepatic veins 
(type 2) or occlusion of small centrilobular veins (type 3). 
Primary causes include congenital causes such as webs and 
diaphragms, outflow obstruction at the level of the right 
atrium, injury, and infection. Rarely the outflow obstruction 
may be due to mass effects from hepatic mass-forming malig-
nancies. Secondary causes most commonly are thrombotic 
including obstruction after chemotherapy or radiation and 
hypercoagulability state due to oral contraceptive use, preg-
nancy, or polycythemia. The imaging findings are variable 
and depend on the disease state. Characteristic findings 
include hepatic venous outflow obstruction. In the acute state, 
the IVC and/or hepatic veins may appear hyperattenuating on 
unenhanced CT images because of the increased attenuation 
a b
Fig. 21.5 Chronic portal venous thrombosis with cavernous transfor-
mation. 16-year-old male patient with Faktor-V-Leiden mutation and 
history of omphalitis with portal vein thrombosis since infancy. Coronal 
(a) and axial (b) T1-weighted contrast-enhanced magnetic resonance 
(MR) images in the portal venous phase demonstrate cavernous trans-
formation of the portal vein with serpentine-like vessels in the porta 
hepatis and splenomegaly. In addition, dilated intra- and extrahepatic 
bile ducts (arrows) are noted caused by stenosis of the distal hepatocho-
ledochal duct probably due to the varices in the porta hepatis (the so- 
called portal biliopathy)
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of a thrombus. On contrast-enhanced CT or MRI, a vascular 
filling defects due to thrombotic material, reduction of hepatic 
vein caliber, missing connection between hepatic veins, and 
IVC can be present, or hepatic veins may not be visible at all. 
In the acute phase, diminished enhancement of the liver 
periphery and accentuated enhancement of central liver parts 
and caudate lobe are seen. Later on peripheral liver enhance-
ment becomes heterogeneous as disorganized, comma-
shaped intrahepatic collateral veins and systemic collateral 
veins develop. Large regenerative nodules in a dysmorphic 
liver are frequent findings in longer- standing venous outflow 
obstruction. These regenerative nodules appear hyperintense 
on hepatobiliary phase images after administration of a hepa-
tocyte-specific contrast agent. Hypertrophy of the caudate 
lobe with variation in attenuation due to separate venous 
drainage should not be interpreted as a tumor [25]. Figure 21.6 
shows an example of acute Budd- Chiari syndrome.
21.3.4  Passive Hepatic Congestion
Passive hepatic congestion is due to chronic right-sided heart 
failure which leads to stasis of blood within the liver paren-
chyma. An enlarged, heterogeneous liver may be seen as a 
manifestation of acute or early cardiac disease. Early arterial 
enhancement of the dilated IVC and central hepatic veins is 
caused by reflux of contrast material from the right atrium 
into the IVC. A heterogeneous, mottled mosaic pattern of 
enhancement is present in the parenchymal phase, a condi-
tion also known as “nutmeg” liver. In long-standing disease, 
progressive cellular necrosis results in a small cirrhotic liver.
a b
Fig. 21.6 Budd-Chiari syndrome. 48-year-old female patient with 
chronic primary immunothrombocytopenia. (a) Axial T1-weighted 
magnetic resonance image in portal venous phase and (b) axial CT 
image in portal venous phase show a filling defect in the thrombosed 
middle and right hepatic vein (arrow) and normal left hepatic vein 
(arrow head). (a, b) Diminished peripheral contrast enhancement is 
seen in the right liver lobe due to acute venous occlusion
Key Points
• MR elastography can accurately diagnose clinically 
significant hepatic fibrosis.
• Hypovascular cirrhotic nodules with hypointense 
appearance on hepatobiliary phase images carry a 
significant risk of transformation into a hypervascu-
lar HCC.
• The diagnosis of HCC in cirrhotic patients can be 
made from a single imaging study when character-
istic enhancement patterns—that is, arterial phase 
hyperenhancement and venous or delayed phase 
washout—are present.
• The presence of arterial or both arterial and venous 
rim enhancement can help differentiate intrahepatic 
cholangiocarcinoma from HCC in the cirrhotic 
liver.
• LI-RADS provides a diagnostic algorithm that uses 
imaging features to categorize the observations 
seen in patients at risk for HCC along a spectrum 
from benign to malignant.
• It may be difficult to distinguish an arterioportal 
shunt from a small hepatocellular carcinoma. 
Repeating imaging after 6 months usually helps dis-
tinguishing these entities.
• Budd-Chiari syndrome is a heterogeneous group 
of disorders characterized by hepatic venous out-
flow obstruction at the level of the hepatic veins, 
the inferior vena cava (IVC), or the right 
atrium [26].
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The role of imaging in the detection, characterization, and 
follow-up of diffuse liver disease has increased due to 
advances in cross-sectional imaging.
Diffuse liver disease is classified classically along patho-
genesis into cirrhosis, vascular diseases, congenital, meta-
bolic and storage, and neoplastic [1–5]. This chapter discusses 
the last three categories and in addition includes both diffuse 
and focal inflammatory/infectious diseases. Elsewhere in this 
syllabus, cirrhosis and vascular diseases are reviewed.
22.2  Metabolic and Storage Diseases
22.2.1  Steatosis and Steatohepatitis
Hepatic steatosis results from a variety of abnormal pro-
cesses including increased production or mobilization of 
fatty acids (e.g., obesity, steroid use) or decreased hepatic 
clearance of fatty acids due to hepatocellular injury (e.g., 
alcoholic liver disease, viral hepatitis). Histopathologically, 
the hallmark of all forms of fatty liver is the accumulation of 
fat globules within the hepatocytes. The distribution of 
 steatosis can be variable, ranging from focal, to regional, to 
diffuse. Diffuse steatosis is common and estimated to occur 
in approximately 30% of obese patients. Patients with steato-
sis are usually asymptomatic although some individuals may 
present with right upper quadrant pain or abnormal liver 
function parameters. Non-alcohol-related liver steatosis is 
also known as nonalcoholic fatty liver disease (NAFLD). 
Histopathologic findings of NAFLD vary from steatosis 
alone to steatosis with inflammation, necrosis, and fibrosis. 
At the most severe end of the NAFLD spectrum resides non-
alcoholic steatohepatitis (NASH), with or without cirrhosis. 
Histopathologic findings of NASH include steatosis 
 (predominately macrovesicular), mixed lobular inflamma-
tion, and hepatocellular ballooning. Unlike steatosis alone, 
NASH may progress to cirrhosis.
CT easily identifies diffuse steatosis. The attenuation 
value of normal liver is usually on average 8 HU greater than 
that of spleen on non-contrast CT images. In patients with 
fatty change, however, an abnormally decreased density will 
be demonstrated, typically 10 and 25 HU less than the spleen 
on non-contrast CT and contrast-enhanced CT images, 
respectively. The diagnosis of hepatic steatosis is more reli-
ably made on non-contrast images.
Learning Objectives
• To describe the pathophysiology of common and 
unusual diffuse diseases of the liver
• To learn to differentiate the overstorage of fat, iron, 
copper, and amyloid in the liver based on cross- 
sectional imaging
• To review diffuse hepatic manifestations of extrahe-
patic neoplasms
• To illustrate typical imaging findings of diffuse and 
focal liver infections including fungal, viral, para-
sitic, and bacterial etiology
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Undoubtedly the most sensitive technique to detect fatty 
change of the liver is the use of inphase and out-of-phase 
gradient echo MR pulse sequences (Fig. 22.1). Multi-echo 
sequences, MR spectroscopy, and other MR techniques have 
been proposed to quantify the fat burden in the liver with 
success. Conjoint iron deposition, however, may be a con-
founding factor in estimating the fat fraction based on dual- 
echo chemical shift imaging. The fat fraction may be 
overestimated, and, therefore, the component of iron deposi-
tion requires correction as suggested by Kang et al.
Hepatic fatty change is, however, not always uniform but 
can present as a focal area of steatosis in an otherwise normal 
liver (focal steatosis) or as subtotal fatty change with sparing 
of certain areas (focal sparing) (Fig. 22.2). On imaging, sev-
eral features allow the correct identification of focal fatty 
change or focal spared areas: (1) the typical periligamentous 
and periportal location, (2) lack of mass effect, (3) sharply 
angulated boundaries of the area, (4) nonspherical shape, (5) 
absence of vascular displacement or distorsion, and (6) lobar 
or segmental distribution [6, 7].
22.2.2  Iron Overload
Iron overload states are categorized in hemochromatosis, 
where the iron accumulates preferentially within the hepato-
cytes, and hemosiderosis, where it is deposited in the Kupffer 
cells.
22.2.2.1 Primary Hemochromatosis
Hereditary or primary hemochromatosis is an autosomal 
recessive disorder of iron metabolism characterized by 
abnormal absorption of iron from the gut with subsequent 
excessive deposition of iron into the hepatocytes, pancre-
atic acinar cells, myocardium, joints, endocrine glands, and 
skin. In addition, the reticuloendothelial system (RES) 
cells in patients with primary hemochromatosis are abnor-
mal and unable to store processed iron effectively. As a 
consequence, patients with primary hemochromatosis don’t 
accumulate iron into the RES. Clinical findings of cirrhosis 
and its complications (portal hypertension, development of 
HCC) predominate in patients with long-lasting disease.
On CT excessive storage of iron into the hepatocytes will 
result in an overall increased density. However, this CT 
appearance of a hyperdense liver is nonspecific since similar 
features can be seen with gold deposition and in Wilson’s 
disease, type IV glycogen storage disease, and following 
amiodarone administration. Performing non-contrast CT in 
patients with suspected hemochromatosis is important 
because excessive iron cannot be detected in the setting of 
enhancing parenchyma. However, the sensitivity of CT for 
iron is often insufficient as there is.
 (a) A minimum threshold for liver iron detection that is five 
times higher than the normal liver iron level.
 (b) Concomitant liver steatosis (hypodense appearance) 
may be similar to the CT appearance of early iron 
overstorage.
MRI is far more specific than any other imaging modalities 
for the characterization of iron overload due to the paramag-
netic properties of iron. The superparamagnetic effect of accu-
mulated iron in the hepatocytes results in significant reduction 
of T2 or T2* relaxation times which diminish the signal inten-
sity on T2-weighted or on T1-weighted multi- echo spoiled 
gradient-echo images. Conversely to excessive storage of fat, 
in iron deposition, there will be an increase of signal intensity 
in chemical shift imaging from the in phase to the opposed 
phase. The amount of iron can be quantified using gradient-
echo sequences with T2* weighting and progressively longer 
echo times. In general, comparison of the signal intensity of 
liver with that of paraspinal muscles provides a useful internal 
control. Hepatocellular carcinomas, complicating 35% of 
patients with advanced hemochromatosis, are usually easily 
detected on both T1- and T2-weighted images due to the back-
ground of decreased signal intensity of the liver [8, 9].
22.2.2.2 Hemosiderosis
In patients with hemosiderosis or siderosis, either due to 
transfusional iron overload states or dyserythropoiesis (e.g., 
thalassemia major, sideroblastic anemia, pyruvate kinase 
deficiency, chronic liver disease), the excessive iron is 
Key Points
• The extent of fatty changes, iron deposition, and 
fibrotic remodeling can be quantified using MRI 
although their simultaneous presence can influence 
each other’s results.
• Metastatic liver disease demonstrates mostly a mul-
tifocal disease, diffuse, and subtle presentation, 
requiring awareness and interpretation of indirect 
features.
• The liver is one of the most affected organs in parasitic 
diseases. Radiologists should be able to recognize and 
suspect the most relevant parasitic diseases, including 
hepatic schistosomiasis and echinococcosis.
• Acute hepatitis results in increased T1 and T2 
relaxation times as well as periportal edema. 
Chronic hepatitis doesn’t necessarily show distinct 
imaging features before developing into cirrhotic 
changes at long term.
• Imaging in infectious diseases might be crucial as 
they can be fatal if not promptly treated. With the help 
of CT and MRI, entities that may manifest with simi-






Fig. 22.1 Diffuse fatty liver. 41-year-old female presenting with epi-
gastric pain. Axial CECT image (a) demonstrates diffuse low attenua-
tion of the liver without displacement of the hepatic vessels. In- (b) and 
out-of-phase (c) T1-weighted new MRI images show significant signal 
drop in the liver on the out-of-phase images
ba
Fig. 22.2 Hemosiderosis. Focal fatty sparing. 59-year-old male with right upper quadrant pain and elevated liver function tests. Axial chemical 
shift MRI images show signal drop of the entire steatotic liver from in- (a) to out-of-phase (b) with focal fatty sparing in liver segment 6
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 processed and accumulates in organs containing reticuloen-
dothelial cells, including liver, spleen, and bone marrow.
By CT, there is diffuse, increased attenuation of liver and 
spleen (Fig. 22.3). In MRI, the extrahepatic signal intensity 
changes in the spleen and bone marrow allow MR imaging to 
distinguish primary hemochromatosis from hemosiderosis. 
Although in general the clinical significance of transfusional 
iron overload states is negligible, patients with chronic 
hemosiderosis can develop symptoms similar to those of the 
primary form as well as cirrhosis and HCC.
22.2.3  Wilson Disease
Wilson disease, also known as hepatolenticular degenera-
tion, is a rare autosomal recessive abnormality of copper 
metabolism characterized by accumulation of toxic levels of 
copper in the brain, cornea (Kayser-Fleischer rings), and 
liver, the latter due to impaired biliary excretion. Hepatic 
deposition of copper, predominantly seen in periportal areas 
and along the hepatic sinusoids, evokes an inflammatory 
reaction resulting in acute hepatitis with fatty change. 
Subsequently, chronic hepatitis may result in liver fibrosis 
and eventually macronodular cirrhosis.
Due to the high atomic number of copper, a hyperdense 
liver may be seen on unenhanced CT scans. However, this 
finding is not universally present, and usually only nonspe-
cific signs such as hepatomegaly, fatty change, and, in 
advanced cases, cirrhosis are observed. During the early stage 
of the disease due to the paramagnetism of ionic copper, MR 
imaging can be valuable by demonstrating focal copper depo-
sitions as multiple nodular lesions, typically appearing hyper-
intense and hypointense on T1- and T2-weighted images, 
respectively, as described by Cheon JE et al [10].
22.2.4  Amyloidosis
Amyloidosis consists of deposition of fibrils of protein- 
mucopolysaccharide complexes throughout the body and is 
classified based on the biochemical composition of the amy-
loid fibrils. Primary amyloidosis is due to the deposition of 
immunoglobulin light chains and is associated with multiple 
myeloma and monoclonal gammopathy. Secondary amyloido-
sis is due to deposition of amyloid A protein and is associated 
with chronic infection, rheumatoid arthritis, and malignancies. 
Exceeded only by the spleen and kidney, the liver is the third 
most common solid organ prone to this deposition.
Hepatic amyloidosis has a nonspecific imaging appear-
ance. The most common finding is diffuse hepatomegaly. CT 
sporadically demonstrates focal areas of low attenuation 
within the liver corresponding to sites of amyloid deposition 
(amyloid pseudotumor). Patients may present with a picture 
of jaundice which is due to intrahepatic cholestasis [11, 12].
22.3  Neoplastic Diseases
22.3.1  Metastatic Disease
Neoplastic infiltration due to diffuse metastatic disease can 
occur with many primary tumors. Melanoma, malignant 
neuroendocrine tumors, pancreatic adenocarcinoma, breast 
carcinoma, and colonic adenocarcinoma are some of the 
more commonly encountered causes of diffuse hepatic meta-
static disease.
CT appearances of hepatic metastases depend on the vas-
cularity of the lesions compared with the normal liver paren-
chyma. Diffuse metastatic involvement may produce only 
subtle imaging findings and be only detectable through 
ba
Fig. 22.3 29-year-old female with long history of sickle cell anemia requiring multiple transfusions. Axial T2-weighted MRI demonstrates sig-
nificantly decreased liver-signal intensity and NECT increased attenuation in the liver due to the iron overload
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 indirect features, such as diffuse parenchymal heterogeneity, 
vascular and architectural distortion, or alterations of the 
liver contour. The latter, particularly seen in patients with 
treated breast cancer metastases, has been reported as the 
“pseudocirrhosis” sign (Fig. 22.4). In addition, treated breast 
cancer metastases may mimic the appearance of liver 
hemangiomata.
22.3.2  Lymphoma
Lymphoma can infiltrate the liver both primarily and second-
arily. Primary lymphoma of the liver is extremely rare. 
Conversely the liver is often secondarily involved in both 
Hodgkin’s and non-Hodgkin’s lymphoma. Typically, the 
liver parenchyma is diffusely infiltrated with microscopic 
nests of neoplastic cells without significant architectural dis-
tortion, and, therefore, lymphomatous involvement is diffi-
cult to detect by imaging alone. Associated abnormalities, 
such as splenomegaly and lymphadenopathy, may narrow 
the differential diagnosis.
22.4  Diffuse Infectious and Inflammatory 
Diseases
22.4.1  Fungal Infections
Hepatosplenic fungal infection is a clinical manifestation of 
disseminated fungal disease in patients with hematologic 
malignancies or compromise of the immunologic system. 
The reported prevalence of fungal dissemination ranges 
from 20% to 40%. Most hepatic fungal microabscesses 
occur in leukemia patients and are caused by Candida albi-
cans [16].
22.4.1.1 Candidiasis
Candida albicans, in the liver, may evoke little or no inflam-
matory reaction, cause a superlative response, or occasion-
ally produce granulomas. The typical histologic pattern of 
hepatic candidiasis is characterized by microabscesses, with 
the yeast or pseudohyphal forms of the fungus in the center 
of the lesion and a surrounding area of necrosis and poly-
morphonuclear infiltrate.
At contrast-enhanced CT, fungal microabscesses usually 
appear as multiple rounds, discrete areas of low attenuation, 
generally ranging from 2 to 20 mm (Fig. 22.5). These micro-
abscesses usually enhance centrally after intravenous admin-
istration of contrast medium, although peripheral 
enhancement may occur.
At MR imaging, the untreated nodules are rounded lesions 
less than 1 cm in diameter that are minimally hypointense on 
T1-weighted and gadolinium-enhanced images and mark-
edly hyperintense on T2-weighted images. After treatment, 
lesions appear mildly to moderately hyperintense on T1- and 
T2-weighted images and demonstrate enhancement on 
gadolinium- enhanced images. A dark ring is usually seen 
around these lesions with all sequences. Completely treated 
lesions are minimally hypointense on T1-weighted images, 
isointense to mildly hyperintense on T2-weighted images, 
moderately hypointense on early gadolinium-enhanced 
images, and minimally hypointense on delayed gadolinium- 
enhanced images. MR imaging is superior to CT and US in 
the detection of these fungal foci [17].
Fig. 22.4 Diffuse metastatic breast cancer (pseudocirrhosis pattern). 
43-year-old female treated for metastatic breast cancer. Axial CECT 
image demonstrates several small low-density lesions in the liver and a 
nodular contour of the liver due to hepatic capsular retraction
Fig. 22.5 Hepatic candidiasis. 66-year-old female with leukemia pre-
senting with abnormal liver function tests. Axial CECT image demon-
strates multiple small low-attenuation lesions seen throughout the liver 
and spleen. Splenomegaly and bilateral pleural effusions are also 
present
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22.4.2  Granulomatous Diseases
Granulomatous hepatitis is associated with a wide variety of 
conditions, most commonly with sarcoidosis, tuberculosis, 
and histoplasmosis. Hepatic granulomas usually appear as 
discrete, sharply defined nodules consisting of aggregates of 
epithelioid cells by a rim of mononuclear cells, predomi-
nantly lymphocytes.
22.4.2.1 Sarcoidosis
Sarcoidosis is a multisystem disorder of unknown patho-
genesis, characterized by noncaseating granulomas. 
Although it may involve almost any organ in the body, 
pulmonary sarcoidosis is most common. Sarcoidosis of 
the liver is also relatively frequently seen, but the granu-
lomas are usually not macroscopically detectable and 
thus may not produce focal abnormalities on imaging 
studies. Classically, the granulomas develop in a periportal 
location resulting in periportal fibrosis, cirrhosis, and 
eventually portal hypertension.
Hepatic contrast-enhanced CT may typically reveal 
multiple, diffuse small low-density areas in both the liver 
and spleen (Fig. 22.6). MRI features of hepatic sarcoidosis 
are also nonspecific and include organomegaly, multiple 
low- signal- intensity lesions relative to background paren-
chyma with all sequences, increased periportal signal, 
irregularity of the portal and hepatic vein branches, and 
patchy areas of heterogeneous signal. Recent literature by 
Ferreira et al. confirms the nonspecific appearance but 
describes as a characteristic feature with large central 
regenerative nodules and wedge-shaped areas of peripheral 
parenchymal atrophy [18, 19].
22.4.2.2 Tuberculosis
Tuberculosis is one of the most common infectious diseases 
worldwide. Generally, tuberculosis in the liver presents as 
either miliary or focal form. Focal hepatic TB is further sub-
divided into nodular (i.e., tuberculous abscess and tubercu-
loma) and tubular or hepatobiliary tuberculosis (i.e., 
tuberculosis involving the intrahepatic ducts). Hepatic mili-
ary tuberculosis is the most common and is reported to occur 
in 50–80% of all patients with terminal pulmonary tubercu-
losis. Miliary tuberculosis is usually not detected by imag-
ing. Hepatomegaly may be the only radiological 
abnormality.
In the healing stage of tuberculosis, CT may show diffuse 
hepatic calcifications (approximately 50% of cases). 
Reported CT findings of nodular tuberculosis are nonspecific 
and include hypoattenuating lesions both before and after 
intravenous contrast administration.
At MR imaging, the lesions are hypointense on 
T1-weighted images and hypo- to isointense on T2-weighted 
images. Tuberculosis lesion differently enhances after gado-
linium administration. Because of these rather nonspecific 
findings with all imaging techniques, percutaneous liver 
biopsy is necessary [20].
22.4.2.3 Histoplasmosis
Histoplasmosis is the most common cause of fungal infec-
tion in the Ohio River Valley of the United States. Fortunately, 
99% of patients exposed to histoplasmosis develop only sub-
clinical infections. Liver involvement is common in dissemi-
nated histoplasmosis, which usually originates in the lungs. 
The most common hepatic findings include portal lympho-
histiocytic inflammation and discrete, well-delineated granu-
a b
Fig. 22.6 Hepatic sarcoidosis. 44-year-old male with fever and hilar 
adenopathy on chest X-ray. Axial T2-weighted (left) and T1-weighted 
post-contrast (right) MR images show multiple small T2-hyperintense, 
T1-hypointense, ring-enhancing lesions throughout the liver. Note the 
small spleen that is consistent with chronic auto infarction from coex-
isting sickle cell anemia
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lomas. In patients with healed histoplasmosis, the presence 
of small, punctate calcifications scattered throughout the 
liver and spleen is typical but nonspecific finding [21].
22.4.3  Parasitic Infections
22.4.3.1 Schistosomiasis
Schistosoma japonicum, S. haematobium, and S. mansoni 
are the three most important species that infect humans. The 
schistosomas live in the bowel lumen and lay eggs in the 
mesenteric veins. The eggs may then embolize to the portal 
vein. The eggs themselves do not survive and subsequently 
calcify. Chronic infections with either S. japonicum or S. 
mansoni result in the formation of cirrhosis and the risk of 
development of hepatocellular carcinoma. Histologically, 
schistosomiasis is characterized by white, pinhead-sized 
granulomas scattered throughout the liver. At the center of 
each granuloma is a schistosome egg. Periportal fibrosis is 
the major pathological consequence of the Schistosoma 
mansoni infection. In severe infections, the surface of the 
liver shows granulomatous involvement and widespread 
fibrous portal enlargement (“pipestem” fibrosis).
At CT, the most pathognomonic pattern is the presence of 
calcified septa, usually aligned perpendicular to the liver 
capsule (“tortoiseshell” or “turtleback” appearance).
22.4.4  Viral Infections
22.4.4.1 Viral Hepatitis
Acute viral hepatitis is a systemic infection that affects the 
liver and is usually caused by one of five viral agents: hepa-
titis A virus, hepatitis B virus (HBV), hepatitis C virus, the 
HBV-associated delta agent or hepatitis D virus, and hepa-
titis E virus. A vast array of other viruses may also produce 
hepatitis, including herpes viruses, yellow-fever virus, 
rubella virus, Coxsackievirus, and adenovirus. The diagno-
sis of acute hepatitis is usually based on serologic, viro-
logic, and clinical findings. Probably the most important 
role of radiology in patients with acute hepatitis is to help 
rule out other diseases that produce similar clinical and bio-
chemical abnormalities, such as extrahepatic cholestasis, 
diffuse metastatic disease, and cirrhosis.
At CT and MR imaging, findings in acute viral hepatitis 
are nonspecific and include hepatomegaly and periportal 
edema. At CT, heterogeneous enhancement and well-defined 
regions of low attenuation may be present. At MR imaging, 
periportal edema appears as high-signal-intensity areas on 
T2-weighted images. Involved areas may be normal or dem-
onstrate decreased signal intensity on T1-weighted images 
and increased signal intensity on T2-weighted images. There 
is also impaired uptake of liver-specific agents. Extrahepatic 
findings in patients with severe acute hepatitis include gall-
bladder wall thickening due to edema and, infrequently, asci-
tes. In chronic hepatitis, the CT and MR imaging features 
resemble those of early-stage liver cirrhosis. Periportal 
lymphadenopathy may be the sole detectable abnormality in 
both acute and chronic hepatitis.
22.4.4.2 HIV Infection
The liver and biliary tracts are frequent sites of involvement 
during the course of HIV infection. Coinfection with hepati-
tis B and C viruses is particularly common due to the shared 
means of transmission of these viruses with HIV. AIDS- 
related cholangiopathy is the newest common manifestation. 
At CT, inflammation of the gallbladder or biliary tree mani-
fests as mural thickening or abnormal contrast enhancement. 
MRCP is more sensitive and specific than US or CT in 
depicting the mural irregularity of the extrahepatic ducts that 
result from the exuberant periductal inflammation, focal 
mucosal ulcers, and interstitial edema found in AIDS-related 
cholangitis.
22.4.5  Uncommon Hepatic Infections
22.4.5.1 Cat-Scratch Disease
Cat-scratch disease is an infection that affects immunocom-
petent children or adolescents. It is caused by Bartonella 
henselae, a gram-negative bacillus that is usually introduced 
by the scratch of a cat. Cat-scratch disease takes many forms, 
from regional lymphadenitis to disseminated infection. The 
typical clinical manifestation of cat-scratch disease is painful 
lymphadenopathy proximal to the site of inoculation. 
Disseminated infection is seen in 5–10% of cases. In the 
abdomen, multiple granulomas ranging from 3 to 30 mm 
may form in the liver and spleen, with or without hepato-
splenomegaly. Histopathologic findings include vascular 
proliferative lesions (peliosis hepatis) and necrotizing granu-
lomatous lesions.
At unenhanced CT, the lesions are hypoattenuating rela-
tive to normal parenchyma. Three different patterns at 
contrast- enhanced CT have been described: (a) persistent 
hypoattenuation relative to the liver, (b) isoattenuation rela-
tive to surrounding tissues, and (c) marginal enhancement. 
Only a few MR imaging studies of cat-scratch disease have 
been described. The lesions appear as low-signal-intensity 
nodules on T1-weighted MR images and as high-signal- 
intensity nodules on T2-weighted images. Peripheral 
enhancement may be seen on gadolinium-enhanced 
T1-weighted images [23, 24].
22.4.5.2 Bacillary Angiomatosis
Bacillary angiomatosis is also a manifestation of infection 
by Bartonella henselae in immunocompromised patients. 
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This is the same organism that causes cat-scratch disease in 
noncompromised patients. It is characterized by localized 
areas of vascular proliferation that may affect the skin, air-
way, mucous membranes, visceral organs, bone, and brain. 
Contrast-enhanced CT may demonstrate multiple diffuse 
low- or high-attenuation lesions less than 1 cm scattered 
throughout the hepatic parenchyma. Ascites, mild periportal 
edema, and intrahepatic biliary ductal dilatation may occur. 
These imaging features are nonspecific and must be distin-
guished, especially in AIDS patients, from hepatic abscesses 
related to other bacteria, viruses, or fungi; AIDS-related 
lymphoma; Kaposi sarcoma; and, less commonly, dissemi-
nated Pneumocystis carinii infection [25].
22.5  Focal Infections
22.5.1  Bacterial (Pyogenic) Abscess
Pyogenic abscess, although uncommon in the antibiotic era, 
is still challenging clinically since its presentation is quite 
variable, from profound septicemia to chronic, indolent 
symptoms.
Enhanced CT can reliably diagnose over 90% of hepatic 
pyogenic abscesses, revealing two main patterns: multiple 
microabscesses (disseminated or clustered) and large mac-
roabscesses. By virtue of its good spatial and contrast resolu-
tion, computed tomography (CT) is the single best method 
for detecting hepatic abscess, with a sensitivity as high as 
97%. On CT scans, abscesses appear as generally rounded 
masses that are hypodense on both contrast and non-contrast 
scans. Central gas, either as air bubbles or an air-fluid level, 
is a specific sign, but it is present in less than 20% of cases. 
A thick, enhancing, peripheral rim is also noted.
At MR imaging, air within the abscess appears as a signal 
void and is therefore more difficult to differentiate from cal-
cifications. However, the shape and location (air-fluid level) 
should enable the correct diagnosis. After administration of 
gadolinium-DTPA, abscesses typically show rim enhance-
ment (the “double-target” sign). Small lesions (<1 cm) may 
enhance homogeneously mimicking hemangiomas. 
Percutaneous, image-guided aspiration followed by drainage 
is the method of choice for definitive diagnosis and treatment 
with success in over 90% of cases.
22.5.2  Amebic Abscess
Hepatic abscess is the most common extraintestinal mani-
festation of amebiasis, affecting approximately 10% of 
patients with amebiasis. Although rare in the continental 
United States, 10% of the world’s population is infected 
with Entamoeba histolytica. Clinically, patients with ame-
bic abscess are more acutely ill than patients with pyogenic 
abscess, with high fever and right upper quadrant pain. 
Diagnosis is made by positive serologic amebic titers, 
although they have false-negative rates of almost 20%.
CT demonstrates well the extrahepatic extensions to chest 
wall, pleura, or adjacent viscera. Percutaneous catheter 
drainage of an amebic abscess is rarely necessary because of 
the effectiveness of amebicidal therapy. Occasionally, percu-
taneous drainage is needed in large, symptomatic abscesses 
with poor response to medical therapy, suspected bacterial 
superinfection, and threatening intrapericardial rupture. The 
CT appearance of amebic abscess is variable and nonspe-
cific. The lesions are usually peripheral, round, or oval areas 
of low attenuation (10–20 Hounsfield units). A peripheral 
rim of slightly higher attenuation can be seen on non- contrast 
scans and shows marked enhancement after administration 
of contrast material.
On MR imaging, amebic liver abscesses are spherical and 
usually solitary lesions with a hyperintense center on 
T2-weighted images and a hypointense center on T1-weighted 
images. The abscess wall is thick, and on gadolinium- 
enhanced images, the enhancement pattern is similar to that 
of pyogenic abscess [26].
22.5.3  Echinococcal Disease
Hydatid disease has two main forms affecting humans 
Echinococcus granulosus and Echinococcus multilocularis 
or alveolaris. These infections have well-defined and dif-
ferent geographic distributions. The pathologic and imag-
ing findings differ dramatically between these parasites.
On CT scans, E. granulosus appears as unilocular or mul-
tilocular, well-defined cysts with either thick or thin walls. 
Daughter cysts are usually seen as areas of lower attenuation 
than the mother cyst and are usually in the periphery of the 
lesion. Daughter cysts can also float free in the lumen of the 
mother cyst, so altering the patient’s position may change the 
position of these cysts, confirming the diagnosis of echino-
coccal disease. Curvilinear ring-like calcification is also a 
common feature.
On MR studies, the cyst component of echinococcal cysts 
is similar to that of other cysts, with long T1 and T2 relax-
ation times. However, MR imaging best demonstrates the 
pericyst, the matrix and hydatid sand (debris consisting of 
freed scolices), and the daughter cysts. The pericyst usually 
has low-signal intensity on T1- and T2-weighted images, 
because of its fibrous component. This rim and a multilocu-
lated or multicystic appearance are distinctive features. The 
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hydatid matrix appears hypointense on T1-weighted images 
and markedly hyperintense on T2-weighted images. When 
present, daughter cysts are hypointense relative to the matrix 
on both T1- and T2-weighted images (Fig. 22.7). Floating 
membranes have low-signal intensities on T1- and 
T2-weighted images.
E. multilocularis appears as a solid large mass or masses, 
with minimal to no enhancement after intravenous adminis-
tration of contrast material and possible small punctate calci-
fication [27–29].
22.6  Concluding Remarks
The spectrum of diffuse liver diseases includes a broad range 
of different entities including metabolic, storage, neoplastic, 
infectious, and inflammatory disorders. They may have 
unique or overlapping image findings. Knowing the typical 
features of the different diffuse and inflammatory liver dis-
eases with CT and MRI techniques allows radiologists to 
play a key role in the diagnosis and management of diffuse 
liver diseases. Likewise, focal inflammatory diseases such as 
abscesses and hydatid disease can be characterized by 
 imaging [14, 22, 30].
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Urinary Obstruction, Stone Disease, 
and Infection
S. O. Schönberg, J. Budjan, and D. Hausmann
23.1  Background
23.1.1  Uncomplicated Versus Complicated 
Urinary Tract Infection
Acute infection is mostly diagnosed based on clinical pre-
sentation and laboratory tests without imaging examinations 
[1]. Urinary tract infections are regarded as uncomplicated in 
otherwise healthy patients without structural or functional 
urinary abnormalities. Complicated urinary tract infections 
are accompanied by factors that potentially decrease therapy 
effectiveness, such as immunocompromission, unusually 
virulent pathogen, and patient-related factors (Table 23.1). 
Imaging of uncomplicated cystitis or pyelonephritis is 
regarded as unnecessary by most authors. In contrary, 
patients who suffer from complicated urinary tract infections 
may benefit from imaging [1, 2].
23.1.2  Imaging
MRI plays an increasingly important role in the diagnostic 
work-up of urological patients as an alternative or comple-
mentary imaging of CT. However, on the one hand, the avail-
ability of MRI scanners is lower than that of CT scanners, 
and on the other hand, the cost of an MRI is significantly 
higher than that of a CT scan. In emergency situations, such 
as trauma, acute bleeding, or renal colic with suspected 
underlying urolithiasis, CT is the imaging modality of 
choice.
MRI examinations usually require more patient coopera-
tion than CT examinations. Non-compliance can signifi-
cantly affect the image quality and thus the diagnostic 
confidence.
Moreover, in the first trimester of pregnancy, MRI should 
only be performed when absolutely necessary and at low- 
field strengths only (1.5 T or less). Certain questions can 
only be answered to a limited extent, as contrast agents are 
contraindicated during pregnancy.
The narrowing of the MRI tube may lead to additional 
problems in emergency situations, on the one hand, caused 
by claustrophobia (if necessary, a premedication with an 
anxiolytic drug may be considered) and, on the other hand, 
by obesity.
Despite these limitations, owing to the superior soft tissue 
contrast, MRI can provide useful information as a supple-
mentary modality in the assessment of inflammatory urinary 
tract diseases.
Learning Objectives
• To understand indications for imaging and choice 
of cross-sectional imaging method depending on 
pathology
• To identify “high-risk” patients to develop severe 
and/or chronic urogenital inflammations
• To learn about sequence composition of a “stan-
dard” MRI protocol and additional potentially use-
ful functional sequences
• To see the MRI appearance of various acute and 
chronic inflammatory urogenital pathologies
• To think of the differential diagnosis (e.g., lym-
phoma or posttransplant lymphoproliferative 
disorder)
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23.2  MRI
23.2.1  Standard Protocol
In clinical routine, there is currently no “universal protocol” 
as the sequences or the image contrasts can differ between 
MRI scanners (especially depending on field strength and 
manufacturers). The examination of the kidneys is performed 
as a standard procedure in supine position using body coils, 
which are placed directly on the abdomen.
A typical protocol for the evaluation of structural and 
inflammatory kidney disease consists of morphological 
sequences such as T2-weighted sequences with or without 
fat saturation in different plane orientations and non- contrast- 
enhanced T1-weighted sequences with or without fat satura-
tion. In this context, most readers prefer the axial and coronal 
plane directions for the evaluation of the urinary tract. In 
addition, normally in-phase and opposed-phase sequences 
(“chemical-shift imaging”) are obtained to detect intracellu-
lar fat proportions. Increasingly, this “standard imaging” is 
flanked by functional techniques, which generate informa-
tion beyond pure morphology (e.g., dynamic contrast- 
enhanced imaging (DCE) or diffusion-weighted imaging 
(DWI)).
For most MRI examinations, intravenous contrast medium 
is injected. After contrast, dynamic axial fat-saturated 
T1-weighted sequences are acquired in arterial, venous, and 
later contrast agent phases. In addition to the axial plane 
direction, a coronal T1-weighted fat-saturated sequence is 
recommended. If, moreover, inflammatory disease in the 
course of the ureters is suspected, additional late phases are 
advisable. These urographic phases are acquired between 10 
and 20 min after contrast medium injection. In order to opti-
mize the urographic images, an additional administration of 
a diuretic or an i.v. water bolus and a parasympatheticolytic 
may be useful.
23.2.2  Additional Protocols
23.2.2.1  Stone Disease
Concrements have no intrinsic MRT signal and consequently 
appear hypointense on T1- and T2-weighted images. In addi-
tion to T2-weighted sequences, late urographic phases can 
be used for the detection of concrements in the urinary tract. 
In the latter, stones may be detected indirectly as a filling 
defect in the course of the ureter.
23.2.2.2  Diffusion-Weighted Imaging (DWI)
In principle, DWI is a technique which enables the visualiza-
tion of diffusion properties (= uniform distribution of parti-
cles) of water molecules in vivo. The average spatial mobility 
of a water molecule per time unit is measured in a defined 
volume. Water diffusion is based on the Brownian molecular 
motion (= temperature-induced movement of particles in liq-
uids) and can be quantified by measuring the “apparent dif-
fusion coefficient (ADC).” A decrease in the space between 
individual cells in tissue, e.g., due to cell swelling, leads to 
reduced mobility of the free water. DWI allows indirect esti-
mations of the cell density; this can be used to differentiate 
pathologies with increased cell density (e.g., tumors or 
abscesses). “Zoomed” single-shot echo-planar imaging 
(EPI)-DWI performed with a small FOV in the phase- 
encoding direction by employment of two independent 
radiofrequency transmit channels (“parallel transmit”) to 
generate spatially tailored 2D parallel radiofrequency (RF). 
RF excitation pulses have been proven useful to increase 
image quality at 3 T. In clinical practice, DWI should now 
become an integral part of the standard MRI protocol renal 
zoomed EPI-DWI with spatially selective radiofrequency 
excitation pulses in two dimensions [3].
23.2.2.3  Advanced T1-Weighted Contrast- 
Enhanced Sequences
Isotropic, highly accelerated (e.g., by “compressed- 
sensing”), dynamic (“4D”) post-contrast T1-weighted 
sequences with a temporal resolution below 10 s may be 
employed to generate perfusion maps in a “one-stop-shop” 
approach for the quantitative analysis of various perfusion 
parameters (e.g., to assess renal function or scarring) aside 
from high-resolution morphologic images. In this context, 
radial T1-weighted sequences are particularly useful in 
patients with impaired breath-hold capabilities as they help 
to reduce motion-induced artifacts. Sequences that combine 
speed and radial acquisition will soon be commercially avail-
able. To date, the clinical value of these sequences to assess 
renal inflammatory disease has not been assessed, and limi-
tations include time-consuming image reconstructions that 
need to be carried out on an external server [4].
Table 23.1 Complicated urinary tract infection (Patient-related factors)
Complicated urinary tract infection
(Patient-related factors)
     • Delayed therapy
     • Male
     • Childhood urinary tract infections
     • Immunocompromised (e.g., HIV)
     • Leukemia
     • Pregnant
     • Elderly patients
     • Diabetes
     • Failed antibiotic treatment
     • Prolonged symptoms
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23.2.2.4  Blood Oxygenation Level-Dependent 
(BOLD) Imaging
BOLD imaging is a noninvasive procedure that allows a rela-
tive assessment of the oxygen partial pressure in tissue. The 
signal of BOLD imaging is based on the different magnetic 
properties of oxyhemoglobin and deoxyhemoglobin and thus 
allows an indirect estimation of the relative local oxygen 
concentration. This technique is currently subject of research 
and has not yet established itself in clinical routine [5, 6].
23.2.2.5  Sodium
In the future, completely new technical approaches could also 
play an increasing role. In studies, the extent to which sodium 
imaging is suitable for detecting and differentiating kidney 
pathologies is investigated. Sodium MRI uses the protons of 
sodium-23 for imaging instead of the hydrogen proton (H-1) 
used in the conventional MRI. Sodium nuclei occur much less 
frequently than H-1 nuclei in the human body. At the same 
time, they exhibit less favorable physical properties for MR 
imaging, which makes this process technically very demand-
ing (e.g., the use of own coils and optimized sequences). The 
technique may also enable to assess kidney function (e.g., 
posttherapeutic after radiation therapy of retroperitoneal sar-
comas). This method has not yet entered clinical routine [7, 8].
23.3  Acute and Chronic Inflammatory 
Renal Diseases
23.3.1  Spectrum of Kidney Infections
Renal inflammations range from acute to chronic and mild to 
severe.
Acute pyelonephritis can be diffuse or focal and may 
resolve or exacerbate to abscess-forming pyelonephritis. 
Immunocompromission might predispose patients to more 
severe or even life-threatening clinical courses like emphyse-
matous pyelonephritis. Renal infections can develop into a 
permanently damaging chronic pyelonephritis or xantho-
granulomatous pyelonephritis [1]. Prolonged untreated 
tuberculosis may lead to scarring, fibrosis, and stricture of 
the urinary collective system. Immunocompromised patients 
are particularly prone to fungal infections (mostly Candida 
and Aspergillus). Some rare infections include malakoplakia 
and eosinophilic cystitis (Table 23.2).
23.3.2  Pyelonephritis
Acute pyelonephritis is the most frequent inflammatory 
change in the kidneys and is usually caused by gram- negative 
bacteria. The incidence of acute pyelonephritis parallels that 
of lower urinary tract infections. It occurs around five times 
more often in females with a steep increase after puberty. 
The parenchyma often enhances inhomogeneously, espe-
cially in the nephrographic contrast medium phase, with 
wedge-shaped zones of lower contrast as an indication of an 
inflammatory process. Unfortunately, a “striated nephro-
gram” is unspecific and can also be present in other condi-
tions like contusion as well as obstruction or renal vein 
thrombosis. Diffuse acute pyelonephritis can lead to renal 
enlargement and poor enhancement of the parenchyma, 
absence or reduced excretion of contrast, and fat imbibition 
in fat-saturated T2-weighted sequences as a sign of 
inflammation.
MRI is superior to CT in the detection of nephritic com-
ponents since the inflammatory changes in the (high) b val-
ues can present as signal elevations by means of DWI or as 
corresponding reductions of the ADC [9]. Furthermore, pus 
can be detected in the kidney globule system (the signal 
behavior is also signal elevation in b-value images and ADC 
reduction corresponding to dark areas on the ADC map), 
although differentiation from tumor or blood coagulation is 
often impossible (Fig. 23.1).
In the protracted course of pyelonephritis, the renal 
parenchyma may become scarred and lose function. 
Chronic pyelonephritis can also be triggered by urine infec-
tions in childhood, reflux, or frequent infections. MRI 
shows polar scars with underlying calyceal distortion and 
atrophy as well as hypertrophy of healthy parenchyma. 
Fetal lobulations can be discriminated by depressions 
located in between calyces rather than overlying calyces. 
Lobar infarctions are distinguished by absence of calyceal 
involvement [1].
23.3.3  Abscess
Abscesses of the kidneys usually develop in the context of 
pyelonephritis, when several small abscesses fuse. All ages 
can be affected, and there is no recognized gender predilec-
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tion. Predisposing factors are diabetes and vesicoureteral 
reflux. Peripheral rim enhancement is frequently seen in 
contrast-enhanced T1-weighted MRT sequences. Abscesses 
may also contain air inclusions, for the detection of which 
CT is significantly more sensitive than MRI; in the latter air 
can only be detected indirectly as areas of signal loss. 
However, MRI allows a reliable detection of kidney 
abscesses, especially through the implementation of DWI 
into clinical routine, and is the imaging method of choice in 
case of unclear findings. Differentiation from renal cell car-
cinoma or lymphoma can, however, be difficult in some 
cases. In particular, the patient’s history as well as short-term 
follow-ups may help.
23.3.4  Pyonephrosis
Pyonephrosis is an infection of the kidney which leads to pus 
deposition in the upper collecting system which can progress 
to obstruction. The most likely cause is concrements, but 
tumors or fibrotic changes can also trigger pyonephrosis. A 
contrast medium level in urine above pus is indicative of 
pyonephrosis. Since pyonephrosis is an emergency, which 
can be diagnosed well by means of CT, MRI is used less 
frequently.
23.3.5  Xanthogranulomatous Pyelonephritis
Xanthogranulomatous pyelonephritis (XPN) is a chronic gran-
ulomatous disease of the renal parenchyma, in which the 
parenchyma is progressively replaced by fat-containing macro-
phages, other inflammatory cells and cell detritus. Recurrent E. 
coli and Proteus mirabilis infection affecting middle-aged 
females and rarely diabetes are associated [10, 11]. In the over-
whelming majority of cases, this inflammatory change arises 
from a chronic urinary obstruction, such as a ureteral constric-
tion. In most patients (90%), a staghorn calculus is found. 
Atypical characteristics comprise lack of calculi (10%), focal 
instead of diffuse involvement (10%), and renal atrophy instead 
of enlargement. Chronic inflammation may develop into fistu-
lae formation to adjacent organs. XPN is usually one-sided. 
Ureteral or renal pelvic stones can often be detected only uni-
laterally in affected patients. In addition to ureteral stones, 
however, subpelvic ureteral stenoses and ureteral masses may 
also be responsible for the chronic urinary accumulation.
The more frequent generalized form of the XPN shows the 
image of an extended renal pelvis and rarefied renal parenchyma 
with the tissue consisting of xanthoma cells (lipid-containing 
macrophages). This is also described as the “bear claw.” In addi-
tion, the perirenal fat tissue exhibits an inflammatory co-reaction, 
which is characterized, in particular, by fluid collections.
a
b
Fig. 23.1 A 54-year-old 
female patient presenting with 
fever and abdominal pain. 
Coronal T2 haste (a) 
depicting wedge-shaped areas 
of increased signal intensity 
in the renal parenchyma and 
organ enlargement. Fluid 
imbibition of the surrounding 
fat tissue is also seen. High 
b-value DWI (b) shows 
corresponding signal 
elevations in the affected 
areas
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MRI is particularly useful in patients with chronic renal 
dysfunction leading to renal impairment. The fat-containing 
cells appear iso-hyperintense in T1- and T2-weighted and a 
signal decrease is seen in fat-saturated sequences.
The diagnosis of the focal form of XPN is often difficult, 
whose appearance resembles that of renal cell carcinoma. In 
these cases, histologic confirmation of the diagnosis must be 
obtained.
23.3.6  Tuberculosis
Renal tuberculosis arises from hematogenous dissemination of 
the disease. In about 50% of the patients, lung involvement can-
not be detected. Caliectasis is seen in early stages in urographic 
phases with a feathery contour; in the protracted course, a 
“phantom calyx” or a cavity communicating with a malformed 
calyx can be present [1]. Later, the granulomas coalesce form-
ing mass-like lesions (tuberculoma) which may rupture into the 
pelvic collective system. Fibrosis leading to infundibular steno-
sis can also occur. The end stage is characterized by a shrunken 
(“putty”) and/or calcified kidney or an enlarged sac with case-
ous material (“case cavernous- type autonephrectomy”). 
Involvement of the ureters is associated with wall thickening 
with strictures and shortening of the ureters. Bladder involve-
ment leads multiple diverticula and organ contraction [1].
23.3.7  Fungal Infection
Immunocompromission in patients with HIV, hematoonco-
logical diseases, or diabetes is the main risk factor for fungal 
infection of the urinary tract that is mostly very severe and 
potentially life-threatening. The most common organisms 
found are Candida and Aspergillus which are usually 
acquired by hematogenous spread or urinary tract infection 
[1]. Multiple renal abscesses and striated nephrogram can be 
seen indicating acute pyelonephritis. Irregular defects in the 
collecting system may correspond to conglomerations of 
fungal hyphae and fungal balls. Fungal infections with 
mucor are rare, in which vessel invasion resulting in infarc-
tions with high mortality can be present. Diffuse punctate 
calcifications, barely visible on MRI, in the kidneys or organs 
of the reticuloendothelial system can be indicative of a 
Pneumocystis carinii infection in HIV patients.
23.3.8  Stone Disease
MRI is the cross-sectional imaging method if, in case of a 
negative result of CT regarding the presence of calculi, a sec-
ondary imaging of the urinary tract is necessary to assess other 
soft tissue-related (e.g., urogenital malignancies) causes of 
urinary obstruction. Due to the low proton content, calculi 
have no MRI signal and can thus only be detected indirectly as 
a signal-free lesion. In T2-weighted sequences or contrast-
enhanced MR urography, filling defects appear as indirect 
indicators for a calculus. A “perinephric imbibition,” that is, 
fluid around the kidneys or ureters, can often be observed.
23.4  Retroperitoneum
23.4.1  Retroperitoneal Fibrosis
Retroperitoneal fibrosis, often referred to as Ormond’s dis-
ease, is a probably autoimmune, in some cases, medically 
mediated chronic inflammation in the retroperitoneum which 
leads to an increasing fibrosis of the structures located there 
(Fig. 23.2). Correspondingly, in the majority of cases, the 
a b c
Fig. 23.2 Coronal (a), sagittal (b), and axial (c) T2-weighted images showing a rare case of entrapment of both kidneys by histopathologically 
proven retroperitoneal fibrosis leading to hydronephrosis
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ureters running here are also affected. The fibrotic tissue, 
which usually spreads out cranially and caudally starting at 
the level of the lower lumbar spine, can be directly visualized 
with sectional imaging. A pannus-like growth around the 
aorta, iliac vessels, and ureters is typical. The ureters are dis-
placed in a characteristic manner to the medial direction. The 
middle third of the ureter is most frequently affected, but all 
ureteral sections may be involved. In the regions surrounding 
the fibrotic tissue, a stenosis of the ureters with a consecutive 
dilatation of the upper sections can occur. Contrast-enhanced 
images indicate the activity of the inflammation since a 
strong contrast agent uptake of the fibrotic tissue indicates 
active inflammation.
23.5  Inflammations of the Bladder
23.5.1  Bladder Infection
The detection of an inflammatory bladder wall change is a 
diagnostic challenge, since it is mostly indicated only by an 
irregular thickening, possibly with an inflammatory reaction 
of the adjacent fat tissue. However, this is a primarily unspe-
cific finding and initially does not permit a reliable differen-
tiation between malignancies, benign inflammatory changes, 
or posttherapeutic changes. Therefore, it is absolutely neces-
sary to take into account the clinic presentation, the history 
of the patient, and the further development of the patient’s 
disease for a differential diagnosis. In MRI, high-resolution 
sequences for assessing the bladder wall or DWI can help 
resolve the diagnostic dilemma.
Another factor which affects the wall thickness of the 
bladder is the filling state. False-positive, pathological condi-
tions can be simulated in a nearly empty bladder. In order to 
achieve a comparable filling state and to increase the detec-
tion of a potential tumor infiltration of the bladder wall, fill-
ing of the bladder is possible via a catheter with dilute 
contrast medium before an MRI examination. However, 
from a practical point of view, it should be noted that filling 
of the urinary bladder during a longer examination can lead 
to a reduced image quality in case of movement artifacts due 
to the urge to urinate.
Bladder infections often appear as nodular, irregular wall 
thickenings of the urinary bladder, since these can cause a 
bullous edema of the urinary bladder wall. Chronic infec-
tions, on the other hand, can lead to fibrotic changes with a 
subsequent contraction of the bladder wall.
Cystitis is defined by a bacterial count above 100,000 per 
mL urine and is most frequently caused by E. coli. In sec-
tional imaging, this often impresses by a wall thickening of 
the urinary bladder. A rare, life-threatening form of cystitis 
found in diabetics and immunosuppressed patients is 
 emphysematous cystitis. This shows gas accumulations in 
the bladder wall, which can expand into the ureter.
Likewise in diabetics the candida infection of the bladder 
is found. The fermentation of sugars in the urinary bladder 
can lead to detectable air, sometimes also to fungus balls.
In irradiated patients, radiation cystitis may occur. 
Here, in the acute phase, there is often a wall edema and 
hemorrhage. In the long term, ulceration, fibrosis, and 
shrinkage can develop. In imaging, the changes are often 
unspecific.
23.5.2  Schistosomiasis
Schistosomiasis, also referred to as bilharzia, is caused by 
parasitic worms. Over 200 million people are infected, with 
the majority in Africa. It is a major health concern in rural 
areas of developing countries predisposing individuals to 
squamous cell carcinoma and urothelial carcinoma. The 
infection generally occurs in the bladder but can spread to 
the ureters and kidneys via reflux. In the acute phase, nodular 
bladder wall thickening is seen in urography or 
MRI. Dystrophic, typically curvilinear calcifications, best 
seen on CT, in the bladder wall or ureter are common find-
ings and are caused by calcified dead ova. Typical additional 
appearances are strictures of the ureters or reflux.
23.5.3  Fistula
Fistula formation can be attributed to various underlying 
pathologies. The most common cause of fistula in Europe is 
a secondary fistula in Crohn’s disease. In smaller fistulae, the 
only clinical indicator can be a chronic cystitis. Frequently, 
larger fistulae lead to air or feces excretion via the urine. In 
MRI, fistula detection can be achieved directly (by filling the 
fistula with contrast medium) or indirectly (only by showing 
the connection of two structures or by air detection in the 
fistula). For fistula detection MRI is superior to CT, since the 
fistulae can be detected relatively specific, on the one hand, 
via T2-weighted sequences with fat suppression and after 
contrast agent application in fat-saturated T1-weighted 
sequences. Furthermore, MRI can be used to detect a con-
comitant abscess via diffusion-weighted imaging with high 
specificity. A direct (via a catheter) or an indirect (urographic 
late phase) filling of the urinary bladder can be performed. 
Depending on the localization of the presumed fistula, rectal 
contrast can also be helpful, although from a practical point 
of view a simultaneous filling does not appear to be useful 
(possibly at different time points).
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23.6  Differential Diagnosis
23.6.1  Lymphoma
Retroperitoneal lymphomas are an important differential 
diagnosis of both, abscess-forming inflammatory disease of 
the kidneys and Ormond’s disease. Renal lymphomas appear 
T1-hypointense and T2-iso−/hyperintense to normal paren-
chyma with poor enhancement relative to healthy renal tissue 
and may mimic acute pyelonephritis. Typically, renal lym-
phomas are associated with restricted diffusion and extremely 
low ADC values similar to those of abscesses (Fig. 23.3).
In renal transplants posttransplant lymphoproliferative 
disorders (PTLD) are quite common and an important dif-
ferential diagnosis to abscess-forming pyelonephritis and 
graft-versus-host disease.
Retroperitoneal lymphomas, in contrast to retroperitoneal 
fibrosis, show a rather mass-forming growth, and structures 
(e.g., ureters) are rather laterally displaced. In doubt, CT can 
be used to guide biopsy, since the diagnosis of retroperito-
neal fibrosis is ultimately made by means of histopathology, 
despite typical image criteria.
23.6.2  Posttherapeutic Change
Patients with gynecologic tumors and rectal or prostatic 
cancers are often treated surgically and/or with chemoradia-
tion, which can lead to ureteric strictures. The ureter may be 
injured in the process of pelvic surgery or transected, poten-
tially causing hydronephrosis or urinoma. Strictures or 
fibrosis leading to ureteric obstruction is common, as well 
as bowel and urinary tract fistulae. Lymphoceles may lead to 
an external compression of the ureter and/or bladder.
a
Fig. 23.3 A 35-year-old male patient with focal T2-hypointense/
T1-isointense lesions showing poor enhancement. Lesions display very 
high signal on high b-value DWI and significantly reduced ADC values 
(a). Lymphoma was diagnosed based on histopathology. Patient 
responded to chemotherapy, which is indicated by increase of ADC val-
ues and decrease of signal on high b-value images (b)
Take-Home Messages
• Sectional imaging, MRI in particular, may be useful 
in complicated urogenital infections.
• Clinical history of patients may help to differentiate 
certain pathologies and to identify “high-risk” 
patients.
• Acute and chronic inflammatory changes can be 
assessed with CT and MRI; MRI is possibly with 
greater significance in some differential diagnosis, 
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whereas CT offers the possibility of direct interven-
tion, e.g., installation of abscess drainage.
• Standard sequences should be accompanied by 
functional imaging (e.g., DWI).
• CT is the modality of choice for imaging of uroli-
thiasis; MRI may help in the further work-up of cer-
tain patients (e.g., to rule out malignancies if no 
calculi are detectable).
• In the investigation of retroperitoneal or ureteral 
pathologies, urographic phases are useful.
• Lymphoma should be considered as a differential 
diagnosis of lower and upper urogenital tract 
inflammation.
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Imaging of Testicular and Scrotal 
Masses: The Essentials
Andreas G. Wibmer and Hebert Alberto Vargas
24.1  Clinical Scenarios Where Imaging  
Is Indicated
The first key to a meaningful radiology report is to be aware 
of the clinical indication for which the imaging study was 
requested.
24.1.1  Scrotal Pain With or Without  
a Palpable Mass
Infection (i.e., epididymitis/orchitis), torsion of the testis or 
testicular appendage, vascular pathologies (e.g., varicocele), 
hydrocele, and trauma are the most common causes of scro-
tal pain. Ultrasound (US) allows differentiation from testicu-
lar neoplasms and helps narrow the differential diagnosis in 
clinically equivocal cases. From an oncologic perspective, a 
few factors should be considered before contemplating these 
diagnoses:
• Their age distribution overlaps with most scrotal and tes-
ticular malignancies, and asymptomatic neoplasms can be 
incidentally identified on imaging.
• About one third of scrotal/testicular malignancies can 
present with scrotal pain.
• Testicular infection, hematomas, and testicular infarcts 
can be focal and mimic testicular neoplasms, although 
the latter are commonly more vascularized on Doppler 
US. In the right clinical setting and absence of internal 
vascularity, focal infarct, hematoma, or infection might 
be an appropriate differential diagnosis and avoid futile 
surgery. However, these cases need to be followed up 
closely to document involution and exclude 
malignancy.
24.1.2  Palpable Painless or Incidental  
Scrotal Mass
In this scenario, the first and most important task of imag-
ing is localizing the mass to differentiate testicular from 
extra- testicular origin. In equivocal cases on US, magnetic 
resonance imaging (MRI) may be used as a problem-solv-
ing tool. As a second step, US (and in some selected cases 
MRI) may narrow the differential diagnosis, most impor-
tantly by identifying cysts, cyst-like lesions, and other 
benign entities with typical appearance (described below). 
In the absence of unequivocally benign imaging findings, it 
is important to clearly convey the suspicion for a malignant 
neoplasm to the referring physician. In case of a testicular 
mass, this often triggers an intervention (orchiectomy), as 
further management hinges on adequate histopathologic 
characterization, which is not always possible through 
biopsies due to the microscopic heterogeneity of many tes-
ticular cancers.
Learning Objectives
• To identify the clinical scenarios where imaging of 
the testes and scrotum is indicated
• To learn the association between imaging features 
and the management of patients with testicular and 
scrotal masses
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24.1.3  Isolated Retroperitoneal 
Lymphadenopathy
Lymphoma, extragonadal germ cell tumors, and testicular 
cancer metastases are the most common etiology for isolated 
retroperitoneal lymphadenopathy. Screening testicular US is 
routinely performed in this scenario. In case of testicular can-
cer, for which retroperitoneal nodes are the first lymphatic 
draining points and considered regional spread (i.e., “N”) in 
the TNM staging system, the spatial distribution of the retro-
peritoneal disease allows for some suggestions on the side of 
the testicular primary. Left-sided tumors typically metasta-
size to left periaortic and preaortic nodes, while right-sided 
cancers metastasize to nodes around the inferior vena cava, 
including inter-aortocaval nodes. These considerations may 
seem somewhat academic for the reporting radiologist, who 
will diligently screen both testes anyway, not least due to the 
possibility of synchronous bilateral testicular cancers, seen in 
about 0.6% of all cases [1]. When confronted with equivocal 
testicular imaging findings, however, this information might 
help to reach a sound conclusion. If a testicular mass is identi-
fied, the objectives of imaging are similar to those described 
in the previous paragraph. Beyond specific imaging charac-
teristics of some entities, which will be described below, the 
following facts might be helpful while interpreting these 
scans:
• Some types of primary testicular cancers, although widely 
metastatic, might be very small or involuted. On imaging, 
these primary tumors can be undetectable, or appear as 
small masses or focal calcifications, a phenomenon that has 
been referred to as “burned-out” primary tumor (Fig. 24.1).
• Some testicular cancers produce high levels of serum tumor 
markers, most notably alpha-fetoprotein (AFP), human 
chorionic gonadotropin (hCG), and lactate dehydrogenase 
(LDH). Although of limited sensitivity and specificity, high 
levels of these markers indicate a testicular origin of retro-
peritoneal lymphadenopathy and might help the radiologist 
to interpret equivocal imaging findings.
24.1.4  Follow-Up After Curative Treatment 
of Testicular Cancer
Patients with treated testicular cancer are at ≥10-fold 
increased risk for developing contralateral metachronous 
cancer with a 15-year cumulative incidence of 1.9% [1]. This 
elevated pretest probability should be considered when per-
forming surveillance studies. Patients having undergone 
treatment, particularly those who had metastatic disease, will 
also need follow-up imaging exams of other parts of the 
body. In this scenario, the following points deserve 
consideration:
• Most recurrences occur within the first 2 years after treat-
ment. Late relapses, although less common, have been 
reported more than 5 years after treatment.
• The most common sites of recurrence are the retroperito-
neal lymph nodes. Follow-up studies, especially com-
puted tomography (CT), often spare the pelvis to minimize 
radiation dose.
 – CAVEAT: In patients with any kind of surgery involv-
ing the scrotum or inguinal canal (e.g., hernia repair, 
orchiopexy, or others), lymphatic drainage is altered, 
and recurrences can occur in variable anatomic pat-
terns, including inguinal lymph node involvement.
 – In patients initially treated with adequate retroperito-
neal lymph node dissection, retroperitoneal recurrence 




Fig. 24.1 A 38-year-old with hip pain. (a) CT of the abdomen and 
pelvis shows left para-aortic and preaortic lymphadenopathy (asterisk), 
raising the suspicion for metastatic left-sided testicular cancer. (b) US 
of the left scrotum shows an intratesticular focal calcification (arrow); 
the right testis was unremarkable (not shown). Histopathology of the 
left orchiectomy specimen confirmed a “burned-out” germ cell tumor
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• The most common site of organ metastases is the lung, 
and CT of the chest is more sensitive and specific for their 
detection than radiographs.
• After chemo- and/or radiotherapy, there is an increased 
long-term risk for secondary malignancies, most com-
monly cancers of the stomach, pancreas, urinary bladder, 
colon, lung, and esophagus and malignant mesothelioma 
of the pleura [2].
24.2  Imaging Characterization of Testicular 
and Scrotal Masses
Ultrasound is the initial imaging examination of choice for 
testicular and scrotal abnormalities; MRI may serve as a 
diagnostic adjuvant in selected cases. The main task of imag-
ing – and also key to characterization – is to localize the 
mass. Masses arising within the testis have a higher likeli-
hood of malignancy than those occurring in extra-testicular 
sites, including the epididymis (although there are some 
exceptions, as outlined below).
24.2.1  Testicular Masses
24.2.1.1  Testicular Malignancies
Are typically heterogeneously hypoechoic compared to nor-
mal testicular tissue on US. They are well-defined, often 
lobulated lesions with internal blood flow detectable on 
Doppler US (Figs. 24.2 and 24.3). The likelihood of malig-
nancy is high if all these features are present; and this high 
level of suspicion must be expressed in the radiology report. 
Characterization of histologic subtypes based on imaging is 
currently not possible; thus orchiectomy is typically the next 
step for most of these patients. These imaging features are 
not specific for testicular cancer and might also be encoun-
tered in benign or nonneoplastic tumor mimics (Fig. 24.4). 
The following paragraphs describe typical imaging features 
of more common benign and nonneoplastic testicular masses 
that may allow for confident exclusion of malignancy based 
on imaging.
24.2.1.2  Testicular Microlithiasis
This frequently encountered entity is defined as the presence 
of five or more echogenic, non-shadowing foci <3 mm per 
testis (Fig. 24.5). Although it can be associated with testicu-
lar cancer, the European Society of Urogenital Radiology 
recommends against follow-up of isolated microlithiasis in 
the absence of risk factors (i.e., personal or family history of 
germ cell tumor, testicular atrophy <12 mL, history of mal-
descent or orchiopexy) [3].
24.2.1.3  Cystic Testicular Lesions
Similar to other organ systems, cysts in the testes are well- 
defined, homogeneously hypoechoic lesions with posterior 
acoustic enhancement on US (Fig. 24.6). Complex cysts have 
some degree of internal echogenicity. However, all cysts lack 
internal vascularity on Doppler US. The differentiation of tunica 
albuginea cysts which are found in a peripheral or paratesticular 
location vs. central cysts has no clinical significance. Ectasia of 
the rete testis is typically encountered in older men and appears 
as a cluster of multiple small cysts and tubules along the testicu-
lar mediastinum (Fig. 24.7). Testicular hematomas and 
abscesses can have large cystic components and, if considered 
as a differential diagnosis in the appropriate clinical setting, 
always need close follow-up. Cystic changes can be seen in tes-
ticular malignancies; however, purely cystic cancers are exceed-
ingly rare.
24.2.1.4  Epidermoid Cysts
This benign lesion can have typical features on US allowing 
for confident diagnosis in most cases. Multiple concentric 
a
b
Fig. 24.2 A 38-year-old with a painless palpable right scrotal mass. (a) 
Gray-scale US of the scrotum shows microlithiasis and an intratesticu-
lar, well-circumscribed, lobulated, heterogeneously hypoechoic mass 
(arrows) with (b) internal vascularity on Doppler US. These features 
are the hallmarks of a malignant testicular neoplasm; the final diagnosis 
of seminoma was established after orchiectomy
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layers of keratinous debris give it a more solid appearance of 
a round hypoechoic lesion with multiple concentric hyperin-
tense internal layers resembling an “onion skin” and lacking 
internal blood flow (Fig. 24.8). Although these findings are 
specific for the entity, some epidermoid cysts can also mimic 
testicular cancers on imaging (Fig. 24.4).
24.2.1.5  Focal Infections, Hematomas, 
and Infarcts
In the adequate clinical context, these entities might be con-
sidered in the differential diagnoses: local or systemic signs 




Fig. 24.3 A 24-year-old with back pain. (a) CT of the abdomen and 
pelvis shows left para-aortic and preaortic lymphadenopathy (arrow), 
suspicious for metastatic left-sided testicular cancer. (b) Gray-scale US 
of the scrotum shows a left-sided intratesticular, well-circumscribed, 
lobulated, heterogeneously hypoechoic mass (arrows) with (c) internal 
flow on Doppler US. These features are the hallmarks of a malignant 
testicular neoplasm; the final diagnosis of mature teratoma was estab-
lished after orchiectomy
Fig. 24.4 A 54-year-old with a painless palpable right scrotal mass. (a) 
US of the scrotum shows an intratesticular, well-circumscribed, lobu-
lated, heterogeneously hypoechoic mass (arrows) with low-level inter-
nal vascularity on Doppler US. These features are the hallmarks of a 
malignant testicular neoplasm, justifying orchiectomy; the final histo-
pathologic diagnosis was epidermoid cyst
Fig. 24.5 Imaging features of microlithiasis. Multiple (i.e., ≥5 per tes-
tis) microcalcifications (i.e., <3 mm) within the testicular parenchyma; 
one microcalcification is marked with an arrow
Fig. 24.6 Imaging features of a simple testicular cyst. A round, well- 
defined, homogeneously hypoechoic lesion (arrow) with posterior 
acoustic enhancement (asterisk) and lack of internal flow
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tal surgery/trauma, torsion, or abnormal states of coagulation 
for hematoma and infarction (Fig. 24.10). All these entities 
share the lack of internal vascular flow on Doppler US. As 
previously mentioned, all cases must be monitored to docu-
ment involution and exclude malignancy.
24.2.1.6  Testicular Adrenal Rest
These benign masses occur in patients with congenital adre-
nal hyperplasia. In addition to clinical history, bilaterality is 
the key to the diagnosis [4], although unilateral appearance 
has been reported [5]. Their imaging features are otherwise 
similar to testicular cancer.
24.2.2  Epididymal Masses
Epididymal masses or mass-like lesions are frequently 
encountered as incidental findings on scrotal ultrasound. 
They are almost always benign and do not require specific 
treatment. Cysts are well-defined, homogeneously 
a
b
Fig. 24.7 Two cases of ectasia of the rete testis. (a) 67-year-old patient 
with prostate cancer and an incidentally discovered testicular lesion. 
US of the scrotum shows a cluster of multiple small cysts and tubules 
along the testicular mediastinum (arrows), consistent with rete testis 
ectasia. (b) In this example of a 70-year-old patient with prostate cancer 
and a remote history of scrotal surgery, rete ectasia is more extensive, 
occupying large parts of the testis
Fig. 24.8 A 23-year-old with a painless palpable scrotal mass. US of 
the scrotum shows a round, well-delineated lesion with multiple con-
centric hyperintense internal layers, resembling an “onion skin,” con-
sistent with epidermoid cyst, justifying a nonsurgical, observational 




Fig. 24.9 An 88-year-old with anastomotic leakage after rectal sur-
gery, pelvic abscesses, sepsis, and painful scrotal swelling. (a) US of 
the scrotum shows a well-circumscribed, lobulated, heterogeneously 
hypoechoic mass (arrows) with (b) intense peripheral (arrow) but no 
central (asterisk) flow on Doppler US. The patient underwent orchiec-
tomy, which confirmed the infectious etiology
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Fig. 24.10 A 56-year-old with painless right scrotal swelling after 
recent right nephrectomy with reported gonadal vein tie off/thrombosis. 
US of the scrotum shows an intratesticular, well-circumscribed, lobu-
lated, heterogeneously hypoechoic mass without internal flow on Power 
Doppler ultrasound (asterisk). The clinical history and imaging appear-
ance suggest partial/focal testicular infarction, and involution was doc-
umented on follow-up US (not shown)
Fig. 24.11 Imaging features of a simple epididymal cyst. A round, 
well-defined, homogeneously hypoechoic lesion within the epididymis 
(arrow) with posterior acoustic enhancement (asterisk) and lack of 
internal flow.
Fig. 24.12 A 61-year-old with resolved scrotal pain but persistent 
swelling after antibiotic therapy for epididymitis. US of the scrotum 
shows a cystic epididymal lesion (asterisk) with multiple small internal 
low-level echoes (the arrow is pointing at one), consistent with 
spermatocele
Fig. 24.13 A 35-year-old with scrotal pain without a palpable mass. 
US of the scrotum shows a round, well-delineated, heterogeneously 
hypoechoic mass within the epididymis without detectable flow on 
Doppler US (asterisk). These imaging findings are non-specific; how-
ever, the epididymal location suggests a benign entity; excisional 
biopsy showed adenomatoid tumor
a
b
Fig. 24.14 A 2-year-old with scrotal swelling and mild scrotal pain. 
(a) Gray-scale US of the scrotum shows a large extra-testicular, 
hypoechoic mass (asterisk); the normal testis is marked with an arrow. 
(b) Doppler US demonstrates intense intralesional blood flow. In this 
age group, the suspicion for extra-testicular rhabdomyosarcoma, which 
was confirmed on histopathology, has to be unequivocally conveyed to 
the referring physician
A. G. Wibmer and H. A. Vargas
263
hypoechoic lesions of varying size, most frequently located 
in the epididymal head (Fig. 24.11). Multiple small low-level 
echoes within a cystic lesion in a patient with prior vasec-
tomy or other inguinal/scrotal surgery are suggestive of a 
spermatocele (Fig. 24.12). The most common solid neo-
plasms of the epididymis are adenomatoid tumors and leio-
myomas. Both entities are well defined and show variable 
size, echogenicity, and vascular flow (Fig. 24.13). The dif-
ferentiation of these benign neoplasms from sperm (cell) 
granulomas is rarely possible and not necessary from a clini-
cal perspective.
24.2.3  Extra-Testicular Masses
As with epididymal tumors, most scrotal neoplasms outside 
the testes are benign, most commonly lipomas and fibrous 
pseudotumors. Scrotoliths are calcified tumor-like masses 
that can be encountered in any part of the scrotum. The rare 
exceptions are paratesticular rhabdomyosarcomas in chil-
dren and adolescents, as well as sarcomas, metastases, and 
locally advanced scrotal skin cancer in adults.
24.2.3.1  Malignant Paratesticular Tumors
Key to the diagnosis of a rhabdomyosarcoma is patient age 
in conjunction with a hypoechoic extra-testicular mass that is 
highly vascular on Doppler US (Fig. 24.14). Paratesticular 
sarcomas are heterogeneous, markedly hypervascular tumors 
of adult men; liposarcomas can contain macroscopic fat 
(Fig. 24.15). The diagnosis of metastases and locally 
advanced skin cancer can be made in the adequate clinical 
context.
24.2.3.2  Fat-Containing Paratesticular Lesions
The presence of fat in an extra-testicular mass, most accu-
rately assessed on MRI, can guide the radiologist toward the 
correct diagnosis. The most common fat-containing parates-
ticular neoplasm is lipoma of the spermatic cord. Large, 
markedly hypervascular fat-containing masses in an adult 
are suspicious for liposarcoma (Fig. 24.15). Fat-containing 
tumor mimics are inguinal-scrotal hernias and fat necrosis 




Fig. 24.15 A 61-year-old with a long-standing history of hydrocele 
and a recent increase of scrotal swelling. (a) Gray-scale US shows an 
extra-testicular, heterogeneously hypointense mass (arrows) with (b) 
intense internal flow on Doppler US; the normal epididymis is marked 
within (asterisk) (a). These findings are suspicious for malignancy; (c) 
the presence of intralesional fat (asterisk) on staging CT suggests lipo-
sarcoma, which was confirmed on histopathology Key Points
• The role of imaging testicular and scrotal masses 
will vary according to the clinical scenario.
• Imaging is helpful to establish or narrow the differ-
ential diagnoses.
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24.3  Concluding Remarks
Understanding the clinical scenario in which a scrotal 
imaging exam is performed is pivotal for meaningful radi-
ology reports. Solid testicular masses with internal vascular 
flow must prompt a high level of suspicion for testicular 
 malignancy, unless unequivocal imaging findings suggest a 
benign diagnosis. Most epididymal and paratesticular 
masses are benign; however, irregularly shaped, ill-defined, 
hypervascular masses may represent malignant tumors.
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